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INVESTIGATOR PROTOCOL AGREEMENT  
CPP FAP-310 
A DOUBLE-BLIND, RANDOMIZED, PHASE III TRIAL OF THE SAFETY AND EFFICACY OF CPP-
1X/SULINDAC COMPARED WITH CPP-1X, SULINDAC AS SINGLE AGENTS IN PATIENTS WITH 
FAMILIAL ADENOMATOUS POLYPOSIS (FAP)  
By signing below I agree: 
1. That my staff and I have read, understand and will adhere to the protocol as written and agree 
that any changes to the protocol will be agreed to and approved by Cancer Prevention 
Pharmaceuticals, except to eliminate an immediate hazard to the patients.  Prior to instituting 
changes I will obtain approval from the Independent Ethics Committee (IEC)/Institutional 
Review Board (IRB)/Research Ethics Board (REB); 
2. To abide by all obligations stated on the FDA Form 1572 and other documents required by 
regulation; 
3. To conduct this study in accordance with the current International Conference on 
Harmonization (ICH) guidance, the Good Clinical Practices (GCP) guidance the US FDA 
regulations , EMA regulations, Health Canada regulations, local competent authority 
regulations, and local IRB/IEC/REB and legal requirements; 
4. To obtain IRB/IEC/REB approval of the protocol, any amendments to the protocol, and 
periodic re-approval as required, and to keep the IRB/IEC/REB informed of adverse events 
and periodically report the status of the study to them; 
5. To ensure that each patient enrolled into the trial, or legally authorized representative has 
read and understands the current patient information, and has signed the Informed Consent 
form; 
6. To ensure that I and all persons assisting me with the study are adequately informed and 
trained about the investigational drug and of their study related duties and functions as 
described in the protocol; 
7. To make prompt reports of Serious Adverse Events (SAEs) and deaths as defined in the 
protocol, the FDA regulations, EMA regulations, local competent authority regulations, and 
Health Canada regulations; 
8. To prepare and maintain adequate and accurate case histories to document all observations 
and other data pertinent to the study on each individual enrolled in the clinical trial. 
Investigator Signature:  ________________________________________  ________________ 
  Date 
Investigator Name (Print):  _____________________________________ 
Institution:  __________________________________________________ 
 __________________________________________________ 
 __________________________________________________ 
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1. GENERAL INFORMATION 
1.1. Protocol Title 
A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X/Sulindac 
Compared with CPP-1X, Sulindac as Single Agents in Patients with Familial Adenomatous 
Polyposis (FAP)  
1.2. Sponsor and Study Monitor 
Cancer Prevention Pharmaceutical, Inc. 
1760 E. River Road, Suite 250 
Tucson, AZ 85718 
Phone: +1 (520) 908-7774 
Fax: +1 (520) 232-2191 
 
Study Coordinator and Medical Monitor 
Alfred M. Cohen, M.D., F.A.C.S., F.A.S.C.R.S. 
Chief Medical Officer 
Cancer Prevention Pharmaceuticals, Inc. 
1760 E. River Road, Suite 250 
Tucson, AZ 85718 
Email: acohen@canprevent.com 
Phone (Main): +1 (520)-908-7774 
Phone (Cell): +1 (520)-400-0116 
 
SAE Reporting, Reporting Contact Numbers 
SAE reporting to occur through the electronic data capture system. 
Phone Contact Information: 
Monday – Friday (8:00 am – 5:00 pm MST), Phone: +1 (520) 908-7774; Fax: +1 (520) 232-2191 
 
Alternative Contact Numbers: 
Alfred Cohen, M.D., cell: +1 (520)-400-0116 or Kathryn Grenier, cell: +1 (520)-444-5869 
 
1.3. Other Medical and/or Technical Departments 
Biostatistician 
Bruce Levin, Ph.D. 
Professor, Department of Biostatistics,  
Mailman School of Public Health, Columbia University 
722 West 168th Street, Room 626a  
New York, NY 10032 
 
Bioanalysis Laboratories 
University of Arizona, BIO5 Institute Oro Valley and Arizona Cancer Center in Tucson, Arizona 
will perform the polyamine, pharmacogenomics and genetics testing for the samples collected. 
 
inVentiv Health Clinique, Inc. (formerly PharmaNet/i3) in Quebec City, Canada will perform the 
bioanalysis for the pharmacokinetic samples collected. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 2.0, April 16, 2013  8 
1.4. Signature Authority for Protocol and Protocol Amendments 
Alfred M. Cohen, M.D., F.A.C.S., F.A.S.C.R.S. 
Chief Medical Officer 
1.5. Clinical Investigators and Study Leadership 
Study Co-Principal Investigators 
Carol Burke, M.D. and James Church M.D., F.A.C.S., F.A.S.C.R.S 
Sue Clark M.D, F.R.C.S. and Professor Robin Phillips, M.S. (Surgery), F.C.R.S. 
Ernest T. Hawk, M.D, M.P.H. 
Clinical Investigators and Sites 
Patrick M. Lynch, J.D., M.D. 
Professor, Dept. of Gastroenterology, Hepatology, 
Nutrition, Division of Internal Medicine 
Ernest T. Hawk, M.D, MPH 
VP for Cancer Prevention and Population Sciences 
Miguel Rodriquez-Bigas, M.D. 
Dept. of Surgery 
University of Texas, M.D. Anderson Cancer Center 
1515 Holcombe Boulevard, Houston, TX 77030 
Carol Burke, M.D. 
Department of Gastroenterology and Hepatology 
James Church, M.D., FACS, FASCRS 
Department of Colorectal Surgery 
Cleveland Clinic 
9500 Euclid Avenue 
Cleveland, OH 44195 
Miss Sue Clark, M.D., FRCS 
Consultant Colorectal Surgery, Assistant Director 
Polyposis Registry 
Professor Robin Phillips, M.S. (Surgery), FRCS 
Clinical Director 
St Mark’s Hospital, Watford Road 
Harrow, Middlesex, HA1 3UJ, UK  
Paul E. Wise, M.D. 
Washington University in St. Louis 
School of Medicine 
Section of Colon and Rectal Surgery 
CB 8109, 660 S. Euclid Ave 
St Louis, MO 63110 
Ramona Lim, M.D., Sapna Syngal, M.D., MPH 
Dana Farber Cancer Institute 
450 Brookline Avenue  
Boston, MA 02215 
Timothy Geiger, M.D. 
Division of General Surgery, Colon and Rectal Surgery  
Vanderbilt Ingram Cancer Center 
2220 Pierce Ave. 
Nashville, TN 37232 
Frank A. Sinicrope, M.D. 
Dept. of Gastroenterology and Hepatology 
Mayo Clinic 
200 First Street, S.W.  
Rochester, MN 55905 
Elena Stoffel, M.D., MPH 
University of Michigan 
Comprehensive Cancer Center 
1500 East Medical Center Drive 
Ann Arbor, MI 48109-5902 
Steve Gallinger, M.D., MSc, FRCS 
Professor of Surgery, Head, Division of 
Hepatobiliary/Pancreatic Surgical Oncology Prgm 
Robert Gryfe, M.D., PhD, Professor of Surgery 
Zane Cohen, M.D. 
Director, Zane Cohen, Centre for Digestive Diseases 
University Health Network and Mount Sinai Hospital 
200 Elizabeth St, 10EN, Room 206, Toronto 
Ontario, Canada M5G2C4 
Evelien Dekker, M.D., PhD 
Academic Medical Centre 
Dept. of Gastroenterology and Hepatology, C2-115 
PO Box 22700 
Amsterdam, The Netherlands, 1100 DE 
Prof. Dr. med Gabriella Möslein, 
St. Joseph's Hospital-Bochum Linden –HELIOS 
Axstraße 35 
Bochum, Germany 44879 
Antoni Castell, M.D. 
Institute De Malties Digestives 
Hospital Clinic, Villarroel 170 
Barcelona, Catalonia, Spain 08036 
Randy Burt, M.D. 
Senior Director of Prevention and Outreach 
Huntsman Cancer Institute Rm 5164  2000 Circle of 
Hope, Salt Lake City, UT 84112 
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1.6. Study Schema 
SCHEMA 
MAJOR ELIGIBILITY CRITERIA 
1.  Diagnosis of Familial Adenomatous Polyposis (FAP) with confirmed APC mutation AND 
age ≥ 18 years. 
 
2.  If prior colorectal surgery, at least 3 years since colectomy/proctocolectomy with ileo-rectal 
anastomosis (IRA) or pouch. 
 
Disease at One or More of These Sites 
 
1. Intact colon (pre-colectomy) 
2. Rectal/Pouch Polyposis 
3. Duodenal Polyposis 
 
Stratification 
Stratification based on FAP-related time to first event prognosis. 
1) best (i.e., longest projected time to first FAP-related event) – rectal/pouch polyposis
2) intermediate – duodenal polyposis 
3) worst – pre-colectomy 
 
If a subject has two or more of these disease sites, the stratum for 




A total of 150 patients 
 
 
CPP-1X (750 mg) CPP-1X (750 mg) Placebo (CPP-1X) 
 +   +   +  
Sulindac (150 mg) Placebo (Sulindac) Sulindac (150 mg) 
For enrolled subjects treatment will continue for 24 months, or until occurrence of an FAP-related event as 
defined in the protocol. Drugs taken once daily. 
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2. BACKGROUND INFORMATION 
2.1. Natural History, Current Surgical and Endoscopic Treatment 
Familial Adenomatous Polyposis (FAP) is a syndrome caused by mutations in the Adenomatous 
Polyposis Coli (APC) tumor suppressor gene and propagated by an autosomal dominant mode of 
inheritance. Details of this syndrome can be found at OMIM ®, (Online Mendelian Inheritance in 
Man), http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=175100, which is an authoritative 
listing of human genes and genetic phenotypes. This database is available to users courtesy of 
NCBI, the National Center for Biotechnology Information.  
FAP is caused by mutations/deletions in the APC gene, which is located on chromosome 5q21-
q22.  Gardner syndrome is a variant of FAP in which desmoid tumors, osteomas, and other 
neoplasms occur together with multiple adenomas of the colon and rectum 
(http://www.cancer.gov/cancertopics/pdq/genetics/colorectal/HealthProfessional/page4/AllPages). 
Most FAP patients will have hundreds to thousands of colorectal adenomas, and without 
prophylactic surgery develop colorectal cancer before the age of 40.  Prophylactic surgery may 
involve total abdominal colectomy with ileal-rectal anastomoses (IRA), accompanied by frequent 
rectal surveillance with polypectomy and cautery/laser ablation as needed.  Patients with 
extensive rectal involvement undergo total proctocolectomy with ileal pouch-anal reconstruction.  
Despite removing the main at-risk organ, many patients develop duodenal neoplasia (bulky 
adenomas/cancer) and require additional localized or Whipple radical surgery.  The Spigelman 
classification (Stage 3 or 4)1 can accurately predict those with adenoma that are most likely to 
progress to cancer.  Bulow and colleagues2 reviewed duodenal polyposis issues in FAP patients.  
Gastric antral adenomas may occur and rarely are symptomatic or progress to cancer.  
Despite total proctocolectomy with ileal pouch reconstruction, approximately 50% of patients 
will develop adenomatous lesions in the neo-rectum.3-6  There are case reports of cancer 
developing in the pouches. All patients who have a residual rectum after total colectomy require 
frequent surveillance, polypectomies and ablations for continuing rectal polyposis. 
Desmoids are “benign tumors” (myofibroblastic) and cause significant morbidity and mortality in 
some patients.  They are not associated with any specific FAP genotype but are more common if 
the APC mutation is distal to codon 1444; the major clinical risk factors are family history and 
prior colectomy.  Women are at greater risk. Growth of these lesions, particularly when they 
involve the root of the mesentery, can lead to extensive surgery, often resulting in resection of 
ileal pouches and permanent ileostomy.  Current treatment involves surgery, radiation, NSAIDS 
and anti-estrogens.  None of these approaches have major impact on the growth of these lesions.7-
9 Although an important site of disease and morbidity for FAP patients, this protocol will focus on 
intestinal polyposis only. 
Vasen and colleagues10 provide evidence-based guidelines for the evaluation and management of 
FAP patients and provides detailed natural history data. 
After prophylactic colectomy, all FAP patients undergo regular surveillance intervention, with 
proctoscopy and upper GI endoscopy every 6-12 months.  Surgical intervention may be required 
for progressive FAP related disease (defined in protocol).  We believe that disease control with 
our combination regimen will delay the occurrence of clinically meaningful events. 
2.2. Pharmacologic Clinical Trials in FAP Patients 
In the general population, certain types of colorectal polyps have increased risk of progression to 
colorectal cancer.  High risk polyps (polyps with villous histology, size ≥1 cm, high grade 
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dysplasia, or multiple adenomas defined as 3 or more) have become the focus of colorectal 
tumorigenesis research due to the higher rate of malignant potential for these.11-15  The biology of 
common colorectal cancer is similar to the FAP phenotype.  Wallace and Lynch16 summarized the 
current status of chemoprevention in FAP patients.  The key drugs/drug combinations are 
described below. 
2.2.1. Sulindac Alone 
Labayle and colleagues17 studied 10 FAP patients with IRA in a randomized placebo controlled 
double blind trial of sulindac 300 mg a day for 4 month intervals.  In rectal assessment of polyp 
counts, there was a statistically significant reduction with sulindac compared to placebo (despite 
the small number of evaluable patients assessed). 
Nugent18 evaluated sulindac at 200 mg twice a day in 24 patients with duodenal neoplasia and in 
this group 12 had an IRA and the rectum was also evaluated.  This was a placebo controlled 
randomized trial.  Benefit was demonstrated in the rectum, but not statistically beneficial in the 
duodenum. 
Giardello and his group19 performed a randomized double blind trial in non-operated FAP 
patients or those who had an IRA.  Sulindac at 150 mg twice a day was the treatment regimen.  
Rectal polyp numbers decreased 56% in the treated group. 
Tonelli et al.,20 studied 15 FAP patients after IRA.  This non-randomized trial used sulindac     
100 mg twice a day.  A benefit was seen after 6 months, but not long-term. 
Cruz-Correa21 studied 12 patients post IRA for rectal polyp control with 150 mg of sulindac twice 
a day.  A major reduction in polyp numbers was demonstrated, but with a 50% incidence of 
gastrointestinal erosions. 
Giardiello and colleagues22 utilized sulindac in 41 non-operated FAP patients, mean age of 13.  
By the end of the study all but 3 of the 21 subjects randomized to the sulindac arm were receiving 
150 mg of sulindac daily twice a day.  Treatment with sulindac for a four-year period was well 
tolerated.  Few adverse events were reported and 93% were grade 1 or grade 2 and included 
leukopenia, photosensitivity, rash, uticaria, diarrhea, vomiting, bleeding, hyperbilirubinemia, 
blurred vision, abdominal pain, and influenza like syndrome.  One subject was withdrawn 
because of possible drug-induced neutropenia.  The incidence of any adverse event did not differ 
significantly between the sulindac group and the placebo group.  There was no demonstrable 
difference in the adenoma formation compared to placebo.  
2.2.2. Celecoxib Alone 
Although FDA approved celecoxib for the treatment of FAP patients in 1999, Pfizer recently 
withdrew the agent’s registration.  Of note, this agent did not become a usual part of standard care 
for these patients.  This is partly due to concerns for patient safety resulting from colorectal 
adenoma prevention studies reported in 2006.23,24  These studies identified a small but finite risk 
of serious cardiovascular events associated with celecoxib treatment. 
Albeit the one most prominent study was performed at MD Anderson, Houston, TX and St. 
Mark’s Hospital, London.25,26  Patients were randomized to placebo control, celecoxib 100 mg 
twice daily, and celecoxib 400 mg twice daily.  In the Steinbach report,25 6 months of celecoxib, 
400 mg twice daily showed a 28% change from baseline in the mean number of rectal polyps, the 
lower dose of the drug (100 mg twice daily) showed an 11.9% change in the mean number of 
polyps compared to baseline.  Similar data were found in the duodenal cohort.  Polyp reduction 
with small baseline tumor burden was only 14.5%, but 31% in more involved baseline duodenal 
adenomatosis.  Again, effect was noted only in the high dose celecoxib patients.  Sixty-eight 
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percent (68%) of patients in the placebo group, 56% of patients in the 100 mg twice daily group, 
and 57% of patients in the 400 mg twice daily group reported one or more adverse events of grade 
2 or higher (NCI CTC, Ver. 3.0).  The most common events were diarrhea and abdominal pain. 
2.2.3. NSAIDs Plus Eflornithine Combination 
This research program was activated in 2002, as a randomized Phase II study (ClinicalTrials.gov 
NCT00033371) comparing the effectiveness of celecoxib +/- eflornithine in FAP.  Accrual was 
discontinued after approximately 111 patients were entered.  Dr. Patrick Lynch, the study 
Principal Investigator, reported results from this trial in abstract form at the 2012 Digestive 
Diseases Week (DDW) meeting in San Diego and the 2012 Collaborative Group of the Americas 
for Inherited Colorectal Cancer in Boston.27,28 
The stated purpose of this study was to “compare the effectiveness of celecoxib with or without 
eflornithine in preventing colorectal cancer in patients who have familial adenomatous 
polyposis”. The outcome measures involved changes in polyp numbers, polyp burden, and 
plaque-like duodenal polyps after 6 months of treatment.  This was a two-arm trial: 
1. Oral celecoxib (400 mg) twice daily with oral eflornithine (500 mg/m2), once daily, vs. 
2. Oral celecoxib twice daily and oral placebo once daily 
The major conclusions from that study were: 
 Addition of eflornithine, at an average daily dose of 750 mg (three 250 mg tablets) to 
celecoxib did not significantly reduce raw adenoma count according to primary endpoint 
measure (polyps in reference cluster in still color photos) compared to celecoxib alone. 
 At least borderline significance of the combination was achieved by secondary measures 
(counts in photos, weighted by diameter, and by video of larger segments of colorectum). 
 No deleterious ototoxicity due to eflornithine was detected. 
 No significant treatment-related adverse events were noted in either arm of the trial. 
 Finding of greater effect on diameter-weighted burden suggests these agents may have 
greater effect at level of adenoma promotion than initiation. 
 Based on findings from another trial, use of a web-based quantitative tool for capturing 
diameter-weighted adenoma counts from videos of total colon or rectum may be more 
informative than approaches to adenoma quantification to date. 
2.2.4. Eflornithine Alone 
There are extensive preclinical studies in mouse models of FAP.  These mouse models express a 
mutant form of the mouse homolog of the human adenomatous polyposis (APC) gene.  When 
these mouse models of FAP are treated with eflornithine alone, the agent causes a dose-dependent 
decrease in the number of both intestinal and colonic polyps.29-31 
There have been no clinical trials in FAP patients using eflornithine alone although other clinical 
trials of eflornithine have shown suppressed tumor growth in multiple tumor types.  As indicated 
above, the Lynch 2012 trial provides the first evidence of effect of eflornithine, at an average 
daily dose of 750 mg in patients with FAP.  There was no eflornithine alone arm in that trial, so 
the data only addresses eflornithine in combination with celecoxib.  However, in that trial there 
was evidence for both safety of eflornithine at 750 mg/day in this patient population (no 
difference between NSAID alone and the combination arm) and efficacy (statistically significant 
effect of combination versus NSAID alone arm) for both total polyp volume and global polyp 
burden measures. 
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The major evidence for benefit of eflornithine derives from prospective, randomized, placebo-
controlled clinical trials of eflornithine alone in patients with elevated risk for developing certain 
forms of cancer.  In one trial of 81 men with a family history of prostate cancer, oral eflornithine 
alone (500 mgs per day for one year) reduced prostate polyamine contents, prostate volumes and 
prostate specific antigen (PSA) doubling times in men, compared to these same parameters in 
men taking placebo tablets.32  In a second study, 291 people with prior non-melanoma skin 
cancers were treated with eflornithine alone (500 mgs/m2 per day for 4-5 years).  In that study, the 
treatment with eflornithine was associated with a highly statistically significant reduction in 
metachronous basal cell skin cancers.33  Toxicities were rare in both of these studies, and 
consisted of infrequent clinically non-significant ototoxicity (meaning that the ototoxicity was not 
apparent to the patient and was only detectable by quantitative audiology testing).  A recent report 
of this eflornithine-related toxicity was reported in detail for a clinical trial evaluating the 
combination of eflornithine and sulindac.34  Clinical studies of eflornithine monotherapy have 
also been conducted with trial endpoints consisting of tissue polyamine contents.  These markers 
are dependent on ornithine decarboxylase (ODC), the eflornithine target protein.  Doses, such as 
those proposed by the sponsor, have been shown to reduce rectal mucosal tissue polyamine 
contents in a randomized placebo-controlled clinical trial.35  This marker study is especially 
relevant to patients with familial adenomatous polyposis (FAP), where the target tissues include 
intestinal and colonic mucosa. 
These clinical trial results are corroborated by clinical translational studies that are based on 
molecular epidemiology investigations.  Examples of this type of evidence include studies 
replicated by three independent groups in humans showing that a polymorphism affecting the 
expression of ODC, the eflornithine target protein, is highly associated with metachronous colon 
adenomas36,37 and sporadic breast cancer.38  In addition, two independent groups have reported 
that this same polymorphism is associated with prostate cancer39 and colon cancer survival.40 
2.3. Sulindac and Eflornithine; Colorectal Polyp Chemoprevention 
Meyskens and colleagues41 performed a Phase III double-blind trial involving resected sporadic 
adenoma patients treated with eflornithine (500 mg once a day) plus sulindac (150 mg once a day) 
compared to placebo/placebo that demonstrated a marked reduction (70%) of metachronous 
adenomas overall, 92% efficacy against advanced adenomas, and 95% efficacy in decreasing the 
risk of developing multiple adenomas compared to placebo.  Additionally, this combination 
regimen was generally well-tolerated. 
2.4. Biology Of Eflornithine 
Ornithine decarboxylase (ODC) is a target of the MYC oncogene and MYC transcription is 
suppressed by the APC gene product.42,43  ODC enzyme activity and polyamine contents are 
elevated in the apparently normal colonic mucosa of genotypic FAP patients, compared to FAP 
normal family members.44  These mechanistic and translational studies in humans indicate that 
ODC enzyme activity is up-regulated in the intestinal and colonic mucosa of patients with FAP. 
Eflornithine, also known as DFMO, is an enzyme-activated, irreversible inhibitor of ODC, an 
essential enzyme in the polyamine synthesis pathway.45  Studies in animal models of FAP 
indicate that eflornithine alone is effective in reducing the number of intestinal29 and colonic30 
tumors.  Eflornithine works in combination with the non-steroidal anti-inflammatory drug 
(NSAID) sulindac to further reduce tissue polyamine contents, as sulindac activates polyamine 
export mechanisms.46  Combination treatment with eflornithine and sulindac dramatically reduce 
the incidence of metachronous colorectal adenomas in patients with prior sporadic adenomas.41  
The majority of sporadic colorectal adenomas have mutations in APC or another gene in the 
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WNT signaling pathway.  In addition, combinations of eflornithine and NSAIDS have been 
shown to reduce the number of advanced adenomas by more than 90% in mouse models of 
FAP.31  These results provide strong rationale that patients with FAP should respond to this 
therapy. 
2.5. Rationale for Eflornithine Dose 
Prior pharmacokinetic (PK) studies had documented linearity of serum eflornithine levels with 
oral doses as low as 100 mg/m2/day.47  Dose-de-escalation studies identified oral daily doses of 
eflornithine, which irreversibly inhibits an essential enzyme in polyamine synthesis pathway, in 
the range of 200-400 mg/m2/day as a dose range that effectively reduced colorectal tissue 
polyamine contents.35  Oral doses in this range achieve serum concentrations that inhibit ornithine 
decarboxylase enzyme activity and polyamine synthesis in cell culture models.48  Based on these 
findings, a Phase III clinical trial of eflornithine combined with the non-steroidal anti-
inflammatory drug (NSAID) sulindac was conducted to evaluate the effect of this combination on 
the incidence of metachronous colorectal adenomas in patients with prior sporadic (non-genetic) 
colorectal polys.41  Based on an average adult body surface area of 1.6 m2,49 a dose of 500 mg 
oral daily dose of eflornithine was selected.  That study found that the combination therapy 
reduced total metachronous colorectal adenomas by 70%, and advanced/multiple metachronous 
colorectal adenomas by more than 90% while also reducing colorectal polyamine levels.41,50  No 
clinically significant toxicities were found to be statistically significant in that study.  Clinically 
non-significant ototoxicities were identified in less than 10% of patients, using quantitative 
audiology methods.34 
Recently, a clinical trial of eflornithine in combination with another NSAID for prevention of 
polyps in FAP patients has been reported.  Lynch et al.27,28 have reported in abstract form only 
results of a trial using 500 mg/m2/day eflornithine, rounded to the nearest 250 mg as 250 mg 
tablets were used in this study, combined with 400 mg BID celecoxib.  After correcting for body 
surface area, the average eflornithine dosage was three (3) 250 mg eflornithine tablets PO daily. 
While the effect of the combination was not different from celecoxib alone for the primary 
endpoint (duodenal and colorectal polyp number), the Lynch et al. study provided evidence for 
effectiveness of the combination versus celecoxib alone (statistically significant reductions in the 
secondary endpoints of polyp volume and global polyp burden).  No differences in toxicities, 
including ototoxicities, were observed between treatment arms in this study.  Another study in 
non-FAP patients but relevant to potential safety issues of the higher eflornithine dose has also 
been reported. Bailey and colleagues treated 291 patients with prior non-melanoma skin cancers 
with 500 mg/m2/day eflornithine for 4-5 years.33  One patient was reported to have subclinical 
ototoxicity in that study. Long-term follow-up of these patients found no increase in adverse 
events in the treatment group compared to placebo.33 
CPP FAP-310 will evaluate the eflornithine-sulindac combination in patients with FAP.  These 
patients are at elevated risk for intestinal and colorectal polyposis and other events related to the 
fact that they harbor germline mutations in the adenomatous polyposis coli (APC) tumor 
suppressor gene.  These genotypic FAP patients express higher levels of the eflornithine target 
gene, ornithine decarboxylase (ODC) and polyamine contents in apparently normal rectal mucosa 
than do non-genotypic familial controls.44  These levels are higher than those reported for patients 
with sporadic risk of colorectal cancer.51 
This study will use three (3) 250 mg eflornithine tablets daily in CPP FAP-310.  This is based on 
both safety and efficacy considerations.  Both the Lynch study (in FAP patients) and the Bailey 
study and others (in non-FAP patients) indicate safety of this eflornithine dose.33  The Lynch 
study provides evidence for efficacy of the higher eflornithine dose in FAP patients.27,28 
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2.6. Rationale for Sulindac Dose 
The dose of sulindac (daily oral dose of 150 mg) for this study was selected on knowledge of its 
physiology and evidence from preclinical and clinical studies. 
Experimental findings in human cell and mouse models indicate that sulindac and other NSAIDS 
activate polyamine catabolism and export.43  Thus, NSAID complement inhibitors of polyamine 
synthesis, like eflornithine, to reduce tissue polyamines.  Cell culture data demonstrated that 
sulindac metabolites reduce cell survival in vitro in a dose dependent manner at doses above 
150µM for 24 hour exposure times.52 
Eflornithine-sulindac combinations are potent inhibitors of intestinal carcinogenesis in mouse 
models,31 Figure 1. 
Figure 1 - Eflornithine-Sulindac Combinations Mouse Model 
 
Ignatenko, Nutrition & Cancer 2008 
 
A detailed review of the clinical pharmacokinetic of sulindac has been written53 and discusses 
long-term twice daily administration which results in accumulation of sulindac in the plasma, 
with the most common side effects being gastrointestinal and include pain, dyspepsia, nausea and 
gastrointestinal cramps. 
Clinical studies demonstrate that a range of orally administered sulindac can cause regression of 
colorectal adenomas.  In the review by Keller and Giardiello,54 sulindac doses from 100 – 300 mg 
administered once or twice daily have been shown to cause regression of colorectal adenomas in 
patients with Familial Adenomatous Polyposis (FAP).  Sulindac side effects noted in most of 
these studies were minimal although at the 300 mg/day of sulindac there may be an increase in 
cardiovascular risk in older high risk patients. 
The studies summarized in the Keller and Giardiello review provides the clinical data to support 
the use of low doses of sulindac are effective in reducing colorectal adenoma burden in FAP 
patients20,21,55,56,57,58 and that standard doses of sulindac (300-400 mg) are associated with 
significant toxicities.  Therefore a low dose of sulindac (150 mg) once per day was selected to be 
combined with eflornithine for treatment of patients with Familial Adenomatous Polyposis that 
are at high risk of developing rectal/intestinal cancer. 
Sulindac used off label is often the choice of clinicians treating FAP patients today.59  A 
commonly used sulindac dose in progressive rectal polyposis is 150 mg twice a day; after a few 
months and demonstration of regression, dosage may be reduced to 150 – 200 mg daily (Burt, 
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personal communication) or to 100 mg or lower.55  There is no direct comparison between 
sulindac dosages.  It is possible that the lower dose may be just as effective, but requires a longer 
time to regression. 
2.7. Summary of Known and Potential Risks 
2.7.1. Cardiac Risk 
A recent pooled-analysis of cardiovascular events in six clinical trials involving non-arthritis 
patients using celecoxib or placebo demonstrates that celecoxib is indeed associated with a dose-
dependent increased risk of cardiovascular events60 – high dose, long duration.  In this analysis, 
three baseline cardiovascular risk categories were proposed: low, moderate, and high, using 
clinical information obtained from routine medical assessment.  It was not known if these 
baseline cardiovascular risk assessments were associated with adverse cardiovascular events 
observed in the Phase III adenoma prevention trial of eflornithine plus sulindac (16 
cardiovascular events occurred in this arm) compared with placebo (9 cardiovascular events 
occurred in the placebo arm).  Therefore members of the UC-Irvine group61 performed detailed 
toxicity analysis of data from the Phase III eflornithine and sulindac versus placebo colorectal 
adenoma prevention trial, with a particular focus on baseline cardiovascular risk assessment.  
Cardiovascular toxicity outcomes were then reported with and without exclusion of high-risk 
patients from the analysis. 
In the original sample of 184 placebo and 191 eflornithine/sulindac patients, respectively, 
baseline cardiovascular risk scores were evenly distributed (low: 27% vs. 30%, moderate: 34% 
vs. 29%, high: 39% vs. 41%).  A greater number of patients with high cardiovascular risk at 
baseline experienced events in the eflornithine/sulindac arm (n=9) compared to placebo (n=3). 
When all patients with high baseline cardiovascular risk were excluded from the analysis, the 
number of cardiovascular events between the treatment (n=7) and placebo (n=6) arm was 
similar.61  These results suggest a possible interaction between eflornithine/sulindac treatment and 
baseline cardiovascular risk score on cardiovascular events.  Furthermore, they have implications 
for this FAP trial, and will affect eligibility (all patients with baseline high cardiovascular risk 
scores are not eligible for enrollment). 
2.7.2. Ototoxicity Risk 
In the Meyskens eflornithine/sulindac Phase III randomized placebo-controlled colon adenoma 
prevention trial41, no significant differences in hearing loss were noted compared to placebo; 
however, minor differences in hearing loss attributed to eflornithine plus sulindac combination 
were observed in detailed longitudinal analyses.34 
Temporary hearing loss is a known toxicity of treatment with eflornithine, thus a comprehensive 
approach was developed to analyze serial air conduction audiograms.  The generalized estimating 
equation method estimated the mean difference between treatment arms with regard to change in 
air conduction pure tone thresholds while accounting for within-subject correlation due to 
repeated measurements at frequencies.  Based on 290 subjects, there was an average difference of 
0.50 dB between subjects treated with eflornithine plus sulindac compared with those treated with 
placebo (95% confidence interval, −0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, 
and frequencies.  In the normal speech range of 500 to 3,000 Hz, an estimated difference of 0.99 
dB (−0.17 to 2.14 dB; P = 0.09) was detected.  Dose intensity did not add information to models. 
There were 14 of 151 (9.3%) in the sulindac/eflornithine group and 4 of 139 (2.9%) in the 
placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more 
consecutive frequencies across the entire range tested (P = 0.02).  Follow-up air conduction done 
at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds 
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of 1.08 dB (−0.81 to 2.96 dB; P = 0.26) between treatment arms.  There was no significant 
difference in the proportion of subjects in the sulindac plus eflornithine group who experienced 
clinically significant hearing loss compared with the placebo group.  The estimated attributable 
risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, −2.0% to 18.8%; 
P = 0.12).  However, there is only a <2 dB difference in mean threshold for patients treated with 
combination compared with those treated elsewhere (other trials) with placebo. 
The eflornithine dose used in the Meyskens 2008 trial of patients with sporadic risk of colorectal 
cancer was 500 mgs orally per day for three years in combination with 150 mg daily sulindac.41 
No difference in ototoxicity was observed between NSAID alone and combination eflornithine 
NSAID arms in the Lynch 2012 trial of FAP patients, using an eflornithine dose of 750 mgs oral 
daily.27,28  Bailey and colleagues have recently updated their study of patients with prior non-
melanoma skin cancer that were treated with 500 mg/m2 (also rounded to the nearest 250 mg as 
they used eflornithine tablets) for 4-5 years.62  The Bailey study demonstrated a significant (P < 
0.05) increase in uniformly transient audiometric (but not clinically detectable) hearing loss in 
participants on eflornithine.33  The follow-up study did not report any clinically significant 
differences in hearing as compared to the placebo group.62 
2.7.3. Sulindac Black Box Warning 
Sulindac like other NSAIDS carries a black box warning to consumers that it may cause increased 
risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke which can be 
fatal and an increased risk of serious gastrointestinal adverse events including bleeding, 
ulceration, and perforation of the stomach and intestines which can be fatal.  Refer to the Sulindac 
product insert (Watson Laboratories, Inc.)63 for further details.  The sulindac dose in this trial is 
one-half the recommended anti-inflammatory dose. 
3. TRIAL OBJECTIVES AND PURPOSE 
3.1. Rationale 
FAP is an orphan disease with multiple major unmet medical needs.  The current standard of 
practice involves prophylactic colectomy or proctocolectomy, followed by proctoscopic 
intervention with surgical polypectomies and/or laser/cautery ablation every 6 – 12 months for the 
rest of their lives.  Many patients have extensive polyposis at a young age, and require surgery 
prior to entering college.  Following prophylactic colon surgery, follow-up intervention by 
proctoscopy and upper GI endoscopy occurs every 6 – 12 months and subsequent surgical 
interventions are generally performed at experienced centers of excellence, requiring frequent, 
inconvenient and expensive travel.  The serial interventions are unpleasant, require dietary 
restriction and enemas.  During surgical procedures, some patients require general anesthesia and 
all patients require sedation.  Surgical procedures for large or multiple adenomas may involve 
snare cautery polypectomy or trans-anal excision and carry risk of bowel perforation and or 
subsequent bleeding.  The greater the frequency and extent of the surgical procedures, the greater 
the morbidity and associated costs.  Such interventions frequently result in reduced compliance 
with medical and surgical recommendations, with subsequent increased likelihood of the 
development of an interval cancer.  In addition, repeated cautery ablations lead to scarring and 
impaired bowel function over the years. 
A major goal of this program is to defer or obviate the need for additional surgical interventions 
in patients with familial adenomatous polyposis.  In patients treated with total abdominal 
colectomy with ileo-rectal anastomoses, the addition of sulindac combined with eflornithine has 
the potential to defer or eliminate the need for a complete proctectomy by polyp control which 
may result in less frequent and less extensive endoscopic or surgical interventions. 
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Prophylactic proctocolectomy does not “cure” patients with this genetic syndrome. FAP related 
disease remains a major problem in the residual rectum, pouch, anal transition zone, duodenum 
and desmoid formation; both can lead to major morbidity and mortality.  Surgical intervention is 
marginally effective, and there are no approved pharmacotherapeutic agents. 
Fifty percent (50%) of patients following total proctocolectomy with ileal pouch anal 
reconstruction develop adenomas in the pouch and require the same extensive follow-up 
evaluations and surgical treatments.  Almost all FAP patients are at risk for progressive duodenal 
adenomatous polyposis which can lead to extensive and frequent surgical endoscopic procedures 
and/or major surgical resections.  Duodenal polyposis is a major cause of morbidity, mortality, 
patient inconvenience and health care costs in FAP patients.  Ninety percent (90%) of patients 
with FAP develop duodenal polyposis2 for which there is no approved pharmacologic agent to 
control this disease.  Five (5) to 10% of patients have Spigelman Stage 4 on screening endoscopy; 
one-third of these patients develop cancer.  Of greater concern from the Bulow analysis is that 
52% of patients with duodenal polyposis who start with Stage 1, 2 or 3 will progress to Stage 4; 
the standard of care for Stage 4 is to consider some type of radical surgical intervention.  The 
complexity of managing such patients is well described in the definitive review of FAP 
management guidelines by Vasen and colleagues.10  The marginal benefit of endoscopic 
management of the duodenum is reviewed and tabulated (Table 4) in the paper by Brosens and 
colleagues.64  The data clearly demonstrate the need and potential efficacy of the pharmacologic 
control of duodenal polyposis; using the well-established Spigelman staging system as an 
objective indicator of polyp burden, along with pre-malignant histology.  The main determinant 
of Stage 4 is the presence of villous adenoma or high grade dysplasia on staging biopsies – 
objective measures of pre-cancerous risk.  
Increasing the time to clinically meaningful endpoints relevant to standard of care by increasing 
the time to important FAP-related events (FAP-related surgery, duodenal polyposis, cancer and 
death) are key factors in regard to the morbidity and mortality of this genetic disease.  FAP 
related surgical or clinical events in the rectum or pouch include surgery related to large or high 
risk adenomas or cancer; for FAP disease in the duodenum includes surgery for enlarging or high 
risk adenomas. 
After IRA surgery, pharmacologic control may minimize the need for additional rectal surgery 
(surgical snare excisions of polyps greater than 5 mm; surgical trans-anal excision of rectal 
polyps; proctectomy) and/or minimize development of pre-cancerous adenoma (dysplastic polyps, 
villous adenoma) and cancer.  After pouch surgery it may minimize need for additional surgery 
(surgical snare excision of polyps greater than 5 mm, surgical trans-anal excision of rectal polyps, 
pouch resection with ileostomy) and/or minimize development of pre-cancerous adenomas and 
cancer. 
In FAP patients with duodenal polyposis, pharmacologic control may suppress development of 
further polyposis, slow or prevent progression to Spigelman Stage 3 and 4 disease, minimize 
progression to dysplastic polyps or villous adenomas, minimize polyposis involving the Ampulla 
of Vater, minimize development of cancer or reduce the need for procedures such as snare 
polypectomy, submucosal excisions, trans-duodenal excisions, duodenectomy, Whipple 
(pancreatic duodenectomy) or related procedures. 
Pharmacologic control in FAP patients has major implications for clinical benefit to reduce the 
morbidity of the disease and thereby improve the current standard of care.  The use of low dose 
sulindac and CPP-1X may prolong the time to occurrence of clinically important FAP-related 
disease events (FAP related events include surgical procedures and progressive advanced 
intestinal polyposis). 
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In addition to the above, the combination drug regimen may provide additional clinical benefit by,  
 Deferring the initial prophylactic colectomy to a more “convenient time” such as after 
graduation from school or after childbirth. 
 Increasing the use of colectomy with ileal-rectal reconstruction rather than total 
proctocolectomy which results in improved quality of life in regard to bowel function and 
reduces the risk of loss of fertility in women. 
 Reducing the risk of progressive rectal/pouch polyposis that requires surgical intervention. 
 Reducing the risk of rectal stump/pouch-related post polypectomy scarring with loss of 
bowel function (absence of compliant rectal reservoir). 
 Deferring or obviate the need for pouch removal with need for permanent ileostomy 
stoma. 
 Deferring or obviate the need for surgical intervention for advanced duodenal polyposis 
with associated morbidity and mortality. 
 Improving health-related quality of life (HRQoL). 
 
3.2. Purpose 
This randomized, double-blind, phase III trial will compare the efficacy, safety and 
pharmacokinetics of the CPP-1X/sulindac combination versus CPP-1X and sulindac as single 
agents over a 24 month treatment period in patients with Familial Adenomatous Polyposis (FAP). 
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4. INVESTIGATIONAL PLAN 
4.1. Study Population 
 Diagnosis of phenotypic classical FAP, age ≥18 years, male and female gender.  Must be 
genotyped, with an APC mutation.  Refer to Section 6.1 for details. 
 Meets eligibility criteria for at least one FAP related disease group defined in Section 6.1. 
 If prior colorectal surgery, at least three years since colectomy with ileal-rectal 
anastomosis (IRA) or total proctocolectomy with ileal pouch-anal reconstruction (pouch). 
 Absence of major cardiac risk factors as defined in Section 6.2. 
 Absence of clinically significant hearing loss requiring a hearing aid. 
 Adequate laboratory studies (hematology, chemistry, and urinalysis) at study entry. 
4.2. Treatment 
 Experimental arm: 750 mg CPP-1X, and 150 mg sulindac 
 Comparator arms:  
o CPP-1X placebo with sulindac (150 mg) 
o CPP-1X (750 mg) with sulindac placebo 
 Treatment is administered as four tablets taken once daily with food (same time of day, 
preferably in the morning), for up to 24 months. 
4.3. Randomization 
A total of 150 eligible patients will be enrolled in this study.  Patients will be randomized to one 
of three treatment groups in equal proportions (i.e., 1:1:1 randomization): 1) CPP-1X plus 
sulindac 2) CPP-1X - placebo plus sulindac, 3) CPP-1X plus sulindac placebo. 
A stratified randomization procedure will be used with stratification based on FAP-related time-
to-first-event prognosis.  The event prognosis groups are represented by 1) best (i.e., longest 
projected time to first FAP-related event) - rectal/pouch polyposis, 2) intermediate - duodenal 
polyposis, and 3) worst - pre-colectomy.  If a subject has two or more of these disease sites, the 
most severe prognosis stratum will be assigned for randomization (e.g. worst > intermediate > 
best).  Since an individual may have more than one disease site involved, the trial will assess time 
to any defined FAP-related event in the patient as a whole. In order to minimize potential 
treatment arm imbalance a centralized randomization process will be used to balance among 
treatment groups within prognostic strata. 
4.4. Primary Outcome 
The primary objective of this trial is to determine whether the combination of CPP-1X plus 
sulindac is superior to either treatment individually, in delaying time to the first occurrence of any 
FAP-related event in the patient as a whole.  This includes: 1) FAP related excisional intervention 
involving the colon, rectum, pouch, duodenum and/or 2) clinically important events which 
includes progression to more advanced duodenal polyposis, cancer or death.  Section 8.2.9 
provides complete detail. 
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4.5. Secondary Outcomes 
Secondary efficacy outcomes in this study will include the following: 
1. To evaluate the potentially effect modifying properties of: 
a. Presence or absence of an ODC polymorphism 
b. The excretion of 4 urinary polyamines (diacetylspermine, n1-acetylspermidine, n8-
acetylspermidine and decarboxylated SAM) 
Other secondary outcomes in this study include the following: 
1. Safety outcomes will be assessed by summary analysis of adverse events and clinical 
laboratory abnormalities. 
2. Pharmacokinetic outcomes will be assessed by evaluating the population 
pharmacokinetics for CPP-1X (eflornithine) and sulindac. 
3. Evaluate tissue and dietary polyamine levels. 
4. Patient reported quality of life will be evaluated using HRQoL and patient utilities. 
5. A pilot evaluation of an FAP-specific assessment, the time to the first FAP-related 
beneficent event, will be studied.  This will involve analyzing the endoscopic polyposis 
data for regression of pre-colectomy colorectal polyposis, rectal/pouch polyposis, and 
regression of duodenal polyposis. 
6. An analysis of the components and subgroups included in the primary analysis, and their 
contribution to the primary outcome. 
4.6. Population Pharmacokinetics for CPP-1X/Sulindac 
All subjects consented, enrolled, and randomized in this study will have pharmacokinetic samples 
drawn at their scheduled 3 month visit.  All patients will have samples drawn on the same 
schedule regardless of treatment arm assigned.  The samples will be obtained before first morning 
dose, then four additional samples over the following eight hours. 
4.7. Polyamine Analysis 
At the scheduled colonoscopy/proctoscopy, a sample of normal rectal mucosa and a random urine 
sample will be obtained at baseline, 6 months and 24 months to assess tissue and urine polyamine 
levels.  Sample handling and processing procedures will be provided in the study manual, are 
described here briefly. 
Biospecimen collection: Normal (tumor-free) rectal mucosal biopsies will be obtained during 
endoscopy procedures.  Biopsy samples will be placed in separate standard cryotube tubes and 
stored in a -70 – 800C freezer.  Random urine samples (15 mL minimum) will be collected and 
stored in a -70 – 800C freezer. 
Polyamine content: Polyamine analysis will be performed as described previously.35  Briefly, 
frozen tissue samples will be homogenized and extracted in 0.2 N perchloric acid.  Urine samples 
will be adjusted to 0.2 N perchloric acid.  Polyamine (spermidine, spermine, and putrescine) 
content will be measured using reverse-phase, ion-paired high performance liquid 
chromatography.  Protein contents will be determined using the bicinchoninic acid (BCA) protein 
assay (Thermo Fisher Scientific, Rockford, IL).  The spermidine-to-spermine ratio (Spd:Spm) 
will be assessed in our analyses to minimize the influence of assay variability.35,65 
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Dietary polyamines: Data will be collected using the Fred Hutchinson Cancer Center food 
frequency questionnaire and will be analyzed using a polyamine database.  Average daily 
consumption of putrescine, spermidine, and spermine will be calculated.66  
4.8. Pharmacogenetic and Genetic Analysis 
A peripheral blood sample will be collected from enrolled patients at baseline for subsequent 
correlative genomic studies relevant to this disease and in the event treatment-related adverse 
events are discovered during the trial. Sample handling and processing procedures, which will be 
provided in the study manual, are described here briefly. 
DNA extraction and genotyping. DNA will extracted from peripheral blood samples using the 
QIAGEN QIAamp DNA Midi or Mini Kits (Qiagen), following the manufacturer's instructions. 
Genotyping of the ODC1 (National Center for Biotechnology Information SNP database ID 
rs2302615) +316 SNP will be conducted using oligonucleotide primers designed to amplify a 
172-bp fragment containing the polymorphic base at +316 (Applied Biosystems).  Allele-specific 
TaqMan probes will be synthesized with different 5′ labels (6-carboxyflourescein or VIC) and the 
same 3′ quencher dye (6-carboxytetramethylrhodamine).  Each PCR reaction (5 μL total) will 
contain 10 ng of participant DNA, 30 pmol of each primer, 12.5 pmol of each TaqMan probe, and 
1× TaqMan Universal PCR Master Mix (Applied Biosystems). 
4.9. Quality of Life 
Assessment of Health-Related Quality of Life (HRQoL) is to better understand and quantify the 
impact of each treatment arm on FAP-related physical and emotional symptoms as well as FAP-
related surgical sequelae.  Specifically, postponing surgery because of reduction of polyps could 
lead to both symptomatic relief as well as reduced stress and worry about cancer, future surgery 
and/or suffering of FAP-related medical and surgical symptoms.  As such, several well-accepted 
and previously published questionnaires have been selected for use in the CPP FAP-310 trial. 
These include the EORTC core questionnaire, QLQ-C30,67 the GI-specific sub-module, QLQ-
CR29,68 and the EQ-5D health utilities index.69,70  These instruments have all been previously 
used in gastrointestinal/colorectal clinical trials and have been validated and translated to ensure 
appropriate cultural/linguistic adaptation suitable for a multi-center, international clinical trial. 
Also being used is a modified version of the Cancer Worry Scale.71 
5. STUDY DRUG INFORMATION 
5.1. CPP-1X [Eflornithine HCl] 
Eflornithine Hydrochloride, also known as DFMO, is an inhibitor of ornithine decarboxylase 
(ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride 
monohydrate.  The clinical dosage form is a yellow, film-coated convex tablet containing 250 mg 
of eflornithine HCl, monohydrate.  Table 1 lists the composition of the 250 mg CPP-1X- tablets.  
The tablets (CPP-1X and CPP-1X-placebo) are packaged and sealed in opaque white HDPE 
bottles, and each bottle contains 100 tablets.  The CPP-1X and CPP-1X placebo tablets are 
supplied by Sanofi-Aventis, Canada, Inc.  
The tablets are to be stored at room temperature (20-250C). 
Study patients will be instructed to take three (3) tablets by mouth once daily with food. 
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Table 1 - Composition of CPP-1X (Eflornithine HCl), 250 mg Tablets 
Ingredients Unit Formula 










Microcrystalline Cellulose 192.85  
 
NF 
Starch 1500 53.40  NF 
Colloidal Silicon Dioxide 1.25 NF 
Magnesium Stearate 2.50 NF 
Total Theoretical Weight 500  -- 
5.1.1. Eflornithine Clinical Pharmacology 
Eflornithine hydrochloride is a member of the following drug classes: 1) inhibitor of ornithine 
decarboxylase (ODC), 2) hirsutism (excess hair growth) retardant, and 3) antiprotozoals. 
Eflornithine is FDA approved as a cream for treatment of female hirsutism, and in intravenous 
form for treatment of trypanosomiasis.  The oral tablet form is not available outside of the clinical 
trial setting in the U.S., and the formulation used in this trial is similar to that used in the Phase III 
colon adenoma clinical trial in combination with sulindac.41 
Contraindications:  Prior hypersensitivity to eflornithine.  Precaution in patients with bone 
marrow suppression or hematologic disorders. 
Common side effects:  Low platelet count was dose-limiting after administration of intravenous 
eflornithine at high doses (up to 3 gm/m2 every 6 hours for 28 days).  Gastrointestinal upset 
(nausea, vomiting [5%], diarrhea [38%]) have also been reported after these high doses of 
eflornithine.  The primary side effect of low doses of eflornithine (750 mg per day for 3-5 years) 
is mild ototoxicity with 45.2% of eflornithine subjects versus 33.6% of placebo subjects having a 
≥15 dB hearing loss at two adjacent frequencies (p=0.07).  The observed audiometric 
abnormalities were usually reversible; 19% and 18% of eflornithine and placebo subjects had 
persistent abnormal audiograms 6 months after stopping study drug. 33  
Infrequent side effects:  Hearing loss/change by audiometry testing has been reported in 8.4% of 
patients on high dose eflornithine.  Rash and alopecia have been reported in 3% of patients.  
Anorexia and abdominal pain have been reported in 2% of patients treated with eflornithine. 
Rare but serious side effects include dizziness (1%), headaches (2%), and seizures (8%) have 
been reported in patients on intravenous eflornithine.  Myelosuppression (including leukopenia, 
[37%], anemia [55%], and thrombocytopenia [14%]) has been reported at high intravenous doses, 
but does not usually occur at the low dose (750 mg) utilized in this study. 33 
Pregnancy and Lactation:  Pregnancy Category C. It is unknown if eflornithine crosses the 
placenta.  Case reports in humans along with animal studies (mice, rats) indicate potential for 
fetotoxicity.  Experiments in rodents indicate that eflornithine blocks yolk sac formation and 
trophoblast differentiation, affecting processes such as vasculogenesis and steroidgenesis.72  The 
World Health Organization has not determined a breast feeding rating for eflornithine due to 
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insufficient data.  The Thompson lactation rating is that infant risk cannot be ruled out.  No 
studies investigating the safety of lactation after eflornithine administration have been conducted, 
nor are there data to determine drug levels in breast milk after drug administration.  
5.1.2. CPP-1X (Eflornithine) Pharmacokinetics 
The dose of CPP-1X (daily oral dose of 750 mg for an adult) for CPP-310 was selected based 
upon its known pharmacology and evidence from clinical studies.  
Time to peak concentration for oral eflornithine is 4-6 hours.   
Absorption: for the oral solution is 54-58% and is unaffected by feeding status.   
Distribution: no protein binding sites, crosses blood-brain barrier, volume of distribution is 0.3-
0.35 liters/kg. 
Metabolism: urinary recovery of unchanged drug as eflornithine is 86% and essentially not 
metabolized. 
Excretion: renal excretion. Elimination half-life: 3-3.5 hours but once daily oral dosing of 500-
750 mg is sufficient to maintain efficacy as indicated in several clinical trials. 
Eflornithine pharmacokinetic references include, Abeloff, et al., 1984,73 Haegele et al., 1981,74 
Meyskens, et al., 1998,35 and Meyskens et al., 2008.41 
5.2. Sulindac 
Sulindac is a non-steroidal, anti-inflammatory indene derivative designated chemically as (Z)-5-
fluoro-2-methyl-1- [[p- (methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid.  It is not a 
salicylate, pyrazolone or propionic acid derivative.  Sulindac, a yellow crystalline compound, is a 
weak organic acid practically insoluble in water below pH 4.5, but very soluble as the sodium salt 
or in buffers of pH 6 or higher.  Table 2 lists the composition of the 150 mg tablets.  Sulindac 
tablets (USP) 150 mg tablets are round yellow tablets imprinted DAN and 5661 and are supplied 
in bottles of 100.  Dispense in a well-closed container with child-resistant closure.  Sulindac and 
sulindac placebo will be supplied by Watson Pharmaceutical, Inc., Corona, CA. 
The tablets are to be stored at room temperature (20-250C). 
Study patients will be instructed to take one (1) tablet by mouth daily with food. 
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Table 2 - Composition of Sulindac 150 mg Tablets 
Ingredients Unit Formula 









Microcrystalline Cellulose 80.63  NF 
Starch 18 NF 
Purified Water * USP 
Stearic Acid 3.82 NF 
Magnesium Stearate 2.55 NF 
Total Theoretical Weight 255  -- 
* = Used in manufacturing process, but does not appear in the final product. 
 
5.2.1. Sulindac Clinical Pharmacology 
Sulindac is a nonsteroidal anti-inflammatory analgesic that inhibits both cyclooxygenase COX I 
and COX II. 
Contraindications:  Treatment of post-operative pain after coronary artery bypass grafting (risk 
of stroke, myocardial infarction).  Hypersensitivity to sulindac or excipient byproducts. 
Hypersensitivity to aspirin or other NSAIDs.  
Common side effects:  As with other NSAIDs, sulindac can produce gastric pain (10%), 
constipation (3-9%), diarrhea (3-9%), dyspepsia (3-9%), and nausea (3-9%).  Dizziness (3-9%), 
headache (3-9%), and rash (3-9%) have also been reported.  Additionally, this side effect is seen 
most often in patients who have had prior ulcers or who are taking anticoagulants or steroids or 
who have abnormal renal or liver functions; potential patients who have these parameters will not 
be eligible for study entry.  At therapeutic doses, gastrointestinal pain occurs in 10%. 
Infrequent side effects:  Flatulence, cramping, anorexia, vomiting, pruritus, nervousness, 
tinnitus, and edema (1%-3%) have been reported.  Gastrointestinal ulcers have been reported in 2-
4% of patients taking NSAIDs.  Bleeding may occur due to platelet inhibition. Gastrointestinal 
ulceration in general is dose-related (the dose used in the current trial will be 50% that typically 
used).  Its potential interaction with eflornithine effect (i.e., possibly delay in wound healing) is 
unknown. 
Rare but serious side effects (≥ 1%):  Hypertension, arrhythmias, thrombotic events, Stevens-
Johnson syndrome and Toxic Epidermal Necrolysis (TEN) have been reported for various 
NSAIDs at low frequency.  Hyperkalemia, esophagitis, gastrointestinal hemorrhage, 
gastrointestinal perforation, and pancreatitis have been reported for NSAIDs including sulindac.  
Anemia, agranulocytosis, leucopenia, thrombocytopenia, aplastic anemia (rare), nephrotoxicity, 
hyperthermia, pneumonitis, bronchospasm, and hepatotoxicity have been reported after sulindac 
use.  Blurred vision, alopecia, anaphylaxis, bitter taste, aseptic meningitis, bone marrow 
suppression, and seizures have been reported. 
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Pregnancy and Lactation:  Pregnancy Category C. Sulindac crosses the placenta.  There have been 
no reports of congenital abnormalities caused by maternal use of sulindac.  However, sulindac 
should be avoided in late pregnancy because of the effects of prostaglandin inhibition (closure of 
the ductus arteriousus) on the fetal cardiovascular system.  It is not known whether this drug is 
excreted in human milk; however, it is secreted in the milk of lactating rats.  Because many drugs 
are excreted in human milk and because of the potential for serious adverse reactions in nursing 
infants from sulindac, a decision should be made whether to discontinue nursing or discontinue 
the drug, taking into account the importance of the drug to the mother. Refer to the Sulindac 
product insert (Watson Laboratories, Inc.)63 for additional information. 
5.2.2. Sulindac Pharmacokinetics 
Refer to the Sulindac product insert (Watson Laboratories, Inc.)63 for additional information. 
Absorption:  90% bioavailability; sulindac must be metabolized to the sulfide metabolite before it 
is pharmacologically active. 
Distribution: Sulindac and its sulfone and sulfide metabolites are 93.1, 95.4 and 97.9% bound to 
plasma proteins.  Sulindac penetrates the blood-brain barrier and placental barriers. 
Metabolism: Sulindac and its sulfone metabolite undergo extensive enterohepatic circulation 
relative to the sulfide metabolite in animals. 
Kinetics:  Tmax for sulindac (150 mg tablet) is 3.9 ± 2.3 hours, and 5.85±4.5 hours for the sulfone 
metabolite and 6.2 ± 3.1 hours for the sulfide metabolite. 
Elimination: Approximately 50% of the administered dose of sulindac is excreted in the urine 
with the conjugated sulfone metabolite accounting for the major portion.  Less than 1% of the 
administered dose of sulindac appears in the urine as the sulfide metabolite.  Approximately 25% 
is found in the feces, primarily as the sulfone and sulfide metabolites.  The mean effective half-
life (T1/2) for sulindac is 7.8 hours and 16.4 hours for the active sulfide metabolite. 
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6. SUBJECT RECRUITMENT, INCLUSION AND EXCLUSION CRITERIA 
Subjects (male and female), ≥ 18 years will be recruited who meet the inclusion criteria below.  
Women and minorities will be represented according to their distribution in the Investigator’s 
clinical population. 
6.1. Patient Characteristics for Eligibility, Inclusion Criteria 
1. Diagnosis of phenotypic classical FAP with disease involvement of the duodenum and/or 
colon/rectum/pouch. 
a. Genotype: APC mutation (with or without family history) required  
b. Classical FAP Phenotype: 100’s to 1,000’s of colorectal adenomatous polyps, usually 
appearing in teenage years 
2. UGI endoscopy/LGI endoscopy (proctoscopy/colonoscopy) performed within 30 days of 
randomization.  
3. Patients with an intact colon/rectum, except for clinical polyposis, and prophylactic surgery is 
being considered as a stratification site. 
4. Rectal/pouch polyposis as a stratification site as follows: 
4.a  At least three years since colectomy with IRA/proctocolectomy with pouch, and 
demonstrating polyposis as defined by Stage 1, 2, 3, of the proposed InSiGHT 2011 
Staging System (Appendix B) and summarized as follows: 
Stage 1:  10-25 polyps, all < 5 mm 
Stage 2:  10-25 polyps, at least one > 1 cm 
Stage 3:  >25 polyps amenable to complete removal, or any incompletely removed sessile 
polyp, or any evidence of high grade dysplasia, even if completely removed. 
[Note: For staging purposes only.] 
4.b  For all subjects, any rectal/pouch polyps > 5 mm must be excised at “baseline”. 
5. Duodenal polyposis as a stratification site; one or more of the following: 
5.a  Current Spigelman Stage 3 or 4. (Refer to Appendix A for Modified Spigelman Score 
and Classification table). 
5.b  Prior surgical endoscopic intervention within the past six months for Spigelman Stage 3 
or 4 that may have been down staged to Spigelman 1 or 2. 
6. Hematopoietic Status (within 30 days prior to randomization): 
a) No significant hematologic abnormalities 
b) WBC at least 3,000/mm3  
c) Platelet count at least 100,000/mm3 
d) Hemoglobin at least 10.0 g/dL 
e) No history of clinical coagulopathy 
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7. Hepatic Status (within 30 days prior to randomization): 
a) Bilirubin no greater than 1.5 times ULN 
b) AST and ALT no greater than 1.5 times ULN 
c) Alkaline phosphatase no greater than 1.5 times ULN 
8. Renal Status (within 30 days prior to randomization): 
a) Creatinine no greater than 1.5 times ULN 
9. Hearing: 
a) No clinically significant hearing loss, defined in Section 6.2, number 9. 
10. If female, neither pregnant nor lactating.  
11. Negative pregnancy test if female of child-bearing potential.  Fertile patients must use 
effective contraception*. 
12. Absence of gross blood in stool; red blood on toilet paper only acceptable.  
13. No discrete gastric or duodenal ulcer greater than 5 mm within the past year except 
Helicobacter pylori-related peptic ulcer disease treated with antibiotics. 
14. No invasive malignancy within the past 5 years except resected non-melanomatous skin 
cancer, papillary thyroid cancer, or precancerous cervical dysplasia. 
15. No other significant medical or psychiatric problems that would preclude study participation 
or interfere with capacity to give informed consent. 
16. Use of 81 mg daily aspirin or 650 mg aspirin not more than once a week are eligible. 
17. No concurrent warfarin, fluconazole, lithium, Pradaxa® or other direct thrombin inhibitors, 
Plavix®, cyclosporine, other NSAIDs (such as ibuprofen, aspirin, diflunisal), diuretics 
(furosemide and thiazides), DMSO, methotrexate, probenecid, propoxyphene hydrochloride, 
Tylenol® (acetaminophen) preparations containing aspirin or cytotoxic chemotherapy drugs. 
18. Willingness to forego concurrent use of supplements containing omega-3 fatty acids, 
corticosteroids, non-steroidal anti-inflammatory drugs or other FAP directed drug therapy. 
19. Able to provide informed consent and follow protocol requirements. 
*Effective contraception methods include the established use of oral, injected or implanted hormonal methods of 
contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods of 
contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal 
foam/gel/film/cream/suppository, male sterilization (with the appropriate post-vasectomy documentation of the 
absence of sperm in the ejaculate), or true abstinence, when this is in line with the preferred and usual lifestyle of 
the subject.  Periodic abstinence (calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are 
not acceptable methods of contraception).  Contraceptives should be used during the study and for at least 2 weeks 
after study treatment.  
 
Male subjects (including men who have had vasectomies) whose partners are pregnant should use condoms for the 
duration of the study and for at least 2 weeks afterwards. 
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6.2. Exclusion Criteria 
1. Prior pelvic irradiation. 
2. Patients receiving corticosteroids within 30 days of enrollment. 
3. Treatment with other investigational agents in the prior 4 weeks. 
4. Use of other non-steroidal anti-inflammatory drugs (such as ibuprofen) exceeding 4 days 
per month, in the prior 6 weeks. 
5. Regular use of aspirin in excess of 650 mg per week. 
6. Treatment with other FAP directed drug therapy (including sulindac or celecoxib, fish oil) 
within 12 weeks of study enrollment. 
7. Hypersensitivity to cyclooxygenase-2 inhibitors, sulfonamides, NSAIDs, or salicylates; 
NSAID associated symptoms of gastritis. 
8. Patients at high cardiovascular disease risk are not eligible for study participation as 
defined below.  
“High risk” for cardiovascular disease is defined as: 
 Clinical diabetes mellitus (Type I or II) requiring glycemic medications, or 
 Prior personal history of cardiovascular disease – heart attack, stroke, transient 
ischemic attack, or symptomatic peripheral vascular disease, or two of the 
following: 
o Taking anti-hypertensive medication 
o Taking lipid lowering medication 
o Current cigarette smoker 
9. Patients with significant hearing loss are not eligible for study participation as defined 
below. 
 Hearing loss that affects everyday life and/or for which a hearing aid is required. 
10. Colon/rectum/pouch with high grade dysplasia or cancer on biopsy or a large polyp (>1 
cm) not amenable to complete removal. 
11. Duodenal cancer on biopsy. 
12. Intra-abdominal desmoid disease, stage III or IV (staging criteria in Appendix C).9,75 
13. Inability to provide informed consent. 
6.3. Replacements and Screen Failures 
Randomized subjects who discontinue early for any reason will NOT be replaced and will not be 
permitted to reenter the study. 
Previously screened subjects may be rescreened for enrollment in the study with prior approval 
from the Medical Monitor.  Subjects who are rescreened 30 days after signing the informed 
consent will need to be re-consented and have all screening procedures repeated to determined 
eligibility. 
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Any screen failed subject based on history, physical exam or laboratory values or endoscopy 
procedures will need to have a screen failure case report form completed by the Investigator or 
study coordinator and available for review by the study Sponsor. 
7. RANDOMIZATION AND STRATIFICATION 
Patients eligible for this trial will be randomized into one of three treatment groups 1:1:1 (CPP-
1X plus sulindac: CPP-1X placebo plus sulindac: CPP-1X plus sulindac placebo) and stratified by 
FAP-related event prognosis using an interactive web-based system as described below.  Patients 
will be randomized no more than 5 working days prior to their scheduled start date of treatment. 
A stratified randomization procedure will be used with stratification based on FAP-related time-
to-first-event prognosis.  The event prognosis groups are represented by 1) best (i.e., longest 
projected time to first FAP-related event) - rectal/pouch polyposis, 2) intermediate - duodenal 
polyposis and 3) worst - pre-colectomy.  If a subject has two or more of these disease sites, the 
most severe prognosis stratum will be assigned for randomization (e.g. worst > intermediate > 
best).  Since an individual may have more than one disease site involved, the trial will assess time 
to any defined FAP-related event in the patient as a whole.  In order to minimize potential 
treatment arm imbalance a centralized randomization process will be used to balance among 
treatment groups within prognostic strata. 
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8. SPECIFIC TREATMENT PLAN AND SUBJECT MANAGEMENT 
8.1. Patient Assessments and Treatment Schedule 
The clinical study schedule/schema (Table 3) provides the schedule for screening, on-study visits and follow-up. 













(6 mos ± 2 wks) 
Months 7 -11 
 
Month 12 









24 mo. ± 2 wks
21
 
FU 30 days 
Off-Study 
± 1 wk 
FU Months 
2-6 Off 
Study ± 1 wk 
Informed Consent X             
Polyposis History1 X             
Medical History X  X  X  X  X  X X14  
GI Symptoms X  X  X  X  X  X X14  
Surgical History X           X14 X19 
Concomitant Medications X X13 X X13 X X13 X X13 X X13 X X14  
Drug Compliance Review  X13 X X13 X X13 X X13 X X13 X   
Adverse Events  X13 X X13 X X13 X X13 X X13 X X14  
Chemistry Panel2 X  X  X  X  X  X   
CBC3 X  X  X  X  X  X   
Urinalysis X  X  X  X  X  X   
Vital Signs4 X  X  X  X  X  X   
Physical Exam5 X  X  X  X  X  X   
Audiometry6 X      X    X   
EKG X  X22  X  X  X  X   
Serum Preg. Test7 X  X  X  X  X  X   
Dispense Medications8  X8 X  X X8 X X8 X X8    
Patient Diary9  X X  X X X X X X    
Food Frequency 
Questionnaire15 
X      X    X   
LGI Endoscopy10 X    X  X  X  X   
Normal Mucosa Biopsy11 
X    X      X 
  
UGI Endoscopy12 X    X  X  X  X   
Pharmacokinetics 
Blood Samples   X
16           
Pharmacogenomic Blood 
Sample X
17             
Polyamine Urine 
Samples18 X    X      X 
  
HRQoL surveys 20 X  X  X  X  X  X   
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FAP Study Schedule Footnotes 
Note: Shaded columns in patient schedule (Table 3) are protocol required in person visits. 
1Polyposis history: Family history, age onset, physician or self-prescribed NSAIDs for polyp control, frequency and extent of post-colectomy interventions; 
specific findings during the past two endoscopies. 
2Chemistry panel includes – electrolytes (Na, K, CL, CO2), liver function tests (AST, ALT, Alkaline phosphatase, bilirubin), BUN, creatinine. 
3CBC – hemoglobin, hematocrit, WBC, platelet count, automated differential. 
4Vital signs – temperature, blood pressure, pulse, respirations, body mass index calculation. 
5Complete Physical Exam – including height (baseline only), weight, vital signs. 
6Audiometry will need to be done using air conduction methodology. 
7Women of child-bearing bearing potential with no prior hysterectomy and pre-menopausal must use an effective contraception method and will have a serum 
pregnancy (HCG) done every 3 months while on study treatment (see Section 6.1, #11). 
8Medications and patient diaries will be dispensed to the subject every 3 months (month 0, 3, 6, 9, 12, 15, 18, and 21) in person or by special arrangements. 
9Patients are to record in their 3-month diaries: medication use, presence of symptoms, and a self-assessment of presence of gross blood or melena. 
10Lower GI (LGI) endoscopy (proctoscopy or colonoscopy) will be done on all randomized patients. 
11During the LGI procedure, normal mucosal biopsy for polyamine analysis will be obtained at; screening/baseline, 6 months and 24 months/EOT. 
12On-study Upper GI (UGI) endoscopy will be done on all randomized patients. 
13Monthly (± 7 days) phone/email contact by the study coordinator to follow-up on medication/drug compliance review, concomitant medications, and 
adverse events. 
14The follow-up will be done as phone call to the patient to review medical history, surgical history for any FAP-related surgical events, concomitant 
medications and adverse events. 
15A food frequency recall questionnaire will be administered at the screening/baseline, 12 and 24 month/EOT visits. 
16A peripheral blood sample (5 mL, lithium heparin) will be collected at each of the following time points:  pre-dose and 1, 2, 4 and 8 hours post dose. 
17A peripheral blood sample (10 mL, EDTA) will be collected at screening/baseline for pharmacogenomic analysis. 
18A random urine sample (15 mL minimum) will be collected at the screening/baseline, 12 and 24 month visits for polyamine analysis. 
19The follow-up will be done monthly as phone call to review endoscopic excisional procedures/surgical history for any FAP-related surgical events. 
20HRQoL surveys will include EORTC QLQ-C30 and QLQ-CR29, EQ-5D health utility index assessment, and modified Cancer Worry Scale. They will be 
collected at screening/baseline, 3, 6, 12, 18, and 24 month/EOT visits. 
21EOT visit will occur within 2 weeks off study treatment for any cause including completion of treatment at 24 months. 
22EKGs will need to be obtained on the day PK samples are collected at pre-dosing, and after the 4 hr PK sample has been obtained. 
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8.2. Patient Accrual Logistics 
8.2.1. Initial Visit – Determining Potential Eligibility 
Based on general medical and polyposis history, prior surgery, cardiac risk assessment and 
clinical hearing loss, current aspirin and NSAID use - patients will be determined to be 
potentially eligible for this trial.  After appropriate discussions, written informed consent will be 
obtained. 
8.2.2. Subsequent Screening for Eligibility 
If the patient has not already been genotyped for FAP, genetic analysis will be performed to 
confirm the presence of an APC mutation.  
Lower GI Endoscopy:  Patients will be evaluated via colonoscopy, flexible or rigid procto-
sigmoidoscopy during the screening phase.  Biopsies, ablations, and snare excisions at baseline 
are performed per the clinician’s standard of care.  If considered eligible based on inclusion 
criteria, a grossly normal mucosa biopsy will be obtained for baseline polyamine measurement.  
Still and video documentation of the colon (vide infra) or the residual rectum or entire pouch will 
also be obtained for archiving.  Polyp size will be determined by visual comparison with a 
biopsy forceps that can measure 5.0 – 5.5 mm in the fully open position.  Procedural details are 
provided in the Investigator Manual.  All randomized patients will have baseline and on-study 
lower GI endoscopy procedures as part of this trial. 
Upper GI Endoscopy:  The duodenum will be evaluated by forward-viewing and/or side-viewing 
gastroscopes (with still and video documentation with closed and open biopsy forceps near 
mucosa).  Procedural details are provided in the Investigator Manual.  All randomized patients 
will have baseline and on-study UGI endoscopy as part of this trial. 
A complete physical exam including height, weight and vital signs will be performed. 
Baseline blood tests within 30 days of randomization: Per eligibility criteria – CBC, chemistry 
profile, urinalysis, and a sample for pharmacogenomic and genetic analysis. 
In order to ascertain how many patients with clinical FAP have baseline hearing deficits, patients 
meeting all the criteria for this trial will undergo air conduction audiometry.  Results will not be 
relevant to eligibility. 
8.2.3. Final Eligibility and Potential Screen Failures 
If the patient has signed the informed consent, and all eligibility criteria are met, the subject will 
be randomized.  Screening UGI, LGI and rectal/pouch images will be submitted to the central 
imaging laboratory for central collection and archiving.  Quality of life questionnaires (EORTC 
QLQ-C30, EORTC QLQ-CR29, EQ-5D, and the modified Cancer Worry Scale) will be provided 
to the subject to complete to obtain baseline values.  A food frequency questionnaire will be 
provided to the subject to complete for baseline values at North American (United States and 
Canada) sites only. 
The patient may be a screen failure based on history, physical exam, genetic assessment, or other 
laboratory values.  A screen failure case report form will need to be completed by the 
Investigator or study coordinator and available for review by the study Sponsor.  
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8.2.4. Drug Administration 
After confirming eligibility, the patient will be randomized to one of the three treatment arms 
(Table 4).  Randomization should be performed within 5 working days prior to the initiation of 
treatment.  Specific procedures for randomization will be included in the study manual. 
Table 4 - Study Medication Schedule1 
AGENT and DOSE ROUTE RX INTERVAL 
CPP-1X 750 mg & Sulindac 150 mg Oral Daily for 24 months 
OR   
CPP-1X placebo & Sulindac 150 mg Oral Daily for 24 months 
OR   
CPP-1X 750 mg & Sulindac placebo Oral Daily for 24 months 
1The medications are to be taken at approximately the same time daily with food. 
* Each CPP-1X tablet = 250 mg;  ** Each sulindac tablet = 150 mg 
The study medication and patient diaries will be dispensed to the patient at the initial treatment 
visit and at 3 month intervals thereafter in person or by special arrangement.  Subjects will be 
instructed to take their medication with food at approximately the same time each day, preferably 
in the morning.  The subject will be instructed to record dosing compliance on a weekly basis in 
the patient diary. 
Based on published data utilized to project event rates, patients will receive treatment for 24 
months.  However, interim analyses prescribed by the Data Monitoring Committee charter may 
result in earlier stopping based on futility or toxicity.  
8.2.5. Follow-up During Treatment Intervention 
Refer to Section 8.1, Table 3 for patient assessments and the treatment schedule for screening, 
on-study, end of treatment and follow-up visits. 
During the 24 month drug intervention, patients will be followed monthly by phone interview for 
assessment of possible toxicities and medication compliance.  A diary of compliance and 
symptoms will be maintained by patients and reviewed during the next office visit.  At each 
interval assessment visit (month 3, 6, 12, 18, and 24), until the subject completes 24 months of 
treatment or the subject comes off study treatment additional drug supplies and patient diaries 
will be provided. 
At the 3-month visit, patients will have a physical exam (including weight and vital signs), blood 
and urine samples obtained for laboratory tests (CBC, chemistry panel, urinalysis), 
pharmacokinetics (PK), and EKGs (pre-dosing and after the 4-hour PK sample collection).  
Women of child bearing potential will also have a serum pregnancy test performed.  
Concomitant medications, adverse events and medication compliance will also be reviewed.  
Quality of life questionnaires (EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and the 
modified Cancer Worry Scale) will be provided to the subject to complete. 
At the 6 month visit, patients will have a physical exam (including weight and vital signs), blood 
samples obtained for laboratory tests (CBC, chemistry panel, urinalysis), EKG and their first on 
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study treatment upper and lower endoscopy procedures.  A second normal rectal/pouch mucosal 
biopsy for polyamine determination will be obtained during the colonoscopy/ proctoscopy 
procedure.  Women of child bearing potential will also have a serum pregnancy test performed. 
Quality of life questionnaires (EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and the 
modified Cancer Worry Scale) will be provided to the subject to complete. 
At the 12 month visit patients will have a physical exam (including weight and vital signs), 
blood samples obtained for laboratory tests (CBC, chemistry panel, urinalysis), audiometry 
testing, EKG and their second set of on study treatment endoscopy procedures.  Women of child 
bearing potential will also have a serum pregnancy test performed. Quality of life questionnaires 
(EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and the modified Cancer Worry Scale) will be 
provided to the subject to complete.  A food frequency questionnaire will be provided to the 
subject to complete at North American (United States and Canada) sites only. 
At the 18 month visit patients will have a physical exam (including weight and vital signs), 
blood samples obtained for laboratory tests (CBC, chemistry panel, urinalysis), EKG, and their 
third on study treatment endoscopy procedures.  Women of child bearing potential will also have 
a serum pregnancy test performed. Quality of life questionnaires (EORTC QLQ-C30, EORTC 
QLQ-CR29, EQ-5D, and the modified Cancer Worry Scale) will be provided to the subject to 
complete. 
8.2.6. Final Intervention Visit/End of Treatment (Month 24 +/- 2 weeks or at end of 
treatment +/- 2 weeks) 
Within 2 weeks off final study pill treatment for any cause, all patients will have a follow-up 
history and physical exam (including weight and vital signs), along with toxicity assessment.  
Repeat blood laboratory tests (CBC, chemistry panel, urinalysis), EKG and audiometry will be 
performed. Women of child bearing potential will also have a serum pregnancy test performed. 
Quality of life questionnaires (EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D and the 
modified Cancer Worry Scale) will be provided to the subject to complete.  A food frequency 
questionnaire will be provided to the subject to complete at North American (United States and 
Canada) sites only.  
Repeat upper and lower endoscopies (with normal mucosa biopsy and random urinalysis for 
polyamine analysis) with image and video documentation will be obtained at the Month 24 visit 
or if the patient has completed at least 3 months of treatment from the previous on-study upper 
and lower endoscopy procedures (including baseline).  
If the patient has an unscheduled upper/lower endoscopy for any reason, these procedures should 
be captured with image and video documentation including the collection of a normal mucosal 
biopsy, if possible.  A random urinalysis for polyamine analysis should be obtained if the 
endoscopy procedure(s) indicate that the patient will go off study treatment. 
If there is a cumulative delay/suspension of study medication for greater than 90 days for any 
reason, the patient will need to be formally taken off-study treatment and complete the End of 
Treatment (EOT) assessments. 
A temporary suspension from taking study medication (less than 90 days), for example, a non-
FAP disease related surgery or procedure will be documented as a treatment delay and the 
patient will continue on study, on their original schedule. 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 2.0, April 16, 2013  36 
8.2.7. Follow-Up (30-days post end of treatment visit +/- 1 week) Off Study 
Thirty-days (30) after completion of the end of study evaluations, patients will be contacted by 
phone for a clinical update in regard to symptoms and interval medical history. The patient will 
provide a clinical update and procedure date for any FAP-related surgical event or major 
endoscopic excisional event that has occurred since the last contact. These include partial 
colectomy, colectomy with IRA, total procto-colectomy, proctectomy, pouch resection, sub-
mucosal resection, trans-duodenal excision, ampullectomy, duodenectomy, or Whipple 
procedure. 
An FAP-related event at any disease site (colon/rectum/pouch, duodenum) will lead to 
discontinuation of the study treatment but follow-up of the subject will continue until the end of 
the 30 day follow-up period. 
8.2.8. Follow-Up (Months 2-6, each month +/- 1 week) Off Study 
For the next 5 months after the 30 day follow-up, if the patient went off study treatment for 
disease progression indicating the need for an any FAP-related surgical event or major 
endoscopic excisional event, and the surgical/endoscopic event had not yet occurred at the time 
of the 30 days post end of treatment visit, patients will be contacted by phone to obtain the 
procedure date of any FAP-related surgical event or major endoscopic excisional event that has 
occurred since the last contact.  These include partial colectomy, colectomy with IRA, total 
procto-colectomy, proctectomy, pouch resection, sub-mucosal resection, trans-duodenal 
excision, ampullectomy, duodenectomy, or Whipple procedure. 
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8.2.9. Definition of FAP-Related Events or Serious and Unexpected Toxicity 
The first FAP related event at any disease site (colon/rectum/pouch, duodenum) will lead to 
discontinuation of the study treatment.  Follow-up of the subject for FAP-related events will 
continue, per protocol, until the end of the 30 day post-treatment. 
FAP-related primary events by disease site are as follows: 
1. Pre-operative, intact colon: 
a) Disease progression^ indicating need for colectomy with IRA or total procto-
colectomy  
 
2. Rectum or pouch events include one or more of the following: 
a) Excisional intervention by surgical snare or trans-anal excision to remove any 
polyp ≥ 10 mm in size (per pathology report) and/or pathologic evidence of high 
grade dysplasia.* 
b) Disease progression^ indicating need for proctectomy 
c) Disease progression^ indicating need for pouch resection 
d) Development of cancer in rectum or pouch 
e) Death 
 
3. Duodenal disease includes the following: 
a) Progression in Spigelman Stage to more advanced stage, refer to Appendix A 
b) Disease progression indicating need for excisional intervention (sub-mucosal 
resection, trans-duodenal excision, ampullectomy, duodenectomy, Whipple 
procedure) 
c) Development of cancer 
d) Death 
 
Note, excisional intervention may include open surgery, trans-anal surgery or endoscopic 
excisions/snare but does not include cautery ablations or hot biopsy. 
*For those subjects stratified to the duodenal group, all concurrent rectal pouch polyps > 5 mm 
must have been removed at baseline for this event to apply. 
^Disease progression is based on endoscopic evaluations compared to baseline demonstrating a 
clinically significant increase in number and/or size of polyps, presence of a large sessile or 
ulcerated adenoma not amenable to removal, high grade dysplasia in any adenoma, or in-situ or 
invasive cancer. 
Discontinuation from study treatment due to a potential treatment related serious adverse event 
may include the following:  
 Gastrointestinal hemorrhage, ≥ grade 3 
 Tinnitus ≥ grade 2, or clinical hearing impairment ≥ grade 3 
 Cardiovascular events include cardiac arrest, cardiac-chest pain, myocardial 
infarction, thromboembolic event, phlebitis (deep or superficial), and spontaneous 
abdominal wall or retroperitoneal hematoma at least 10 cm in maximum dimension.  
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Adverse events and serious adverse events must be recorded carefully and completely on the 
case report forms and SAE report forms.  Adverse event reporting and grading will be done 
using the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. 
If a patient comes off study treatment for any of the above listed FAP or SAE events, the subject 
will need to complete all tests, procedures and assessments required at the Final Intervention/End 
of Treatment visit, including 30-day follow-up. 
All patients who go off study treatment due to an FAP-related event, toxicity, or intercurrent 
illness, or who withdraw consent for further treatment will be followed for at least 30 days from 
their last dose of study medication or until the event resolves. 
8.3. Study Blinding Information and Criteria for Protocol Treatment Removal 
8.3.1. Blinding and Unblinding 
Treatment will be provided in a double blind manner such that neither the subject, Investigator, 
clinic staff nor the Sponsor will know which combination is being administered.  Randomization 
numbers will be assigned based on information obtained from an interactive web-based response 
system. 
Participant treatment will be unblinded only if the study physician demonstrates a compelling 
medical need for this information.  Specifically, we expect that unblinding of an individual study 
subject’s treatment assignment may occur if in the opinion of the Investigator, and the Medical 
Monitor, identification of the study medication is necessary to protect the welfare of the subject.  
The study Medical Monitor must approve the request verbally and later in writing prior to 
unblinding to ensure that reasons for the unblinding are adequate.  The Medical Monitor is a 
Sponsor representative who has medical authority for the evaluation of the safety aspects of the 
clinical trial.  The study drug may be discontinued without unblinding the participant. 
8.3.2. Protocol Treatment Withdrawal (Off-Study Treatment) 
Participants will be withdrawn from protocol treatment under the following circumstances: 
1. Evidence of an FAP-related event as defined in Section 8.2.9. 
2. Clinical reduction in hearing acumen requiring use of a hearing aid. 
3. Pregnancy while on treatment, see Section 11.8. 
4. Intercurrent illness which would, in the judgment of the treating physician, affect 
assessments of clinical status to a significant degree and/or require discontinuation of 
drugs.  Participants will not discontinue study drugs for other medical events which are 
not considered to be treatment related.  This determination will be made by the treating 
physician.  
5. Cumulative delay of study intervention > 90 days for any reason. 
6. Completion of 24 months intervention.  Duration of intervention will be 24 months from 
the first day of study treatment initiation regardless study visit and or procedure delays. 
7. At the request of the Sponsor in situations such as protocol violations or concerns about 
the patient’s safety. 
8. The patient is lost to follow-up. 
9. The patient may withdraw from the study-treatment at any time for any reason. 
10. Patient death. 
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8.3.3. Protocol Withdrawal (Off-Study) 
1. The patient may withdraw from the study at any time for any reason. 
9. DISEASE ASSESSMENT AND SAMPLE COLLECTION 
9.1. Baseline Endoscopy 
A. Colon, Rectal, Pouch Assessment 
Colonoscopy or flexible sigmoidoscopy will be used to assess the colon, rectum or the neo-
rectum (ileal pouch) and video images captured for archiving and subsequent review.  The last 
images will be retroflexed pictures of the distal rectum or pouch at the anorectal ring.  One pass 
will be performed.  Further details will be provided in the Imaging Manual. 
Rectal/Neorectal Pouch 
The entire residual rectum or pouch will be video-captured three times by: 
 Advancing flexible scope to ileo-rectal anastomosis or proximal pouch.  After 
advancement, the scope will be “twirled” to visualize all walls of the bowel as it is 
withdrawn. 
 Retroflexed views of the distal rectum will be obtained at each visualization. 
 Images of the bowel will be obtained using biopsy forceps in the fully open position 
placed near the mucosa.  
Rectal/Neorectal Pouch Enumeration and Measurement 
 Number of polyps in the rectum or pouch 
 Endoscopic estimation of polyp size will be determined by visual comparison to a biopsy 
forceps that can measure, 5.0 - 5.5mm in the fully open position. 
o Number of polyps between 5 – 10 mm 
o Number of polyps > 10 mm 
 All polyps > 5 mm in diameter will be removed. 
Smaller polyps may be ablated per the treating institutions standard of care and three additional 
sets of video images will then be obtained as “baseline”.  
B. Duodenal Assessment 
Duodenal assessment will use a forward and/or side-viewing endoscope with video images 
captured for subsequent review.  The Spigelman classification (Appendix A) at screening will be 
utilized to stage the initial extent of disease and assess subject eligibility.  A side-viewing scope 
may be used to improve assessment of the ampulla of Vater/papilla.  Ampullary biopsies (with 
histology) and snare excisions will be performed per the protocol, Investigator Manual, and the 
institution’s standard of care and the results of these procedures will be used as the subject’s 
baseline Spigelman classification.  Further details will be provided in the Imaging Manual. 
The screening stage will be the initial Spigelman Stage (extent of polyposis combined with 
histology) and the baseline Spigelman Stage will be the post-snare intervention. 
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9.2. Follow-up Endoscopies 
At six month intervals (+/- two weeks) – per Section 8.1, patients will undergo repeat upper and 
lower endoscopy.  At any interval assessment, if any subject requires an excisional intervention 
(as defined in Section 8.2.9), or has duodenal Spigelman stage progression, the subject will be 
considered to have an FAP-related event and will come off study treatment.  
9.3. Imaging Submission 
All de-identified images will be captured on DVD or flash drive, de-identified, and forwarded a 
central imaging laboratory for archiving.  All data will be de-identified in regard to patient, site 
and treatment but patient study ID number will be available for baseline and subsequent 
comparison as appropriate.  Post-hoc global assessment by blinded reviewers not involved in this 
trial will perform the assessment - using a 5 point scale - much less, somewhat less, none or 
minor changes, somewhat worse, much worse.  This process will be defined in detail and 
included in the imaging manual for still and video endoscopy image submission. 
9.4. Population Pharmacokinetic Sampling  
All patients will have blood samples obtained for pharmacokinetic studies.  Pharmacokinetic 
sampling will occur once at the scheduled 3 month visit.  Samples may be collected within ± 2 
weeks of this visit.  These visits start in the morning, to allow for subjects to hold their morning 
study medication dose, and for samples to be taken during standard working hours. 
The patient will be contacted by a study coordinator at least three (3) days prior to the scheduled 
visit to remind the patient to not take their morning dose of study medication on the day of the 
planned visit. 
On the morning of the visit, upon patient arrival, it will be verified that the patient did not take 
their morning dose of study medication.  Those patients that mistakenly took their morning dose 
will be sent home and rescheduled within the next week.  Thereafter, a pre-dose blood sample (5 
mL, lithium heparin vacutainer tube) will be collected and a pre-dose EKG will be obtained.  
The patient will then take their study medications in the usual manner.  The patient may then 
leave the clinic and have their typical breakfast.  
Table 5 – Pharmacokinetic Sample Number and Sampling Times 
Sample Number Target Time No Earlier Than No Later Than 
1 Pre-dose* NA NA 
2 1 hour 45 minutes 75 minutes 
3 2 hours 90 minutes 150 minutes 
4 4 hours* 3 hours 5 hours 
5 8 hours 6 hours 10 hours 
*EKGs need to be done after the pre-dose and 4 hour samples have been collected. 
Post dose blood samples will be collected (5 mL each) at 1, 2, 4, and 8 hours following the 
morning dose of study medication (see Table 5).  Deviations around these sample times should 
be no more than ± 15 minutes, ± 30 minutes, ± 60 minutes (1 hour), ± 120 minutes (2 hours), 
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respectively, keeping in mind that the third and fourth samples must be at least one hour apart.  
On the pharmacokinetic sampling case report form page, study coordinators will record the time 
of the pre-dose blood sample and the time breakfast was finished.  Also the relative ideal blood 
sampling times (relative to dose time), and the actual blood sampling times will be recorded.  
Missed samples or samples collected outside of the time windows will still be stored and 
analyzed.  Collected blood samples will be processed, stored, and shipped to a central laboratory 
according to procedures provided in the study manual. 
Plasma concentration data from this trial will be pooled with data from other clinical trials, when 
available, for analysis.  For each drug, a database will be constructed that includes the nominal 
and recorded dosing history, plasma analyte concentrations, demographic (body size, age, race, 
gender) data, laboratory data (hepatic and renal function), medical history (colonic resection), 
and clinical trial identifier.  These data will be analyzed using methods appropriate for sparse 
data (mixed-effects modeling using NONMEM). 
9.5. Polyamine Sample Collection (Normal Mucosa Biopsy, Random Urine Sample) 
Patient tissue samples will undergo a baseline polyamine assay (examination of grossly normal 
rectal mucosal cup forcep biopsy and random urine sample - minimum 15 mL) pre-treatment, as 
a component of the screening process, and at the 6 month and 24 month proctoscopy evaluation.  
Collected tissue and urine samples will be processed, stored, and shipped to a central laboratory 
according to procedures provided in the study manual. 
For patients who have signed the Optional Research Use of Biospecimens portion of the 
informed consent, left over urine or tissue samples may be used for exploratory assessment of 
levels of expression of RNA, proteins, or other molecules, such as polyamines, in the polyamine 
synthesis pathway, the APC signaling pathway, and other related pathways.  Analysis may 
include mutation status for genes involved in the polyamine synthesis pathway, APC pathway, or 
other FAP related pathways. 
9.6. Pharmacogenomic and Genetic Testing Sample Collection 
Patients will have 10 mL of peripheral blood collected in an EDTA vacutainer tube during their 
baseline/screening visit for subsequent correlative science research.  Collected blood samples 
will be processed and shipped to a central laboratory according to procedures provided in the 
study manual. 
For patients who have signed the Optional Research Use of Biospecimens portion of the 
informed consent, left over blood samples may be used for exploratory assessment of levels of 
expression of RNA, proteins, or other molecules, such as polyamines, in the polyamine synthesis 
pathway, the APC signaling pathway, and other related pathways.  Analysis may include 
mutation status for genes involved in the polyamine synthesis pathway, APC pathway, or other 
FAP related pathways. 
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10. QUALITY OF LIFE AND DIETARY ASSESSMENTS 
10.1. Assessment of Quality of Life and Patient Preferences 
For this study, we plan to use four (4) instruments to measure HRQoL and patient preferences or 
utilities.  These instruments include the EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and a 
modified Cancer Worry Scale. 
 The EORTC QLQ-C30 is a self-administered quality of life questionnaire67 with multi-
dimensional scales.  It consists of both multi-item scales and single item measures, 
including five functioning domains, a global quality of life domain, three symptom 
domains and six single items.  
 The EORTC QLQ-CR29 gastrointestinal / colorectal sub-module68 is composed of 4 
functional and 18 symptom related sub-scales.  The 4 functional scales include body 
image, weight, anxiety and sexual function.  The symptom related scales include single 
item and multi-item questions concerning stool frequency, bleeding and mucous 
discharge, stool leakage, abdominal bloating, flatulence, embarrassment and site-specific 
pain among others. 
 The EuroQol EQ-5D is a standardized instrument for use as a measure of health outcome 
and is applicable to a wide range of health conditions and treatments.69,70  It provides a 
simple descriptive profile and a single index value for health status. 
 The Cancer Worry Scale71 is a brief psychometric instrument that was designed to assess 
both the frequency of worrying about “getting cancer some day” and measuring the 
impact of worry on mood and performing daily activities.  This scale was originally 
developed by Caryn Lerman and her colleagues to study breast cancer and has been 
modified for use in this FAP trial.  
The validity and reliability of both the QLQ-C30 and the QLQ-CR29 questionnaires have been 
studied by the EORTC Study Group on Quality of Life and both instruments will be scored 
according to the EORTC Scoring Manual and analyzed accordingly. 
HRQoL measures will be obtained at baseline and at 3, 6, 12, 18, and 24 months post-
enrollment/end of treatment.  For each single item or multi-item sub-scale, a linear 
transformation will be applied to standardize raw scores to range between 0 and 100.  HRQoL 
secondary endpoints will include all single item or multi-item sub-scales from both the EORTC 
QLQ-C30 and QLQ-CR29 and patients will be considered as deteriorated (or improved) for a 
given single item or multi-item sub-scale if their change score from baseline was 10 points or 
more on the standardized scale. 
In addition to the HRQoL assessment, patient preferences (or utilities) will also be assessed.  
Data will be collected at baseline and at 3, 6, 12, 18, and 24 months post-enrollment/end of 
treatment and preference weights among the treatment arms will be determined using the 
EuroQol EQ-5D assessment of individual health states.69,70  Quality-adjusted survival among the 
three treatment arms will be generated by multiplying the utility value by the amount of time 
spent in a specified health state.  
The modified version of the Cancer Worry Scale will also be administered at baseline and at 3, 6, 
12, 18, and 24 months post-enrollment/end of treatment and it will be scored according to the 
guidance provided by Lerman et al.71 
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10.2. Dietary Assessment 
The Food Frequency Questionnaire (FFQ) is the most common dietary assessment tool used in 
large epidemiologic studies of diet and health.  The self-administered FFQ booklet asks 
participants to report the frequency of consumption and portion size of approximately 125 line 
items over a defined period of time (e.g. the last month; the last three months).  Each line item is 
defined by a series of foods or beverages.  Additional questions on food purchasing and 
preparation methods enable the analysis software to further refine nutrient calculations.  The 
FFQ was developed by the Nutrition Assessment Shared Resource (NASR) of the Fred 
Hutchinson Cancer Research Center.  NASR periodically updates its standard FFQ to reflect 
U.S. food consumption patterns and major changes in the market place.76,77  Data from the FFQ 
will be analyzed using a polyamine database66 and will calculate the average daily levels of 
putrescine, spermidine, and spermine.in the diet.  Dietary assessments via the FFQ will be 
obtained at baseline, 12 months and 24 months/end of treatment for subjects at North American 
(U.S. and Canada) sites only.  The results of the FFQ will be used to corroborate results from 
another recent trial78 that indicate consumption of a diet high in polyamines is associated with 
reduced treatment efficacy.  The results of this trial along with the earlier findings of Zell et al.40 
could lead to dietary restrictions in combination with the combined eflornithine-sulindac therapy. 
11. ASSESSMENT OF SAFETY 
11.1. Cardiac Risk 
All patients will undergo a baseline medical history evaluation and EKG for cardiovascular 
disease risk assessment.  Only subjects meeting the inclusion criteria will be enrolled in the 
study.  On-study cardiac risk assessments, for each patient, will take place throughout the study 
via ongoing adverse event assessments and periodic EKG evaluations at baseline, and months 3, 
6, 12, 18 and 24 (end of treatment).  
11.2. Ototoxicity Risk 
All patients will undergo air conduction audiometry for hearing impairment as part of the 
screening process and at months 12 and 24 (end of treatment).  Patient diaries will indicate the 
presence of symptoms and will instruct the patient to contact the treating doctor for assessment. 
These data will not be used to exclude patients from this study.  
At the 3, 6, 12, 18 and 24 month visits, the patient will undergo a clinical assessment for 
ototoxicity adverse events symptoms by the research nurse or other medically qualified 
individual. 
11.3. Gastrointestinal Risk 
Patient’s diaries will indicate presence of symptoms and will instruct the patient to contact the 
treating doctor for assessment.  Stool will be self-assessed by patients to determine if gross blood 
or melena is present.  If so, treating doctor will be contacted and the patient assessed.  Patient 
will perform stool assessments, which will be recorded in their diary. 
At the 3, 6, 12, 18 and 24 month visits, the patient will undergo a clinical assessment for 
gastrointestinal adverse events symptoms by the research nurse or other medically qualified 
individual. 
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11.4. Safety Parameters 
Patients will be followed for safety from the start of treatment through 30 days after treatment 
discontinuation.  Serious adverse events will be followed until resolved or returned to baseline, 
even if longer than 30 days from the subject’s off study treatment or off study date.   
Adverse events and serious adverse events must be recorded carefully and completely on the 
case report forms and SAE report forms.  Adverse event reporting and grading will be done 
using the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0, 
(http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf).   
Serious adverse events must be reported to the Institutional Review Board (IRB)/Independent 
Ethics Review Committee (IEC)/Research Ethics Board (REB) by the Investigator and to 
regulatory authorities (FDA, National Health Authorities) by the Sponsor, according to 
established policy and regulatory requirements.  Adverse events will also be coded to an organ 
system class.  Summaries of safety data will be completed for the study population. 
11.5. Adverse Events 
Adverse event means any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related (FDA definition) and is defined by the EU and 
Canadian regulations as any untoward medical occurrence in a patient or clinical trial subject 
administered a medicinal product and which does not necessarily have a causal relationship with 
this treatment. 
An adverse event (also referred to as an adverse experience) can be any unfavorable and 
unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a drug, without any judgment about causality.  An adverse event can 
arise from any use of the drug and from any route of administration, formulation, or dose, 
including overdose. 
An adverse reaction means any adverse event caused by the drug.  Adverse reactions are a subset 
of all suspected adverse reactions for which there is reason to conclude that the drug caused the 
event. 
An adverse event does not include; pre-existing disease, conditions, or laboratory abnormalities 
present at the start of the study that do not worsen in frequency or intensity; situations where an 
untoward medical occurrence has not occurred (e.g., hospitalizations for cosmetic or elective 
surgery or social/convenience admissions); the disease being studied or signs or symptoms 
associated with the disease unless more severe than expected for the patient’s condition. 
An unexpected adverse event is an event that is not listed in the Investigator’s Brochure (IB) at 
the specificity or severity observed or is mentioned in the IB as occurring with a class of drugs or 
as anticipated from the pharmacological properties of the drug, but not mentioned as occurring 
with the drug(s) under investigation. 
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11.6. Serious Adverse Events 
A serious adverse event determined by the opinion of the Investigator or Sponsors is defined as 
1. Death; 
2. A life-threatening event (places the patient at immediate risk of death); 
3. Requires inpatient hospitalization or prolongs hospitalization; 
4. Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions; 
5. Congenital anomaly/birth defect; 
6. Important medical events (IMEs) may be considered serious when, based on medical 
judgment, they may jeopardize the patient and require intervention to prevent one of the 
above serious outcomes. 
An adverse event or suspected adverse reaction is considered “life-threatening” if, in the view of 
either the Investigator or Sponsor, its occurrence places the patient at immediate risk of death.  It 
does not include an adverse event or suspected adverse reaction that, had it occurred in a more 
serious form, might have caused death. 
11.7. Reporting of AEs, SAEs, Serious and Unexpected Adverse Experiences 
Subject Reporting of an Adverse Event 
Subjects will be instructed to contact the Investigator or Research Nurse to report any symptom.  
The Investigator will question each subject regarding symptoms at the time of each physical 
examination.  All adverse experiences, including duration and severity will be captured in the 
Case Report Forms provided by the Sponsor. 
Reporting Serious Adverse Events (SAEs) to Sponsor 
Serious Adverse Events are to be documented and reported to the Sponsor from the day the 
subject receives his/her first treatment through 30 days after the subject’s off study treatment 
date.  SAE follow-up needs to continue until the event is resolved or returned to baseline. 
Serious Adverse Events occurring to a subject after the 30 day off study treatment date should be 
reported to the Sponsor only if the SAE could be attributed to study treatment. 
An Investigator shall report to the Sponsor via telephone, fax or e-mail, any Serious Adverse 
Event regardless of causality, within 24 hours of receipt of information. 
Reporting to the Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC)/Research Ethics Board (REB) 
SAE’s must be reported to the IRB/IEC/REB by the Investigator according to each institution’s 
policy and procedures. 
Reporting to Regulatory Authorities and Participating Investigators 
The Sponsor will notify appropriate regulatory authorities by fax, telephone or in writing of any 
unexpected fatal or life-threatening suspected adverse reaction associated with the use of the 
study drug as soon as possible, but in no event later than 7 calendar days after initial receipt of 
the information. 
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The Sponsor shall notify appropriate regulatory authorities and all participating Investigators in 
writing via IND safety reports/CIOMS reports of any serious and unexpected adverse experience 
associated with the use of the drug; and such reports shall be made as soon as possible but in no 
event later than 7 or 15 calendar days after the Sponsor’s initial receipt of the information, 
depending on the reporting requirements. 
The Sponsor will submit IND safety reports/CIOMS reports to FDA, Heath Canada, EMA, and 
National Competent Authorities as required, and all participating Investigators no later than 7 or 
15 calendar days after the Sponsor determines that the suspected adverse reaction or other 
information qualifies for expedited reporting based on country specific regulatory requirements  
If any regulatory authority requests any additional data or information, the Sponsor will submit it 
as soon as possible, but no later than 15 calendar days after receiving the request. 
The Sponsor will report all adverse experiences to the U.S. FDA in Annual Reports to the IND, 
and to all applicable regulatory authorities annually as required, in addition to the final report of 
the clinical trial. 
11.8. Reporting of Pregnancy 
If following initiation of study treatment, it is discovered that a patient is pregnant or may have 
become pregnant at the time of investigational drug exposure, the investigational drug will be 
permanently discontinued.  The Investigator must notify the Medical Monitor within 24 hours of 
learning of the pregnancy and record the pregnancy on the Pregnancy Reporting Form and 
submit it to Cancer Prevention Pharmaceuticals via fax or email.  All study required procedures 
for study discontinuation and follow-up must be completed unless contraindicated by the 
pregnancy.  The Investigator must report using the Pregnancy Reporting Form, follow-up 
information regarding the course of the pregnancy, including perinatal and neonatal outcome.  
Generally, infants should be followed for a minimum of 6-8 weeks but additional follow up is 
not needed when a newborn is healthy. 
Pregnancy itself is not considered an AE or SAE but any pregnancy complication or elective 
termination of a pregnancy for medical reasons will be recorded as an AE or SAE and reported 
as described in Sections 11.4 - 11.8. 
11.9. Concomitant Medications 
All concomitant medications and medications taken within 30 days before the first study drug 
administration until the subject’s off study treatment date will be coded to therapeutic drug 
classes and generic names using for example the WHO Drug classification dictionary. 
Patients are to be instructed to not take the following medications or supplements while on study 
treatment: corticosteroids (such as prednisone), NSAIDS (such as ibuprofen, celecoxib, aspirin, 
diflunisal), supplements containing omega-3-fatty acids (such as fish oil), anticoagulants (such 
as warfarin, Pradaxa®, and Plavix®) or other direct thrombin inhibitors), fluconazole, lithium, 
furosemide and thiazides, DMSO, methotrexate, probenecid, propoxyphene hydrochloride, 
Tylenol® (acetaminophen) preparations containing aspirin or cytotoxic chemotherapy drugs. 
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12. STATISTICAL CONSIDERATIONS 
The Statistical Analysis Plan (SAP) will focus on analysis of the primary and secondary 
endpoints, in order to assess the extent to which the combination of CPP-1X 750 mg daily + 150 
mg sulindac is more effective than each agent alone in delaying the time to the first FAP-related 
event in Familial Adenomatous Polyposis (FAP) patients.  Eligible patients who have given 
informed consent will enter the study the intent to participate for the full treatment period of 24 
months.  Accrual is expected to take 6 – 12 months. 
The Statistical Analyses Plan will include method descriptions and will pre-specify the statistical 
approaches to be used, primary and secondary study endpoints, data handling conventions and 
randomization processes.  
A total of 150 eligible patients will be enrolled in this study, 50 per treatment group.  Patients 
will be randomized to one of three treatment groups within the prognostic strata defined in 
Section 4.3 in equal proportions (i.e., 1:1:1 randomization): 1) CPP-1X plus sulindac, 2) CPP-1X 
placebo plus sulindac, 3) CPP-1X plus sulindac placebo.   
The study is double blinded, so neither patients nor Investigator nor Sponsor will be aware of 
treatment assignment. 
For the primary efficacy analyses, we will use the intent-to-treat (ITT) population, defined as all 
patients who have a signed a voluntary and fully informed consent form, have been deemed 
eligible to participate by the Investigator based on the screening assessments, and have been 
randomized to one of the three study arms.  Patients will be analyzed in the group to which they 
were randomized, whether or not they received their assigned treatment, any treatment 
whatsoever, or completed their treatment course and follow-up.  The safety outcome will be 
analyzed using all patients in the ITT population who received at least one dose of study drug 
(safety population).  
12.1. Primary Efficacy Objective and Analysis 
The primary objective of this trial is to determine whether the combination of CPP-1X + 
sulindac is superior to either single-agent treatment individually in delaying time to the first 
occurrence of any FAP-related event.  Section 8.2.9 provides complete detail on FAP-related 
events. 
Thus the primary objective contains two treatment comparisons:  
1. CPP-1X active + sulindac active vs. CPP-1X placebo + sulindac active,  
and 
2. CPP-1X active + sulindac active vs. CPP-1X active + sulindac placebo 
Each comparison will be performed at the 2-sided p = 0.05 level.  
The decision to seek regulatory approval based upon the results of the primary objective will be 
taken sequentially.  If the result of comparison 1 is significant at level 0.05, FDA approval will 
be sought.  If comparison 1 is significant, then if the result of comparison 2 is also significant at 
level 0.05, EMA approval will be sought as well.  But if the result of comparison 1 is not 
significant at level 0.05, neither FDA nor EMA approval will be sought.  This procedure is 
formally equivalent to a closed sequential test procedure for controlling the probability of 
making a false claim that regulatory criteria are satisfied at level 0.05. 
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The analytic method for the primary analysis will be a time-to-event analysis using the log-rank 
test.  Cox proportional hazards regression models will be used for secondary assessments80.  
Graphical analyses (log-minus-log plots) will be used to check the assumption of constant hazard 
ratios. 
For the primary analysis, two log-rank tests will be performed with treatment coded as a binary 
value (i.e., 0 or 1). Time to event curves will be displayed using the method of Kaplan and 
Meier81.  Additional analyses involving the overall 3-treatment group comparison, and use of 
additional study populations or the two pairwise treatment comparisons, will be performed as 
supplemental analyses. 
If an FAP related event occurs, that patient will be said to have an observed or uncensored event 
and will be considered a treatment failure.  Generally, a patient will be considered a treatment 
failure if for any reason, the endpoint determination cannot be made per the pre-specified study 
requirements.  The time to this imputed event will be from randomization to the last recorded 
patient visit.  A patient who is lost to follow-up for reasons deemed unrelated to his or her 
endpoint status will be treated as a censored observation as of the last patient visit.  If a patient 
does not have a FAP related event at the 24 month close-out visit, the patient will be treated as a 
censored observation as of the actual follow-up time for the close-out visit. 
12.2. Secondary Efficacy Outcome and Analysis 
The secondary efficacy outcome in this study will include the following: 
1. To evaluate the potentially effect modifying properties of : 
a. Presence or absence of an ODC polymorphism 
b. The excretion of 4 urinary polyamines (diacetylspermine, n1-acetylspermidine, 
n8-acetylspermidine and decarboxylated SAM) 
These five secondary variables will be assessed regardless of study outcome, but their use as 
potential label claims will only apply if a statistically significant treatment effect is found in the 
primary analysis.  For the secondary efficacy analysis, for each secondary variable, a 
corresponding term will be added to the primary analysis as well as an interaction term (product 
of the treatment indicator and secondary variable).  The coefficient of the interaction term (only) 
will be tested to determine if the secondary variable alters the magnitude of the treatment effect. 
Corresponding to each of the two primary analyses, the Hochberg step-up method82 will be 
employed to control the overall family-wise error rate with overall alpha set at the two-sided 
0.05 level. 
12.3. Other Secondary Outcomes 
Other secondary outcomes will include the following: 
1. Safety outcomes will be assessed by summary analysis of adverse events and clinical 
laboratory abnormalities. 
2. Pharmacokinetic outcomes will be assessed by evaluating the population 
pharmacokinetics for CPP-1X (eflornithine) and sulindac. 
3. Evaluate tissue and dietary polyamine levels. 
4. Patient reported quality of life will be evaluated using HRQoL and patient utilities. 
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5. A pilot evaluation of an FAP-specific assessment, the time to the first FAP-related 
beneficent event, will be studied.  This will involve analyzing the endoscopic polyposis 
data for regression of pre-colectomy colorectal polyposis, rectal/pouch polyposis, and 
regression of duodenal polyposis. 
6. An analysis of the components and subgroups included in the primary analysis, and their 
contribution to the primary outcome. 
12.4. Sample Size Determination 
For the purposes of power calculations, we assume the following:  
1) The level of statistical significance is set at 0.05, using a 2-sided log-rank test for time-to-
first FAP-related event, for each of the two between-group comparisons (i.e. CPP-1X + 
sulindac vs. CPP-1X and CPP-1X plus sulindac vs. sulindac); 
2) A doubling of the time to occurrence of the primary event from either of the single agent 
treatment arms to the combination treatment group; 
3) Power of at least 85% to detect the above-mentioned treatment effect comparing the 
combination arm vs. either of the two single treatment arms; 
4) The two single-agent treatment groups have the same event rate. 
For this situation, 49 events would be needed for the two-group situation at the 2-sided 0.05 level 
with 85% power and the doubling of the time to primary event.79  Assuming two-year event 
proportions of 70% in either of the two single-agent groups and 40% in the combination arm 
with 50 patients per arm, the expected number of patients with an FAP related event in either of 
the two single-agent groups would be 35 and 20 in the combination arm.  Thus we expect to have 
55 patients with a FAP related event in each comparison, achieving almost 89% power.  The 
standard deviation around this expectation is 4.74, so we would be highly likely to observe at 
least the required 49 events.  Even if the total number of events in either comparison were only 
43, there will still be 80% power to detect the design effect size, namely, a hazard rate ratio of 
0.4243 = (ln 0.60)/(ln 0.30) corresponding to the doubling of event-free follow-up over two 
years.  
In total we expect to observe 35+35+20=90 primary endpoints among the three groups (plus or 
minus 5.7).  To achieve this number of events, we plan to have a 3 year study (with up to 12 
months enrollment assuming no sample size reassessment plus 2 years of treatment and follow-
up for the last-enrolled patients). 
This is based on our review of limited single-agent data for eflornithine and sulindac, in which 
the 2-year event free rates imply a single overall event free rate of 60% for combination 
treatment group and 30% in each single agent treatment group. 
12.5. Populations for Analysis 
12.5.1. Intent-to-Treat (ITT) Population  
The intent-to-treat population includes all patients who have signed a voluntary and fully 
informed consent form, have been deemed eligible to participate by the Investigator based on the 
screening assessments, and have been randomized to one of the three study arms (CPP-1X plus 
sulindac, CPP-1X placebo plus sulindac, CPP-1X plus sulindac placebo).  Patients will be 
analyzed in the group to which they were randomized, whether or not they received any 
treatment or completed their treatment and follow-up. 
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12.5.2. Safety Population 
The safety population is defined as all ITT patients who received at least one dose of study 
medication.  Patients who do not receive any study treatment (CPP-1X or sulindac or their 
combination) are excluded from this population.  Patients will be analyzed in the treatment group 
for which actual treatment was initially received. 
12.5.3. Per Protocol Population 
The per-protocol population is defined as the subset of the ITT population who completed all 24 
months of treatment and has primary endpoint determinations performed per protocol 
specifications. 
12.5.4. Other Populations 
Within the entire patient population there will be subsets who did not receive 24 months of daily 
medication.  The patient diary and pill count will define the extent of compliance.  This subgroup 
of patients will be categorized into various groups only for purposes of exploratory and 
sensitivity analysis including: 
 Patient withdrawn for personal reasons 
 Treatment discontinued because of disease symptoms 
 Treatment discontinued because of patient symptoms 
 Compliance <80% treatments taken 
 Treatment discontinued because of intercurrent medical or surgical illness. 
12.6. Other Statistical Methods  
12.6.1. Demographic and Baseline Characteristics 
Patients in the three populations (ITT, Safety, Per Protocol) will be summarized for demographic 
and baseline characteristics in a descriptive fashion.  Namely, categorical and continuous-valued 
data will be displayed using standard summary statistics (e.g., frequency tables, n, means, 
medians, standard deviations, and ranges).  Data will be presented per group and overall.   
Demographic features summarized will include age, gender, race and the institution at which 
each patient registered, among other features.  Baseline characteristics will include laboratory 
values and disease-related characteristics, as well as any other relevant values.  Categorical data 
will be compared among groups using chi-squared methods, while continuous-valued data will 
be compared using standard nonparametric methods (e.g., the Kruskal-Wallis test).83 
12.6.2. Patient Disposition and Treatment Summaries 
Subjects will be assigned for analysis to the treatment group to which they were randomized, 
regardless of whether the patients received any treatment. 
Patient disposition and treatment will be summarized for ITT and safety populations defined 
previously.  Patient disposition will be consistent with the CONSORT criteria,84 and will include 
per treatment group enumeration of all patients randomized, number ineligible, early termination 
due to AE/SAE, the number of subjects with an SAE, deaths, dropout for other reasons, and the 
number of subjects lost to follow-up.  Additional summaries will include reasons for patients 
discontinuing treatment and/or modifying treatment dosages, and a summary of patients’ 
treatment status.  A listing of screened and ineligible patients along with the reason for each also 
will be summarized. 
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12.6.3. Categorical or Continuous-Valued Secondary Outcome and Safety Data 
For categorical data, comparisons will be made between treatment groups using standard chi-
square techniques as the primary approach.  In particular, Cochran-Mantel Haenszel one degree 
of test will be used to reflect the stratified randomization.  Exact p-values and 95% confidence 
intervals by the point probability method will be reported85. 
For continuous endpoints, standard analysis of covariance (ANCOVA) methods will be used as 
the primary approach to compare treatment groups at end of treatment with the following 
covariates: baseline value, binary indicator variables for the two highest-risk stratification levels 
used in the randomization (using the lowest-risk, i.e., rectum/pouch polyposis, group as the 
reference stratum), and a binary treatment indicator (1=combination treatment, 0=single 
treatment). 
For ordered categorical data, a Kruskal-Wallis nonparametric test for ordered categorical 
response will be used to compare treatment groups.83 
Treatment-emergent adverse events will be enumerated and analyzed according to the incidence, 
intensity, type of adverse events, and clinically significant changes in the patient’s physical 
examination findings, vital signs and clinical laboratory results.  Safety variables will be 
tabulated and presented for all patients in the safety and per-protocol populations as defined 
previously.  
Adverse events will be graded and coded using the NCI Common Terminology Criteria for 
Adverse Events (CTCAE, Version 4).  Treatment-emergent events will be tabulated, where 
treatment-emergent is defined as any adverse event that occurs after administration of the first 
dose of study drug and through 30 days after the last dose of study drug, or any event that is 
present at baseline and continues after the first dose of study treatment but worsens in intensity.  
Events that are considered related to treatment (possibly, probably or definitely drug-related) 
also will be tabulated separately.  Tables that enumerate adverse events by severity will also be 
provided.  Deaths, serious adverse events and events resulting in study discontinuation will be 
tabulated in data listings including additional relevant information on each patient.  Tables will 
be presented both overall (all arms combined), by each treatment group separately, and by cell. 
Where appropriate, statistical comparisons between treatment arms will be provided using the 
above-mentioned methods for analysis of categorical data. 
12.6.4. Subgroup Analyses 
Subgroups will be analyzed in the spirit of exploratory analyses including but not limited to the 
various study populations and within each level of randomization strata separately. 
12.6.5. Health Related Quality of Life (HRQoL) 
For this study four (4) instruments to measure HRQoL and patient preferences or utilities will be 
administered to subjects at baseline and at 3, 6, 12, 18, and 24 months post-enrollment/end of 
treatment.  These instruments include the EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and 
a modified Cancer Worry Scale. 
The validity and reliability of both the QLQ-C30 and the QLQ-CR29 questionnaires have been 
studied by the EORTC Study Group on Quality of Life and both instruments will be scored 
according to the EORTC Scoring Manual and analyzed accordingly.  For each single item or 
multi-item sub-scale, a linear transformation will be applied to standardize raw scores to range 
between 0 and 100.  HRQoL secondary endpoints will include all single item or multi-item sub-
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scales from both the EORTC QLQ-C30 and QLQ-CR29 and patients will be considered as 
deteriorated (or improved) for a given single item or multi-item sub-scale if their change score 
from baseline was 10 points or more on the standardized scale.   
Patient preferences (or utilities) will also be assessed using the EuroQoL EQ-5D.  Preference 
weights among the treatment arms will be determined using the EuroQol EQ-5D assessment of 
individual health states.69,70  Quality-adjusted survival among the three treatment arms will be 
generated by multiplying the utility value by the amount of time spent in a specified health state.  
The modified version of the Cancer Worry Scale will also be administered and it will be scored 
according to the guidance provided by Lerman et al71. 
This trial has three strata and three treatment options with 150 patients to be entered. HRQoL 
data will be obtained while patients are receiving treatment.  Hence, HRQoL trends comparing 
the nine subsets will be obtained, but comparative longitudinal analyses defining the impact of 
an FAP-related event on QoL will not be feasible until subsequent long-term studies are 
performed. 
12.6.6. Dietary Assessment 
The FFQ was developed by the Nutrition Assessment Shared Resource (NASR) of the Fred 
Hutchinson Cancer Research Center. NASR periodically updates its standard FFQ to reflect U.S. 
food consumption patterns and major changes in the market place.76,77  Data from the FFQ will 
be analyzed using a polyamine database66 and will calculate the average daily levels of 
putrescine, spermidine, and spermine in the diet.  Dietary assessments via the FFQ will be 
obtained at baseline, 12 months and 24 months/end of treatment for subjects at North American 
(U.S. and Canada) sites only.  The results of the FFQ will be used to corroborate results from 
another recent trial78 that indicate consumption of a diet high in polyamines is associated with 
reduced treatment efficacy. 
12.7. General Procedures for Handling of Missing Data 
Every reasonable effort will be made to continue follow-up of all study participants, including 
those who discontinue randomized therapy, to prevent data loss.  It is recognized that missing 
values represent a potential source of bias in a clinical trial and so every effort will be 
undertaken to fulfill all the requirements of the protocol concerning the collection and 
management of data. 
For the primary time to event analysis, the only possible patient outcome is an observed FAP-
related event or a censored observation.  Participants who are lost to follow-up for reasons 
deemed unrelated to their health status will be censored at the time their status is last known, 
based upon data collected at the last recorded clinic visit.  For patients who may have missed a 
study visit, every effort will be made to obtain endoscopic results at their close-out visit and 
those endoscopy results will be used for the primary analysis.  A patient will be considered a 
treatment failure if for any reason, the endpoint determination cannot be made per the pre-
specified protocol.  The time to this imputed event will be from randomization to the last 
recorded patient visit.  Any secondary or sensitivity analysis that includes this assumption will 
be clearly noted.  Similarly, any sensitivity analysis that incorporates the last observation carried 
forward (LOCF) method, to compensate for early patient dropouts or missing data, will be 
clearly noted. 
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Secondary analysis data include the presence of a specific genetic mutation, and urinary 
metabolite concentrations (see Section 12.2).  The primary analysis of the secondary objectives 
will include collected data only, without imputing or weighting data to compensate for missing 
data.  Sensitivity analyses of these data will be performed to explore study results more fully, in 
a manner consistent with ICH Guidance “E9 Statistical Principles for Clinical Trials 
(September, 1998)”. 
All available efficacy and safety data will be included in data listings and tabulations.  Data that 
are potentially spurious or erroneous will be examined using standard data management 
operating procedures, prior to database lock and statistical analysis.  
12.8. Interim Monitoring and the Data Monitoring Committee 
A Data Monitoring Committee (DMC) will oversee the performance and safety conduct of this 
study.  The DMC will consist of at least three members (two MDs and one statistician as voting 
members) who will receive confidential reports on a periodic basis.  The DMC will be 
responsible for decisions regarding possible termination of the study for either futility or safety 
reasons. 
A detailed DMC Charter will be produced separately at a later time by the DMC membership.  It 
is anticipated that any reviews of study data will be performed in a blinded manner, looking at 
pooled data (all treatment groups combined into one group) to assess mission-critical parameters 
such as overall recruitment and event rates.  Any pre-specified interim analyses will be 
conducted in a blinded (A versus B) manner.  Of course, patient safety issues take precedence 
over bias-protection and control of type I error, and so the DMC will have the privilege of 
breaking the blind on a need-to-know basis if safety issues of concern arise in order to consider 
risk-benefit issues.  Details concerning DMC responsibilities and duties may be submitted as a 
stand-alone document to the FDA, including items such as specification of early termination 
rules and other matters as the DMC deems to be important and relevant to the ethical conduct of 
this study.  
CPP will inform the DMC that there will be two study evaluations for the DMC to consider 
during the trial, one interim look for sample size reassessment and one look for futility (based on 
a blinded A/B comparison). 
The method for reassessment of sample size is based upon the FDA Guidance, “Adaptive Design 
Clinical Trials for Drugs and Biologics (February 2010)”.  There will be no hypothesis testing.  
The DMC will perform an assessment of the observed trial event rate based on pooled data only.  
They will make a recommendation to the sponsor on whether the pooled event rate is sufficient 
to preserve the integrity of the trial, and if not, to recommend a revised sample size.  For this 
assessment the study statistician will estimate the overall observed event rate and 90% 
confidence interval.  This assessment will be performed using data from a single time point, 
when enrollment is approximately 95% complete.  With this approach study enrollment can 
continue uninterrupted at the study sites, if it is decided to increase study sample size. 
The futility assessment will occur when approximately 50% of maximum trial information has 
been amassed.  Assuming a constant enrollment rate over 1 year and full enrollment achieved at 
one year, that would occur at approximately 1.5 years from enrollment start.  At that time 
patients would have an average of approximately 1.0 year on study treatment.  Unless the DMC 
requires it on ethical grounds, no early stopping for positive efficacy is proposed. 
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12.9. Pharmacokinetic Analysis for Eflornithine and Sulindac 
The text that follows applies to each of the two compounds, eflornithine and sulindac.  Separate 
analyses will be performed for each drug. 
To perform the population pharmacokinetic analysis, a dataset will be constructed as follows: 
1. All subjects with at least one sample will be included in the analysis.  Actual sample time 
will be used in the analysis. 
2. Dosing history will be assembled based on CRF data.  Dosing records will assume 100% 
compliance, except as documented in the CRF. 
3. The dataset will be constructed using a script in R (www.R-project.org).  All steps will be 
documented.  All decisions regarding handling of aberrant data will be documented. 
4. Covariate data (age, extent of prior colectomy, body size, gender, race, laboratory values, 
etc.) will be included in the dataset.  The dataset will be constructed using values 
obtained temporal to the time of sampling. 
The pharmacokinetic analysis will be performed using NONMEM (version 7.1 or greater).  
Graphics will be created using PLT Tools (version 3.0 or greater) using R (version 2.11 or 
greater).  Initially, linear compartmental models will be applied to the data.  The choice between 
1-, 2-, and 3-compartment models will be based on the graphics and the minimum value of the 
objective function.  If graphics suggest nonlinearity in pharmacokinetics with respect to dose 
and/or concentration, nonlinear models will be evaluated. 
Once the optimal structural and error model has been determined, covariate effects will be 
assessed using a variety of tools including graphics of post hoc parameter estimates vs. 
covariates, a general linear model of parameters as a function of covariates, or an automated 
covariate search (PLT Tools).  Covariates will be incorporated into the model if they are 
physiologically appropriate, achieve statistical significance (generally requiring a P value < 0.01 
in this exploratory environment), and improve the graphics. 
Once a final model is determined, the model will undergo validation.  The strength of covariate 
effects will be determined using likelihood profiles.  Confidence intervals for parameter 
estimates will be determined using bootstrap techniques.  If appropriate, a visual predictive 
check will be performed. 
All NONMEM outputs and graphics will be provided with the population pharmacokinetic 
report.  Results will be summarized detailing the process of model building.  The report will 
include key graphics demonstrating the fit of the model to the data and covariate effects. 
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13. STUDY MANAGEMENT AND REPORTING PROCEDURES  
13.1. Data Monitoring  
A Data Monitoring Committee (DMC) will oversee the performance and safety conduct.  The 
DMC will consist of at least three members (two MDs and one statistician as voting members) 
who will receive confidential reports on a periodic basis.  The DMC will be responsible for 
decisions regarding possible termination of the study for either futility or safety reasons, refer to 
Section 11, Assessment of Safety and Section 12.8, Interim Monitoring and the Data Monitoring 
Committee. 
13.2. Patient Tablet Dispensing Record 
Three (3) month supplies of study drug(s) are issued in person or by special arrangement.  
Patients will keep a written diary concerning their compliance in taking the four tablets daily. 
The drugs are to be taken at approximately the same time each day with food, preferably in the 
morning.  If the dose is missed, the tablets may be taken with mid-day or evening meals.  If an 
entire day is missed, this should be indicated in the weekly dose accountability in the medication 
diary, but double-dosing the following day is not allowed.  If the patient vomits within an hour 
after taking the tablets, the patient will record a missed dose in the diary. If the patient vomits 
more than 1 hour after taking the tablets, no dose was missed.  In either case, no additional 
tablets are to be taken until the scheduled dose the next day.  Any unused medication must be 
returned at the subject’s next scheduled visit and an accounting of the medication will be 
performed and recorded by the research nurse or other qualified individual. 
13.3. Investigator Documentation 
The Investigator will provide the Sponsor with a fully executed FDA form 1572 including the 
Investigator’s dated curriculum vitae.  A current curriculum vitae is also required for each sub-
Investigator listed on the FDA Form 1572.  A current dated curriculum vitae is defined as 
updated within 2 years. 
The Investigator will indicate on the FDA Form 1572 the name and location of the clinical 
laboratory which will be used for patient evaluation.  The laboratory’s certification, certification 
number and date of certification and the laboratory normal values will be provided.  Any 
changes in the clinical laboratory or laboratory values will be provided promptly to the Sponsor 
who will report it to the FDA. 
The Investigators and Sub-Investigators must provide CPP with an FDA Form 3454 certifying 
the absence of financial interests and arrangements, or Form 3455 disclosing such financial 
interests and arrangements and any steps taken to minimize bias. 
13.4. Protocol Amendments 
All amendments to the study protocol must be submitted to the IRB/IEC/REB for written 
approval.  The approval letter, signed by the IRB/IEC/REB Chairperson, must refer specifically 
to the Investigator, the protocol number and protocol title, the protocol amendment number and 
the date of the protocol amendment.  A copy of the approval letter and revised informed consent 
document (if appropriate) must be sent to CPP.  A protocol amendment may be implemented 
only after it has been approved by the IRB/IEC/REB and submitted to the FDA and other 
regulatory agencies as appropriate.  In the case of a protocol change intended to eliminate an 
apparent immediate hazard to subjects, the change may be implemented immediately, but the 
change must then be documented in a protocol amendment and approved as described above. 
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13.5. Access to Source Data and Documents 
Monitors and/or auditors of CPP or representatives of the Sponsor must be allowed to visit and 
monitor all study site locations periodically to assess the data, quality and study integrity.  The 
monitors and/or auditors will review study records (typically CRFs) and directly compare them 
with the source documents and discuss the conduct of the study with the Investigator, and verify 
that the investigational site is compliant and continues to be acceptable.  In addition the site may 
be audited by government inspectors who must be allowed access to CRFs, source documents 
and other study files.  The site must promptly notify CPP of any inspections scheduled by 
regulatory authorities, and also forward copies of the inspection reports to CPP. 
13.6. Investigational Agent Records and Accountability 
It is the Investigator’s responsibility to ensure that accountability records of drug use and 
disposition are maintained at the study site and that the drug is maintained in a secure location 
under storage conditions prescribed by the Sponsor.  The site pharmacist or appointed 
investigational agent monitor will be the individual completing the records or logs for 
accountability and drug dispensing at each site.  The site pharmacist must comply with all 
applicable regulations and guidelines.  The logs should include the amount of drug received; 
amount currently on site, drug lot or batch numbers; amount dispensed to each study subject with 
appropriate subject study identification numbers; non-study disposition (wastage, broken), 
amount returned to site and Sponsor, amount destroyed at study if requested.  CPP will provide 
forms to assist with drug inventory if the site does not have an established procedure that meets 
the requirements.  Drug inventory records will be inspected by the Sponsor’s study monitors 
during the period of study treatment.  Audits will be done to verify drug accountability.  If a site 
has been determined to be non-compliant with drug accountability corrective action will be 
initiated. 
At the completion or termination of the study, all unused investigational agent will be returned to 
the repository unless authorized in writing to be destroyed at the site.  If the drug is to be 
destroyed on site, appropriate policies and procedures at the site must be in place for proper 
disposal of chemotherapeutic agents.  These procedures will be reviewed by Sponsor’s study 
monitors prior to providing written authorization for on-site drug destruction.  The unused study 
drug can only be destroyed after being inspected and reconciled by the Sponsor’s study monitor.   
13.7. Data Handling and Record Retention 
Following the completion and closure of the clinical study, in accordance with applicable 
regulatory requirements, the Investigator will maintain a copy of all study records in a safe and 
secure location.  Completed original CRFs, which are dated and signed by the investigator, and 
any resolved query reports will be retained by the Sponsor.  A copy of each completed CRF and 
signed resolved query report must be retained at the investigational site.  The Investigator will 
retain a copy of all study records in a secure location for a period of 2 years after licensure for 
marketing of drug or 15 years from the close of the trial or until receipt of notification by 
Sponsor that clinical development of this treatment has been terminated. 
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13.8. Protocol Deviations 
The Investigator is not permitted to alter or deviate from the protocol without a written waiver 
from the Sponsor.  This waiver should also be reported by the Investigator to his/her 
IRB/IEC/REB.  An immediate and unapproved deviation is permitted if immediate subject safety 
concerns mandate a deviation. 
13.9. Study Termination 
The Sponsor may terminate the study at any time.  If the study is terminated, the Sponsor will 
promptly notify the Investigator to enter no further patients on the study and remove current 
patients from the study.  The Sponsor will also inform regulatory authorities of the action. 
1. The study will also be terminated when the objectives have been fully met and all of the 
designated data collected. 
2. The Sponsor reserves the right to terminate an Investigator’s participation in this clinical 
trial for refusal of the Investigator and/or site to comply with any requirements stated in 
this clinical protocol. 
13.10. Use of Data and Publication 
All data and results and intellectual property rights in the data and results that are derived from 
the study will be property of CPP.  CPP may utilize the results and data in variety of ways 
including submission to regulatory authorities or to other investigators under disclosure.  Data 
from any individual center must not be published or presented until the complete multicenter 
study has been published or presented in full.  Subsequently, an investigator may use the data 
derived from the clinical study for scientific purposes but must discuss any publication with the 
Sponsor prior to submission or release of any data.  The Sponsor is aware of the rights of an 
Investigator to publish the results when the study is completed, and the Investigator must provide 
a draft of the abstract or manuscript to the Sponsor within 30 to 60 days prior to submission of 
the abstract or manuscript.  The Sponsor will provide a timely review and response to the 
Investigator.  In the event of a difference of opinion between the Investigator and Sponsor, all 
efforts will be put forth to find a solution that is agreeable to both the Sponsor and Investigator.  
However, the final decision for submission/dissemination of results rests solely with the 
Investigator. 
14. HUMAN SUBJECTS 
The study will not be initiated until a protocol has been filed to the IND or approved by the 
appropriate regulatory authorities and the informed consent documents have been fully reviewed 
and approved by each participating institution’s IRB/IEC/REB.  The approval and associated 
documents will be provided to the Sponsor.  All relevant regulations of the regulatory authorities 
will be followed. 
14.1. Ethical Conduct 
The study will be conducted in compliance with the regulations from the FDA, Health Canada, 
local competent authorities, and the EMA, including Protection of Human Volunteers (21 CFR 
50), Institutional Review Boards (21 CFR 56), Good Clinical Practice guidelines (ICH), and 
Obligations of Clinical Investigators (21 CFR 312), Food and Drug Regulations (C.R.C., C.870), 
C.05.001 - Division 5, Drugs For Clinical Trials Involving Human Subjects, Regulation (EU) 
No.1235/2010, Directive 2010/84/EU, Directive 2001/20/EC (The Clinical Trials Directive), 
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Commission Directive 2005/28/EC (The GCP Directive), and any other applicable country 
specific regulations. 
The protocol will be reviewed and approved by each institution’s IRB/IEC/REB, and as 
applicable, any country or regional IRB/IEC/REB.  Written documentation of the IRB/IEC/REB 
approval of the protocol and informed consent must be provided by the Investigator to the 
Sponsor prior to study initiation.  Serious adverse events regardless of causality will be reported 
to the Sponsor and to the IRB/IEC/REB, and the Investigator will keep the IRB/IEC/REB 
informed as to the progress of the study. 
14.2. Informed Consent 
The Investigator or his designee will explain the nature of the study and will inform the patient 
that participation is voluntary and that they can withdraw at any time.  Written informed consent 
and required authorization to use private information will be obtained and documented from each 
patient prior to entry into the study. 
The consent form generated by the Investigator must be approved by the IRB/IEC/REB and be 
acceptable to Cancer Prevention Pharmaceuticals.  Each subject’s signed informed consent form 
must be kept on file by the Investigator for possible inspection by regulatory authorities and or 
Cancer Prevention Pharmaceuticals personnel or representatives of Cancer Prevention 
Pharmaceuticals. 
14.3. Confidentiality 
The Investigator and his staff shall maintain the confidentiality of all patient records.  Patient 
data will be made available upon request to monitors from CPP Corporation (study Sponsor), 
regulatory authorities, the Institutional Review Board, Independent Ethics Committee, or 
Research Ethics Board, and to other government agencies that have responsibility for clinical 
research activities. 
Data that is released by the Investigator to the Sponsor, regulatory authorities, or the 
IRB/IEC/REB will not be directly traceable to the subject.  In the event that a publication of this 
research incorporates a subject’s medical data, the data will not identify the subject. 
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15. LISTING OF ABBREVIATIONS 
Abbreviation Description 
AE Adverse event 
ALT Alanine Amino Transferase 
a.m. Morning 
APC Adenomatous Polyposis Coli-tumor suppressor gene 
AST Aspartate Amino Transferase 
BCA Bicinchoninic acid 
BID Twice a day 
0C Degrees centigrade 
CBC Complete blood cell count 
CFR Code Federal Regulations 
CIOMS Council for International Organizations of Medical Sciences 
cm Centimeters 
COX Cyclooxygenase 
CPP Cancer Prevention Pharmaceuticals 
CPP-1X Eflornithine, DFMO, difluoromethylorthine 
CRC colorectal cancer 
CRF Case report form 
CTCAE Common Terminology Criteria for Adverse Events 
dB Decibels 
DFMO Eflornithine, CPP-1X, difluoromethylorthine 
dL deciliter 
DMC Data Monitoring Committee 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic Acid 
DSMB Data Safety and Monitoring Board 
EDTA Ethylene Diamine Tetra Acetic Acid 
EFS Event free survival 
EKG Electrocardiogram 
EORTC European Organization for Research and Treatment of Cancer 
EOT End of Treatment 
FAP Familial Adenomatous polyposis 
FDA Food and Drug Administration 
FFQ Food Frequency Questionnaire 
GCP Good Clinical Practices 
GI Gastrointestinal 
HCG Human Chorionic Gonadotropin 
HDPE High density polyethlylene 
HGD High grade dysplasia 
HRQoL Health-Related Quality of Life 
IB Investigator’s Brochure 
ICH International Committee on Harmonization 
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IME Important medical event 
IND Investigational New Drug Application 
InSiGHT International Society for Gastrointestinal Hereditary Tumours 
IRA Ileal-rectal anastomosis 
IRB/IEC/REB 
Institutional Review Board/Independent Ethics Committee/Research 
Ethics Board 
ITT Intent-to treat 
IUD Intrauterine device 
IUS Intrauterine system 
LGI Lower gastrointestinal 




MST Mountain Standard Time 
N Normal 
NCBI National Center for Biotechnology information 
NCI National Cancer Institute 
NSAIDS Nonsteroidal anti-inflammatory drugs 
NASR Nutrition Assessment Shared Resource 
ODC Ornithine decarboxylase 
OMIM Online Mendelian Inheritance in Man 
PCR Polymerase Chain Reaction 
PK Pharmacokinetics 
PO By mouth, orally 
PSA Prostate specific antigen 
QLQ  Quality of Life Questionnaire  
QoL  Quality of Life  
RNA Ribonucleic acid 
RX Treatment 
SAE Serious Adverse Event 
SAP Statistical Analysis Plan 
SNP Single nucleotide polymorphism 
Spd:Spm Spermidine to spermine ratio 
SWOG Southwest Oncology Group 
TEN Toxic epidermal necrosis 
UGI Upper gastrointestinal 
ULN Upper limit of normal 
US United States 
T1/2 Half-life 
WBC White Blood Cell 
WHO World Health Organization 
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APPENDIX A SPIGELMAN’S SCORE AND STAGE 
Modified Spigelman’s Score and Classification (Saurin, 2004) 
 Score 
Factor 1 Point 2 Points 3 Points 
No. of polyps 1-4 5-20 > 20 
Polyp size, mm 1-4 5-10 > 10 
Histology Tubulous Tubulovillous Villous 
Dysplasia Low grade — High grade* 
NOTE:  Classification as follows based on score scale. 
Stage 0: no polyps 
Stage 1: 1 to 4 points 
Stage 2: 5 to 6 points 
Stage 3: 7 to 8 points 
Stage 4: 9 to 12 points 
 
*High-grade dysplasia would be assigned to any epithelium showing nuclear stratification all the 
way to the tops of the cells and loss of mucin production. It can encompass intraepithelial 
carcinoma if the cells are pleomorphic or even cribiformed in architecture but still all located 
above the basement membrane. 
Vienna Classification of Gastrointestinal Epithelial Neoplasia (Schlemper et al., 2000) 
Category 1 Negative for neoplasia/dysplasia 
Category 2 Indefinite for neoplasia/dysplasia 
Category 3 Non-invasive low grade neoplasia (low grade adenoma/dysplasia) 
Category 4 Non-invasive high grade neoplasia 
4.1 High grade adenoma/dysplasia 
4.2 Non-invasive carcinoma (carcinoma in situ)a 
4.3 Suspicion of invasive carcinoma 
Category 5 Invasive neoplasia 
5.1 Intramucosal carcinomab 
5.2 Submucosal carcinoma or beyond 
a Non-invasive indicated absence of evident invasion. 
b Intramucosal indicated invasion into the lamina propria or muscularis mucosae. 
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InSiGHT Meeting 2011, San Antonio, TX 
Stage Polyp Description Recommended 
Intervention 
Comment 
0 0-10 polyps, all <5mm Repeat FS in 1 years  
1 10-25 polyps 
most <5mm, none >1cm 
Ablate polyps; repeat 
sigmoidoscopy in 1 year 
Chemopreventive 
may be considered 
2 10-25 polyps, any >1cm, 
amenable to complete removal  
Repeat sigmoidoscopy 6 
months 
Polypectomy preferred 





3 > 25 polyps amenable to 
complete removal,  or any 
incompletely removed sessile 
polyp, or any evidence of HGD, 
even if completely excised 
Repeat sigmoidoscopy 3-6 
months; consider 
proctectomy 
Large polyps must 
be removed; 
second opinion on 
polyp management 
helpful 
4 >25 polyps not amenable to 
complete removal, or any 
incompletely excised sessile 
polyp showing HGD; any 
invasive cancer 
Proctectomy/pouch 
revision +/- ileostomy 
clearly indicated within 3 
months 
Any decision to 
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APPENDIX C Desmoid Staging System 
 
Stage Description 
I Asymptomatic, <10 cm maximum diameter, and not growing 
II Mildly symptomatic, <10 cm maximum diameter, and not 
growing 
III Moderately symptomatic or bowel/ureteric obstruction, or 10 
to 20 cm, or slowly growing 
IV Severely symptomatic, or >20 cm, or rapidly growing 
 
Mildly symptomatic = sensation of mass, pain, but no restrictions;  
Moderately symptomatic = sensation of mass, pain; restrictive but not hospitalized;  
Severely symptomatic = sensation of mass, pain; restrictive and hospitalized. 
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APPENDIX D Event Rate Summary Table 
Familial Adenomatous Polyposis (FAP) Review:  Evidence-Based Projected Event Rates at 2 Years 
Rectum (after IRA) and Pouch (after Ileal-Pouch Anal Reconstruction)
Key References Comments Event/Rate 
Bertagnolli, et al., N Eng J Med, 2006 
Bulow, et al., Dis Colon Rectum, 2008 
Church, et al., Surg Onc Clin N Am, 2009 
Church, et al., Dis colon Rectum, 2005 
Groves, et al., Dis Colon Rectum, 2005 
Huang, et al., Church, Familial Cancer, 2011 
Nieuwenhuis, et al., Dis Colon Rectum, 2009 
Tonelli, et al., J Surg Onc, 2000 
Vasen, The Lancet, 1996 
West, et al., Gut, 2010 
 
 
 80% of patients develop adenomas within the pouch body. 
 71% ↓of adenomas after 4-6 mo. Sulindac (300-400mg/day)-
analysis combined randomized studies. 
 Incidence of pouch adenomas is time-dependent with 42% of 
patients at 7 yrs from pouch construction. 
 Median time from pouch construction to diagnosis pouch 
adenomas, 4.7 yrs (0.5-12 yrs). 
 Celecoxib treated patients, median time to first polypectomy 
post IRA was 18.69 months; 90.9% (30 patients) had a post 
IRA rectal polypectomy. 
 Celecoxib treated patients, post IPAA, 3 of 24 pts (12.5%) had 
post IPAA polypectomy, 21 censored.  25th and 50th percentiles 
of time to first polypectomy in IPAA patients was 169.9 months 
 80% of patients develop adenomas within the pouch body. 
 Celecoxib treated patients, median time to first polypectomy post IRA was 18.69 months; 





Key References Comments Event/Rate 
Bulow, et al., Gut, 2004 
Bulow, et al., Familial Cancer, 2011 
Brosens, et al., Gut 2005 
Cruz-Correa, et al., Gastroenterology, 2002 
Church, Surg Onc. Clin N Am, 2009 
Clark , et al., Familial Cancer, 2011 
Groves, et al., Gut, 2002 
Johnson, et al., Gastrointest Surg, 2010 
Phillips , et al., Gut 2002 
Saurin, et al., JCO, 2004 
Vasen, et al., Gut, 2008 
van Heumen, et al., Familial Cancer, 2011 
 95-100% of all FAP patients develop duodenal adenomas 
 10-25% of patients have Stage III/IV 
 36% of Spigelman Stg IV develop cancer 
 Endoscopic resection/ablation - local recurrence rate 72.5% 
with mean follow-up interval of 12.8 months.  Surgical 
resection-30% mean follow-up of 44 months, Definitive 
resection 47 pts with recurrence rate of 9%.  Surgical morbidity-
48%. 
 Patients down staged from Spigelman stage IV demonstrate 
increased rate of disease progression back to severe disease. 
 Recurrence rate of adenoma development is > 50% after endoscopic treatment and 
treatment is associated with 17% complication rate (perforation, hemorrhage, 
pancreatitis) 
 Rate of progression between Spigelman stages variable, 4 – 11 yrs 
 
Pre-Colectomy 
 Comments Event/Rate 
  Diagnosis with recommendation to proceed with prophylactic 
colectomy or proctocolectomy. 
 
 
Summary Projected 2 year Event Rate: Excisional 
intervention and/or high risk adenoma – 40-60% 
Summary Projected 2 Year Event Rate: Excisional 
intervention, cancer – 50% 
Summary Projected 2 Year Event Rate: Excisional 
intervention, cancer – 90% 
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INVESTIGATOR PROTOCOL AGREEMENT  
CPP FAP-310 
A DOUBLE-BLIND, RANDOMIZED, PHASE III TRIAL OF THE SAFETY AND EFFICACY OF CPP-
1X/SULINDAC COMPARED WITH CPP-1X, SULINDAC AS SINGLE AGENTS IN PATIENTS WITH 
FAMILIAL ADENOMATOUS POLYPOSIS (FAP)  
By signing below, I agree: 
1. That my staff and I have read, understand and will adhere to the protocol as written and agree 
that any changes to the protocol will be agreed to and approved by Cancer Prevention 
Pharmaceuticals, except to eliminate an immediate hazard to the patients.  Prior to instituting 
changes, I will obtain approval from the Independent Ethics Committee (IEC)/Institutional 
Review Board (IRB)/Research Ethics Board (REB); 
2. To abide by all obligations stated on the FDA Form 1572 and other documents required by 
regulation; 
3. To conduct this study in accordance with the current International Conference on 
Harmonization (ICH) guidance, the Good Clinical Practices (GCP) guidance the US FDA 
regulations, EMA regulations, Health Canada regulations, local competent authority 
regulations, and local IRB/IEC/REB and legal requirements; 
4. To obtain IRB/IEC/REB approval of the protocol, any amendments to the protocol, and 
periodic re-approval as required, and to keep the IRB/IEC/REB informed of adverse events 
and periodically report the status of the study to them; 
5. To ensure that each patient enrolled into the trial, or legally authorized representative has 
read and understands the current patient information, and has signed the Informed Consent 
form; 
6. To ensure that I and all persons assisting me with the study are adequately informed and 
trained about the investigational drug and of their study related duties and functions as 
described in the protocol; 
7. To make prompt reports of Serious Adverse Events (SAEs) and deaths as defined in the 
protocol, the FDA regulations, EMA regulations, local competent authority regulations, and 
Health Canada regulations; 
8. To prepare and maintain adequate and accurate case histories to document all observations 
and other data pertinent to the study on each individual enrolled in the clinical trial. 
Investigator Signature:  ________________________________________  ________________ 
  Date 
Investigator Name (Print):  _____________________________________ 
Institution:  __________________________________________________ 
 __________________________________________________ 
 __________________________________________________ 
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Chief Medical Officer 
Cancer Prevention Pharmaceuticals, Inc. 
Email: acohen@canprevent.com 
Phone (Main): +1 (520) 908-7774 
Phone (Cell): +1 (520) 400-0116 
 
Legal Representative EU 
Cancer Prevent Pharma Ltd   Andrew B. Hadlington, Wessex Pharma Services Ltd 
Tower 42, Level 30    19 Webster Road, Winchester, 
International Finance Center 25  Hants SO22 5NT 
London ECN2 1HQ United Kingdom Phone/Fax: +44 1962 843331 




SAE Reporting, Reporting Contact Numbers 
SAE reporting to occur through the electronic data capture system or via paper CRF submission. 
Chiltern Drug Safety contact information: 
Phone: 1 (919) 462-8867 (US/Canada); 001 (919) 462-8867 (EU) 
Fax: 1 (919) 468-2288 (US/Canada); 001 (919) 468-2288 (EU) 
Email: dsafety@chiltern.com 
 
CPP Phone Contact Information: 
Monday – Friday (8:00 am – 5:00 pm MST), Phone: +1 (520) 908-7774; Fax: +1 (520) 232-2191 
 
Alternative CPP Contact Numbers: 
Alfred Cohen, M.D., cell: +1 (520) 400-0116 or Kathryn Grenier, cell: +1 (520) 444-5869 
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1.3. Other Medical and/or Technical Departments 
Biostatistician 
Bruce Levin, Ph.D. 
Professor, Department of Biostatistics,  
Mailman School of Public Health, Columbia University 
722 West 168th Street, Room 626a  
New York, NY 10032 
Bioanalysis Laboratories 
Metabolon Inc., 617 Davis Drive, Ste. 400, Durham NC, 27713, USA, will perform the testing for 
the polyamine samples collected. 
Molecular MD Inc., 1341 SW Custer Drive, Portland OR, 97219, USA, will perform the testing for 
the pharmacogenomic samples collected 
inVentiv Health Clinique, Inc., 2500 rue Einstein Street, Québec City, Québec G1P 0A2, Canada, 
will perform the bioanalysis for the pharmacokinetic samples collected. 
1.4. Signature Authority for Protocol and Protocol Amendments 
Alfred M. Cohen, M.D., F.A.C.S., F.A.S.C.R.S. 
Chief Medical Officer 
1.5. Clinical Investigators and Study Leadership 
Study Co-Principal Investigators 
Carol Burke, M.D. and James Church M.D., F.A.C.S., F.A.S.C.R.S 
Jewell Samadder, M.D. 
Ernest T. Hawk, M.D, M.P.H. 
Prof. Dr. Med Gabriella Möslein 
Clinical Investigators and Sites 
Patrick M. Lynch, J.D., M.D. 
Professor, Dept. of Gastroenterology, Hepatology, 
Nutrition, Division of Internal Medicine 
University of Texas, M.D. Anderson Cancer 
Center 
1515 Holcombe Boulevard,  
Houston, TX 77030 USA 
Carol Burke, M.D. 
Department of Gastroenterology and Hepatology 
James Church, M.D., FACS, FASCRS 
Department of Colorectal Surgery 
Cleveland Clinic 
9500 Euclid Avenue 
Cleveland, OH 44195 USA 
Dr. Alex Henderson, Prof. Sir John Burn  
Institute of Genetic Medicine 
International Centre for Life 
Central Parkway 
Newcastle Upon Tyne and Wear 
NEI 3BZ United Kingdom 
Paul E. Wise, M.D. 
Washington University in St. Louis 
School of Medicine 
Section of Colon and Rectal Surgery 
CB 8109, 660 S. Euclid Ave 
St Louis, MO 63110 USA 
Ramona Lim, M.D., Sapna Syngal, M.D., MPH 
Dana Farber Cancer Institute 
450 Brookline Avenue  
Boston, MA 02215 USA 
Priyanka Kanth, M.D. 
Huntsman Cancer Institute  
2000 Circle of Hope,  
Salt Lake City, UT 84112 USA 
Frank A. Sinicrope, M.D. 
Dept. of Gastroenterology and Hepatology 
Mayo Clinic 
200 First Street, S.W.  
Rochester, MN 55905 USA 
Elena Stoffel, M.D., MPH 
University of Michigan 
Comprehensive Cancer Center 
1500 East Medical Center Drive 
Ann Arbor, MI 48109 USA 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  8 
Steve Gallinger, M.D., MSc, FRCS 
Professor of Surgery, Head, Division of 
Hepatobiliary/Pancreatic Surgical Oncology Prgm 
Robert Gryfe, M.D., PhD, Zane Cohen, M.D. 
Zane Cohen, Centre for Digestive Diseases 
Univ. Health Network and Mount Sinai Hospital 
200 Elizabeth St, 10EN, Room 206, Toronto 
Ontario, M5G2C4 Canada  
Prof. Evelien Dekker, M.D., PhD 
Academic Medical Centre 
Dept. of Gastroenterology and Hepatology,  
C2-115 
PO Box 22700 
Amsterdam, 1100 DE, The Netherlands 
Prof. Dr. Med Christian Strassburg 
Dr. Robert Hüenburg 
Department of Hepato-Gastroenterology 
University of Bonn Hospital, Bldg. 334, 2nd floor 
Sigmund Freud Str 25 
Bonn, 53127 Germany   
Antoni Castells, M.D. 
Institute De Malalties Digestives 
Hospital Clinic, Villarroel 170 
Barcelona, Catalonia, 08036 Spain  
Anil Rustgi, M.D. 
University of Pennsylvania 
Perelman School of Medicine 
3400 Civic Center Blvd, 4 S Pavilion 
Philadelphia, PA 19104 USA 
Samir Gupta, M.D. 
University of California San Diego 
Clinical and Translational Research Institute 
9500 Gilman Dr. MC 0990 
La Jolla, CA 92037 USA 
Fiona Lalloo, M.D. 
Manchester Centre For Genomic Medicine 
Central Manchester University  
Saint Mary’s Hospital- Oxford Road 
Manchester, M13 9WL United Kingdom 
Giovanna da Silva, M.D. 
Cleveland Clinic Florida 
2950 Cleveland Clinic Blvd. 
Weston, FL 33331 USA 
Professor Eric Van Cutsem, M.D., Ph.D. 
Leuven Cancer Institute 
University Hospitals Leuven 
3000 Leuven, Belgium 
Dr. Jennifer Weiss, M.D. 
University of Wisconsin-Madison 
Division of Gastroenterology and Hepatology 
UWM Centennial Building 
1686 Highland Avenue 
Madison, WI 53792 USA 
William Grady, M.D. 
Fred Hutchinson Cancer Research Center 
/University of Washington 
1100 Fairview Avenue N., D4-100 
Seattle, WA 98109 USA 
Field Willingham, M.D. 
Emory University 
Division of Digestive Diseases 
1365 E. Clifton Rd. NE 
Building B, Suite 1200 
Atlanta, GA 30322 USA 
Molly Cone, M.D. 
Vanderbilt-Ingram Cancer Center 
1211 21st Avenue South 
Medical Arts Building, Room 711 
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1.6. Study Schema 
MAJOR ELIGIBILITY CRITERIA 
1. Diagnosis of Familial Adenomatous Polyposis (FAP) with confirmed APC mutation AND age ≥ 18 
years. 
2. If prior colorectal surgery, at least 3 years since colectomy/proctocolectomy with ileo-rectal 
anastomosis (IRA) or pouch. 
Disease at One or More of These Sites 
1. Intact colon (pre-colectomy) 2. Rectal/Pouch Polyposis 3. Duodenal Polyposis 
Stratification 
Stratification based on FAP-related time to first event prognosis. 
1. best (i.e., longest projected time to first FAP-related event) – rectal/pouch polyposis 
2. intermediate – duodenal polyposis 
3. worst – pre-colectomy 
If a subject has two or more of these disease sites, the stratum for randomization will be 
according to the most severe prognosis stratum as defined above. 
Randomization 





Randomized subjects will receive 24 months of treatment and complete their final assessment or come off-
study for an FAP-related event or for other reasons (for example, safety issues, non-compliance, withdrew 
consent, lost to follow-up).  
Subjects completing 24 months of treatment without an FAP-related event may continue on treatment for 
up to 48 months based on their randomization date as follows: 
1. If randomized between November 2015 and April 2016 eligible for up to 36 months of treatment 
2. If randomized between May 2015 and October 2015 eligible for up to 42 months of treatment 
3. If randomized between July 2014 and April 2015 eligible for up to 48 months of treatment 
or until one of the following occurs: 
1. Subject has an FAP-related event or comes off study for other reasons 
2. Trial end-date of April 30, 2019 has been reached 
3. 90 FAP-related events have occurred 
4. Less than 90 FAP-related events have accrued prior to April 30, 2019 and an earlier trial end-date 
has been set by the Sponsor and reviewed by the DMC 
5. An earlier trial end date prior to April 30, 2019 has been recommended by the DMC for safety 
reason and approved by the Sponsor 
 
CPP-1X (750 mg) CPP-1X (750 mg) Placebo (CPP-1X) 
 +   +   +  
Sulindac (150 mg) Placebo (Sulindac) Sulindac (150 mg) 
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2. BACKGROUND INFORMATION 
2.1. Natural History, Current Surgical and Endoscopic Treatment 
Familial Adenomatous Polyposis (FAP) is a syndrome caused by mutations in the Adenomatous 
Polyposis Coli (APC) tumor suppressor gene and propagated by an autosomal dominant mode of 
inheritance. Details of this syndrome can be found at OMIM ®, (Online Mendelian Inheritance in 
Man), http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=175100, which is an authoritative 
listing of human genes and genetic phenotypes. This database is available to users’ courtesy of 
NCBI, the National Center for Biotechnology Information.  
FAP is caused by mutations/deletions in the APC gene, which is located on chromosome 5q21-
q22.  Gardner syndrome is a variant of FAP in which desmoid tumors, osteomas, and other 
neoplasms occur together with multiple adenomas of the colon and rectum 
(http://www.cancer.gov/cancertopics/pdq/genetics/colorectal/HealthProfessional/page4/AllPages). 
Most FAP patients will have hundreds to thousands of colorectal adenomas, and without 
prophylactic surgery develop colorectal cancer before the age of 40.  Prophylactic surgery may 
involve total abdominal colectomy with ileal-rectal anastomoses (IRA), accompanied by frequent 
rectal surveillance with polypectomy and cautery/laser ablation as needed.  Patients with 
extensive rectal involvement undergo total proctocolectomy with ileal pouch-anal reconstruction.  
Despite removing the main at-risk organ, many patients develop duodenal neoplasia (bulky 
adenomas/cancer) and require additional localized or Whipple radical surgery.  The Spigelman 
classification (Stage 3 or 4)1 can accurately predict those with adenomas that are most likely to 
progress to cancer.  Bulow and colleagues2 reviewed duodenal polyposis issues in FAP patients.  
Gastric antral adenomas may occur and rarely are symptomatic or progress to cancer.  
Despite total proctocolectomy with ileal pouch reconstruction, approximately 50% of patients will 
develop adenomatous lesions in the neo-rectum.3-6  There are case reports of cancer developing in 
the pouches. All patients who have a residual rectum after total colectomy require frequent 
surveillance, polypectomies and ablations for continuing rectal polyposis. 
Desmoids are “benign tumors” (myofibroblastic) and cause significant morbidity and mortality in 
some patients.  They are not associated with any specific FAP genotype but are more common if 
the APC mutation is distal to codon 1444; the major clinical risk factors are family history and 
prior colectomy.  Women are at greater risk. Growth of these lesions, particularly when they 
involve the root of the mesentery, can lead to extensive surgery, often resulting in resection of 
ileal pouches and permanent ileostomy.  Current treatment involves surgery, radiation, NSAIDS 
and anti-estrogens.  None of these approaches have major impact on the growth of these lesions.7-
9 Although an important site of disease and morbidity for FAP patients, this protocol will focus on 
intestinal polyposis only. 
Vasen and colleagues10 provide evidence-based guidelines for the evaluation and management of 
FAP patients and provides detailed natural history data. 
After prophylactic colectomy, all FAP patients undergo regular surveillance intervention, with 
proctoscopy and upper GI endoscopy every 6-12 months.  Surgical intervention may be required 
for progressive FAP related disease (defined in protocol).  We believe that disease control with 
our combination regimen will delay the occurrence of clinically meaningful events. 
2.2. Pharmacologic Clinical Trials in FAP Patients 
In the general population, certain types of colorectal polyps have increased risk of progression to 
colorectal cancer.  High risk polyps (polyps with villous histology, size ≥1 cm, high grade 
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dysplasia, or multiple adenomas defined as 3 or more) have become the focus of colorectal 
tumorigenesis research due to the higher rate of malignant potential for these.11-15  The biology of 
common colorectal cancer is similar to the FAP phenotype.  Wallace and Lynch16 summarized the 
current status of chemoprevention in FAP patients.  The key drugs/drug combinations are 
described below. 
2.2.1. Sulindac Alone 
Labayle and colleagues17 studied 10 FAP patients with IRA in a randomized placebo controlled 
double blind trial of sulindac 300 mg a day for 4 month intervals.  In rectal assessment of polyp 
counts, there was a statistically significant reduction with sulindac compared to placebo (despite 
the small number of evaluable patients assessed). 
Nugent18 evaluated sulindac at 200 mg twice a day in 24 patients with duodenal neoplasia and in 
this group 12 had an IRA and the rectum was also evaluated.  This was a placebo controlled 
randomized trial.  Benefit was demonstrated in the rectum, but treatment was not statistically 
beneficial in the duodenum. 
Giardello and his group19 performed a randomized double blind trial in non-operated FAP patients 
or those who had an IRA.  Sulindac at 150 mg twice a day was the treatment regimen.  Rectal 
polyp numbers decreased 56% in the treated group. 
Tonelli et al.,20 studied 15 FAP patients after IRA.  This non-randomized trial used sulindac     
100 mg twice a day.  A benefit was seen after 6 months, but not long-term. 
Cruz-Correa21 studied 12 patients post IRA for rectal polyp control with 150 mg of sulindac twice 
a day.  A major reduction in polyp numbers was demonstrated, but with a 50% incidence of 
gastrointestinal erosions. 
Giardiello and colleagues22 utilized sulindac in 41 non-operated FAP patients, mean age of 13.  
By the end of the study all but 3 of the 21 subjects randomized to the sulindac arm were receiving 
150 mg of sulindac daily twice a day.  Treatment with sulindac for a four-year period was well 
tolerated.  Few adverse events were reported and 93% were grade 1 or grade 2 and included 
leukopenia, photosensitivity, rash, urticaria, diarrhea, vomiting, bleeding, hyperbilirubinemia, 
blurred vision, abdominal pain, and influenza like syndrome.  One subject was withdrawn 
because of possible drug-induced neutropenia.  The incidence of any adverse event did not differ 
significantly between the sulindac group and the placebo group.  There was no demonstrable 
difference in the adenoma formation compared to placebo. 
2.2.2. Celecoxib Alone 
Although FDA approved celecoxib for the treatment of FAP patients in 1999, Pfizer withdrew the 
agent’s registration.  Of note, this agent did not become a usual part of standard care for these 
patients.  This is partly due to concerns for patient safety resulting from colorectal adenoma 
prevention studies reported in 2006.23,24  These studies identified a small but finite risk of serious 
cardiovascular events associated with celecoxib treatment. 
Albeit the one most prominent study was performed at MD Anderson, Houston, TX and St. 
Mark’s Hospital, London.25,26  Patients were randomized to placebo control, celecoxib 100 mg 
twice daily, and celecoxib 400 mg twice daily.  In the Steinbach report,25 6 months of celecoxib, 
400 mg twice daily showed a 28% change from baseline in the mean number of rectal polyps, the 
lower dose of the drug (100 mg twice daily) showed an 11.9% change in the mean number of 
polyps compared to baseline.  Similar data were found in the duodenal cohort.  Polyp reduction 
with small baseline tumor burden was only 14.5%, but 31% in more involved baseline duodenal 
adenomatosis.  Again, effect was noted only in the high dose celecoxib patients.  Sixty-eight 
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percent (68%) of patients in the placebo group, 56% of patients in the 100 mg twice daily group, 
and 57% of patients in the 400 mg twice daily group reported one or more adverse events of grade 
2 or higher (NCI CTC, Ver. 3.0).  The most common events were diarrhea and abdominal pain. 
2.2.3. NSAIDs Plus Eflornithine Combination 
This research program was activated in 2002, as a randomized Phase II study (ClinicalTrials.gov 
NCT00033371) comparing the effectiveness of celecoxib +/- eflornithine in FAP.  Accrual was 
discontinued after approximately 111 patients were entered.27,28 
The stated purpose of this study was to “compare the effectiveness of celecoxib with or without 
eflornithine in preventing colorectal cancer in patients who have familial adenomatous 
polyposis”. The outcome measures involved changes in polyp numbers, polyp burden, and 
plaque-like duodenal polyps after 6 months of treatment.  This was a two-arm trial: 
1. Oral celecoxib (400 mg) twice daily with oral eflornithine (500 mg/m2), once daily, vs. 
2. Oral celecoxib twice daily and oral placebo once daily 
The major conclusions from that study were: 
• Addition of eflornithine, at an average daily dose of 750 mg (three 250 mg tablets) to 
celecoxib did not significantly reduce raw adenoma count according to primary endpoint 
measure (polyps in reference cluster in still color photos) compared to celecoxib alone. 
• At least borderline significance of the combination was achieved by secondary measures 
(counts in photos, weighted by diameter, and by video of larger segments of colorectum). 
• No deleterious ototoxicity due to eflornithine was detected. 
• No significant treatment-related adverse events were noted in either arm of the trial. 
• Finding of greater effect on diameter-weighted burden suggests these agents may have 
greater effect at level of adenoma promotion than initiation. 
• Based on findings from another trial, use of a web-based quantitative tool for capturing 
diameter-weighted adenoma counts from videos of total colon or rectum may be more 
informative than approaches to adenoma quantification to date. 
2.2.4. Eflornithine Alone 
There are extensive preclinical studies in mouse models of FAP.  These mouse models express a 
mutant form of the mouse homolog of the human adenomatous polyposis (APC) gene.  When 
these mouse models of FAP are treated with eflornithine alone, the agent causes a dose-dependent 
decrease in the number of both intestinal and colonic polyps.29-31 
There have been no clinical trials in FAP patients using eflornithine alone although other clinical 
trials of eflornithine have shown suppressed tumor growth in multiple tumor types.  As indicated 
above, the Lynch trial provides the first evidence of effect of eflornithine, at an average daily dose 
of 750 mg in patients with FAP.28  There was no eflornithine alone arm in that trial, so the data 
only addresses eflornithine in combination with celecoxib.  However, in that trial there was 
evidence for both safety of eflornithine at 750 mg/day in this patient population (no difference 
between NSAID alone and the combination arm) and efficacy (statistically significant effect of 
combination versus NSAID alone arm) for both total polyp volume and global polyp burden 
measures. 
The major evidence for benefit of eflornithine derives from prospective, randomized, placebo-
controlled clinical trials of eflornithine alone in patients with elevated risk for developing certain 
forms of cancer.  In one trial of 81 men with a family history of prostate cancer, oral eflornithine 
alone (500 mg per day for one year) reduced prostate polyamine contents, prostate volumes and 
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prostate specific antigen (PSA) doubling times in men, compared to these same parameters in 
men taking placebo tablets.32  In a second study, 291 people with prior non-melanoma skin 
cancers were treated with eflornithine alone (500 mg/m2 per day for 4-5 years).  In that study, the 
treatment with eflornithine was associated with a highly statistically significant reduction in 
metachronous basal cell skin cancers.33  Toxicities were rare in both of these studies, and 
consisted of infrequent clinically non-significant ototoxicity (meaning that the ototoxicity was not 
apparent to the patient and was only detectable by quantitative audiology testing).  A recent report 
of this eflornithine-related toxicity was reported in detail for a clinical trial evaluating the 
combination of eflornithine and sulindac.34  Clinical studies of eflornithine monotherapy have 
also been conducted with trial endpoints consisting of tissue polyamine contents.  These markers 
are dependent on ornithine decarboxylase (ODC), the eflornithine target protein.  Doses, such as 
those proposed by the Sponsor, have been shown to reduce rectal mucosal tissue polyamine 
contents in a randomized placebo-controlled clinical trial.35  This marker study is especially 
relevant to patients with familial adenomatous polyposis (FAP), where the target tissues include 
intestinal and colonic mucosa. 
These clinical trial results are corroborated by clinical translational studies that are based on 
molecular epidemiology investigations.  Examples of this type of evidence include studies 
replicated by three independent groups in humans showing that a polymorphism affecting the 
expression of ODC, the eflornithine target protein, is highly associated with metachronous colon 
adenomas36,37 and sporadic breast cancer38  In addition, two independent groups have reported 
that this same polymorphism is associated with prostate cancer39 and colon cancer survival.40 
2.3. Sulindac and Eflornithine; Colorectal Polyp Chemoprevention 
Meyskens and colleagues41 performed a Phase III double-blind trial involving resected sporadic 
adenoma patients treated for three (3) years with eflornithine (500 mg once a day) plus sulindac 
(150 mg once a day) compared to placebo/placebo that demonstrated a marked reduction (70%) 
of metachronous adenomas overall, 92% efficacy against advanced adenomas, and 95% efficacy 
in decreasing the risk of developing multiple adenomas compared to placebo.  Additionally, this 
combination regimen was generally well-tolerated. 
2.4. Biology Of Eflornithine 
Ornithine decarboxylase (ODC) is a transcriptional target of the MYC oncoprotein and MYC 
transcription is suppressed by the APC gene product.42,43  ODC enzyme activity and polyamine 
contents are elevated in the apparently normal colonic mucosa of genotypic FAP patients, 
compared to FAP normal family members.44  These mechanistic and translational studies in 
humans indicate that ODC enzyme activity is up-regulated in the intestinal and colonic mucosa of 
patients with FAP. 
Eflornithine, also known as DFMO, is an enzyme-activated, irreversible inhibitor of ODC, an 
essential enzyme in the polyamine synthesis pathway.45  Studies in animal models of FAP 
indicate that eflornithine alone is effective in reducing the number of intestinal29 and colonic30 
tumors.  Eflornithine works in combination with the non-steroidal anti-inflammatory drug 
(NSAID) sulindac to further reduce tissue polyamine contents, as sulindac activates polyamine 
export mechanisms.46  Combination treatment with eflornithine and sulindac dramatically reduce 
the incidence of metachronous colorectal adenomas in patients with prior sporadic adenomas.41  
The majority of sporadic colorectal adenomas have mutations in APC or another gene in the 
WNT signaling pathway.  In addition, combinations of eflornithine and NSAIDS have been 
shown to reduce the number of advanced adenomas by more than 90% in mouse models of 
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FAP.31  These results provide strong rationale that patients with FAP should respond to this 
therapy. 
2.5. Rationale for Eflornithine Dose 
Prior pharmacokinetic (PK) studies had documented linearity of serum eflornithine levels with 
oral doses as low as 100 mg/m2/day.47  Dose-de-escalation studies identified oral daily doses of 
eflornithine, which irreversibly inhibits an essential enzyme in polyamine synthesis pathway, in 
the range of 200-400 mg/m2/day as a dose range that effectively reduced colorectal tissue 
polyamine contents.35  Oral doses in this range achieve serum concentrations that inhibit ornithine 
decarboxylase enzyme activity and polyamine synthesis in cell culture models.48  Based on these 
findings, a Phase III clinical trial of eflornithine combined with the non-steroidal anti-
inflammatory drug (NSAID) sulindac was conducted to evaluate the effect of this combination on 
the incidence of metachronous colorectal adenomas in patients with prior sporadic (non-genetic) 
colorectal polys.41  Based on an average adult body surface area of 1.6 m2,49 a dose of 500 mg 
oral daily dose of eflornithine was selected.  That study found that the combination therapy 
reduced total metachronous colorectal adenomas by 70%, and advanced/multiple metachronous 
colorectal adenomas by more than 90% while also reducing colorectal polyamine levels.41,50  No 
clinically significant toxicities were found to be statistically significant in that study.  Clinically 
non-significant ototoxicities were identified in less than 10% of patients, using quantitative 
audiology methods.34 
Recently, a clinical trial of eflornithine in combination with another NSAID for prevention of 
polyps in FAP patients has been reported.  Lynch et al.27,28 have reported results of a trial using 
500 mg/m2/day eflornithine, rounded to the nearest 250 mg as 250 mg tablets were used in this 
study, combined with 400 mg BID celecoxib.  After correcting for body surface area, the average 
eflornithine dosage was three (3) 250 mg eflornithine tablets PO daily. While the effect of the 
combination was not different from celecoxib alone for the primary endpoint (duodenal and 
colorectal polyp number), the Lynch et al. study provided evidence for effectiveness of the 
combination versus celecoxib alone (statistically significant reductions in the secondary endpoints 
of polyp volume and global polyp burden).  No differences in toxicities, including ototoxicities, 
were observed between treatment arms in this study.  Another study in non-FAP patients but 
relevant to potential safety issues of the higher eflornithine dose has also been reported. Bailey 
and colleagues treated 291 patients with prior non-melanoma skin cancers with 500 mg/m2/day 
eflornithine for 4-5 years.33  One patient was reported to have subclinical ototoxicity in that study. 
Long-term follow-up of these patients found no increase in adverse events in the treatment group 
compared to placebo.33 
CPP FAP-310 will evaluate the eflornithine-sulindac combination in patients with FAP.  These 
patients are at elevated risk for intestinal and colorectal polyposis and other events related to the 
fact that they harbor germline mutations in the adenomatous polyposis coli (APC) tumor 
suppressor gene.  These genotypic FAP patients express higher levels of the eflornithine target 
gene, ornithine decarboxylase (ODC) and polyamine contents in apparently normal rectal mucosa 
than do non-genotypic familial controls.44  These levels are higher than those reported for patients 
with sporadic risk of colorectal cancer.51 
This study will use three (3) 250 mg eflornithine tablets daily in CPP FAP-310.  This is based on 
both safety and efficacy considerations.  Both the Lynch study (in FAP patients) and the Bailey 
study and others (in non-FAP patients) indicate safety of this eflornithine dose.28,33  The Lynch 
study provides evidence for efficacy of the higher eflornithine dose in FAP patients.28 
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2.6. Rationale for Sulindac Dose 
The dose of sulindac (daily oral dose of 150 mg) for this study was selected on knowledge of its 
physiology and evidence from preclinical and clinical studies. 
Experimental findings in human cell and mouse models indicate that sulindac and other NSAIDS 
activate polyamine catabolism and export.43  Thus, NSAID complement inhibitors of polyamine 
synthesis, like eflornithine, to reduce tissue polyamines.  Cell culture data demonstrated that 
sulindac metabolites reduce cell survival in vitro in a dose dependent manner at doses above 
150µM for 24 hour exposure times.52 
Eflornithine-sulindac combinations are potent inhibitors of intestinal carcinogenesis in mouse 
models,31 Figure 1. 
 
Figure 1 - Eflornithine-Sulindac Combinations Mouse Model 
 
Ignatenko, Nutrition & Cancer 2008 
 
A detailed review of the clinical pharmacokinetic of sulindac has been written53 and discusses 
long-term twice daily administration which results in accumulation of sulindac in the plasma, 
with the most common side effects being gastrointestinal and include pain, dyspepsia, nausea and 
gastrointestinal cramps. 
Clinical studies demonstrate that a range of orally administered sulindac can cause regression of 
colorectal adenomas.  In the review by Keller and Giardiello,54 sulindac doses from 100 – 300 mg 
administered once or twice daily have been shown to cause regression of colorectal adenomas in 
patients with Familial Adenomatous Polyposis (FAP).  Sulindac side effects noted in most of 
these studies were minimal although at the 300 mg/day of sulindac there may be an increase in 
cardiovascular risk in older high risk patients. 
The studies summarized in the Keller and Giardiello review provides the clinical data to support 
the use of low doses of sulindac are effective in reducing colorectal adenoma burden in FAP 
patients20,21,55,56,57,58 and that standard doses of sulindac (300-400 mg) are associated with 
significant toxicities.  Therefore, a low dose of sulindac (150 mg) once per day was selected to be 
combined with eflornithine for treatment of patients with Familial Adenomatous Polyposis that 
are at high risk of developing rectal/intestinal cancer. 
Sulindac used off label is often the choice of clinicians treating FAP patients today.59  A 
commonly used sulindac dose in progressive rectal polyposis is 150 mg twice a day; after a few 
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months and demonstration of regression, dosage may be reduced to 150 – 200 mg daily (Burt, 
personal communication) or to 100 mg or lower.55  There is no direct comparison between 
sulindac dosages.  It is possible that the lower dose may be just as effective but requires a longer 
time to regression. 
2.7. Summary of Known and Potential Risks 
2.7.1. Cardiac Risk 
A recent pooled-analysis of cardiovascular events in six clinical trials involving non-arthritis 
patients using celecoxib or placebo demonstrates that celecoxib is indeed associated with a dose-
dependent increased risk of cardiovascular events60 – high dose, long duration.  In this analysis, 
three baseline cardiovascular risk categories were proposed: low, moderate, and high, using 
clinical information obtained from routine medical assessment.  It was not known if these baseline 
cardiovascular risk assessments were associated with adverse cardiovascular events observed in 
the Phase III adenoma prevention trial of eflornithine plus sulindac (16 cardiovascular events 
occurred in this arm) compared with placebo (9 cardiovascular events occurred in the placebo 
arm).  Therefore, members of the UC-Irvine group61 performed detailed toxicity analysis of data 
from the Phase III eflornithine and sulindac versus placebo colorectal adenoma prevention trial, 
with a particular focus on baseline cardiovascular risk assessment.  Cardiovascular toxicity 
outcomes were then reported with and without exclusion of high-risk patients from the analysis. 
In the original sample of 184 placebo and 191 eflornithine/sulindac patients, respectively, 
baseline cardiovascular risk scores were evenly distributed (low: 27% vs. 30%, moderate: 34% 
vs. 29%, high: 39% vs. 41%).  A greater number of patients with high cardiovascular risk at 
baseline experienced events in the eflornithine/sulindac arm (n=9) compared to placebo (n=3). 
When all patients with high baseline cardiovascular risk were excluded from the analysis, the 
number of cardiovascular events between the treatment (n=7) and placebo (n=6) arm was 
similar.61  These results suggest a possible interaction between eflornithine/sulindac treatment and 
baseline cardiovascular risk score on cardiovascular events. 
2.7.2. Ototoxicity Risk 
In the Meyskens eflornithine/sulindac Phase III randomized placebo-controlled colon adenoma 
prevention trial41, no significant differences in hearing loss were noted compared to placebo; 
however, minor differences in hearing loss attributed to eflornithine plus sulindac combination 
were observed in detailed longitudinal analyses.34 
Temporary hearing loss is a known toxicity of treatment with eflornithine, thus a comprehensive 
approach was developed to analyze serial air conduction audiograms.  The generalized estimating 
equation method estimated the mean difference between treatment arms with regard to change in 
air conduction pure tone thresholds while accounting for within-subject correlation due to 
repeated measurements at frequencies.  Based on 290 subjects, there was an average difference of 
0.50 dB between subjects treated with eflornithine plus sulindac compared with those treated with 
placebo (95% confidence interval, −0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, 
and frequencies.  In the normal speech range of 500 to 3,000 Hz, an estimated difference of 0.99 
dB (−0.17 to 2.14 dB; P = 0.09) was detected.  Dose intensity did not add information to models. 
There were 14 of 151 (9.3%) in the sulindac/eflornithine group and 4 of 139 (2.9%) in the placebo 
group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive 
frequencies across the entire range tested (P = 0.02).  Follow-up air conduction done at least 6 
months after end of treatment showed an adjusted mean difference in hearing thresholds of 1.08 
dB (−0.81 to 2.96 dB; P = 0.26) between treatment arms.  There was no significant difference in 
the proportion of subjects in the sulindac plus eflornithine group who experienced clinically 
significant hearing loss compared with the placebo group.  The estimated attributable risk of 
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ototoxicity from exposure to the drug is 8.4% (95% confidence interval, −2.0% to 18.8%; P = 
0.12).  However, there is only a <2 dB difference in mean threshold for patients treated with 
combination compared with those treated elsewhere (other trials) with placebo. 
The eflornithine dose used in the Meyskens 2008 trial of patients with sporadic risk of colorectal 
cancer was 500 mgs orally per day for three years in combination with 150 mg daily sulindac.41 
No difference in ototoxicity was observed between NSAID alone and combination eflornithine 
NSAID arms in the Lynch trial of FAP patients, using an eflornithine dose of 750 mgs oral 
daily.27,28  Bailey and colleagues have recently updated their study of patients with prior non-
melanoma skin cancer that were treated with 500 mg/m2 (also rounded to the nearest 250 mg as 
they used eflornithine tablets) for 4-5 years.62  The Bailey study demonstrated a significant (P < 
0.05) increase in uniformly transient audiometric (but not clinically detectable) hearing loss in 
participants on eflornithine.33  The follow-up study did not report any clinically significant 
differences in hearing as compared to the placebo group.62 
2.7.3. Sulindac Black Box Warning 
Sulindac like other NSAIDS carries a black box warning to consumers that it may cause increased 
risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke which can be 
fatal and an increased risk of serious gastrointestinal adverse events including bleeding, 
ulceration, and perforation of the stomach and intestines which can be fatal.  Refer to the Sulindac 
product insert (Actavis, formerly Watson Laboratories, Inc.)63 and the recent FDA Drug Safety 
Communication64 for further details.  The sulindac dose in this trial is one-half the recommended 
anti-inflammatory dose. 
3. TRIAL OBJECTIVES AND PURPOSE 
3.1. Rationale 
FAP is an orphan disease with multiple major unmet medical needs.  The current standard of 
practice involves prophylactic colectomy or proctocolectomy, followed by proctoscopic 
intervention with surgical polypectomies and/or laser/cautery ablation every 6 – 12 months for the 
rest of their lives.  Many patients have extensive polyposis at a young age and require surgery 
prior to entering college.  Following prophylactic colon surgery, follow-up intervention by 
proctoscopy and upper GI endoscopy occurs every 6 – 12 months and subsequent surgical 
interventions are generally performed at experienced centers of excellence, requiring frequent, 
inconvenient and expensive travel.  The serial interventions are unpleasant, require dietary 
restriction and enemas.  During surgical procedures, some patients require general anesthesia and 
all patients require sedation.  Surgical procedures for large or multiple adenomas may involve 
snare cautery polypectomy or trans-anal excision and carry risk of bowel perforation and or 
subsequent bleeding.  The greater the frequency and extent of the surgical procedures, the greater 
the morbidity and associated costs.  Such interventions frequently result in reduced compliance 
with medical and surgical recommendations, with subsequent increased likelihood of the 
development of an interval cancer.  In addition, repeated cautery ablations lead to scarring and 
impaired bowel function over the years. 
A major goal of this program is to defer or obviate the need for additional surgical interventions 
in patients with familial adenomatous polyposis.  In patients treated with total abdominal 
colectomy with ileo-rectal anastomoses, the addition of sulindac combined with eflornithine has 
the potential to defer or eliminate the need for a complete proctectomy by polyp control which 
may result in less frequent and less extensive endoscopic or surgical interventions. 
Prophylactic proctocolectomy does not “cure” patients with this genetic syndrome. FAP related 
disease remains a major problem in the residual rectum, pouch, anal transition zone, duodenum 
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and desmoid formation; both can lead to major morbidity and mortality.  Surgical intervention is 
marginally effective, and there are no approved pharmacotherapeutic agents. 
Fifty percent (50%) of patients following total proctocolectomy with ileal pouch anal 
reconstruction develop adenomas in the pouch and require the same extensive follow-up 
evaluations and surgical treatments.  Almost all FAP patients are at risk for progressive duodenal 
adenomatous polyposis which can lead to extensive and frequent surgical endoscopic procedures 
and/or major surgical resections.  Duodenal polyposis is a major cause of morbidity, mortality, 
patient inconvenience and health care costs in FAP patients.  Ninety percent (90%) of patients 
with FAP develop duodenal polyposis2 for which there is no approved pharmacologic agent to 
control this disease.  Five (5) to 10% of patients have Spigelman Stage 4 on screening endoscopy; 
one-third of these patients develop cancer.  Of greater concern from the Bulow analysis is that 
52% of patients with duodenal polyposis who start with Stage 1, 2 or 3 will progress to Stage 4; 
the standard of care for Stage 4 is to consider some type of radical surgical intervention.  The 
complexity of managing such patients is well described in the definitive review of FAP 
management guidelines by Vasen and colleagues.10  The marginal benefit of endoscopic 
management of the duodenum is reviewed and tabulated (Table 4) in the paper by Brosens and 
colleagues.65  The data clearly demonstrate the need and potential efficacy of the pharmacologic 
control of duodenal polyposis; using the well-established Spigelman staging system as an 
objective indicator of polyp burden, along with pre-malignant histology.  The main determinant of 
Stage 4 is the presence of villous adenoma or high grade dysplasia on staging biopsies – objective 
measures of pre-cancerous risk.  
Increasing the time to clinically meaningful endpoints relevant to standard of care by increasing 
the time to important FAP-related events (FAP-related surgery, duodenal polyposis, cancer and 
death) are key factors in regard to the morbidity and mortality of this genetic disease.  FAP 
related surgical or clinical events in the rectum or pouch include surgery related to large or high 
risk adenomas or cancer; for FAP disease in the duodenum it includes surgery for enlarging or 
high risk adenomas. 
After IRA surgery, pharmacologic control may minimize the need for additional rectal surgery 
(surgical snare excisions of polyps greater than 5 mm; surgical trans-anal excision of rectal 
polyps; proctectomy) and/or minimize development of pre-cancerous adenoma (dysplastic polyps, 
villous adenoma) and cancer.  After pouch surgery it may minimize need for additional surgery 
(surgical snare excision of polyps greater than 5 mm, surgical trans-anal excision of rectal polyps, 
pouch resection with ileostomy) and/or minimize development of pre-cancerous adenomas and 
cancer. 
In FAP patients with duodenal polyposis, pharmacologic control may suppress development of 
further polyposis, slow or prevent progression to Spigelman Stage 3 and 4 disease, minimize 
progression to dysplastic polyps or villous adenomas, minimize polyposis involving the Ampulla 
of Vater, minimize development of cancer or reduce the need for procedures such as snare 
polypectomy, submucosal excisions, trans-duodenal excisions, duodenectomy, Whipple 
(pancreatic duodenectomy) or related procedures. 
Pharmacologic control in FAP patients has major implications for clinical benefit to reduce the 
morbidity of the disease and thereby improve the current standard of care.  The use of low dose 
sulindac and CPP-1X may prolong the time to occurrence of clinically important FAP-related 
disease events (FAP related events include surgical procedures and progressive advanced 
intestinal polyposis). 
 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  19 
In addition to the above, the combination drug regimen may provide additional clinical benefit by,  
• Deferring the initial prophylactic colectomy to a more “convenient time” such as after 
graduation from school or after childbirth. 
• Increasing the use of colectomy with ileal-rectal reconstruction rather than total 
proctocolectomy which results in improved quality of life in regard to bowel function and 
reduces the risk of loss of fertility in women. 
• Reducing the risk of progressive rectal/pouch polyposis that requires surgical intervention. 
• Reducing the risk of rectal stump/pouch-related post polypectomy scarring with loss of 
bowel function (absence of compliant rectal reservoir). 
• Deferring or obviate the need for pouch removal with need for permanent ileostomy 
stoma. 
• Deferring or obviate the need for surgical intervention for advanced duodenal polyposis 
with associated morbidity and mortality. 
• Improving health-related quality of life (HRQoL). 
 
3.2. Rationale for Treatment Duration Extension up to 48 Months 
The initial statistical analysis plan used detailed event rate projections based on an extensive 
review of the published literature (Refer to Appendix E) and determined that a sample size of 150 
randomized subjects would be required for the primary endpoint analysis.  Because of logistical 
reasons, subject accrual was completed in April 2016 with 171 patients randomized.   
In February 2016, a blinded data review was done to project a more realistic estimate of FAP-
related event rates at the completion of the trial with a maximum of 24 months of treatment.  
Based on this analysis, it was considered unlikely we would reach the projected 90 events before 
the end of the study.  To reduce the risk of a false-negative trial (because of inadequate events 
after two years of study treatment in 171 randomized subjects), several mitigation options were 
explored.  The protocol was amended to extend treatment duration to a maximum of 36 months. 
Over 90% of subjects who reached 24 months without an FAP-related event consented to the trial 
extension. 
As of June 2017, there have been 53 FAP-related primary endpoint events.  Under the current 
event rates and with an estimated trial end-date of April 2018, projections once again do not 
indicate a high likelihood of 90 events.  Various statistical analyses, using Weibull methodology, 
indicate that under current hazard rate assumptions to maintain power > 85%, an additional trial 
extension may be required.  This protocol amendment offers all active subjects a longer-term 
blinded treatment until study completion at or before April 2019. This means, based on the date of 
randomization, a treatment extension of up to 36, 42 or 48 months.  The study will complete for 
reasons defined in Section 4.2. 
There have been five safety data monitoring committee meetings for CPP FAP-310 study, the 
most recent June 2017.  To date, the DMC has not identified any safety issues and there have 
been no recommended protocol modifications due to safety.  Additionally, for CPP FAP-310, the 
Medical Monitor performs a monthly blinded review of all adverse events to evaluate for events 
not commonly associated with drug exposure or to look for an increase in events above what is 
typical for the population under study. 
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At the time of the amendment for the treatment extension, there have been twenty-six (26) serious 
adverse events (SAEs) that have been reported from the CPP FAP-310.  Two events were 
classified as SUSARs; however, no subject treatment arm assignments were unblinded.  
Twenty-one (21) of the twenty-six (26) SAEs were classified as not related to study treatment by 
the study investigators.  There were eleven (11) gastrointestinal events. These included five (5) 
small bowel/intestinal obstructions.  This type of event is not uncommon in the FAP population, 
particularly those with multiple surgeries.  There was one (1) gastrointestinal events of ileus and 
one (1) ileal stricture.  The subject with ileus had additional episodes prior to taking the study 
drugs.  Ileus and ileal stricture are expected events in the FAP and post colon surgery patient 
populations.  There was also one (1) event of rectal bleeding that was from a post-polypectomy 
ulceration.  Bleeding is a common complication from an endoscopic excision and there was also 
one (1) procedural complication that involved a post-polypectomy bleed.   
There was one (1) event of pancreatitis in a subject with a prior history of pancreatitis and one (1) 
subject with acute pancreatitis.  The subject with pancreatitis was hospitalized for six weeks and 
the event was a life-threatening, grade 4 serious adverse event.  In the case of acute pancreatitis, 
the investigator indicated that the likely cause was ampullary adenomatous disease.  FAP patients 
are at a higher risk of pancreatitis than the general population66.  Pancreatitis is a rare, but 
identified risk of sulindac.  The Investigator’s Brochure, Sulindac package Insert and published 
reports indicate that pancreatitis is associated with the use of sulindac.67 
One (1) subject experienced grade 3 constipation which quickly resolved with evacuation and 
pain management. Although constipation is a common side effect of both eflornithine and 
sulindac as documented in the Investigator’s Brochure, the investigator evaluated as not related 
due to the timing and rapid resolution of the event. 
There was one (1) event in the nervous system disorders category that was a seasonal migraine in 
a subject had a history of this type of event.  For neoplasms, there was one (1) diagnosis of lung 
adenocarcinoma with a brain lesion, unrelated to treatment.  There was also one (1) event of 
chronic myeloid leukemia, unrelated to treatment. In addition to the post-polypectomy bleed 
described above, there were three other (3) events in the injury/complications category.  There 
was one (1) wound complication related to cellulitis of an incarcerated umbilical surgical scar. 
This was unrelated to study treatment and related to multiple prior surgeries. One (1) event of 
seroma complication post-desmoid surgery was unrelated to treatment and is a known 
complication of abdominal surgery.  The one (1) event of anastomotic stricture was a 
hospitalization for the treatment of a pre-existing anal stenosis and was unrelated to treatment.  
One subject had perforated knee bursitis, likely infectious in origin, that was classified as 
unrelated to study medication.  One (1) subject with pre-existing COPD experienced an 
exacerbation that required medication and oxygen therapy, but was not related to treatment.  The 
subject with acute pancreatitis described above also experienced grade 3 hyperglycemia and was 
diagnosed with type 2 diabetes.  This event was unlikely to be related to treatment, but is reported 
to be a very rare complication of sulindac and is listed in the Investigator’s Brochure.  
The remaining five (5) events were classified as being possibly (4) or probably (1) related to 
treatment.  One (1) event of worsening of depression was listed as possibly related to treatment.  
Depression is covered in the Reference Safety Information as a known side effect of sulindac and 
with the side effect of emotional lability for eflornithine.  For vascular disorders, there was one 
(1) thromboembolic event (DVT without pulmonary embolism) listed as possibly related to 
treatment.  This is a known risk of sulindac and is listed in the Reference Safety Information in 
the Investigator’s Brochure.  One (1) subject experienced severe nausea (grade 3) approximately 
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4 months after study treatment began.  This was possibly related to treatment; nausea is listed as a 
complication of both eflornithine and sulindac. 
There were two (2) events that were classified as SUSARS.  One (1) subject experience psychosis 
and paranoia, grade 3.  This began 6-8 weeks prior to the month 24 end of treatment visit and 
progressed to the point of paranoid psychosis resulting in hospitalization and treatment with anti-
psychotic, anxiolytic and insomnia medications.  The investigator assessed this event as possibly 
related.  Eflornithine has a known side effect of emotional lability and sulindac has an uncommon 
side effect of psychic disturbances, including acute psychosis, both listed in the Reference Safety 
Information.  After discharge, the subject completed the study.  The second SUSAR was a 
spontaneous abortion.  The subject had a positive pregnancy test and stopped study medication 
upon confirmation.  Approximately 2 months after discontinuation, the subject lost the fetus due 
to a suspected placental abruption.  The subject had a history of miscarriage and the event was 
classified as possibly related.  The Sponsor determined that the SAE of spontaneous abortion was 
not related to the study medication.  Eflornithine is known to be embryotoxic in animal studies 
and is listed as a safety risk in the Investigator’s Brochure.  
The constituents for this combination therapy, eflornithine and sulindac, are considered as having 
well-established medicinal use within the meaning of Annex I to Directive 2001/83.  Both active 
substances have been authorized in medicinal products for various therapeutic indications for 
doses, duration and frequency exceeding that which is used in the CPP FAP-310 Phase III clinical 
study.  Randomized clinical trials of eflornithine and sulindac alone or in combination indicate 
that these agents have minimal toxicities when used for treatment periods of 3 or more years in 
patients with risk of cancer.  The minimal toxicities observed to date in CPP FAP-310 for 
treatment of FAP patients with eflornithine and sulindac for up to 3 years supports the extension 
of the treatment time in CPP FAP-310 from 3 to up to 4 years at a dose level of 750 mg/day 
eflornithine and 150 mg/day sulindac. 
This protocol amendment may extend the trial by up to 12 months, and offers subjects (based on 
their randomization date) treatment up to 48 months. The end of study will not be beyond April 
30, 2019. Actual duration of treatment for each subject is based on the occurrence of an FAP-
related event, censoring for standard reasons unrelated to FAP-related endpoint indicators, or the 
final end of study date. In the absence of an FAP-related event, subjects will receive study 
treatment for 24 to 48 months. The final decision concerning the trial end-date if prior to April 30, 
2019, will be based on accrued FAP-related primary endpoints, number of subjects still active on 
trial, FAP event projections, and additional safety reviews. Assuming continued acceptable safety 
profile, this approach will minimize the risk of a false negative trial. 
3.3. Purpose 
This randomized, double-blind, phase III trial will compare the efficacy, safety and 
pharmacokinetics of the CPP-1X/sulindac combination versus CPP-1X and sulindac as single 
agents with up to a 48-month maximum treatment period in patients with Familial Adenomatous 
Polyposis (FAP). 
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4. INVESTIGATIONAL PLAN 
4.1. Study Population 
• Diagnosis of phenotypic classical FAP, age ≥18 years, male and female gender.  Must be 
genotyped, with an APC mutation.  Refer to Section 6.1 for details. 
• Meets eligibility criteria for at least one FAP related disease group defined in Section 6.1. 
• If prior colorectal surgery, at least three years since colectomy with ileal-rectal 
anastomosis (IRA) or total proctocolectomy with ileal pouch-anal reconstruction (pouch). 
• Absence of major cardiac risk factors as defined in Section 6.2. 
• Absence of clinically significant hearing loss requiring a hearing aid. 
• Adequate laboratory studies (hematology, chemistry, and urinalysis) at study entry. 
4.2. Treatment 
• Experimental arm: 750 mg CPP-1X, and 150 mg sulindac 
• Comparator arms:  
1. CPP-1X placebo with sulindac (150 mg) 
2. CPP-1X (750 mg) with sulindac placebo 
• Treatment is administered as four tablets taken once daily with food (same time of day, 
preferably in the morning), for up to 48 months. 
• Randomized subjects will receive 24 months of treatment and complete their final 
assessment or come off-study for an FAP-related event or for other reasons (for example, 
safety issues, non-compliance, withdrew consent, lost to follow-up).  
• Subjects completing 24 months of treatment without an FAP-related event can continue on 
treatment for up to 48 months based on their randomization date as follows: 
1. If randomized between November 2015 and April 2016 eligible for up to 36 
months of treatment 
2. If randomized between May 2015 and October 2015 eligible for up to 42 months 
of treatment 
3. If randomized between July 2014 and April 2015 eligible for up to 48 months of 
treatment 
or until one of the following occurs: 
1. Subject has an FAP-related event or comes off study for other reasons 
2. Trial end-date of April 30, 2019 has been reached 
3. 90 FAP-related events have occurred 
4. Less than 90 FAP-related events have accrued prior to April 30, 2019 and an 
earlier trial end-date has been set by the Sponsor and reviewed by the DMC 
5. An earlier trial end date prior to April 30, 2019 has been recommended by the 
DMC for safety reason and approved by the Sponsor 
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4.3. Randomization 
At least 150 eligible patients will be enrolled in this study.  Subjects will be randomized to one of 
three treatment groups in equal proportions (i.e., 1:1:1 randomization): 1) CPP-1X plus sulindac 
2) CPP-1X - placebo plus sulindac, 3) CPP-1X plus sulindac placebo. 
A stratified randomization procedure will be used with stratification based on FAP-related time-
to-first-event prognosis.  The event prognosis groups are represented by 1) best (i.e., longest 
projected time to first FAP-related event) - rectal/pouch polyposis, 2) intermediate - duodenal 
polyposis, and 3) worst - pre-colectomy.  If a subject has two or more of these disease sites, the 
most severe prognosis stratum will be assigned for randomization (e.g. worst > intermediate > 
best).  Since an individual may have more than one disease site involved, the trial will assess time 
to any defined FAP-related event in the subject as a whole. In order to minimize potential 
treatment arm imbalance a centralized randomization process will be used to balance among 
treatment groups within prognostic strata. 
4.4. Primary Outcome 
The primary objective of this trial is to determine whether the combination of CPP-1X plus 
sulindac is superior to either treatment individually, in delaying the time from the date of 
randomization to the date of the first occurrence of any FAP-related event in the subject as a 
whole.  This includes: 1) FAP related excisional intervention involving the colon, rectum, pouch, 
duodenum and/or 2) clinically important events which includes progression to more advanced 
duodenal polyposis (Stage 2, 3 or 4), cancer or death.  Section 8.2.14 provides complete detail. 
4.5. Secondary Outcomes 
Secondary Efficacy Analyses: 
Any improvement observed by the investigator during upper gastrointestinal (UGI) and lower 
gastrointestinal (LGI) visualization (i.e. endoscopy and colonoscopy) at the 6 and 12-month study 
visits will be described using the variables UGI Observed Improvement (UGIOI), and LGI 
Observed Improvement (LGIOI).  Each patient will have one pair of UGIOI and LGIOI outcomes 
(refer to Protocol Section 12.0 and the Statistical Analysis Plan for more detail). 
Other Secondary Outcomes in this Study Include the Following: 
To explore how study treatment group relates to other efficacy outcomes, genotype, phenotype, 
disease locations and endoscopic findings, additional analyses are planned (refer to the Statistical 
Analysis Plan for more details).   
The UGIOI and LGIOI outcomes will be tabulated and summarized using the month 6 visit 
scores, alone.  Similarly, the UGIOI and LGIOI outcomes will tabulated and summarized across 
all study visits. 
As both part of the primary analysis, and further explored in these additional analyses, median 
time to event for each treatment group will be determined.  This will be explored for each of the 
study populations (i.e. ITT, per protocol, and others), study disease stratum groups, and in the 
disease site subgroups. 
Pharmacokinetic data (plasma concentrations measured at patient visits) will be used to estimate 
population pharmacokinetic parameters for the CPP-1X (eflornithine), sulindac, and CPP-1X 
(eflornithine) + sulindac treatment groups (i.e., for each analyte for those patients on combination 
treatment). 
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The subcategories of FAP events will be explored by disease stratum groups, and by disease site 
subgroups.  
The presence or absence of ODC polymorphisms, including the single nucleotide polymorphisms 
(SNPS) rs2302615 and rs2302616 and their relation to treatment group and outcome will be 
tested with the likelihood ratio test. 
The excretion of 5 urinary polyamines (diacetylspermine, n1-acetylspermidine, n8-
acetylspermidine, decarboxylated SAM, and putrescine) will be assessed in relation to treatment 
group and outcome, using the single point concentration data gathered from the urine samples 
harvested at each study visit. 
Patient reported health related quality of life measures will be evaluated using HRQoL.  
Tissue and dietary polyamine levels, as collected at patient study visits will be analyzed together 
with the results of the dietary questionnaires and related to treatment group and study outcomes. 
Safety outcome data and analyses are described in detail in the Statistical Analysis Plan. 
4.6. Population Pharmacokinetics for CPP-1X/Sulindac 
All subjects consented, enrolled, and randomized in this study will have pharmacokinetic samples 
drawn at their scheduled 3-month visit.  All subjects will have samples drawn on the same 
schedule regardless of treatment arm assigned.  The samples will be obtained before first morning 
dose, then four additional samples over the following eight hours. 
4.7. Polyamine Analysis 
At each colonoscopy/proctoscopy while on study treatment, a sample of normal rectal mucosa 
and a random urine sample will be obtained to assess tissue and urine polyamine levels.  Sample 
handling and processing procedures will be provided in the study manual, are described here 
briefly. 
Biospecimen collection: Normal (tumor-free) rectal mucosal biopsies will be obtained during 
endoscopy procedures.  Biopsy samples will be placed in separate standard cryotube tubes and 
stored in a -70 – 800C freezer.  Random urine samples (15 mL minimum) will be collected and 
stored in a -70 – 800C freezer. 
Polyamine content: Polyamine analysis will be performed as described previously.35  Briefly, 
frozen tissue samples will be homogenized and extracted in 0.2 N perchloric acid.  Urine samples 
will be adjusted to 0.2 N perchloric acid.  Polyamine (spermidine, spermine, and putrescine) 
content will be measured using reverse-phase, ion-paired high performance liquid 
chromatography.  Protein contents will be determined using the bicinchoninic acid protein assay 
(Thermo Fisher Scientific, Rockford, IL).  The spermidine-to-spermine ratio (Spd:Spm) will be 
assessed in our analyses to minimize the influence of assay variability.35,68 
Dietary polyamines: Data will be collected using the Fred Hutchinson Cancer Center food 
frequency questionnaire and will be analyzed using a polyamine database.  Average daily 
consumption of putrescine, spermidine, and spermine will be calculated.69  
4.8. Pharmacogenetic and Genetic Analysis 
A peripheral blood sample will be collected from enrolled subjects at baseline for subsequent 
correlative genomic studies relevant to this disease and in the event treatment-related adverse 
events are discovered during the trial. Sample handling and processing procedures, which will be 
provided in the study manual, are described here briefly. 
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DNA extraction and genotyping. DNA will be extracted from peripheral blood samples using the 
QIAGEN QIAamp DNA Midi or Mini Kits (Qiagen), following the manufacturer's instructions. 
Genotyping of the ODC1 (National Center for Biotechnology Information SNP database ID 
rs2302615) +316 SNP will be conducted using a PCR amplification of the targeted region and bi-
directional cycle sequencing of purified target amplicon using PCR/Sanger sequencing primers.  
The sequencing reaction will be analysed on an Applied Biosystems 3730 Genetic Analyzer. The 
PCR amplicon will be sequenced in both forward and reverse directions to confirm the SNP. 
4.9. Quality of Life 
Assessment of Health-Related Quality of Life (HRQoL) is to better understand and quantify the 
impact of each treatment arm on FAP-related physical and emotional symptoms as well as FAP-
related surgical sequelae.  Specifically, postponing surgery because of reduction of polyps could 
lead to both symptomatic relief as well as reduced stress and worry about cancer, future surgery 
and/or suffering of FAP-related medical and surgical symptoms.  As such, several well-accepted 
and previously published questionnaires have been selected for use in the CPP FAP-310 trial. 
These include the EORTC core questionnaire, QLQ-C30,70 the GI-specific sub-module, QLQ-
CR29,71 and the EQ-5D health utilities index.72,73  These instruments have all been previously 
used in gastrointestinal/colorectal clinical trials and have been validated and translated to ensure 
appropriate cultural/linguistic adaptation suitable for a multi-center, international clinical trial. 
Also being used is a modified version of the Cancer Worry Scale.74 
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5. STUDY DRUG INFORMATION 
5.1. CPP-1X [Eflornithine HCl] 
Eflornithine, also known as DFMO, is an inhibitor of ornithine decarboxylase (ODC) designated 
chemically as 2-(difluoromethyl)-DL-ornithine.   
The clinical dosage form of CPP-1X (eflornithine HCl) is a yellow, film-coated convex tablet 
containing 231 mg per tablet of anhydrous eflornithine HCl as eflornithine HCl monohydrate (250 
mg per tablet). 
Table 1 lists the composition of the 250 mg CPP-1X tablets.  The tablets (CPP-1X and CPP-1X-
placebo) are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 
tablets.  The CPP-1X and CPP-1X placebo tablets are supplied by Sanofi-Aventis, Canada, Inc.  
The tablets are to be stored at room temperature (20-250C). 
Study subjects will be instructed to take three (3) tablets by mouth once daily with food. 
Table 1 - Composition of CPP-1X (Eflornithine HCl), 250 mg Tablets 
Ingredients Unit Formula 











Microcrystalline Cellulose 192.85  NF 
Starch 1500 53.40 NF 
Colloidal Silicon Dioxide 1.25 NF 
Magnesium Stearate 2.50 NF 
Total Theoretical Weight 500 -- 
 
5.1.1. Eflornithine Clinical Pharmacology 
Eflornithine hydrochloride is a member of the following drug classes: 1) inhibitor of ornithine 
decarboxylase (ODC), 2) hirsutism (excess hair growth) retardant, and 3) antiprotozoals. 
Eflornithine is FDA approved as a cream for treatment of female hirsutism, and in intravenous 
form for treatment of trypanosomiasis.  The oral tablet form is not available outside of the clinical 
trial setting in the US and EU.  The formulation used in this trial is similar to that used in the 
Phase III colon adenoma clinical trial in combination with sulindac.41 
Contraindications:  Prior hypersensitivity to eflornithine.  Precaution in patients with bone 
marrow suppression or hematologic disorders. 
Common side effects:  Low platelet count was dose-limiting after administration of intravenous 
eflornithine at high doses (up to 3 gm/m2 every 6 hours for 28 days).  Gastrointestinal upset 
(nausea, vomiting [5%], diarrhea [38%]) have also been reported after these high doses of 
eflornithine.  The primary side effect of low doses of eflornithine (750 mg per day for 3-5 years) 
is mild ototoxicity with 45.2% of eflornithine subjects versus 33.6% of placebo subjects having a 
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≥15 dB hearing loss at two adjacent frequencies (p=0.07).  The observed audiometric 
abnormalities were usually reversible; 19% and 18% of eflornithine and placebo subjects had 
persistent abnormal audiograms 6 months after stopping study drug.33  
Infrequent side effects:  Hearing loss/change by audiometry testing has been reported in 8.4% of 
patients on high dose eflornithine.  Rash and alopecia have been reported in 3% of patients.  
Anorexia and abdominal pain have been reported in 2% of patients treated with eflornithine. 
Rare but serious side effects include dizziness (1%), headaches (2%), and seizures (8%) have 
been reported in patients on intravenous eflornithine.  Myelosuppression (including leukopenia, 
[37%], anemia [55%], and thrombocytopenia [14%]) has been reported at high intravenous doses, 
but does not usually occur at the low dose (750 mg) utilized in this study.33 
Pregnancy and Lactation:  Pregnancy Category C. It is unknown if eflornithine crosses the 
placenta.  Case reports in humans along with animal studies (mice, rats) indicate potential for 
fetotoxicity.  Experiments in rodents indicate that eflornithine blocks yolk sac formation and 
trophoblast differentiation, affecting processes such as vasculogenesis and steroidgenesis.75  The 
World Health Organization has not determined a breast-feeding rating for eflornithine due to 
insufficient data.  The Thompson lactation rating is that infant risk cannot be ruled out.  No 
studies investigating the safety of lactation after eflornithine administration have been conducted, 
nor are there data to determine drug levels in breast milk after drug administration.  
5.1.2. CPP-1X (Eflornithine) Pharmacokinetics 
The dose of CPP-1X (daily oral dose of 750 mg for an adult) for CPP-310 was selected based 
upon its known pharmacology and evidence from clinical studies.  
Time to peak concentration for oral eflornithine is 4-6 hours.   
Absorption: for the oral solution is 54-58% and is unaffected by feeding status.   
Distribution: no protein binding sites, crosses blood-brain barrier, volume of distribution is 0.3-
0.35 liters/kg. 
Metabolism: urinary recovery of unchanged drug as eflornithine is 86% and essentially not 
metabolized. 
Excretion: renal excretion. Elimination half-life: 3-3.5 hours but once daily oral dosing of 500-
750 mg is sufficient to maintain efficacy as indicated in several clinical trials. 
Eflornithine pharmacokinetic references include, Abeloff, et al., 1984,76 Haegele et al., 1981,77 
Meyskens, et al., 1998,35 and Meyskens et al., 2008.41 
5.2. Sulindac 
Sulindac is a non-steroidal, anti-inflammatory indene derivative designated chemically as (Z)-5-
fluoro-2-methyl-1- [[p- (methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid.  It is not a 
salicylate, pyrazolone or propionic acid derivative.  Sulindac, a yellow crystalline compound, is a 
weak organic acid practically insoluble in water below pH 4.5, but very soluble as the sodium salt 
or in buffers of pH 6 or higher.  Table 2 lists the composition of the 150 mg tablets.  Sulindac 
tablets (USP) 150 mg tablets are round yellow tablets imprinted DAN and 5661 and are supplied 
in bottles of 100.  Dispense in a well-closed container with child-resistant closure.  Sulindac and 
sulindac placebo will be supplied by Actavis, formerly Watson Pharmaceutical, Inc., Corona, CA.  
Sulindac is marketed in the US for relief of signs and symptoms of the following conditions:  
osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder 
(bursitis/tendinitis), and acute gouty arthritis. 
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The sulindac tablets are to be stored at room temperature (20-250C). 
Study subjects will be instructed to take one (1) tablet by mouth daily with food. 
Table 2 - Composition of Sulindac 150 mg Tablets 
Ingredients Unit Formula 









Microcrystalline Cellulose 80.63  NF 
Starch 18 NF 
Purified Water * USP 
Stearic Acid 3.82 NF 
Magnesium Stearate 2.55 NF 
Total Theoretical Weight 255  -- 
* = Used in manufacturing process, but does not appear in the final product. 
5.2.1. Sulindac Clinical Pharmacology 
Sulindac is a nonsteroidal anti-inflammatory analgesic that inhibits both cyclooxygenase COX I 
and COX II. 
Contraindications:  Treatment of post-operative pain after coronary artery bypass grafting (risk 
of stroke, myocardial infarction).  Hypersensitivity to sulindac or excipient byproducts. 
Hypersensitivity to aspirin or other NSAIDs.  
Common side effects:  As with other NSAIDs, sulindac can produce gastric pain (10%), 
constipation (3-9%), diarrhea (3-9%), dyspepsia (3-9%), and nausea (3-9%).  Dizziness (3-9%), 
headache (3-9%), and rash (3-9%) have also been reported.  Additionally, this side effect is seen 
most often in patients who have had prior ulcers or who are taking anticoagulants or steroids or 
who have abnormal renal or liver functions; potential patients who have these parameters will not 
be eligible for study entry.  At therapeutic doses, gastrointestinal pain occurs in 10%. 
Infrequent side effects:  Flatulence, cramping, anorexia, vomiting, pruritus, nervousness, 
tinnitus, and edema (1-3%) have been reported.  Gastrointestinal ulcers have been reported in 2-
4% of patients taking NSAIDs.  Bleeding may occur due to platelet inhibition. Gastrointestinal 
ulceration in general is dose-related (the dose used in the current trial will be 50% that typically 
used).  Its potential interaction with eflornithine effect (i.e., possibly delay in wound healing) is 
unknown. 
Rare but serious side effects (≥ 1%):  Hypertension, arrhythmias, thrombotic events, Stevens-
Johnson syndrome and Toxic Epidermal Necrolysis (TEN) have been reported for various 
NSAIDs at low frequency.  Hyperkalemia, esophagitis, gastrointestinal hemorrhage, 
gastrointestinal perforation, and pancreatitis have been reported for NSAIDs including sulindac.  
Anemia, agranulocytosis, leucopenia, thrombocytopenia, aplastic anemia (rare), nephrotoxicity, 
hyperthermia, pneumonitis, bronchospasm, and hepatotoxicity have been reported after sulindac 
use.  Blurred vision, alopecia, anaphylaxis, bitter taste, aseptic meningitis, bone marrow 
suppression, and seizures have been reported. 
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Pregnancy and Lactation:  Pregnancy Category C. Sulindac crosses the placenta.  There have been 
no reports of congenital abnormalities caused by maternal use of sulindac.  However, sulindac 
should be avoided in late pregnancy because of the effects of prostaglandin inhibition (closure of 
the ductus arteriousus) on the fetal cardiovascular system.  It is not known whether this drug is 
excreted in human milk; however, it is secreted in the milk of lactating rats.  Because many drugs 
are excreted in human milk and because of the potential for serious adverse reactions in nursing 
infants from sulindac, a decision should be made whether to discontinue nursing or discontinue 
the drug, taking into account the importance of the drug to the mother.  Refer to the Sulindac 
product insert (Actavis, formerly Watson Laboratories, Inc.)78 for additional information. 
5.2.2. Sulindac Pharmacokinetics 
Refer to the Sulindac product insert (Actavis, formerly Watson Laboratories, Inc.)78 for additional 
information. 
Absorption:  90% bioavailability; sulindac must be metabolized to the sulfide metabolite before it 
is pharmacologically active. 
Distribution: Sulindac and its sulfone and sulfide metabolites are 93.1, 95.4 and 97.9% bound to 
plasma proteins.  Sulindac penetrates the blood-brain barrier and placental barriers. 
Metabolism: Sulindac and its sulfone metabolite undergo extensive enterohepatic circulation 
relative to the sulfide metabolite in animals. 
Kinetics:  Tmax for sulindac (150 mg tablet) is 3.9 ± 2.3 hours, and 5.85±4.5 hours for the sulfone 
metabolite and 6.2 ± 3.1 hours for the sulfide metabolite. 
Elimination: Approximately 50% of the administered dose of sulindac is excreted in the urine 
with the conjugated sulfone metabolite accounting for the major portion.  Less than 1% of the 
administered dose of sulindac appears in the urine as the sulfide metabolite.  Approximately 25% 
is found in the feces, primarily as the sulfone and sulfide metabolites.  The mean effective half-
life (T1/2) for sulindac is 7.8 hours and 16.4 hours for the active sulfide metabolite. 
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6. SUBJECT RECRUITMENT, INCLUSION AND EXCLUSION CRITERIA 
Subjects (male and female), ≥ 18 years will be recruited who meet the inclusion criteria below.  
Women and minorities will be represented according to their distribution in the Investigator’s 
clinical population. 
6.1. Patient Characteristics for Eligibility, Inclusion Criteria 
1. Diagnosis of phenotypic classical FAP with disease involvement of the duodenum and/or 
colon/rectum/pouch. 
a) Genotype: APC mutation (with or without family history) required  
b) Classical FAP Phenotype: 100’s to 1,000’s of colorectal adenomatous polyps, usually 
appearing in teenage years 
2. UGI endoscopy/LGI endoscopy (proctoscopy/colonoscopy) performed within 30 days of 
randomization.  
3. Patients with an intact colon/rectum and prophylactic surgery is being considered as a 
stratification site. 
4. Rectal/pouch polyposis as a stratification site as follows: 
4.a  At least three years since colectomy with IRA/proctocolectomy with pouch, and 
demonstrating polyposis as defined by Stage 1, 2, 3, of the proposed InSiGHT 2011 
Staging System (Appendix B) and summarized as follows: 
Stage 1:  10-25 polyps, all < 5 mm 
Stage 2:  10-25 polyps, at least one > 1 cm 
Stage 3:  >25 polyps amenable to complete removal, or any incompletely removed sessile 
polyp, or any prior evidence of high grade dysplasia, even if completely 
removed. [Note: For staging purposes only.] 
4.b  For all subjects, any rectal/pouch polyps > 5 mm must be excised at “baseline”. 
5. Duodenal polyposis as a stratification site; one or more of the following: 
5.a  Current Spigelman Stage 3 or 4. (Refer to Appendix A for Modified Spigelman Score 
and Classification table). 
5.b  Prior surgical endoscopic intervention within the past six months for Spigelman Stage 3 
or 4 that may have been down staged to Spigelman 1 or 2. 
6. Hematopoietic Status (within 30 days prior to randomization): 
a) No significant hematologic abnormalities 
b) WBC at least 3,000/mm3  
c) Platelet count at least 100,000/mm3 
d) Hemoglobin at least 10.0 g/dL 
e) No history of clinical coagulopathy 
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7. Hepatic Status (within 30 days prior to randomization): 
a) Bilirubin no greater than 1.5 times ULN 
b) AST and ALT no greater than 1.5 times ULN 
c) Alkaline phosphatase no greater than 1.5 times ULN 
8. Renal Status (within 30 days prior to randomization): 
a) Creatinine no greater than 1.5 times ULN 
9. Hearing: 
a) No clinically significant hearing loss, defined in Section 6.2, number 9. 
10. If female, neither pregnant nor lactating.  
11. Negative pregnancy test if female of child-bearing potential.  Fertile patients must use 
effective contraception*.  Confirmation of postmenopausal status unless surgically sterile**. 
12. Absence of gross blood in stool; red blood on toilet paper only acceptable.  
13. No discrete gastric or duodenal ulcer greater than 5 mm within the past year except 
Helicobacter pylori-related peptic ulcer disease treated with antibiotics. 
14. No invasive malignancy within the past 5 years except resected non-melanomatous skin 
cancer, papillary thyroid cancer, or precancerous cervical dysplasia. 
15. No other significant medical or psychiatric problems that would preclude study participation 
or interfere with capacity to give informed consent. 
16. Use of 81 to 100 mg daily aspirin or up to 700 mg aspirin not more than once a week are 
eligible. 
17. No concurrent warfarin, fluconazole, lithium, Pradaxa® or other direct thrombin inhibitors, 
Plavix®, cyclosporine, other NSAIDs (such as ibuprofen, aspirin in excess of 700 mg weekly, 
diflunisal), diuretics (furosemide and thiazides), DMSO, methotrexate, probenecid, 
propoxyphene hydrochloride, Tylenol® (acetaminophen) preparations containing aspirin or 
cytotoxic chemotherapy drugs. 
18. Willingness to forego concurrent use of supplements containing omega-3 fatty acids, oral 
corticosteroids, non-steroidal anti-inflammatory drugs or other FAP directed drug therapy. 
19. Able to provide written informed consent and follow protocol requirements. 
*Fertile male or female, effective contraception methods include the established use of oral, injected or implanted 
hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier 
methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal 
foam/gel/film/cream/suppository, male sterilization (with the appropriate post-vasectomy documentation of the 
absence of sperm in the ejaculate), or true abstinence, when this is in line with the preferred and usual lifestyle of 
the subject.  Periodic abstinence (calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are 
not acceptable methods of contraception.  Contraceptives should be used during the study and for at least 2 weeks 
after study treatment.  
Male subjects (including men who have had vasectomies) whose partners are pregnant should use condoms while 
the partner is pregnant. If the partner is still pregnant when the subject goes off study, the subject should continue 
condom uses for at least 2 weeks afterwards. 
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**Postmenopausal status may be confirmed by any of the following: a) ≥ 12 months spontaneous amenorrhea; b) 6 
months spontaneous amenorrhea with serum FSA levels > 30 IU/L79,80; c) ≥ 6 weeks postsurgical bilateral 
oophorectomy; d) ≥ 6 weeks postsurgical hysterectomy. 
6.2. Exclusion Criteria 
1. Prior pelvic irradiation. 
2. Patients receiving oral corticosteroids within 30 days of enrollment. 
3. Treatment with other investigational agents in the prior 4 weeks. 
4. Use of other non-steroidal anti-inflammatory drugs (such as ibuprofen) exceeding 4 days 
per month, in the prior 6 weeks. 
5. Regular use of aspirin in excess of 700 mg per week. 
6. Treatment with other FAP directed drug therapy (including sulindac or celecoxib, fish oil) 
within 12 weeks of study enrollment. 
7. Hypersensitivity to cyclooxygenase-2 inhibitors, sulfonamides, NSAIDs, or salicylates; 
NSAID associated symptoms of gastritis. 
8. Patients must not have cardiovascular disease risk factors as defined below.  
• Uncontrolled high blood pressure (systolic blood pressure > 150 mm Hg; 
• Unstable angina;  
• History of documented myocardial infarction or cerebrovascular accident; 
• New York Heart Association Class III or IV heart failure (Refer to Appendix C); 
• Known uncontrolled hyperlipidemia defined as LDL-C ≥ 190 mg/dL or triglycerides ≥ 
500 mg/dL. 
9. Patients with significant hearing loss are not eligible for study participation as defined 
below. 
• Hearing loss that affects everyday life and/or for which a hearing aid is required. 
10. Intact colon/rectum or retained rectum or ileal pouch:  
a) cancer on biopsy 
b) high grade dysplasia found on polyp biopsy where the polyp is not completely 
removed 
c) a large polyp (>1 cm) not completely removed. 
11. Duodenal cancer on biopsy. 
12. Intra-abdominal desmoid disease, stage III or IV (staging criteria in Appendix D).9,81 
13. Inability to provide informed consent. 
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6.3. Replacements and Screen Failures 
Randomized subjects who discontinue early for any reason will NOT be replaced and will not be 
permitted to reenter the study. 
Previously screened subjects may be rescreened for enrollment in the study with prior approval 
from the Medical Monitor.  Subjects who are rescreened 30 days after signing the informed 
consent will need to be re-consented and have all screening procedures repeated to determined 
eligibility. 
Any screen failed subject based on history, physical exam or laboratory values or endoscopy 
procedures will need to have a screen failure case report form completed by the Investigator or 
study coordinator and available for review by the study Sponsor. 
 
7. RANDOMIZATION AND STRATIFICATION 
Subjects eligible for this trial will be randomized into one of three treatment groups 1:1:1 (CPP-
1X plus sulindac: CPP-1X placebo plus sulindac: CPP-1X plus sulindac placebo) and stratified by 
FAP-related event prognosis using an interactive web-based system as described below.  Subjects 
will be randomized no more than 5 working days prior to their scheduled start date of treatment. 
A stratified randomization procedure will be used with stratification based on FAP-related time-
to-first-event prognosis.  The event prognosis groups are represented by 1) best (i.e., longest 
projected time to first FAP-related event) - rectal/pouch polyposis, 2) intermediate - duodenal 
polyposis and 3) worst - pre-colectomy.  If a subject has two or more of these disease sites, the 
most severe prognosis stratum will be assigned for randomization (e.g. worst > intermediate > 
best).  Since an individual may have more than one disease site involved, the trial will assess the 
time from the date of randomization to the date of the first occurrence of any FAP-related event in 
the subject as a whole.  In order to minimize potential treatment arm imbalance a centralized 
randomization process will be used to balance among treatment groups within prognostic strata. 
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8. SPECIFIC TREATMENT PLAN AND SUBJECT MANAGEMENT 
8.1. Subject Assessments and Treatment Schedule 
The clinical study schedule/schema (Table 3) provides the schedule for screening, on-study visits and follow-up. 



































FU 30 days 
Off-Study  




 (± 1 wk) (± 2 wks) (± 1 wk) (± 2 wks) (± 1 wk) (± 2 wks) (± 1 wk) ± 2 wks21 (± 1 wk) 
Informed Consent X                X26   
Polyposis History1 X                   
Medical History24 X  X  X    X    X    X X14  
GI Symptoms X  X  X    X    X    X X14  
Surgical History X                 X14 X19 
Concomitant 
Medications 




 X13 X X13 X X13 X13 X13 X X13 X13 X13 X X13 X13 X13 X 
  
Adverse Events  X13 X X13 X X13 X13 X13 X X13 X13 X13 X X13 X13 X13 X X14  
Chemistry Panel2 X  X  X    X    X    X   
CBC3 X  X  X    X    X    X   
Urinalysis25 X  X  X    X    X    X   
Vital Signs4 X  X  X    X    X    X   
Physical Exam/Review 
of Systems5 








Audiometry6 X        X        X   
EKG22 X  X23  X    X    X    X   
Serum Preg. Test7 X  X  X  X7  X  X7  X  X7  X   
Dispense Medications8  X8 X  X  X8  X  X8  X  X8     
Subject Diary9  X X  X  X  X  X  X  X     
Food Frequency 
Questionnaire15 








LGI Endoscopy10 X    X    X    X    X   
Normal Mucosa 








UGI Endoscopy12 X    X    X    X    X   
Pharmacokinetics 
Blood Samples 




























HRQoL surveys 20 X  X  X    X    X    X   
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FAP Study Schedule Footnotes (Table 3) 
Note: Shaded columns in subject schedule (Table 3) are protocol required in person visits. 
1. Polyposis history: Family history, age onset, physician or self-prescribed NSAIDs for polyp control, frequency and extent of post-colectomy interventions; specific 
findings during the past two endoscopies. 
2. Chemistry panel includes – electrolytes (Na, K, CL, CO2), liver function tests (AST, ALT, Alkaline phosphatase, bilirubin), BUN/urea, creatinine. 
3. CBC panel includes – hemoglobin, hematocrit, WBC, platelet count, automated differential. 
4. Vital signs – temperature, blood pressure, pulse, respirations. 
5. Physical Exam/Review of body systems (includes body system assessment - HEENT, hepatic, renal, genitourinary, reproductive, hematologic/immunologic, 
endocrine/metabolic, musculoskeletal, neurologic [i.e., grossly normal, walk into office, speech normal, no tremors, alert and oriented], dermatologic, cardiovascular, 
respiratory, gastrointestinal) – including height (baseline only), weight, vital signs. 
6. Audiometry will need to be done using air conduction methodology (250, 500, 1000, 2000, 4000 and 8000 Hz). 
7. Women of child-bearing bearing potential with no prior hysterectomy and pre-menopausal must use an effective contraception method and will have a serum pregnancy 
(HCG) done every 3 months while on study treatment (see Section 6.1, #11). 
8. Medications and subject diaries will be dispensed to the subject every 3 months (month 0, 3, 6, 9, 12, 15, 18, and 21) in person or by special arrangements. 
9. Subjects are to record in their 3-month diaries: medication use, presence of symptoms, and a self-assessment of presence of gross blood or melena. 
10. Lower GI (LGI) endoscopy (proctoscopy or colonoscopy) will be done on all randomized subjects that have an intact colon or rectum/pouch. 
11. During the LGI procedure, normal mucosal biopsy for polyamine analysis will be obtained at; screening/baseline, 6, 12, 18, and 24 months/EOT. For subjects with 
permanent ileostomy, endoscopy not required; normal mucosal biopsies are performed on the visible ileostomy stoma.  
12. On-study Upper GI (UGI) endoscopy will be done on all randomized subjects that have a duodenum. 
13. Monthly (± 7 days) phone/email contact by the study coordinator to follow-up on medication/drug compliance review, concomitant medications, and adverse events. 
14. The follow-up will be done as phone call to the subject to review medical history, surgical history for any FAP-related surgical events, concomitant medications and 
adverse events. 
15. A food frequency recall questionnaire will be administered at the screening/baseline, 12 and 24 month/EOT visits. US and Canada sites only. 
16. A peripheral blood sample (5 mL, lithium heparin) will be collected at each of the following time points:  pre-dose and 1, 2, 4 and 8 hours post dose. 
17. A peripheral blood sample (10 mL, EDTA) will be collected at screening/baseline for pharmacogenomic analysis. 
18. A random urine sample (15 mL minimum) will be collected at the screening/baseline, 6, 12, 18 and 24 month/EOT visits for polyamine analysis. 
19. The follow-up will be done monthly as phone call to review endoscopic excisional procedures/surgical history for any FAP-related surgical events. 
20. HRQoL surveys will include EORTC QLQ-C30 and QLQ-CR29, EQ-5D health utility index assessment, and modified Cancer Worry Scale. They will be collected at 
screening/baseline, 3, 6, 12, 18, and 24 month/EOT visits. 
21. EOT visit will occur within 2 weeks off study treatment for any cause including completion of treatment at 24 months. 
22. Subject needs to be in the supine position for 10 minutes prior to the EKG, including EKGs collected during PK sampling.  
23. 2-EKGs will be done on the day PK samples are collected: 1) before pre-dose sample and prior to dose, and 2) before the 4 hr PK sample is obtained.   
24. Medical history includes – standard review of major systems, with particular attention to cardiovascular, cerebrovascular, peripheral vascular, gastrointestinal and 
hearing issues. Interaction with outside physicians should be documented. 
25. Urinalysis panel includes – color, clarity/appearance, specific gravity, pH, protein, glucose, ketones and blood. 
26. Subjects completing the initial 24 month treatment without an FAP-related event and participating in the extension study must be consented at this visit.  Go to Table 4, 
for month 24 additional extension procedures. For those subjects not participating in the extension study, this will be the end of treatment visit. 
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 ± 1 wk 
Informed Consent X                  
Medical History19     X    X    X    X X13 
GI Symptoms     X    X    X    X X13 
Surgical History                  X13 
Concomitant Medications  X12 X12 X12 X X12 X12 X12 X X12 X12 X12 X X12 X12 X12 X X13 
Drug Compliance Review  X12 X12 X12 X X12 X12 X12 X X12 X12 X12 X X12 X12 X12 X  
Adverse Events  X12 X12 X12 X X12 X12 X12 X X12 X12 X12 X X12 X12 X12 X X13 
Chemistry Panel1     X    X    X    X  
CBC2     X    X    X    X  
Urinalysis20     X    X    X    X  
Vital Signs3     X    X    X    X  
Physical Exam4     X    X    X    X  
Audiometry5         X        X  
EKG18     X    X    X    X  
Serum Preg. Test6   X6  X  X6  X  X6  X  X6  X  
Dispense Medications7 X  X7  X  X7  X  X7  X  X7    
Subject Diary8 X  X  X  X  X  X  X  X    
Food Frequency 
Questionnaire14 
        X        X  
LGI Endoscopy9     X    X    X    X  
Normal Mucosa Biopsy10     X    X    X    X  
UGI Endoscopy11     X    X    X    X  
Polyamine Urine Samples15     X    X    X    X  
HRQoL surveys 16     X    X    X    X  
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FAP Study Schedule Treatment Extension Footnotes (Table 4) 
Note: Shaded columns in subject schedule (Table 4) are protocol required in person visits. 
1. Chemistry panel includes – electrolytes (Na, K, CL, CO2), liver function tests (AST, ALT, Alkaline phosphatase, bilirubin), BUN, creatinine. 
2. CBC panel includes – hemoglobin, hematocrit, WBC, platelet count, automated differential. 
3. Vital signs – temperature, blood pressure, pulse, respirations. 
4. Physical Exam/Review of body systems (includes body system assessment - HEENT, hepatic, renal, genitourinary, reproductive, hematologic/immunologic, 
endocrine/metabolic, musculoskeletal, neurologic [i.e., grossly normal, walk into office, speech normal, no tremors, alert and oriented], dermatologic, cardiovascular, 
respiratory, gastrointestinal) – including height (baseline only), weight, vital signs. 
5. Audiometry will need to be done using air conduction methodology (250, 500, 1000, 2000, 4000 and 8000 Hz). 
6. Women of child-bearing bearing potential with no prior hysterectomy and pre-menopausal must use an effective contraception method and will have a serum pregnancy 
(HCG) done every 3 months while on study treatment (see Section 6.1, #11). 
7. Medications and subject diaries will be dispensed to the subject every 3 months (month 24, 27, 30,33, 36, 39, 42, and 45) in person or by special arrangements. 
8. Subjects are to record in their 3-month diaries: medication use, presence of symptoms, and a self-assessment of presence of gross blood or melena. 
9. Lower GI (LGI) endoscopy (proctoscopy or colonoscopy) will be done on all randomized subjects that have an intact colon or rectum/pouch. 
10. During the LGI procedure, normal mucosal biopsy for polyamine analysis will be obtained at months 30, 36, 42 and 48/EOT visits. For subjects with permanent 
ileostomy, endoscopy not required; normal mucosal biopsies are performed on the visible ileostomy stoma.  
11. On-study Upper GI (UGI) endoscopy will be done on all randomized subjects that have a duodenum. 
12. Monthly (± 7 days) phone/email contact by the study coordinator to follow-up on medication/drug compliance review, concomitant medications, and adverse events. 
13. The follow-up will be done as phone call to the subject to review medical history, surgical history for any FAP-related surgical events, concomitant medications and 
adverse events. 
14. A food frequency recall questionnaire will be administered at month 36 and 48/EOT visit. US and Canada sites only. 
15. A random urine sample (15 mL minimum) will be collected at months 24, 30, 36, 42 and 48/EOT visits for polyamine analysis. 
16. HRQoL surveys will include EORTC QLQ-C30 and QLQ-CR29, EQ-5D health utility index assessment, and modified Cancer Worry Scale. They will be collected at 
months 30, 36, 42 and 48/EOT visits. 
17. EOT visit will occur within 2 weeks off study treatment for any cause including completion of treatment at 48 months. 
18. Subject needs to be in the supine position for 10 minutes prior to the EKG.  
19. Medical history includes – standard review of major systems, with particular attention to cardiovascular, cerebrovascular, peripheral vascular, gastrointestinal and hearing 
issues. Interaction with outside physicians should be documented. 
20. Urinalysis panel includes – color, clarity/appearance, specific gravity, pH, protein, glucose, ketones and blood. 
21. These procedures are in addition to those listed for Month 24 on the initial treatment schedule (Table 3). 
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8.2. Patient Accrual Logistics 
8.2.1. Initial Visit – Determining Potential Eligibility 
Based on general medical and polyposis history, prior surgery, cardiac risk assessment and 
clinical hearing loss, current aspirin and NSAID use - patients will be determined to be 
potentially eligible for this trial.  After appropriate discussions, written informed consent will be 
obtained. 
8.2.2. Subsequent Screening for Eligibility 
If the patient has not already been genotyped for FAP, genetic analysis will be performed to 
confirm the presence of an APC mutation.  
Lower GI Endoscopy:  Patients will be evaluated via colonoscopy, flexible or rigid procto-
sigmoidoscopy during the screening phase.  Biopsies, ablations, and snare excisions at baseline 
are performed per the clinician’s standard of care.  If considered eligible based on inclusion 
criteria, a grossly normal mucosa biopsy will be obtained for baseline polyamine measurement.  
Still and video documentation of the colon (vide infra) or the residual rectum or entire pouch will 
also be obtained for archiving.  Polyp size will be determined by visual comparison with biopsy 
forceps that can measure 5.0 – 5.5 mm in the fully open position.  Procedural details are provided 
in the Investigator Manual.  All randomized patients with an intact colon or rectum/pouch will 
have baseline and on-study lower GI endoscopy procedures as part of this trial. 
Upper GI Endoscopy:  The duodenum will be evaluated by forward-viewing and/or side-viewing 
gastroscopes (with still and video documentation with closed and open biopsy forceps near 
mucosa).  Procedural details are provided in the Investigator Manual.  All randomized patients 
with a duodenum will have baseline and on-study UGI endoscopy as part of this trial. Subjects 
stratified to the duodenal group must have duodenal biopsies of all polyps 1 cm or larger to 
determine HGD and histology required for determining Stage 3 or 4 Spigelman status.  
A physical exam/review of body systems, height, weight and vital signs will be performed. 
Baseline blood and urine tests within 30 days of randomization: Per eligibility criteria – CBC, 
chemistry profile, urinalysis, and a sample for pharmacogenomic and genetic analysis. 
In order to ascertain how many patients with clinical FAP have baseline hearing deficits, patients 
meeting all the criteria for this trial will undergo air conduction audiometry.  Results will not be 
relevant to eligibility. 
8.2.3. Final Eligibility and Potential Screen Failures 
If the patient has signed the informed consent, and all eligibility criteria are met, the subject will 
be randomized.  Screening UGI, LGI and rectal/pouch images will be submitted to the central 
imaging laboratory for central collection and archiving.  Quality of life questionnaires (EORTC 
QLQ-C30, EORTC QLQ-CR29, EQ-5D, and the modified Cancer Worry Scale) will be provided 
to the subject to complete to obtain baseline values.  A food frequency questionnaire will be 
provided to the subject to complete for baseline values at North American (United States and 
Canada) sites only. 
The patient may be a screen failure based on history, physical exam, genetic assessment, or other 
laboratory values.  A screen failure case report form will need to be completed by the 
Investigator or study coordinator and available for review by the study Sponsor.  
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8.2.4. Drug Administration 
After confirming eligibility, the patient will be randomized to one of the three treatment arms 
(Table 5).  Randomization should be performed within 5 working days prior to the initiation of 
treatment.  Specific procedures for randomization will be included in the study manual. 
Table 5 - Study Medication Schedule1 
AGENT and DOSE ROUTE RX INTERVAL 
CPP-1X 750 mg & Sulindac 150 mg Oral Daily for up to 48 
months 
OR   
CPP-1X placebo & Sulindac 150 mg Oral Daily for up to 48 
months 
OR   
CPP-1X 750 mg & Sulindac placebo Oral Daily for up to 48 
months 
1The medications are to be taken at approximately the same time daily with food. 
* Each CPP-1X tablet = 250 mg;  ** Each sulindac tablet = 150 mg 
The study medication and subject diaries will be dispensed to the subject at the initial treatment 
visit and at 3 month intervals thereafter in person or by special arrangement.  Subjects will be 
instructed to take their medication with food at approximately the same time each day, preferably 
in the morning.  The subject will be instructed to record dosing compliance on a weekly basis in 
the subject diary. 
Based on published data utilized to project event rates, subjects will receive treatment for up to 
48 months.  However, interim analyses prescribed by the Data Monitoring Committee charter 
may result in earlier stopping based on futility or toxicity.  
8.2.5. Initial 24-Month Treatment Intervention Assessments 
Refer to Section 8.1, Table 3 and Table 4 for subject assessments and the treatment schedule for 
screening, on-study, end of treatment and follow-up visits. 
During the initial 24-month drug intervention, subjects will be followed monthly by phone or in 
person visits interview for assessment of possible toxicities and medication compliance.  A diary 
of compliance and symptoms will be maintained by subjects and reviewed during the next office 
visit.  At each interval assessment visit (month 3, 6, 12, 18, and 24), until the subject completes 
24 months of treatment or the subject comes off study treatment additional drug supplies and 
subject diaries will be provided. 
At months 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23 (+ 1 week), a follow-up visit via 
phone contact will be performed to assess for side effects, other medications, to remind subjects 
to complete their diary and to continue to take their study medications. 
At the 3-month visit (+ 1 week), subjects will have a physical exam/review of body systems 
(including weight and vital signs), blood and urine samples obtained for laboratory tests (CBC, 
chemistry panel, urinalysis), pharmacokinetics (PK), and EKGs (before the pre-dose sample, 
prior to drug administration and before the 4-hour PK sample collection.  Subject needs to be in 
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the supine position for 10 minutes prior to the EKG).  Women of child bearing potential will also 
have a serum pregnancy test performed.  Concomitant medications, adverse events and 
medication compliance will also be reviewed.  Quality of life questionnaires (EORTC QLQ-C30, 
EORTC QLQ-CR29, EQ-5D, and the modified Cancer Worry Scale) will be provided to the 
subject to complete. 
At the 6-month and 18-month visits (+ 2 weeks), subjects will have a physical exam/review of 
body systems (including weight and vital signs), blood samples obtained for laboratory tests 
(CBC, chemistry panel, urinalysis), a random urine sample will be obtained for polyamine 
determination, EKG (Subject needs to be in the supine position for 10 minutes prior to the EKG) 
and their first on study treatment upper and lower endoscopy procedures with image and video 
documentation will be obtained.  A normal rectal/pouch mucosal biopsy for polyamine 
determination will be obtained during the colonoscopy/proctoscopy procedure.  Women of child 
bearing potential will also have a serum pregnancy test performed. Concomitant medications, 
adverse events and medication compliance will also be reviewed. Quality of life questionnaires 
(EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and the modified Cancer Worry Scale) will 
be provided to the subject to complete. Study drug and diaries will be dispensed. 
At the 9-month, 15-month and 21-month visits (+ 1 week), subjects will have drug and diary 
dispensing. Women of child bearing potential will also have a serum pregnancy test performed.  
Concomitant medications, adverse events and medication compliance will also be reviewed. 
At the 12-month and 24-month visits (+ 2 weeks), subjects will have a physical exam/review of 
body systems (including, weight and vital signs), blood samples obtained for laboratory tests 
(CBC, chemistry panel, urinalysis), a random urine sample will be obtained for polyamine 
determination, audiometry testing, EKG (Subject needs to be in the supine position for 10 
minutes prior to the EKG) and their second set of on study treatment endoscopy procedures with 
image and video documentation will be obtained. A normal mucosal biopsy for polyamine 
determination will be obtained during the colonoscopy/proctoscopy procedure.  Women of child 
bearing potential will also have a serum pregnancy test performed. Concomitant medications, 
adverse events and medication compliance will also be reviewed. Quality of life questionnaires 
(EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and the modified Cancer Worry Scale) will 
be provided to the subject to complete.  A food frequency questionnaire will be provided to the 
subject to complete at North American (United States and Canada) sites only. Study drug and 
diaries will be dispensed at 12-month and if the subject continues on the treatment extension at 
24-month. 
Subjects completing the initial 24 months of study treatment, without an FAP related event, and 
have completed the 24 month visit procedures as outlined below may be eligible to participate in 
the 24 month treatment extension (See Section 8.2.10).  For those subjects that do not go on to 
the treatment extension, this will be the end of treatment visit.  It must be documented in the 
subject’s medical record why the subject declined participation in the treatment extension if they 
met the requirements for participation, see Section 8.2.10. 
8.2.6. Initial 24 Month Treatment Intervention Early Termination (+ 2 weeks) 
Within 2 weeks off final study pill treatment for any cause, all subjects will have a follow-up 
history and physical exam/review of body systems (including, weight and vital signs), along with 
toxicity assessment.  Repeat blood laboratory tests (CBC, chemistry panel, and urinalysis), a 
random urine sample will be obtained for polyamine determination, EKG (Subject needs to be in 
the supine position for 10 minutes prior to the EKG) and audiometry will be performed.  Women 
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of child bearing potential will also have a serum pregnancy test performed.  Concomitant 
medications, adverse events and medication compliance will also be reviewed.  Quality of life 
questionnaires (EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D and the modified Cancer 
Worry Scale) will be provided to the subject to complete.  A food frequency questionnaire will 
be provided to the subject to complete at North American (United States and Canada) sites only.  
Repeat upper and lower endoscopies with image and video documentation will be obtained at the 
Month 24/EOT visit or if the subject has completed at least 3 months of treatment from the 
previous on-study upper and lower endoscopy procedures (including baseline).  A normal 
mucosal biopsy sample for polyamine determination will be obtained during the 
colonoscopy/proctoscopy procedure. 
If the subject has an unscheduled upper/lower endoscopy for any reason, these procedures should 
be captured with image and video documentation including the collection of a normal mucosal 
biopsy, if possible.  A random urine sample should be obtained for polyamine determination, if 
possible. 
Subjects will be formally taken off-study treatment and complete the End of Treatment (EOT) 
assessments if there is a cumulative delay/suspension of study medication for any reason of: 
▪ > 90 days from randomization to month 36 
▪ > 105 days from randomization to month 42 
▪ > 120 days from randomization to month 48 
A temporary suspension from taking study medication as stated above (for example, due to a 
non-FAP disease related surgery or procedure), will be documented as a treatment delay and the 
subject will continue on study, on their original schedule. 
8.2.7. Initial 24 Month Treatment Intervention Follow-Up (30-days post end of treatment 
visit +/- 1 week) Off Study 
Thirty-days (30) after completion of the end of study evaluations, subjects will be contacted by 
phone for a clinical update in regard to symptoms and interval medical history.  Concomitant 
medications and adverse events will also be reviewed.  The subject will provide a clinical update 
and procedure date for any FAP-related surgical event or major endoscopic excisional event that 
has occurred since the last contact. These include partial colectomy, colectomy with IRA, total 
procto-colectomy, proctectomy, pouch resection, sub-mucosal resection, trans-duodenal 
excision, ampullectomy, duodenectomy, or Whipple procedure. 
An FAP-related event at any disease site (colon/rectum/pouch, duodenum) will lead to 
discontinuation of the study treatment but follow-up of the subject will continue until the end of 
the 30 day follow-up period. 
8.2.8. Initial 24 Month Treatment Intervention Follow-Up (Months 2-6, each month +/- 1 
week) Off Study 
For the next 5 months after the 30 day follow-up, if the subject went off study treatment for 
disease progression indicating the need for an any FAP-related surgical event or major 
endoscopic excisional event, and the surgical/endoscopic event had not yet occurred at the time 
of the 30 days post end of treatment visit, subjects will be contacted by phone to obtain the 
procedure date of any FAP-related surgical event or major endoscopic excisional event that has 
occurred since the last contact.  These include partial colectomy, colectomy with IRA, total 
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procto-colectomy, proctectomy, pouch resection, sub-mucosal resection, trans-duodenal 
excision, ampullectomy, duodenectomy, or Whipple procedure. 
8.2.9. Treatment Extension Intervention (Months 25 - 48) 
Subjects completing the initial 24 months of study treatment, without an FAP related event, and 
have completed all the 24 month visit procedures as outlined in Section 8.2.6 and Table 3 and 
Table 4 may be eligible to participate in the treatment extension.  
In order to participate, a subject must meet the following requirements: 
1. Subject has completed 24 months of treatment without an FAP related event. 
2. Subject has completed all the month 24 visit procedures. 
3. Subject is no more than 14 days beyond the 24 month or 36 month visit. 
4. Subject has signed the informed consent for treatment extension. 
Once the above requirements are met, the subject will have drug and diary dispensed. 
At months 25, 26, 28, 29, 31, 32, 34, 35, 37, 38, 40, 41, 43, 44, 46, and 47 (+ 1 week), a follow-
up visit via phone contact to assess for side effects, other medications, to remind subjects to 
complete their diary and to continue to take their study medications. 
At the 27-month, 33-month, 39-month and 45-month visits (+ 1 week), subjects will have drug 
and diary dispensing. Women of child bearing potential will also have a serum pregnancy test 
performed.  Concomitant medications, adverse events and medication compliance will also be 
reviewed. 
At the 30-month and 42-month visits (+ 2 weeks), subjects will have a physical exam/review of 
body systems (including weight and vital signs), blood samples obtained for laboratory tests 
(CBC, chemistry panel, urinalysis), a random urine sample will be obtained for polyamine 
determination, EKG (Subject needs to be in the supine position for 10 minutes prior to the EKG) 
and their first on study treatment upper and lower endoscopy procedures.  A normal rectal/pouch 
mucosal biopsy for polyamine determination will be obtained during the 
colonoscopy/proctoscopy procedure.  Women of child bearing potential will also have a serum 
pregnancy test performed. Concomitant medications, adverse events and medication compliance 
will also be reviewed. Quality of life questionnaires (EORTC QLQ-C30, EORTC QLQ-CR29, 
EQ-5D, and the modified Cancer Worry Scale) will be provided to the subject to complete. 
At the 36-month, and 48-month visits (+ 2 weeks), subjects will have a physical exam/review of 
body systems (including, weight and vital signs), blood samples obtained for laboratory tests 
(CBC, chemistry panel, urinalysis), a random urine sample will be obtained for polyamine 
determination, audiometry testing, EKG (Subject needs to be in the supine position for 10 
minutes prior to the EKG) and their second set of on study treatment endoscopy procedures. A 
normal mucosal biopsy for polyamine determination will be obtained during the 
colonoscopy/proctoscopy procedure.  Study drug and diaries will be dispensed at 36-month if 
eligible to continue. Women of child bearing potential will also have a serum pregnancy test 
performed. Concomitant medications, adverse events and medication compliance will also be 
reviewed. Quality of life questionnaires (EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and 
the modified Cancer Worry Scale) will be provided to the subject to complete.  A food frequency 
questionnaire will be provided to the subject to complete at North American (United States and 
Canada) sites only. 
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8.2.10. Treatment Extension - End of Treatment/Early Termination (+/- 2 weeks) 
Within 2 weeks of final study pill treatment for any cause, all subjects will have a follow-up 
history and physical exam/review of body systems (including, weight and vital signs), along with 
toxicity assessment.  Repeat blood laboratory tests (CBC, chemistry panel, and urinalysis), EKG 
(Subject needs to be in the supine position for 10 minutes prior to the EKG) and audiometry will 
be performed. Women of child bearing potential will also have a serum pregnancy test 
performed. Concomitant medications, adverse events and medication compliance will also be 
reviewed. Quality of life questionnaires (EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D and 
the modified Cancer Worry Scale) will be provided to the subject to complete.  A food frequency 
questionnaire will be provided to the subject to complete at North American (United States and 
Canada) sites only.  
Repeat upper and lower endoscopies with image and video documentation will be obtained at the 
end of treatment visit if the subject has completed at least 3 months of treatment from the 
previous on-study upper and lower endoscopy procedures (including month-24). A normal 
mucosal biopsy will be obtained during the colonoscopy/proctoscopy procedure and a urine 
sample will be collected for polyamine determination. 
If the subject has an unscheduled upper/lower endoscopy for any reason, these procedures should 
be captured with image and video documentation including the collection of a normal mucosal 
biopsy, if possible.  A random urine sample should be obtained for polyamine determination, if 
possible. 
8.2.11. Treatment Extension Follow-Up (30-days post end of treatment visit +/- 1 week) 
Off Study 
Thirty-days (30) after completion of the treatment extension evaluations, subjects will be 
contacted by phone for a clinical update in regard to symptoms and interval medical history.  
Concomitant medications and adverse events will also be reviewed. The subject will provide a 
clinical update and procedure date for any FAP-related surgical event or major endoscopic 
excisional event that has occurred since the last contact. These include partial colectomy, 
colectomy with IRA, total procto-colectomy, proctectomy, pouch resection, sub-mucosal 
resection, trans-duodenal excision, ampullectomy, duodenectomy, or Whipple procedure. 
An FAP-related event at any disease site (colon/rectum/pouch, duodenum) will lead to 
discontinuation of the study treatment but follow-up of the subject will continue until the end of 
the 30 day follow-up period. 
8.2.12. Termination of Treatment Extension Procedures 
Subjects on the treatment extension can continue on treatment for up to 48 months based on their 
date of randomization as follows: 
1. If randomized between November 2015 and April 2016 eligible for up to 36 months 
2. If randomized between May 2015 and October 2015 eligible for up to 42 months 
3. If randomized between July 2014 and April 2015 eligible for up to 48 months 
or until one of the following occurs: 
1. Subject has an FAP-related event or comes off study for other reasons 
2. Trial end-date of April 30, 2019 has been reached 
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3. 90 FAP-related events have occurred 
4. Less than 90 FAP-related events have accrued prior to April 30, 2019 and an earlier trial 
end-date has been set by the Sponsor and reviewed by the DMC 
5. An earlier trial end date prior to April 30, 2019 has been recommended by the DMC for 
safety reason and approved by the Sponsor. 
8.2.13. Treatment Compliance 
Subjects will be formally taken off-study treatment and complete the End of Treatment (EOT) 
assessments if there is a cumulative delay/suspension of study medication for any reason of: 
▪ > 90 days from randomization to month 36 
▪ > 105 days from randomization to month 42 
▪ > 120 days from randomization to month 48 
8.2.14. Definition of FAP-Related Events or Serious and Unexpected Toxicity 
The time from the date of randomization to the date of the first occurrence of any FAP-related 
event at any disease site (colon/rectum/pouch, duodenum) will lead to discontinuation of the 
study treatment.  Follow-up of the subject for FAP-related events will continue, per protocol, 
until the end of the 30 day post-treatment. 
FAP-related primary events by disease site are as follows: 
1. Pre-operative, intact colon: 
a) Disease progression^ indicating need for colectomy with IRA or total procto-
colectomy  
 
2. Rectum or pouch events include one or more of the following: 
a) Excisional intervention by surgical snare or trans-anal excision to remove any 
polyp ≥ 10 mm in size (per pathology report) and/or pathologic evidence of high 
grade dysplasia.* 
b) Disease progression^ indicating need for proctectomy 
c) Disease progression^ indicating need for pouch resection 
d) Development of cancer in rectum or pouch 
e) Death 
 
3. Duodenal disease includes the following: 
a) Progression in Spigelman Stage to more advanced stage (Stage 2, 3 or 4), refer to 
Appendix A 
b) Disease progression indicating need for excisional intervention (sub-mucosal 
resection, trans-duodenal excision, ampullectomy, duodenectomy, Whipple 
procedure) 
c) Development of cancer 
d) Death 
 
Note, excisional intervention may include open surgery, trans-anal surgery or endoscopic 
excisions/snare but does not include cautery ablations or hot biopsy. 
*For those subjects stratified to the duodenal group, all concurrent rectal pouch polyps > 5 mm 
must have been removed at baseline for this event to apply. 
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^Disease progression is based on endoscopic evaluations compared to baseline demonstrating a 
clinically significant increase in number and/or size of polyps (~25% increase in disease burden), 
presence of a large sessile or ulcerated adenoma not amenable to removal, high grade dysplasia 
in any adenoma, or in-situ or invasive cancer. 
Discontinuation from study treatment due to a potential treatment related serious adverse event 
may include the following:  
• Gastrointestinal hemorrhage, ≥ grade 3 
• Tinnitus ≥ grade 2, or clinical hearing impairment ≥ grade 3 
• Cardiovascular events include cardiac arrest, cardiac-chest pain, myocardial 
infarction, thromboembolic event, phlebitis (deep or superficial), and spontaneous 
abdominal wall or retroperitoneal hematoma at least 10 cm in maximum dimension.  
• Grade ≥ 3 Cardiac ischemia/infarction or cerebrovascular ischemia, whether related 
to study drug or not. 
Adverse events and serious adverse events must be recorded carefully and completely on the 
case report forms and SAE report forms.  Adverse event reporting and grading will be done 
using the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. 
If a subject comes off study treatment for any of the above listed FAP or SAE events, the subject 
will need to complete all tests, procedures and assessments required at the Final Intervention/End 
of Treatment visit, including 30-day follow-up. 
All subjects who go off study treatment due to an FAP-related event, toxicity, or intercurrent 
illness, or who withdraw consent for further treatment will be followed for at least 30 days from 
their last dose of study medication.  
8.3. Study Blinding Information and Criteria for Protocol Treatment Removal 
8.3.1. Blinding and Unblinding 
Treatment will be provided in a double blind manner such that neither the subject, Investigator, 
clinic staff nor the Sponsor will know which combination is being administered.  Randomization 
numbers will be assigned based on information obtained from an interactive web-based response 
system. 
Subject treatment will be unblinded in emergency situations by the study Investigator if it is in 
the best interest of the trial subject in order to provide medical care to the subject and includes 
medical decisions such as whether to start or stop treatment or institute alternative treatment if 
required.  Specifically, we expect that unblinding of an individual study subject’s treatment 
assignment may occur if in the opinion of the Investigator that the identification of the study 
medication is necessary to protect the welfare of the subject. The study drug may be discontinued 
without unblinding the participant. 
If the blind is prematurely broken for a subject, it is the responsibility of the Investigator to 
promptly document and explain any unblinding to Cancer Prevention Pharmaceuticals within 24 
hours of the blind being broken. 
Unblinding of subject treatment is done via the IWRS by the Investigator.  If the Investigator is 
unable to access IWRS, the Drug Safety Group at Chiltern should be contacted at 1-919-468-
2288 (US) and 001-919-468-2288 (EU) for a subject’s treatment code. 
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8.3.2. Protocol Treatment Withdrawal (Off-Study Treatment) 
Participants will be withdrawn from protocol treatment under the following circumstances: 
1. Evidence of an FAP-related event as defined in Section 8.2.14.  
2. Clinical reduction in hearing acumen requiring use of a hearing aid. 
3. Grade ≥ 3 cardiac ischemia/infarction or cerebrovascular ischemia, whether related to 
study drug or not. 
4. Pregnancy while on treatment, see Section 11.8. 
5. Intercurrent illness which would, in the judgment of the treating physician, affect 
assessments of clinical status to a significant degree and/or require discontinuation of 
drugs.  Participants will not discontinue study drugs for other medical events which are 
not considered to be treatment related.  This determination will be made by the treating 
physician.  
6. Cumulative delay of study intervention for any reason as follow: 
• > 90 days from randomization to month 36 
• > 105 days from randomization to month 42 or 
• > 120 days from randomization to month 48 
The first day of study treatment initiation is the randomization date regardless of study 
visit and/or procedure delays. 
7. Completion of treatment intervention. 
8. At the request of the Sponsor in situations such as protocol violations or concerns about 
the subject’s safety. 
9. The subject is lost to follow-up. 
10. The subject may withdraw from the study-treatment at any time for any reason. 
11. Subject death. 
8.3.3. Protocol Withdrawal (Off-Study) 
1. The subject may withdraw from the study at any time for any reason. 
9. DISEASE ASSESSMENT AND SAMPLE COLLECTION 
9.1. Baseline Endoscopy 
A. Colon, Rectal, Pouch Assessment 
Colonoscopy or flexible sigmoidoscopy will be used to assess the colon, rectum or the neo-rectum 
(ileal pouch) and video images captured for archiving and subsequent review.  The last images 
will be retroflexed pictures of the distal rectum or pouch at the anorectal ring.  One pass will be 
performed.  Further details will be provided in the Imaging Manual. 
Rectal/Neorectal Pouch 
The entire residual rectum or pouch will be video-captured three times by: 
▪ Advancing flexible scope to ileo-rectal anastomosis or proximal pouch.  After 
advancement, the scope will be “twirled” to visualize all walls of the bowel as it is 
withdrawn. 
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▪ Retroflexed views of the distal rectum will be obtained at each visualization. 
▪ Images of the bowel will be obtained using biopsy forceps in the fully open position 
placed near the mucosa. 
Rectal/Neorectal Pouch Enumeration and Measurement 
▪ Number of polyps in the rectum or pouch 
▪ Endoscopic estimation of polyp size will be determined by visual comparison to a biopsy 
forceps that can measure, 5.0 - 5.5mm in the fully open position. 
o Number of polyps between 5 – 10 mm 
o Number of polyps > 10 mm 
▪ All rectal/pouch polyps > 5 mm in diameter must be excised at baseline if the subject will 
be stratified to the rectum/pouch group.  For details concerning subjects stratified to the 
rectal/pouch polyposis group (with or without involvement of the duodenum) please see 
Section 6.1, #4.  For details concerning subjects stratified to the duodenal polyposis group 
(with or without involvement of rectum/pouch at stratification) please see Section 8.2.14.  
Smaller polyps may be ablated per the treating institutions standard of care and three additional 
sets of video images will then be obtained as “baseline”.  
B. Duodenal Assessment 
Duodenal assessment will use a forward and/or side-viewing endoscope with video images 
captured for subsequent review.  The Spigelman classification (Appendix A) at screening will be 
utilized to stage the initial extent of disease and assess subject eligibility.  A side-viewing scope 
may be used to improve assessment of the ampulla of Vater/papilla.  Ampullary biopsies (with 
histology) and snare excisions will be performed per the protocol, Investigator Manual, and the 
institution’s standard of care and the results of these procedures will be used as the subject’s 
baseline Spigelman classification.  Further details will be provided in the Imaging Manual. 
The screening stage will be the initial Spigelman Stage (extent of polyposis combined with 
histology) and the baseline Spigelman Stage will be the post-snare intervention. 
9.2. Follow-up Endoscopies 
At six month intervals (+/- two weeks) – per Section 8.1, subjects will undergo repeat upper and 
lower endoscopy.  At any interval assessment, if any subject requires an excisional intervention 
(as defined in Section 8.2.14), or has duodenal Spigelman stage progression (Stage 2, 3 or 4), the 
subject will be considered to have an FAP-related event and will come off study treatment.  
9.3. Imaging Submission 
All de-identified images will be captured on DVD or flash drive, de-identified, and forwarded to 
a central imaging laboratory for archiving.  All data will be de-identified in regard to subject, site 
and treatment but subject study ID number will be available for baseline and subsequent 
comparison as appropriate.  Post-hoc global assessment by blinded reviewers not involved in this 
trial will perform the assessment - using a 5 point scale - much less, somewhat less, none or 
minor changes, somewhat worse, much worse.  This process will be defined in detail and 
included in the imaging manual for still and video endoscopy image submission. 
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9.4. Population Pharmacokinetic Sampling  
All subjects will have blood samples obtained for pharmacokinetic studies.  Pharmacokinetic 
sampling will occur once at the scheduled 3-month visit.  Samples may be collected within ± 1 
weeks of this visit.  These visits start in the morning, to allow for subjects to hold their morning 
study medication dose, and for samples to be taken during standard working hours. 
The subject will be contacted by a study coordinator at least three (3) days prior to the scheduled 
visit to remind the subject to not take their morning dose of study medication on the day of the 
planned visit. 
On the morning of the visit, upon subject arrival, it will be verified that the subject did not take 
their morning dose of study medication.  Those subjects that mistakenly took their morning dose 
will be sent home and rescheduled within the next week.   
Prior to the pre-dose blood sample collection, a resting EKG will be obtained (subject needs to 
be in the supine position for 10 minutes prior to the EKG).  After the EKG was obtained, a pre-
dose blood sample (5 mL, lithium heparin vacutainer tube) will be collected.   
The subject will then take their study medications in the usual manner.  The subject may then 
leave the clinic and have their typical breakfast.  Subjects will be asked to note the time breakfast 
was finished, as that will be recorded. 
Table 6 – Pharmacokinetic Sample Number, Sampling Times and EKG collection 
Sample 
Number 
Target Time No Earlier Than No Later Than 
 
EKG – Prior to pre-dose sample collection and drug administration 
1 
Pre-dose* NA NA 
2 
1 hour post dose 45 minutes 75 minutes 
3 
2 hours post dose 90 minutes 150 minutes 
 
EKG – Prior to 4 hour sample collection 
4 4 hours post dose* 3 hours 5 hours 
5 8 hours post dose 6 hours 10 hours 
*EKGs need to be done 1) before the pre-dose sample and before drug administration 
and 2) before the 4 hour samples are collected. 
Post dose blood samples will be collected (5 mL each) at 1, 2, 4, and 8 hours following the 
morning dose of study medication (see Table 5).  Deviations around these sample times should 
be no more than ± 15 minutes, ± 30 minutes, ± 60 minutes (1 hour), ± 120 minutes (2 hours), 
respectively, keeping in mind that the fourth and fifth samples must be at least one hour apart.   
At the 4 hour time point and prior to the 4 hour blood sample collection, a resting EKG will be 
obtained (subject needs to be in the supine position for 10 minutes prior to the EKG).  After the 
EKG is obtained, the 4 hour time point blood sample (5 mL, lithium heparin vacutainer tube) 
will be collected. 
On the pharmacokinetic sampling case report form page, study coordinators will record the time 
of the pre-dose blood sample and the time breakfast was finished.  Also, the relative ideal blood 
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sampling times (relative to dose time), and the actual blood sampling times will be recorded.  
Missed samples or samples collected outside of the time windows will still be stored and 
analyzed.  Collected blood samples will be processed, stored, and shipped to a central laboratory 
according to procedures provided in the study manual. 
Plasma concentration data from this trial will be pooled with data from other clinical trials, when 
available, for analysis.  For each drug, a database will be constructed that includes the nominal 
and recorded dosing history, plasma analyte concentrations, demographic (body size, age, race, 
gender) data, laboratory data (hepatic and renal function), medical history (colonic resection), 
and clinical trial identifier.  These data will be analyzed using methods appropriate for sparse 
data (mixed-effects modeling using NONMEM). 
9.5. Polyamine Sample Collection (Normal Mucosa Biopsy, Random Urine Sample) 
Subject tissue samples will undergo a baseline polyamine assay (examination of grossly normal 
rectal mucosal cup forcep biopsy and random urine sample - minimum 15 mL) pre-treatment, as 
a component of the screening process, and at each endoscopy/proctoscopy evaluation.  Collected 
tissue and urine samples will be processed, stored, and shipped to a central laboratory according 
to procedures provided in the study manual. 
For subjects who have signed the Optional Research Use of Biospecimens portion of the 
informed consent, left over urine or tissue samples may be used for exploratory assessment of 
levels of expression of RNA, proteins, or other molecules, such as polyamines, in the polyamine 
synthesis pathway, the APC signaling pathway, and other related pathways.  Analysis may 
include mutation status for genes involved in the polyamine synthesis pathway, APC pathway, or 
other FAP related pathways. 
9.6. Pharmacogenomic and Genetic Testing Sample Collection 
Subjects will have 10 mL of peripheral blood collected in an EDTA vacutainer tube during their 
baseline/screening visit for subsequent correlative science research.  Collected blood samples 
will be processed and shipped to a central laboratory according to procedures provided in the 
study manual. 
For subjects who have signed the Optional Research Use of Biospecimens portion of the 
informed consent, left over blood samples may be used for exploratory assessment of levels of 
expression of RNA, proteins, or other molecules, such as polyamines, in the polyamine synthesis 
pathway, the APC signaling pathway, and other related pathways.  Analysis may include 
mutation status for genes involved in the polyamine synthesis pathway, APC pathway, or other 
FAP related pathways. 
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10. QUALITY OF LIFE AND DIETARY ASSESSMENTS 
10.1. Assessment of Quality of Life and Subject Preferences 
For this study, we plan to use four (4) instruments to measure HRQoL and subject preferences or 
utilities.  These instruments include the EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and a 
modified Cancer Worry Scale. 
• The EORTC QLQ-C30 is a self-administered quality of life questionnaire70 with multi-
dimensional scales.  It consists of both multi-item scales and single item measures, 
including five functioning domains, a global quality of life domain, three symptom 
domains and six single items.  
• The EORTC QLQ-CR29 gastrointestinal / colorectal sub-module71 is composed of 4 
functional and 18 symptom related sub-scales.  The 4 functional scales include body 
image, weight, anxiety and sexual function.  The symptom related scales include single 
item and multi-item questions concerning stool frequency, bleeding and mucous 
discharge, stool leakage, abdominal bloating, flatulence, embarrassment and site-specific 
pain among others. 
• The EuroQol EQ-5D is a standardized instrument for use as a measure of health outcome 
and is applicable to a wide range of health conditions and treatments.72,73  It provides a 
simple descriptive profile and a single index value for health status. 
• The Cancer Worry Scale74 is a brief psychometric instrument that was designed to assess 
both the frequency of worrying about “getting cancer some day” and measuring the 
impact of worry on mood and performing daily activities.  This scale was originally 
developed by Caryn Lerman and her colleagues to study breast cancer and has been 
modified for use in this FAP trial.  
The validity and reliability of both the QLQ-C30 and the QLQ-CR29 questionnaires have been 
studied by the EORTC Study Group on Quality of Life and both instruments will be scored 
according to the EORTC Scoring Manual and analyzed accordingly. 
HRQoL measures will be obtained at baseline, month 3, at every interim endoscopy visit, and at 
end of treatment.  For each single item or multi-item sub-scale, a linear transformation will be 
applied to standardize raw scores to range between 0 and 100.  HRQoL secondary endpoints will 
include all single item or multi-item sub-scales from both the EORTC QLQ-C30 and QLQ-CR29 
and subjects will be considered as deteriorated (or improved) for a given single item or multi-
item sub-scale if their change score from baseline was 10 points or more on the standardized 
scale. 
In addition to the HRQoL assessment, subject preferences (or utilities) will also be assessed.  
Data will be collected at baseline, month 3, at every interim endoscopy visit, and at end of 
treatment and preference weights among the treatment arms will be determined using the 
EuroQol EQ-5D assessment of individual health states.72,73  Quality-adjusted survival among the 
three treatment arms will be generated by multiplying the utility value by the amount of time 
spent in a specified health state.  
The modified version of the Cancer Worry Scale will also be administered at baseline, month 3, 
at every interim endoscopy visit, and at end of treatment and it will be scored according to the 
guidance provided by Lerman et al.74 
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10.2. Dietary Assessment 
The Food Frequency Questionnaire (FFQ) is the most common dietary assessment tool used in 
large epidemiologic studies of diet and health.  The self-administered FFQ booklet asks 
participants to report the frequency of consumption and portion size of approximately 125 line 
items over a defined period of time (e.g. the last month; the last three months).  Each line item is 
defined by a series of foods or beverages.  Additional questions on food purchasing and 
preparation methods enable the analysis software to further refine nutrient calculations.  The 
FFQ was developed by the Nutrition Assessment Shared Resource (NASR) of the Fred 
Hutchinson Cancer Research Center.  NASR periodically updates its standard FFQ to reflect 
U.S. food consumption patterns and major changes in the market place.82,83  Data from the FFQ 
will be analyzed using a polyamine database69 and will calculate the average daily levels of 
putrescine, spermidine, and spermine in the diet.  Dietary assessments via the FFQ will be 
obtained at baseline, months 12, 24, 36 and 48/end of treatment for subjects at North American 
(U.S. and Canada) sites only.  The results of the FFQ will be used to corroborate results from 
another recent trial84 that indicate consumption of a diet high in polyamines is associated with 
reduced treatment efficacy.  The results of this trial along with the earlier findings of Zell et al40 
could lead to dietary restrictions in combination with the combined eflornithine-sulindac therapy. 
11. ASSESSMENT OF SAFETY 
11.1. Cardiac Risk 
All subjects will undergo a baseline medical history evaluation and EKG for cardiovascular 
disease risk assessment.  Subjects with cardiovascular risk factors as defined in Section 6.2 are 
not eligible for study participation.  On-study cardiac risk assessments, for each subject, will take 
place throughout the study via ongoing adverse event assessments and periodic EKG evaluations 
at baseline, and months 3, 6, 12, 18, 24, 30, 36, 42 and 48/end of treatment.  
11.2. Ototoxicity Risk 
All subjects will undergo air conduction audiometry for hearing impairment as part of the 
screening process and at months 12, 24, 36 and 48/end of treatment.  Subject diaries will indicate 
the presence of symptoms and will instruct the subject to contact the treating doctor for 
assessment. These data will not be used to exclude subjects from this study.  
At months 3, 6, 12, 18, 24, 30, 36, 42 and 48/end of treatment, the subject will undergo a clinical 
assessment for ototoxicity adverse events symptoms by the research nurse or other medically 
qualified individual. 
11.3. Gastrointestinal Risk 
Subject’s diaries will indicate presence of symptoms and will instruct the subject to contact the 
treating doctor for assessment.  Stool will be self-assessed by subjects to determine if gross blood 
or melena is present.  If so, treating doctor will be contacted and the subject assessed.  Subject 
will perform stool assessments, which will be recorded in their diary. 
At months 3, 6, 12, 18, 24, 30, 36, 42 and 48/end of treatment, the subject will undergo a clinical 
assessment for gastrointestinal adverse events symptoms by the research nurse or other medically 
qualified individual. 
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11.4. Safety Parameters 
Subjects will be followed for safety from the start of treatment through 30 days after treatment 
discontinuation.  Serious adverse events will be followed until resolved or returned to baseline, 
even if longer than 30 days from the subject’s off study treatment or off study date.   
Adverse events and serious adverse events must be recorded carefully and completely on the 
case report forms and SAE report forms.  Adverse event reporting and grading will be done 
using the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03, 
(http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf).   
Serious adverse events must be reported to the Institutional Review Board (IRB)/Independent 
Ethics Review Committee (IEC)/Research Ethics Board (REB) by the Investigator and to 
regulatory authorities (FDA, National Health Authorities) by the Sponsor, according to 
established policy and regulatory requirements.  Adverse events will also be coded to an organ 
system class.  Summaries of safety data will be completed for the study population. 
11.5. Adverse Events 
Adverse event means any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related (FDA definition) and is defined by the EU and 
Canadian regulations as any untoward medical occurrence in a subject or clinical trial subject 
administered a medicinal product and which does not necessarily have a causal relationship with 
this treatment. 
An adverse event (also referred to as an adverse experience) can be any unfavorable and 
unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a drug, without any judgment about causality.  An adverse event can 
arise from any use of the drug and from any route of administration, formulation, or dose, 
including overdose. 
An adverse reaction means any adverse event caused by the drug.  Adverse reactions are a subset 
of all suspected adverse reactions for which there is reason to conclude that the drug caused the 
event. 
An adverse event does not include: pre-existing disease, conditions, or laboratory abnormalities 
present at the start of the study that do not worsen in frequency or intensity; situations where an 
untoward medical occurrence has not occurred (e.g., hospitalizations for cosmetic or elective 
surgery or social/convenience admissions); the disease being studied or signs or symptoms 
associated with the disease unless more severe than expected for the subject’s condition. 
For the FDA, an unexpected adverse event is an event that is not listed in the Investigator’s 
Brochure (IB) at the specificity or severity observed or is mentioned in the IB as occurring with a 
class of drugs or as anticipated from the pharmacological properties of the drug, but not 
mentioned as occurring with the drug(s) under investigation. 
The Reference Safety Information (RSI) is located in the IB Ver. CPP-201-IB08 and subsequent 
versions, which is to be used for the purposes of determining expectedness and SAE/SUSAR 
reporting. 
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11.6. Serious Adverse Events 
A serious adverse event determined by the opinion of the Investigator or Sponsors is defined as 
1. Death; 
2. A life-threatening event (places the subject at immediate risk of death); 
3. Requires in subject hospitalization or prolongs hospitalization; 
4. Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions; 
5. Congenital anomaly/birth defect; 
6. Important medical events (IMEs) may be considered serious when, based on medical 
judgment, they may jeopardize the subject and require intervention to prevent one of the 
above serious outcomes. 
An adverse event or suspected adverse reaction is considered “life-threatening” if, in the view of 
either the Investigator or Sponsor, its occurrence places the subject at immediate risk of death.  It 
does not include an adverse event or suspected adverse reaction that, had it occurred in a more 
serious form, might have caused death. 
11.7. Reporting of AEs, SAEs, Serious and Unexpected Adverse Experiences 
Subject Reporting of an Adverse Event 
Subjects will be instructed to contact the Investigator or Research Nurse to report any symptom.  
The Investigator will question each subject regarding symptoms at the time of each physical 
examination/review of body systems.  All adverse experiences, including duration and severity 
will be captured in the Case Report Forms provided by the Sponsor. 
All adverse events are to be documented from the day the subject receives his/her first study 
treatment through 30 days after the subject’s off study treatment date (date of last dose). 
Reporting Serious Adverse Events (SAEs) to Sponsor 
Serious Adverse Events are to be documented and reported to the Sponsor from the day the 
subject receives his/her first treatment through 30 days after the subject’s off study treatment 
date.  SAE follow-up needs to continue until the event is resolved or returned to baseline. Serious 
Adverse Events occurring to a subject after the 30-day off study treatment date should be 
reported to the Sponsor only if the SAE could be attributed to study treatment. 
An Investigator shall report to the Sponsor via telephone, fax or e-mail, any Serious Adverse 
Event regardless of causality, within 24 hours of receipt of information. 
Reporting to the Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC)/Research Ethics Board (REB) 
SAE’s must be reported to the IRB/IEC/REB by the Investigator according to each institution’s 
policy and procedures. 
Reporting to Regulatory Authorities and Participating Investigators 
The Sponsor will notify appropriate regulatory authorities by fax, telephone or in writing of any 
unexpected fatal or life-threatening suspected adverse reaction associated with the use of the 
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study drug as soon as possible, but in no event later than 7 calendar days after initial receipt of 
the information. 
The Sponsor shall notify appropriate regulatory authorities and all participating Investigators in 
writing via IND safety reports/CIOMS reports of any serious and unexpected adverse experience 
associated with the use of the drug; and such reports shall be made as soon as possible but in no 
event later than 7 or 15 calendar days after the Sponsor’s initial receipt of the information, 
depending on the reporting requirements. 
The Sponsor will submit IND safety reports/CIOMS reports to FDA, Heath Canada, EMA, and 
National Competent Authorities as required, and all participating Investigators no later than 7 or 
15 calendar days after the Sponsor determines that the suspected adverse reaction or other 
information qualifies for expedited reporting based on country specific regulatory requirements.  
If any regulatory authority requests any additional data or information, the Sponsor will submit it 
as soon as possible, but no later than 15 calendar days after receiving the request. 
The Sponsor will report all adverse experiences to the U.S. FDA in Annual Reports to the IND, 
and to all applicable regulatory authorities annually as required, in addition to the final report of 
the clinical trial. 
11.8. Reporting of Pregnancy 
If following initiation of study treatment, it is discovered that: 
• A female subject is pregnant or may have become pregnant at the time of investigational 
drug exposure, the investigational drug will be immediately discontinued until further 
assessment. If it is determined that study drug should be permanently discontinued, all study 
required procedures for study discontinuation and follow-up must be completed unless 
contraindicated by the pregnancy.   
• For male subjects, if their partner is pregnant or may have become pregnant, the male subject 
must agree to the use of a barrier birth control method as stated in section 6.1 #11 [Male 
subjects (including men who have had vasectomies) whose partners are pregnant should use 
condoms while the partner is pregnant. If the partner is still pregnant when the subject goes 
off study, the subject should continue condom uses for at least 2 weeks afterwards].  If he 
does not agree to the above, he will be terminated from the study and all study required 
procedures for study discontinuation and follow-up must be completed. 
The Investigator must notify the Medical Monitor within 24 hours of learning of the pregnancy 
and record the pregnancy on the Pregnancy Reporting Form and submit it to Cancer Prevention 
Pharmaceuticals via fax or email.  
The Investigator must report using the Pregnancy Reporting Form, follow-up information 
regarding the course of the pregnancy, including perinatal and neonatal outcome.  Generally, 
infants should be followed for a minimum of 6-8 weeks but additional follow up is not needed 
when a newborn is healthy. 
Pregnancy itself is not considered an AE or SAE but any pregnancy complication or elective 
termination of a pregnancy for medical reasons will be recorded as an AE or SAE and reported 
as described in Sections 11.4 - 11.8. 
11.9. Concomitant Medications 
All concomitant medications and medications taken within 30 days before the first study drug 
administration until the subject’s off study treatment date, and concomitant medications for AEs 
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recorded within the 30-days post-EOT, will be coded to therapeutic drug classes and generic 
names using, for example, the WHO Drug classification dictionary. 
Subjects are to be instructed to not take the following medications or supplements while on study 
treatment: oral corticosteroids (such as prednisone), NSAIDS (such as ibuprofen, celecoxib, 
aspirin in excess of 700 mg weekly), diflunisal, supplements containing omega-3-fatty acids 
(such as fish oil), anticoagulants (such as warfarin, Pradaxa®, Eliquis®, Plavix®, and other direct 
thrombin inhibitors), fluconazole, lithium, furosemide and thiazides, DMSO, methotrexate, 
probenecid, propoxyphene hydrochloride, Tylenol® (acetaminophen) preparations containing 
aspirin or cytotoxic chemotherapy drugs. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  56 
12. STATISTICAL CONSIDERATIONS 
The Statistical Analysis Plan (SAP) will focus on analysis of the primary and secondary 
endpoints, in order to assess the extent to which the combination of CPP-1X 750 mg daily + 150 
mg sulindac is more effective than each agent alone in delaying the time from the date of 
randomization to the date of the first occurrence of any FAP-related event in Familial 
Adenomatous Polyposis (FAP) patients.  Eligible patients who have given informed consent will 
enter the study with the intent to participate for the full treatment period.  Accrual is expected to 
take 12-24 months.  Eligible patients who have given informed consent will enter the treatment 
extension phase with the intent to participate for the full study extension treatment period of up 
to an additional 24 months. 
The Statistical Analyses Plan will include method descriptions and will pre-specify the statistical 
approaches to be used, primary and secondary study endpoints, data handling conventions and 
randomization processes.  
At least 150 eligible patients will be enrolled in this study, with at least 50 per treatment group.  
Patients will be randomized to one of three treatment groups within the prognostic strata defined 
in Section 4.3 in equal proportions (i.e., 1:1:1 randomization): 1) CPP-1X plus sulindac, 2) CPP-
1X placebo plus sulindac, 3) CPP-1X plus sulindac placebo.   
The study is double blinded, so neither subjects nor Investigator nor Sponsor will be aware of 
treatment assignment. 
For the primary efficacy analyses, we will use the intent-to-treat (ITT) population defined as all 
subjects that have been randomized to one of the three study arms.  Subjects will be analyzed in 
the group to which they were randomized, whether or not they received their assigned treatment, 
any treatment whatsoever, or completed their treatment course and follow-up.  The safety 
outcome will be analyzed using all subjects in the ITT population who received at least one dose 
of study drug (safety population).  
12.1. Primary Efficacy Objective and Analysis 
The primary objective of this trial is to determine whether the combination of CPP-1X + sulindac 
is superior to either single-agent treatment individually in delaying the time from the date of 
randomization to the date of the first occurrence of any FAP-related event.  Section 8.2.14 
provides complete detail on FAP-related events. 
Thus the primary objective contains two treatment comparisons:  
1. CPP-1X placebo + sulindac active vs. CPP-1X active + sulindac active,  
and 
2. CPP-1X active + sulindac placebo vs. CPP-1X active + sulindac active 
These two treatment comparisons will be performed sequentially as described below. 
The combination of CPP-1X active + sulindac active is specified as the reference treatment 
group because it is common to both comparisons.  In addition, because the purpose of the 
combination treatment is to delay the time from randomization to FAP-related disease 
progression compared to single-agent treatments, formulating the hypothesis tests in this manner 
will allow a positive rather than a negative Z-score for the test statistic to be interpreted as 
supportive of this purpose. 
Each comparison will be performed at the 2-sided 0.05 level of statistical significance. 
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As explained in the Statistical Analysis Plan, the decision to seek regulatory approval based upon 
the results of the primary objective will be taken sequentially. 
CPP will sequentially perform the two primary comparisons as part of the primary analysis, each 
at the 2-sided p = 0.05 level.  All information concerning these comparisons will be clearly 
provided to both Agencies.  The single treatment comparison requested by FDA will be 
available, as will the two comparisons requested by EMA, both at the requested level of alpha.  
This approach fulfills the differing requirements for the primary comparison as asked for by each 
Agency.  
We note that this approach is both a fixed-sequence and gatekeeping approach.  It is fixed-
sequence in that the comparison of combination with single-agent Sulindac takes place before 
the comparison of combination with single-agent Eflornithine and the first serves as a gatekeeper 
for the second (i.e., no declaration of significance in the second comparison will be made if the 
first comparison is not significant at the 0.05 level).  Therefore, the type I error in the sequential 
testing is well controlled.  In addition, because both tests must be significant for EMA approval, 
the type I error of the second test in the sequence is less than 0.05. 
The analytic method for the primary analysis will be a time-to-event analysis using the stratified 
log-rank test.  The stratified Cox proportional hazards regression models will be used for 
secondary assessments.85  Graphical analyses (log-minus-log plots) will be used to check the 
assumption of constant hazard ratios.  For the primary analysis, two stratified log-rank tests will 
be performed with treatment coded as a binary value (i.e., 0 or 1). Time to event curves will be 
displayed using the method of Kaplan and Meier86.  Additional analyses involving the overall 3-
treatment group comparison and use of additional study populations or the two pairwise 
treatment comparisons, will be performed as supplemental analyses. 
If an FAP-related event occurs, that patient will be said to have an observed or uncensored event 
and will be considered a treatment failure.  If a subject withdraws, that subject will be treated as 
a censored observation as of the last recorded clinic visit (endoscopic disease assessment). 
If a subject has not progressed or is not known to have died at the date of analysis cut-off, time to 
first FAP-related event will be censored at the date of the last adequate endoscopy procedures 
before the cut-off date.  Similarly, if a subject discontinues study participation due to toxicity and 
begins receiving other therapy, the time to FAP event will be censored at the date of the last 
adequate endoscopy procedure.   
Prior to the primary analysis, balance will be assessed between the three arms in terms of key 
potential confounders measured at the baseline visit.  If any of these variables is found 
significantly out of balance across the three groups using a 2 degree of freedom test of 
homogeneity at the 0.01 level of significance, it will be incorporated into -a sensitivity analysis 
using a stratified Cox model including that term in addition to the treatment arm.  The primary 
result for the trial will be the unadjusted stratified log-rank test.  The covariate-adjusted score test 
(adjusted stratified log-rank test) will serve only as a secondary analysis to aide in the 
interpretation of the primary result. 
12.2. Secondary Efficacy Outcome and Analysis 
Any improvement observed by the investigator during upper gastrointestinal (UGI) and lower 
gastrointestinal (LGI) visualization (i.e. endoscopy and colonoscopy) at the 6 and 12-month 
study visits will be described using the variables UGI Observed Improvement (UGIOI), and LGI 
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Observed Improvement (LGIOI).  Each patient will have one pair of UGIOI and LGIOI 
outcomes (refer to the Statistical Analysis Plan for more detail). 
UGIOI and LGIOI are binary outcomes derived from numerical determinations (henceforth, 
“investigator change scores” or more briefly, “scores”) assigned by the investigator during each 
procedure, using a scale (–2, –1, 0, +1, +2) which corresponds, respectively, to the investigator’s 
overall qualitative assessment of: much worse, worse, no change, improved, much improved.  At 
the month 6 procedures the investigator scores UGI and LGI findings as changes from baseline.  
At the month 12 procedures, the UGI and LGI findings are scored relative to the month 6 
procedures. 
The UGIOI (and respectively, the LGIOI) secondary endpoint independently summarizes the 
corresponding 6- and 12-month investigator change scores according to whether or not there was 
any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to 
baseline or month 6), under the condition that there be no worsening at either timepoint 
(compared to the preceding timepoint).  Refer to the Statistical Analysis Plan for further details 
on the planned analysis.  
12.3. Other Secondary Outcomes 
Other secondary outcomes will include the following: 
To explore how study treatment group relates to other efficacy outcomes, genotype, phenotype, 
disease locations and endoscopic findings, additional analyses are planned.  These analyses will 
be performed in the ITT group, the Per Protocol Group, and other defined subgroups (see 
protocol Section 12.5, Populations for Analysis and the Statistical Analysis Plan) wherever 
possible and will all be clearly noted as such. 
The UGIOI and LGIOI outcomes will be tabulated and summarized using the month 6 visit 
scores, alone.  Similarly, the UGIOI and LGIOI outcomes will tabulated and summarized across 
all study visits. 
As both part of the primary analysis, and further explored in these additional analyses, median 
time to event for each treatment group will be determined. This will be explored for each of the 
study populations (i.e. ITT, per protocol, and others), study disease stratum groups, and in the 
Disease Site subgroups (refer to the Statistical Analysis Plan for more details). 
Pharmacokinetic data (plasma concentrations measured at patient visits) will be used to estimate 
population pharmacokinetic parameters for the CPP-1X (eflornithine), sulindac, and CPP-1X 
(eflornithine) + sulindac treatment groups (i.e., for each analyte for those patients on 
combination treatment). 
The subcategories of FAP events will be explored by disease stratum groups, and by Disease Site 
subgroups (refer to the Statistical Analysis Plan). 
The presence or absence of ODC polymorphisms, including the single nucleotide polymorphisms 
(SNPS) rs2302615 and rs2302616 and their relation to treatment group and outcome will be 
tested with the likelihood ratio test. 
The excretion of 5 urinary polyamines (diacetylspermine, n1-acetylspermidine, n8-
acetylspermidine, decarboxylated SAM, and putrescine) will be assessed in relation to treatment 
group and outcome, using the single point concentration data gathered from the urine samples 
harvested at each study visit. 
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Patient reported health related quality of life measures will be evaluated using HRQoL (refer to 
Statistical Analysis Plan for more details). 
Tissue and dietary polyamine levels, as collected at patient study visits will be analyzed together 
with the results of the dietary questionnaires and related to treatment group and study outcomes. 
Safety outcome data and analyses are described in detail in the Statistical Analysis Plan. 
12.4. Sample Size Determination 
The primary endpoint of this trial, time to meaningful clinical events in an orphan disease 
population, is novel and to date there are no published trials to draw upon that have incorporated 
the exact FAP-related endpoint of this trial.  Available data from primary literature sources 
include clinical studies where polyps were counted over a fixed time period, in different FAP 
populations (see Appendix E for tabulated listing).   
From these data a reasonable range of event frequencies was estimated to produce the sample 
size and power calculations incorporated into this trial.  These time-to-event estimates were 
reviewed by key FAP opinion leaders prior to finalization of the study design.  The following 
reflects the possible range of FAP events it was thought plausible to observe. 
12.4.1. Power Calculation Assumptions 
1) The level of statistical significance is set at 0.05, using a 2-sided stratified log-rank test for 
time-to-first FAP-related event in continuous time, for each of the two between-group 
comparisons (i.e. single agent sulindac vs. CPP-1X plus sulindac and single agent CPP-1X vs. 
CPP-1X plus sulindac).  The only covariates in the log-rank test will be the treatment groups; 
2) A doubling of the two-year event-free proportion from either of the single agent treatment 
arms to the combination treatment group;  
3) Power of at least 85% to detect the above-mentioned treatment effect comparing either of the 
two single treatment arms to the combination arm; 
4) The two single-agent treatment groups have approximately the same event rate. 
The following calculations are based on our review of limited single-agent data for eflornithine 
and sulindac, where FAP clinical trial primary endpoints involved polyp counting.  Extrapolating 
these data to two-year event-free proportions implies a single overall two-year event-free 
proportion of at least 60% to 70% for the combination treatment group and 30% in each single 
agent treatment group.   
12.4.2. Hazard Rates 
Because the power of time-to-event analyses depends on the total number of observed primary 
endpoints (“events”) and the hazard ratio in a given two-arm comparison of a single-agent versus 
combination therapy, we translate the above doubling of two-year event-free proportions into 
hazard ratios under a simplifying assumption of exponentially distributed time-to-event.   
Furthermore, the stratified log-rank test is an optimal test (locally most powerful) under the 
assumption that the ratio of the two groups’ hazard functions remains constant over time (the 
proportional hazards assumption).  Note that the much stronger assumption, that the individual 
hazard functions themselves remain constant over time, would be dubious in this trial.  
Therefore, irrespective of how the two-year event-free proportions are translated into hazard 
ratios, it is the latter which forms the design alternative parameter for the trial. 
Under the exponential assumption, the hazard ratio (HR) comparing one treatment arm to 
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another is given by the natural logarithm of the two-year event-free proportion for the first arm 
divided by the natural logarithm of the two-year event-free proportion for the other arm.  Thus if 
the combination arm is assumed to have a two-year event-free proportion of 60%, which is 
double that of the 30% two-year event-free proportions assumed for the single-agent arms, the 
HR is {log(0.60) / log(0.30)} = 0.4243.  This is the design alternative hazard ratio for this trial 
as it represents the minimum clinically meaningful treatment effect desired for the combination 
therapy compared to either single-agent therapy.  Insofar as the combination therapy may have a 
two-year event-free proportion of at least 60%, and may prove to be perhaps 70% or greater, the 
design alternative HR of 0.4243 is conservative; the true (albeit unknown) HR is thought 
possibly to range from 0.4243 down to 0.30 = {log(0.70) / log(0.30)}. 
Given that the primary hypotheses are stated in terms of comparing either single-agent arm to the 
combination arm, we note that the equivalent design alternative hazard ratio becomes  
{log(0.30) / log(0.60)} = 1/0.4243 = 2.357. 
For the anticipated range of hazard ratios, 25 to 49 events would be needed for each two-group 
comparison at the 2-sided 0.05 level to achieve 85% power88,89   Assuming two-year event 
proportions of 70% in either of the two single-agent groups and 30% to 40% in the combination 
arm with 50 patients per arm, the expected number of patients with an FAP-related event in 
either of the two single-agent groups would be 35 and 15 - 20 in the combination arm.  The study 
design expectation is to have 50 - 55 patients with a FAP-related event in each two arm 
comparison, achieving at least 85% power under the design alternative.  The standard deviation 
around the expectation of 55 events is 4.74, so observing the required number of 49 events or 
more would be highly likely (the probability is about 91%).  If the total number of events in 
either comparison were only 43, there will still be 80% power to declare a significant treatment 
difference under the design alternative of 0.4243. 
As the two-year event proportion in the combination arm decreases from 40% with a 
corresponding decrease in the hazard ratio, the likelihood of observing the required number of 
events to maintain 85% power actually increases.  For example, at the lower expectation of 50 
events arising from an assumed two-year event proportion of 30% in the combination arm, the 
standard deviation of the total number of events in a two-arm comparison decreases to 4.58 and 
the probability that the observed number of events will exceed the 25 required to achieve 85% at 
a HR of 0.30 is virtually certain. 
12.5. Populations for Analysis 
12.5.1. Intent-to-Treat (ITT) Population  
The intent-to-treat population includes all patients that have been randomized to one of the three 
study arms (CPP-1X plus sulindac, CPP-1X placebo plus sulindac, CPP-1X plus sulindac 
placebo).  Patients will be analyzed in the group to which they were randomized, whether or not 
they received any treatment or completed their treatment and follow-up. 
12.5.2. Safety Population 
The safety population is defined as all ITT patients who received at least one dose of study 
medication.  Patients who do not receive any study treatment (CPP-1X or sulindac or their 
combination) are excluded from this population.  Patients will be analyzed in the treatment group 
for which actual treatment was initially received. 
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12.5.3. Per Protocol Population 
The per-protocol population is defined as the subset of the ITT population that fulfill all protocol 
eligibility, intervention, and outcome assessments. 
12.5.4. Other Populations 
Within the entire study patient population there will be subsets who did not receive the full 
course of per protocol treatment.  The major indicators for premature withdrawal are delineated 
below.  The patient diary and pill count will define the extent of treatment compliance during the 
study. 
For exploratory and sensitivity analyses the following subsets will be included in secondary 
analyses: 
• Subject withdrawn for personal reasons 
• Treatment discontinued because of disease symptoms 
• Treatment discontinued because of patient symptoms 
• Compliance <80% treatments taken 
• Treatment discontinued because of intercurrent medical or surgical illness. 
12.6. Other Statistical Methods  
12.6.1. Demographic and Baseline Characteristics 
Patients in the three populations (ITT, Safety, Per Protocol) will be summarized for demographic 
and baseline characteristics in a descriptive fashion.  Namely, categorical and continuous-valued 
data will be displayed using standard summary statistics (e.g., frequency tables, n, means, 
medians, standard deviations, and ranges).  Data will be presented per group and overall.   
Demographic features summarized will include age, gender, race, institution at which each 
patient registered, and country among other features.  Baseline characteristics will include 
laboratory values and disease-related characteristics, as well as any other relevant values.  
Categorical data will be compared among groups using chi-squared methods, while continuous-
valued data will be compared using standard nonparametric methods (e.g., the Kruskal-Wallis 
test).90  Significance will be defined at the 0.05 level, unless otherwise noted.  Thus p-values less 
than or equal to 0.05 will be declared significant. 
12.6.2. Patient Disposition and Treatment Summaries 
Subjects will be assigned for analysis to the treatment group to which they were randomized, 
regardless of whether the patients received any treatment. 
Subject disposition and treatment will be summarized for ITT and safety populations defined 
previously.  Subject disposition will be consistent with the CONSORT criteria,91 and will include 
per treatment group enumeration of all patients randomized, the number deemed ineligible, the 
number of FAP-related events, and the number of study drop outs.  These will be further 
described in subgroups such as drop outs due to adverse events, serious adverse events, 
administrative withdrawals for non-compliance, withdrawals of consent for continued follow-up, 
withdrawals for other reasons, and the number lost to follow-up.  Additional summaries will 
include reasons for patients discontinuing treatment and/or modifying treatment dosages.  A 
listing of screened and ineligible patients along with the reason for each also will be summarized. 
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12.6.3. Categorical or Continuous-Valued Secondary Outcome and Safety Data 
For categorical data, comparisons will be made between treatment groups using standard chi-
square techniques as the primary approach.  In particular, Cochran-Mantel Haenszel one degree 
of freedom test will be used to reflect the stratified randomization.  Exact p-values and 95% 
confidence intervals by the point probability method will be reported92. 
For continuous endpoints, standard analysis of covariance (ANCOVA) methods will be used as 
the primary approach to compare treatment groups at end of treatment with the following 
covariates: baseline value, binary indicator variables for the two highest-risk stratification levels 
used in the randomization (using the lowest-risk, i.e., rectum/pouch polyposis, group as the 
reference stratum), and a binary treatment indicator (1=combination treatment, 0=single 
treatment). 
For ordered categorical data, a Kruskal-Wallis nonparametric test for ordered categorical 
response will be used to compare treatment groups.90 
Treatment-emergent adverse events will be enumerated and analyzed according to the incidence, 
intensity, type of adverse events, and clinically significant changes in the patient’s physical 
examination findings, vital signs and clinical laboratory results.  Safety variables will be 
tabulated and presented for all patients in the safety and per-protocol populations as defined 
previously.  
Adverse events will be graded and coded using the NCI Common Terminology Criteria for 
Adverse Events (CTCAE, Version 4.03).  Treatment-emergent events will be tabulated, where 
treatment-emergent is defined as any adverse event that occurs after administration of the first 
dose of study drug and through 30 days after the last dose of study drug, or any event that is 
present at baseline and continues after the first dose of study treatment but worsens in intensity.  
Events that are considered related to treatment (possibly, probably or definitely drug-related) 
also will be tabulated separately.  Tables that enumerate adverse events by severity will also be 
provided.  Deaths, serious adverse events and events resulting in study discontinuation will be 
tabulated in data listings including additional relevant information on each patient.  Tables will 
be presented both overall (all arms combined), by each treatment group separately, and by cell. 
Where appropriate, statistical comparisons between treatment arms will be provided using the 
above-mentioned methods for analysis of categorical data. 
12.6.4. Subgroup Analyses 
Subgroups will be analyzed in the spirit of exploratory analyses including but not limited to the 
various study populations and separately within each disease-prognosis stratum. 
12.6.5. Health Related Quality of Life (HRQoL) 
For this study four (4) instruments to measure HRQoL and patient preferences or utilities will be 
administered to subjects at baseline and months 3, 6, 12, 18, 24, 30 36, 42 and 48/end of 
treatment.  These instruments include the EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and 
a modified Cancer Worry Scale. 
The validity and reliability of both the QLQ-C30 and the QLQ-CR29 questionnaires have been 
studied by the EORTC Study Group on Quality of Life and both instruments will be scored 
according to the EORTC Scoring Manual and analyzed accordingly.  For each single item or 
multi-item sub-scale, a linear transformation will be applied to standardize raw scores to range 
between 0 and 100.  HRQoL secondary endpoints will include all single item or multi-item sub-
scales from both the EORTC QLQ-C30 and QLQ-CR29 and patients will be considered as 
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deteriorated (or improved) for a given single item or multi-item sub-scale if their change score 
from baseline was 10 points or more on the standardized scale.   
Patient preferences (or utilities) will also be assessed using the EuroQoL EQ-5D.  Preference 
weights among the treatment arms will be determined using the EuroQol EQ-5D assessment of 
individual health states.72,73  Quality-adjusted survival among the three treatment arms will be 
generated by multiplying the utility value by the amount of time spent in a specified health state.  
The modified version of the Cancer Worry Scale will also be administered and it will be scored 
according to the guidance provided by Lerman et al74. 
HRQoL data will be obtained while patients are receiving treatment.  At the time of an FAP-
related event (primary outcome), additional long-term clinical follow-up and QoL data will not 
be obtained as part of this trial.  Hence, HRQoL trends comparing the nine subsets will be 
obtained, but comparative longitudinal analyses defining the impact of an FAP-related event on 
QoL will not be feasible until subsequent long-term studies are performed. 
12.6.6. Dietary Assessment 
The FFQ was developed by the Nutrition Assessment Shared Resource (NASR) of the Fred 
Hutchinson Cancer Research Center. NASR periodically updates its standard FFQ to reflect U.S. 
food consumption patterns and major changes in the market place.82,83  Data from the FFQ will 
be analyzed using a polyamine database69 and will calculate the average daily levels of 
putrescine, spermidine, and spermine in the diet.  Dietary assessments via the FFQ will be 
obtained at baseline, months 12, 24, 36, 42 (only if end of treatment) and 48/end of treatment for 
subjects at North American (U.S. and Canada) sites only. 
12.7. General Procedures for Handling of Missing Data 
Every reasonable effort will be made to continue follow-up of all study participants, including 
those who discontinue randomized therapy, to prevent data loss.  It is recognized that missing 
values represent a potential source of bias in a clinical trial and so every effort will be undertaken 
to fulfill all the requirements of the protocol concerning the collection and management of data. 
For the primary time to event analysis, the only possible patient outcome is an observed FAP-
related event, or a censored observation.  Participants who are lost to follow-up for reasons 
deemed unrelated to their health status will be censored at the time their status is last known, 
based upon data collected at the last recorded clinic visit.  For patients who may have missed a 
study visit, every effort will be made to obtain endoscopic results at their close-out visit and 
those endoscopy results will be used for the primary analysis.   
Secondary analysis data include the presence of a specific genetic mutation, and urinary 
metabolite concentrations (See Section 12.2). The main analysis of the secondary objectives will 
include collected data only, without imputing or weighting data to compensate for missing data.  
For sensitivity analyses involving secondary endpoints with missing data, we will use the last 
observation carried forward (LOCF) method to complete the missing data.  Any sensitivity 
analysis that incorporates LOCF will be clearly noted.  Sensitivity analyses of these data will be 
performed to explore study results more fully, in a manner consistent with ICH Guidance “E9 
Statistical Principles for Clinical Trials (February, 1998)”. 
All available efficacy and safety data will be included in data listings and tabulations.  Data that 
are potentially spurious or erroneous or appear as outliers will be examined using standard data 
management operating procedures, prior to database lock and statistical analysis. 
IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  64 
12.8. Interim Monitoring and the Data Monitoring Committee 
A Data Monitoring Committee (DMC) will oversee the performance and safety conduct of this 
study.  The DMC will consist of at least three members (two MDs and one statistician as voting 
members) who will receive confidential reports on a periodic basis.  The DMC will be 
responsible for decisions regarding possible termination of the study for either futility or safety 
reasons. 
A detailed DMC Charter will be produced separately by the DMC membership.  It is anticipated 
that any reviews of study data will be performed in a blinded manner, looking at pooled data (all 
treatment groups combined into one group) to assess mission-critical parameters such as overall 
recruitment and event rates.  Any pre-specified interim analyses will be conducted in a blinded 
manner.  Of course, patient safety issues take precedence over bias-protection and control of type 
I error, and so the DMC will have the privilege of breaking the blind on a need-to-know basis if 
safety issues of concern arise in order to consider risk-benefit issues.  Details concerning DMC 
responsibilities and duties may be submitted as a stand-alone document to the FDA and EMA, 
including items such as specification of early termination rules and other matters as the DMC 
deems to be important and relevant to the ethical conduct of this study.  
CPP will inform the DMC that there will be two study evaluations for the DMC to consider 
during the trial, one interim look for sample size reassessment and one look for futility. 
The method for reassessment of sample size is based upon the FDA Guidance, “Adaptive Design 
Clinical Trials for Drugs and Biologics (February 2010)”.  There will be no hypothesis testing.  
The DMC will assess the observed trial event rate based on pooled data only.  They will make a 
recommendation to the Sponsor on whether the pooled event rate is sufficient to preserve the 
integrity of the trial, and if not, to recommend a revised sample size.  For this assessment the 
study statistician will, if possible, estimate the overall observed event rate and 90% confidence 
interval.  This assessment will be performed using data from a single time point, when 
enrollment is approximately 95% complete.  If this type of assessment is not possible, then as 
assessment will be performed taking into consideration the total number of subjects randomized, 
total number of events, total number of dropouts, and cumulative study safety data. 
Prespecified Interim Efficacy and Futility Analysis 
A pre-specified interim efficacy and futility analysis will be conducted in a blinded manner.  The 
assessment will be performed after a total of 45 primary endpoints have occurred, which 
represents 50% of expected maximum trial information, or as soon thereafter as possible.  Refer 
to the Statistical Analysis Plan for more details. 
The analysis will be performed for each of the two treatment comparisons contained in the 
primary objective:  
1. CPP-1X placebo + sulindac active vs. CPP-1X active + sulindac active,  
and 
2. CPP-1X active + sulindac placebo vs. CPP-1X active + sulindac active  
The efficacy analysis will use a modified Haybittle-Peto stopping rule based on the stratified log-
rank Z-score.  If that Z-score equals or exceeds 3.2905 in absolute value, for either two-arm 
comparison, the difference between treatment arms would be declared statistically significant at 
the two-tailed 0.001 level of significance.  In that case it may be reasonable for the DMC to 
initiate a conversation about stopping the trial on ethical grounds.  Assuming this is not the case 
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and the trial continues to its planned end, the Z-score criterion for declaring significance at the 
5% level at the end of the trial will be increased in magnitude to plus or minus 1.962 in order to 
preserve the overall type I error rate for the trial at 0.05. 
For the futility analysis, the DMC will be provided with the numerical value of the stratified log-
rank Z-score.  The futility analysis uses a one-sided futility stopping criterion of Z = −0.50. That 
is, if the Z-score is less than or equal to −0.50, an investigation will be initiated to consider 
stopping the trial for futility or discontinuing one of the single-agent treatment arms.  The futility 
stopping criterion of Z = −0.50 is consistent with a conditional power of less than 20%.  That is, 
assuming between 44 and 60 FAP-related events have occurred by trial end in either of the two-
arm comparisons (where between 52 and 55 are expected), if the log-rank critical ratio Z-score 
were equal to −0.5 (or less) when one-half the expected total number of events had been 
observed (namely, 45 across all three arms), then under the design alternative hazard ratio of 
2.3569, there would be no more than a 20% chance of declaring a significant benefit of the 
combination therapy compared to the single agent therapy if the trial were to continue to the 
planned end. In that case, it would be reasonable for the DMC to consider stopping or altering 
the trial on grounds of futility.  The DMC will also be provided with the conditional power of the 
observed Z-score for each two-arm comparison. 
Any numerical values generated from the futility analysis (such as Z-score, conditional power, 
etc.) must be treated as confidential by the DMC and Independent Statistician at the CRO.  If the 
DMC recommendation is to continue the study as planned, such numerical values will not be 
forwarded or conveyed in any manner to the Steering Committee, Sponsor, or any other parties. 
12.9. Pharmacokinetic Analysis for Eflornithine and Sulindac 
The text that follows applies to each of the two compounds, eflornithine and sulindac.  Separate 
analyses will be performed for each drug. 
To perform the population pharmacokinetic analysis, a dataset will be constructed as follows: 
1. All subjects with at least one sample will be included in the analysis.  Actual sample time 
will be used in the analysis. 
2. Dosing history will be assembled based on CRF data.  Dosing records will assume 100% 
compliance, except as documented in the CRF. 
3. The dataset will be constructed using a script in R (www.R-project.org).  All steps will be 
documented.  All decisions regarding handling of aberrant data will be documented. 
4. Covariate data (age, extent of prior colectomy, body size, gender, race, laboratory values, 
etc.) will be included in the dataset.  The dataset will be constructed using values 
obtained temporal to the time of sampling. 
The pharmacokinetic analysis will be performed using NONMEM (version 7.1 or greater).  
Graphics will be created using PLT Tools (version 3.0 or greater) using R (version 2.11 or 
greater).  Initially, linear compartmental models will be applied to the data.  The choice between 
1-, 2-, and 3-compartment models will be based on the graphics and the minimum value of the 
objective function.  If graphics suggest nonlinearity in pharmacokinetics with respect to dose 
and/or concentration, nonlinear models will be evaluated. 
Once the optimal structural and error model has been determined, covariate effects will be 
assessed using a variety of tools including graphics of post hoc parameter estimates vs. 
covariates, a general linear model of parameters as a function of covariates, or an automated 
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covariate search (PLT Tools).  Covariates will be incorporated into the model if they are 
physiologically appropriate, achieve statistical significance (generally requiring a P value < 0.01 
in this exploratory environment), and improve the graphics. 
Once a final model is determined, the model will undergo validation.  The strength of covariate 
effects will be determined using likelihood profiles.  Confidence intervals for parameter 
estimates will be determined using bootstrap techniques.  If appropriate, a visual predictive 
check will be performed. 
All NONMEM outputs and graphics will be provided with the population pharmacokinetic 
report.  Results will be summarized detailing the process of model building.  The report will 
include key graphics demonstrating the fit of the model to the data and covariate effects. 
 
13. STUDY MANAGEMENT AND REPORTING PROCEDURES  
13.1. Data Monitoring  
A Data Monitoring Committee (DMC) will oversee the performance and safety conduct.  The 
DMC will consist of at least three members (two MDs and one statistician as voting members) 
who will receive confidential reports on a periodic basis.  The DMC will be responsible for 
decisions regarding possible termination of the study for either futility or safety reasons, refer to 
Section 11, Assessment of Safety and Section 12.8, Interim Monitoring and the Data Monitoring 
Committee. 
13.2. Patient Tablet Dispensing Record 
Three (3) month supplies of study drug(s) are issued in person or by special arrangement.  
Subjects will keep a written diary concerning their compliance in taking the four tablets daily. 
The drugs are to be taken at approximately the same time each day with food, preferably in the 
morning.  If the dose is missed, the tablets may be taken with mid-day or evening meals.  If an 
entire day is missed, this should be indicated in the weekly dose accountability in the medication 
diary, but double-dosing the following day is not allowed.  If the subject vomits within an hour 
after taking the tablets, the subject will record a missed dose in the diary. If the subject vomits 
more than 1 hour after taking the tablets, no dose was missed.  In either case, no additional 
tablets are to be taken until the scheduled dose the next day.  Any unused medication must be 
returned at the subject’s next scheduled visit and an accounting of the medication will be 
performed and recorded by the research nurse or other qualified individual. 
13.3. Investigator Documentation 
The Investigator will provide the Sponsor with a fully executed FDA form 1572 including the 
Investigator’s dated curriculum vitae.  A current curriculum vitae is also required for each sub-
Investigator listed on the FDA Form 1572.  A current dated curriculum vitae is defined as 
updated within 2 years. 
The Investigator will indicate on the FDA Form 1572 the name and location of the clinical 
laboratory which will be used for subject evaluation.  The laboratory’s certification, certification 
number and date of certification and the laboratory normal values will be provided.  Any changes 
in the clinical laboratory or laboratory values will be provided promptly to the Sponsor who will 
report it to the FDA. 
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The Investigators and Sub-Investigators must provide CPP with an FDA Form 3454 certifying 
the absence of financial interests and arrangements, or Form 3455 disclosing such financial 
interests and arrangements and any steps taken to minimize bias. 
13.4. Protocol Amendments 
All amendments to the study protocol must be submitted to the IRB/IEC/REB for written 
approval.  The approval letter, signed by the IRB/IEC/REB Chairperson, must refer specifically 
to the Investigator, the protocol number and protocol title, the protocol amendment number and 
the date of the protocol amendment.  A copy of the approval letter and revised informed consent 
document (if appropriate) must be sent to CPP.  A protocol amendment may be implemented 
only after it has been approved by the IRB/IEC/REB and submitted to the FDA and other 
regulatory agencies as appropriate.  In the case of a protocol change intended to eliminate an 
apparent immediate hazard to subjects, the change may be implemented immediately, but the 
change must then be documented in a protocol amendment and approved as described above. 
13.5. Access to Source Data and Documents 
Monitors and/or auditors of CPP or representatives of the Sponsor must be allowed to visit and 
monitor all study site locations periodically to assess the data, quality and study integrity.  The 
monitors and/or auditors will review study records (typically CRFs) and directly compare them 
with the source documents and discuss the conduct of the study with the Investigator and verify 
that the investigational site is compliant and continues to be acceptable.  In addition, the site may 
be audited by government inspectors who must be allowed access to CRFs, source documents 
and other study files.  The site must promptly notify CPP of any inspections scheduled by 
regulatory authorities, and also forward copies of the inspection reports to CPP. 
13.6. Investigational Agent Records and Accountability 
It is the Investigator’s responsibility to ensure that accountability records of drug use and 
disposition are maintained at the study site and that the drug is maintained in a secure location 
under storage conditions prescribed by the Sponsor.  The site pharmacist or appointed 
investigational agent monitor will be the individual completing the records or logs for 
accountability and drug dispensing at each site.  The site pharmacist must comply with all 
applicable regulations and guidelines.  The logs should include the amount of drug received; 
amount currently on site, drug lot or batch numbers; amount dispensed to each study subject with 
appropriate subject study identification numbers; non-study disposition (wastage, broken), 
amount returned to site and Sponsor, amount destroyed at study if requested.  CPP will provide 
forms to assist with drug inventory if the site does not have an established procedure that meets 
the requirements.  Drug inventory records will be inspected by the Sponsor’s study monitors 
during the period of study treatment.  Audits will be done to verify drug accountability.  If a site 
has been determined to be non-compliant with drug accountability corrective action will be 
initiated. 
At the completion or termination of the study, all unused investigational agent will be returned to 
the repository unless authorized in writing to be destroyed at the site.  If the drug is to be 
destroyed on site, appropriate policies and procedures at the site must be in place for proper 
disposal of chemotherapeutic agents.  These procedures will be reviewed by Sponsor’s study 
monitors prior to providing written authorization for on-site drug destruction.  The unused study 
drug can only be destroyed after being inspected and reconciled by the Sponsor’s study monitor.   
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13.7. Data Handling and Record Retention 
Following the completion and closure of the clinical study, in accordance with applicable 
regulatory requirements, the Investigator will maintain a copy of all study records in a safe and 
secure location.  Completed original CRFs, which are dated and signed by the investigator, and 
any resolved query reports will be retained by the Sponsor.  A copy of each completed CRF and 
signed resolved query report must be retained at the investigational site.  The Investigator will 
retain a copy of all study records in a secure location for a minimum period of 2 years after 
licensure for marketing of drug or 15 years from the close of the trial or until receipt of 
notification by Sponsor that clinical development of this treatment has been terminated. 
13.8. Protocol Deviations 
The Investigator is not permitted to alter or deviate from the protocol without a written waiver 
from the Sponsor.  This waiver should also be reported by the Investigator to his/her 
IRB/IEC/REB.  An immediate and unapproved deviation is permitted if immediate subject safety 
concerns mandate a deviation. 
13.9. Study Termination 
The Sponsor may terminate the study at any time.  If the study is terminated, the Sponsor will 
promptly notify the Investigator to enter no further subjects on the study and remove current 
subjects from the study.  The Sponsor will also inform regulatory authorities of the action. 
1. The study will also be terminated when the objectives have been fully met and all of the 
designated data collected. 
2. The Sponsor reserves the right to terminate an Investigator’s participation in this clinical 
trial for refusal of the Investigator and/or site to comply with any requirements stated in 
this clinical protocol. 
13.10. Use of Data and Publication 
All data and results and intellectual property rights in the data and results that are derived from 
the study will be property of CPP.  CPP may utilize the results and data in variety of ways 
including submission to regulatory authorities or to other investigators under disclosure.  Data 
from any individual center must not be published or presented until the complete multicenter 
study has been published or presented in full.  Subsequently, an investigator may use the data 
derived from the clinical study for scientific purposes but must discuss any publication with the 
Sponsor prior to submission or release of any data.  The Sponsor is aware of the rights of an 
Investigator to publish the results when the study is completed, and the Investigator must provide 
a draft of the abstract or manuscript to the Sponsor within 30 to 60 days prior to submission of 
the abstract or manuscript.  The Sponsor will provide a timely review and response to the 
Investigator.  In the event of a difference of opinion between the Investigator and Sponsor, all 
efforts will be put forth to find a solution that is agreeable to both the Sponsor and Investigator.  
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14. HUMAN SUBJECTS 
The study will not be initiated until a protocol has been filed to the IND or approved by the 
appropriate regulatory authorities and the informed consent documents have been fully reviewed 
and approved by each participating institution’s IRB/IEC/REB.  The approval and associated 
documents will be provided to the Sponsor.  All relevant regulations of the regulatory authorities 
will be followed. 
14.1. Ethical Conduct 
The study will be conducted in compliance with the regulations from the FDA, Health Canada, 
local competent authorities, and the EMA, including Protection of Human Volunteers (21 CFR 
50), Institutional Review Boards (21 CFR 56), Good Clinical Practice guidelines (ICH), and 
Obligations of Clinical Investigators (21 CFR 312), Food and Drug Regulations (C.R.C., C.870), 
C.05.001 - Division 5, Drugs For Clinical Trials Involving Human Subjects, Regulation (EU) 
No.1235/2010, Directive 2010/84/EU, Directive 2001/20/EC (The Clinical Trials Directive), 
Commission Directive 2005/28/EC (The GCP Directive), and any other applicable country 
specific regulations. 
The protocol will be reviewed and approved by each institution’s IRB/IEC/REB, and as 
applicable, any country or regional IRB/IEC/REB.  Written documentation of the IRB/IEC/REB 
approval of the protocol and informed consent must be provided by the Investigator to the 
Sponsor prior to study initiation.  Serious adverse events regardless of causality will be reported 
to the Sponsor and to the IRB/IEC/REB, and the Investigator will keep the IRB/IEC/REB 
informed as to the progress of the study. 
14.2. Informed Consent 
The Investigator or his designee will explain the nature of the study and will inform the subject 
that participation is voluntary and that they can withdraw at any time.  Written informed consent 
and required authorization to use private information will be obtained and documented from each 
subject prior to entry into the study. 
The consent form generated by the Investigator must be approved by the IRB/IEC/REB and be 
acceptable to Cancer Prevention Pharmaceuticals.  Each subject’s signed informed consent form 
must be kept on file by the Investigator for possible inspection by regulatory authorities and or 
Cancer Prevention Pharmaceuticals personnel or representatives of Cancer Prevention 
Pharmaceuticals. 
14.3. Confidentiality 
The Investigator and his staff shall maintain the confidentiality of all subject records.  Subject 
data will be made available upon request to monitors from CPP Corporation (study Sponsor), 
regulatory authorities, the Institutional Review Board, Independent Ethics Committee, or 
Research Ethics Board, and to other government agencies that have responsibility for clinical 
research activities. 
Data that is released by the Investigator to the Sponsor, regulatory authorities, or the 
IRB/IEC/REB will not be directly traceable to the subject.  In the event that a publication of this 
research incorporates a subject’s medical data, the data will not identify the subject. 
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15. LISTING OF ABBREVIATIONS 
Abbreviation Description 
AE Adverse event 
ALT Alanine Amino Transferase 
a.m. Morning 
APC Adenomatous Polyposis Coli-tumor suppressor gene 
AST Aspartate Amino Transferase 
BID Twice a day 
0C Degrees centigrade 
CBC Complete blood cell count 
CFR Code Federal Regulations 
CIOMS Council for International Organizations of Medical Sciences 
cm Centimeters 
COX Cyclooxygenase 
CPP Cancer Prevention Pharmaceuticals 
CPP-1X Eflornithine, DFMO, difluoromethylorthine 
CRC colorectal cancer 
CRF Case report form 
CTCAE Common Terminology Criteria for Adverse Events 
dB Decibels 
DFMO Eflornithine, CPP-1X, difluoromethylorthine 
dL deciliter 
DMC Data Monitoring Committee 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic Acid 
EDTA Ethylene Diamine Tetra Acetic Acid 
EFS Event free survival 
EKG Electrocardiogram 
EORTC European Organization for Research and Treatment of Cancer 
EOT End of Treatment 
EU Europe 
FAP Familial Adenomatous polyposis 
FDA Food and Drug Administration 
FFQ Food Frequency Questionnaire 
GCP Good Clinical Practices 
GI Gastrointestinal 
HCG Human Chorionic Gonadotropin 
HDPE High density polyethlylene 
HEENT Head, Ear, Eyes, Nose, Throat 
HGD High grade dysplasia 
HRQoL Health-Related Quality of Life 
IB Investigator’s Brochure 
ICH International Committee on Harmonization 
IME Important medical event 
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Abbreviation Description 
IND Investigational New Drug Application 
InSiGHT International Society for Gastrointestinal Hereditary Tumours 
IRA Ileal-rectal anastomosis 
IRB/IEC/REB Institutional Review Board/Independent Ethics Committee/Research Ethics Board 
ITT Intent-to treat 
IUD, IUS Intrauterine device, Intrauterine system 
LGI Lower gastrointestinal 
LGIOI LGI Observed Improvement 




MST Mountain Standard Time 
N Normal 
NCBI National Center for Biotechnology information 
NCI National Cancer Institute 
NSAIDS Nonsteroidal anti-inflammatory drugs 
NASR Nutrition Assessment Shared Resource 
ODC Ornithine decarboxylase 
OMIM Online Mendelian Inheritance in Man 
PCR Polymerase Chain Reaction 
PK Pharmacokinetics 
PO By mouth, orally 
PSA Prostate specific antigen 
QLQ  Quality of Life Questionnaire  
QoL  Quality of Life  
RNA Ribonucleic acid 
RSI Reference Safety Information 
RX Treatment 
SAE Serious Adverse Event 
SAP Statistical Analysis Plan 
SNP Single nucleotide polymorphism 
Spd:Spm Spermidine to spermine ratio 
SWOG Southwest Oncology Group 
TEN Toxic epidermal necrosis 
UGI Upper gastrointestinal 
UGIOI UGI Observed Improvement 
ULN Upper limit of normal 
US United States 
T1/2 Half-life 
WBC White Blood Cell 
WHO World Health Organization 
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APPENDIX A SPIGELMAN’S SCORE AND STAGE 
Modified Spigelman’s Score and Classification (Saurin, 2004)93 
 Score 
Factor 1 Point 2 Points 3 Points 
No. of polyps 1-4 5-20 > 20 
Polyp size, mm 1-4 5-10 > 10 
Histology Tubulous Tubulovillous Villous 
Dysplasia Low grade — High grade* 
NOTE:  Classification as follows based on score scale. 
Stage 0: no polyps 
Stage 1: 1 to 4 points 
Stage 2: 5 to 6 points 
Stage 3: 7 to 8 points 
Stage 4: 9 to 12 points 
*High-grade dysplasia would be assigned to any epithelium showing nuclear stratification all the 
way to the tops of the cells and loss of mucin production. It can encompass intraepithelial 
carcinoma if the cells are pleomorphic or even cribiformed in architecture but still all located above 
the basement membrane. 
Comment: All adenomas in the duodenum demonstrate at least low grade dysplasia; if intermediate 
grade use low grade for points. 
Vienna Classification of Gastrointestinal Epithelial Neoplasia (Schlemper et al., 2000)94 
Category 1 Negative for neoplasia/dysplasia 
Category 2 Indefinite for neoplasia/dysplasia 
Category 3 Non-invasive low grade neoplasia (low grade adenoma/dysplasia) 
Category 4 Non-invasive high grade neoplasia 
4.1 High grade adenoma/dysplasia 
4.2 Non-invasive carcinoma (carcinoma in situ)a 
4.3 Suspicion of invasive carcinoma 
Category 5 Invasive neoplasia 
5.1 Intramucosal carcinomab 
5.2 Submucosal carcinoma or beyond 
a Non-invasive indicated absence of evident invasion. 
b Intramucosal indicated invasion into the lamina propria or muscularis mucosae. 
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Patients who cannot be allotted a particular stage (e.g., patients with mix polyposis) contact 
Cancer Prevention Pharmaceuticals for assistance with staging assignment. 
Stage Polyp Description Recommended 
Intervention 
Comment 
0 0-10 polyps, all <5mm Repeat FS in 1 years  
1 10-25 polyps 
most <5mm, none >1cm 
Ablate polyps; repeat 
sigmoidoscopy in 1 year 
Chemopreventive 
may be considered 
2 10-25 polyps, any >1cm, 
amenable to complete removal  
Repeat sigmoidoscopy 6 
months 
Polypectomy preferred 





3 > 25 polyps amenable to 
complete removal, or any 
incompletely removed sessile 
polyp, or any prior evidence of 
HGD, even if completely 
excised 
Repeat sigmoidoscopy 3-6 
months; consider 
proctectomy 
Large polyps must 
be removed; 
second opinion on 
polyp management 
helpful 
4 >25 polyps not amenable to 
complete removal, or any 
incompletely excised sessile 
polyp showing HGD; any 
invasive cancer 
Proctectomy/pouch 
revision +/- ileostomy 
clearly indicated within 3 
months 
Any decision to 






IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  79 
APPENDIX C NEW YORK HEART ASSOCIATION CLASSIFICATION TABLE 
NYHA Classification - The Stages of Heart Failure 
In order to determine the best course of therapy, physicians often assess the stage of heart failure 
according to the New York Heart Association (NYHA) functional classification system.  This 
system relates symptoms to everyday activities and the patient's quality of life. 
Class Patient Symptoms 
Class I (Mild) No limitation of physical activity. Ordinary physical activity does 
not cause undue fatigue, palpitation, or dyspnea (shortness of 
breath). 
Class II (Mild) Slight limitation of physical activity. Comfortable at rest, but 
ordinary physical activity results in fatigue, palpitation, or 
dyspnea. 
Class III (Moderate) Marked limitation of physical activity. Comfortable at rest, but 
less than ordinary activity causes fatigue, palpitation, or dyspnea. 
Class IV (Severe) Unable to carry out any physical activity without discomfort. 
Symptoms of cardiac insufficiency at rest. If any physical activity 
is undertaken, discomfort is increased. 
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APPENDIX D Desmoid Staging System9 
 
Stage Description 
I Asymptomatic, <10 cm maximum diameter, and not 
growing* 
II Mildly symptomatic, <10 cm maximum diameter, and not 
growing 
III Moderately symptomatic or bowel/ureteric obstruction, or 10 
to 20 cm, or slowly growing 
IV Severely symptomatic, or >20 cm, or rapidly growing 
 
Mildly symptomatic = sensation of mass, pain, but no restrictions;  
Moderately symptomatic = sensation of mass, pain; restrictive but not hospitalized;  
Severely symptomatic = sensation of mass, pain; restrictive and hospitalized. 




IND 103,678 Cancer Prevention Pharmaceuticals, Inc. 
FAP – CPP-1X (Eflornithine HCl/Sulindac) 
CPP FAP-310 Ver. 5.2, 17January2019  81 
APPENDIX E Event Rate Summary Table 
Familial Adenomatous Polyposis (FAP) Review:  Evidence-Based Projected Event Rates at 2 Years 
Rectum (after IRA) and Pouch (after Ileal-Pouch Anal Reconstruction) 
Key References Comments Event/Rate 
Bertagnolli, et al., N Eng J Med, 2006 
Bulow, et al., Dis Colon Rectum, 2008 
Church, et al., Surg Onc Clin N Am, 2009 
Church, et al., Dis colon Rectum, 2005 
Groves, et al., Dis Colon Rectum, 2005 
Huang, et al., Church, Familial Cancer, 2011 
Nieuwenhuis, et al., Dis Colon Rectum, 2009 
Tonelli, et al., J Surg Onc, 2000 
Vasen, The Lancet, 1996 
West, et al., Gut, 2010 
 
 
• 80% of patients develop adenomas within the pouch body. 
• 71% ↓of adenomas after 4-6 mo. Sulindac (300-400mg/day)-
analysis combined randomized studies. 
• Incidence of pouch adenomas is time-dependent with 42% of 
patients at 7 yrs from pouch construction. 
• Median time from pouch construction to diagnosis pouch 
adenomas, 4.7 yrs (0.5-12 yrs). 
• Celecoxib treated patients, median time to first polypectomy 
post IRA was 18.69 months; 90.9% (30 patients) had a post IRA 
rectal polypectomy. 
• Celecoxib treated patients, post IPAA, 3 of 24 pts (12.5%) had 
post IPAA polypectomy, 21 censored.  25th and 50th percentiles 
of time to first polypectomy in IPAA patients was 169.9 months 
• 80% of patients develop adenomas within the pouch body. 
• Celecoxib treated patients, median time to first polypectomy post IRA was 18.69 





Key References Comments Event/Rate 
• Recurrence rate of adenoma development is > 
50% after endoscopic treatment and treatment is 
associated with 17% complication rate 
(perforation, hemorrhage, pancreatitis) 
• Rate of progression between Spigelman stages 
variable, 4 – 11 yrs 
 
• 95-100% of all FAP patients develop duodenal adenomas 
• 10-25% of patients have Stage III/IV 
• 36% of Spigelman Stg IV develop cancer 
• Endoscopic resection/ablation - local recurrence rate 72.5% with 
mean follow-up interval of 12.8 months.  Surgical resection-
30% mean follow-up of 44 months, Definitive resection 47 pts 
with recurrence rate of 9%.  Surgical morbidity-48%. 
• Patients down staged from Spigelman stage IV demonstrate 
increased rate of disease progression back to severe disease. 
 
Pre-Colectomy 
 Comments Event/Rate 
 • Diagnosis with recommendation to proceed with prophylactic 
colectomy or proctocolectomy. 
 
 
Summary Projected 2 year Event Rate: Excisional 
intervention and/or high risk adenoma – 40-60% 
Summary Projected 2 Year Event Rate: Excisional 
intervention, cancer – 90% 
Summary Projected 2 Year Event Rate: Excisional 
intervention, cancer – 50% 
 
Company Confidential  Page 1 of 1 
Study ID: CPP FAP-310 
A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X / Sulindac Compared with 
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List of Changes for Protocol Amendment 
From Version 2.0, 16April2013 to Version 2.1, 10June2013 
Location Change Reason for Change 
Global Change Change Version 2.0, 16April2013  
To: Version 2.1, 10June2013 
Update protocol version 
and date 
Sec. 1.2 Added: SAE reporting to occur through the electronic data capture 
system or via paper CRF submission. 
Ockham Drug Safety contact information: 
Phone: 1-919-462-8867 (US/Canada); 001-919-462-8867 (EU) 
Fax: 1-919-468-2288 (US/Canada); 001-919-468-2288 (EU) 
Update to SAE reporting  
contact information 
Sec.  8.1.3 Deleted: Participant treatment will be unblinded only if the study 
physician demonstrates a compelling medical need for this 
information.  Specifically, we expect that unblinding of an individual 
study subject’s treatment assignment may occur if in the opinion of the 
Investigator, and the Medical Monitor, identification of the study 
medication is necessary to protect the welfare of the subject.  The 
study Medical Monitor must approve the request verbally and later in 
writing prior to unblinding to ensure that reasons for the unblinding are 
adequate.  The Medical Monitor is a Sponsor representative who has 
medical authority for the evaluation of the safety aspects of the clinical 
trial.  The study drug may be discontinued without unblinding the 
participant. 
Added: Subject treatment will be unblinded in emergency situations 
by the study Investigator if it is in the best interest of the trial subject in 
order to provide medical care of the subject and includes medical 
decisions such as whether to start or stop treatment or institute 
alternative treatment if required.  Specifically, we expect that 
unblinding of an individual study subject’s treatment assignment may 
occur if in the opinion of the Investigator that the identification of the 
study medication is necessary to protect the welfare of the subject. The 
study drug may be discontinued without unblinding the participant.   
If the blind is prematurely broken for a subject, it is the responsibility 
of the Investigator to promptly document and explain any unblinding 
to Cancer Prevention Pharmaceuticals within 24 hours of the blind 
being broken. 
Unblinding of subject treatment is done via the IWRS by the 
Investigator.  If the Investigator is unable to access IWRS, the Drug 
Safety Group at Ockham should be contacted at 1-919-468-2288 (US) 




5th para, 1st sentence 




Added: For the EU, Reference Safety Information (RSI) is located in 
the IB (Ver. CPP-201-IB05 and subsequent versions), Section 7.3, 
page 73, which is to be used for the purposes of determining 
expectedness and SAE/SUSAR reporting. 
EU Regulations 
Requirement 
Sec. 15. Added: RSI - Reference Safety Information Administrative 
clarification 
End   
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A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X / Sulindac 
Compared with CPP-1X, Sulindac as Single Agents in Patients with Familial Adenomatous Polyposis 
(FAP)  
 
List of Changes for Protocol Amendment 
From Version, 2.0, 16April2013 to Version 2.1, 10June2013 to Version 3.0, 29May2014 
Location Change Reason for Change 
Global Change Change Version 2.1, 10June2013 
To: Version 3.0, 29May2014 
Update protocol 
version and date 
Cover/Title Page Added: to include the EudraCT Number 2012-000427-41 and NCT 
number 01483144 
Updated Version and Date Ver. 3.0, 29May2014 
Combined cover page and title page as one. 
Admin. clarification  
Sec. 1.2 Added:  Legal Representative EU 
Andrew B. Hadlington, Wessex Pharma Services Ltd 
19 Webster Road, Winchester, 
Hants  SO22 5NT 
Phone/Fax: +44 1962 843331 
Mobile: +44 7796 394475 
Admin. clarification  
Sec. 1.5 Deleted Sue Clark and Professor Robin Phillips as Study Co-Principal 
Investigators 
Added: Prof. Möslein to study leadership 
Deleted Ernest Hawk and Miguel as Investigators (MD Anderson 
Cancer Center 
Deleted Sue Clark and Professor Robin Phillips as Clinical Site 
Replaced Randall Burt with Jewel Samadder as PI – Huntsman 
Cancer Institute.  
Added: Prof. Sir John Burn, Dr. Alex Henderson as Clinical Site – UK 
Added: “Prof” to title of Evelien Dekker-NE 
Change: Malties to “Malalties” 
Added:  Prof. Med. Christian Strassburg and Dr. Robert Hüneburg and 
University of Bonn, Deleted St. Joseph’s Bochum 
Update to reflect 
current investigator 
list  
Sec. 2.2.1, 2nd para Inserted: “treatment was”, to read as follows: Benefit was 
demonstrated in the rectum, but treatment was not statistically 
beneficial in the duodenum. 
Corrected typo: urticaria 
Admin. clarification 
2.4 Revised first sentence as follows: Ornithine decarboxylase (ODC) is 
a transcriptional target of the MYC oncoprotein…. 
Admin. clarification 
Sec. 2.7.1 Deleted Furthermore, they have implications for this FAP trial, and 
will affect eligibility (all patients with baseline high cardiovascular risk 
scores are not eligible for enrollment) 
Revised based on 
cardiovascular criteria 
Sec. 5.1.1 Added:…..trial setting in the US “and EU”.  The formulation….. Admin. clarification  
Sec. 5.2 Added: Sulindac is marketed in the US for relief of signs and 
symptoms of the following conditions:  osteoarthritis, rheumatoid 
arthritis, ankylosing spondylitis, acute painful shoulder 
(bursitis/tendinitis), and acute gouty arthritis. 
Changed: The tablets…. to The sulindac tablets….. 
Provides additional 
information on the use 
of sulindac in the U.S.  
Sec. 6.1, #3. Deleted…., except for clinical polyposis…. Admin. clarification  
Sec. 6.1., #4a Added to Stage 3: …..or any “prior” evidence….. Admin. clarification 
Sec. 6.1 # 11   
Sec. 6.1 #11 Added Confirmation of postmenopausal status unless surgically 
sterile**. 
**Postmenopausal status may be confirmed by any of the following: a) 
≥ 12 months spontaneous amenorrhea; b) 6 months spontaneous 
amenorrhea with serum FSA levels > 30 IU/L [Pagana KD, Pagana 
Clarification on how 
to determine 
postmenopausal status  
 
Company Confidential  Page 2 of 4 
Location Change Reason for Change 
TJ (2010). Mosby’s Manual of Diagnostic and Laboratory Tests, 4th 
ed. St. Louis: Mosby Elsevier. and Kahwati LC, 54 Nov 2005, The 
Journal of Family Practice]; c) ≥ 6 weeks postsurgical bilateral 
oophorectomy; d) ≥ 6 weeks postsurgical hysterectomy. 
footnote * added: “Fertile male or female, effective….. 
Sec. 6.1 #11 footnote changed from: … should use condoms for the duration of the 
study and for at least 2 weeks afterwards. 
To: … should use condoms should use condoms while the partner is 
pregnant. If the partner is still pregnant when the subject goes off 
study, the subject should continue condom uses for at least 2 weeks 
afterwards. 
Admin. clarification 
Sec. 6.1, #16 Changed: use of 81 mg to “81 to 100 mg“ daily of aspirin…. Or 
“650” to “up to 700”…. 
European standard of 
care for prophylactic 
aspirin use is 100 mg. 
Sec. 6.1, # 19 Added: “written”… Admin. clarification  
Sec. 6.2, #2 Added: ….”oral”…. Admin. clarification  
Sec. 6.2, #5 Changed: 650 to 700 Update total based on 
European standard 
size for low dose 
aspirin  
Sec 6.2, #8 Changed from:  
Patients at high cardiovascular disease risk are not eligible for study 
participation as defined below.  
“High risk” for cardiovascular disease is defined as: 
 Clinical diabetes mellitus (Type I or II) requiring glycemic 
medications, or 
 Prior personal history of cardiovascular disease – heart 
attack, stroke, transient ischemic attack, or symptomatic 
peripheral vascular disease, or two of the following: 
 Taking anti-hypertensive medication 
 Taking lipid lowering medication 
o Current cigarette smoker 
To: 
Patients must not have cardiovascular disease risk factors as defined 
below.  
 Uncontrolled high blood pressure (systolic blood pressure > 
150 mm Hg; 
 Unstable angina;  
 History of documented myocardial infarction or 
cerebrovascular accident; 
 New York Heart Association Class III or IV heart failure 
(Refer to Appendix C); 
 Known uncontrolled hyperlipidemia defined as LDL-C ≥ 190 
mg/dL or triglycerides ≥ 500 mg/dL. 
Updates 
cardiovascular criteria 
for entry. See cover 
letter for submission 
for details on this 
change.  
Sec 6.2, #12 Changed: Appendix C to “D” Admin. clarification  
Sec. 8.1 Changed: Mo 1-2 to Mo 0-1-2 
Added for clarification a column for month 9, 15 and 21 to note that a 
serum pregnancy test is to be done in WOCBP 
Added to footnote 2: CBC “panel includes” 
Added to footnote #5: “…(body system assessment - HEENT, hepatic, 
renal, genitourinary, reproductive, hematologic/immunologic, 
endocrine/metabolic, musculoskeletal, neurologic [i.e., grossly normal, 
walk into office, speech normal, no tremors, alert and oriented], 
dermatologic, cardiovascular, respiratory, gastrointestinal)…” 
Added to footnote 6:  (250, 500, 1000, 2000, 4000 and 8000 Hz) 
Added to footnote 15: US and Canada sites only 
Provides additional 
detail on what is 
required for tests and 
procedures  
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Location Change Reason for Change 
Changed footnote # 18: 12 to 6. 
Added to footnote 22: “2” EKGs will “done” …. “after pre-dose 
sample but prior to dose”, and … 
Added footnote # 23: 23Medical history includes – standard review of 
major systems, with particular attention to cardiovascular, 
cerebrovascular, peripheral vascular, gastrointestinal and hearing 
issues. Interaction with outside physicians should be documented. 
Added footnote # 24: 24Urinalysis panel includes – color, 
clarity/appearance, specific gravity, pH, protein, glucose, ketones and 
blood. 
Sec.8.2.2 Added to paragraph 4: review of body systems, Clarifies what will 
done during the 
physical exam 
Sec. 8.2.5 Added to month 3: …. (after the pre-dose sample, but prior to drug 
administration….) 
Added to months 3, 6, 12, and 18: review of body systems, 
Added:  
At the 9 month visit patients will have drug and diary dispensing. 
Women of child bearing potential will also have a serum pregnancy 
test performed.  Concomitant medications, adverse events and 
medication compliance will also be reviewed. 
Added: 
At the 15 month visit patients will have drug and diary dispensing. 
Women of child bearing potential will also have a serum pregnancy 
test performed.  Concomitant medications, adverse events and 
medication compliance will also be reviewed. 
Added: 
At the 21 month visit patients will have drug and diary dispensing. 
Women of child bearing potential will also have a serum pregnancy 
test performed.  Concomitant medications, adverse events and 
medication compliance will also be reviewed. 
Added to paragraphs for months 6, 12 and 18: “Concomitant 
medications, adverse events and medication compliance will also be 
reviewed”. 
Clarifies the timing for 
the EKG  
Sec. 8.2.6 Added to first paragraph: Concomitant medications, adverse events 
and medication compliance will also be reviewed. 
Added: review of body systems, 
Updates the 
information to be 
collected during the 
visit 
Sec. 8.2.7 Added to first paragraph: Concomitant medications and adverse 
events will also be reviewed. 
Admin. clarification 
Sec. 8.2.9 Added: Discontinuation from study treatment …. Grade ≥ 3 Cardiac 
ischemia/infarction or cerebrovascular ischemia, whether related to 
study drug or not 
Updated safety 
monitoring  based on 
revised cardiovascular 
criteria 
Sec. 8.3.1 Changed: changed “of” to “to” Admin. clarification 
Sec. 8.3.2 Added: #3. Grade ≥ 3 cardiac ischemia/infarction or cerebrovascular 
ischemia, whether related to study drug or not. 
Updated safety 
monitoring based on 
revised cardiovascular 
criteria 
Sec. 8.3.2 Changed: re-arranged all numbers after number 3 
Added to # 7: …”(randomization date)” and …”of” 
Admin. clarification 
Sec.9.1.A Added: 
All rectal/pouch polyps > 5 mm in diameter must be excised at 
baseline if the subject will be stratified to the rectum/pouch group.  For 
details concerning patients stratified to the rectal/pouch polyposis 
group (with or without involvement of the duodenum) please see 
Clarifies when >5 mm 
polyps need to be 
removed from the 
rectum/pouch based 
on the stratification 
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Location Change Reason for Change 
Section 6.1.4.  For details concerning patients stratified to the duodenal 
polyposis group (with or without involvement of rectum/pouch at 
stratification) please see Section 8.2.9. 
group for the subject. 
Sec. 9.4 Added in 3rd paragraph:  
…will be collected and “after this, a” pre-dose …   
Patients will be asked to note the time breakfast was finished, as that 
will be recorded. 
Admin. clarification 
Sec. 9.4 Change to table 5 footnote: … pre-dose “sample but before drug 
administration” and “after the” 4… 
Admin. clarification 
Sec. 9.4 Changed in 4rd paragraph: third and fourth samples to: fourth and 
fifth samples 
Admin. clarification so 
table matches text 
Sec. 11.1 Change from: Only subjects meeting the inclusion criteria will be 
enrolled in the study.  To: Subjects with cardiovascular risk factors as 
defined in Section 6.2 are not eligible for study participation.   
Updates eligibility 
status based on 
cardiovascular risk 
factors.  
Sec. 13.7  4th sentence, Added: “minimum” Admin. clarification  
Sec. 15 Added: HEENT-Head, Ears, Eyes Nose Throat, and EU-Europe Added abbreviations 
used in text 
Sec. 16 Added Reference  
#75 Pagana KD, Pagana TJ (2010). Mosby’s Manual of Diagnostic 
and Laboratory Tests, 4th ed. St. Louis: Mosby Elsevier. 
#76 Kahwati LC, Haigler, L, Rideout S.  What is the best way to 
diagnose menopause?. The Journal of Family Practice 54:11: 
1000-1002, 2005. 
Reference numbers updated 








classification that is 
now a part of 
eligibility criteria. 
End   
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Study ID: CPP FAP-310 
A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X / Sulindac 
Compared with CPP-1X, Sulindac as Single Agents in Patients with Familial Adenomatous Polyposis 
(FAP)  
 
List of Changes for Protocol Amendment 
From Version 3.0, 29May2014 to Version 3.1, 20March2015 
Location Change Reason for 
Change 
Global Change Change Version 3.0, 29May2014 
To: Version 3.1, 20March2015 
Update protocol 
version and date 
Table of Contents Update Table of Contents to reflect changes.  
Section 1.3 Change:  University of Arizona, BIO5 Institute Oro Valley and Arizona 
Cancer Center in Tucson, Arizona will perform the polyamine, 
pharmacogenomics and genetics testing for the samples collected. 
To: Metabolon Inc., 617 Davis Drive, Ste. 400, Durham NC, 27713, 
USA, will perform the testing for the polyamine samples collected. 
Molecular MD Inc. 1341 SW Custer Drive, Portland OR, 97219, USA, 
will perform the testing for the pharmacogenomic samples collected 
inVentiv Health Clinique, Inc. rue Einstein Street, Québec City, Québec 
G1P 0A2, Canada, will perform the bioanalysis for the pharmacokinetic 
samples collected. 




Section 1.5 Added Investigators 
Prof. Dr. Med Christian Strassburg 
Robert Hüenburg, M.D. 
Department of Hepato-Gastroenterology 
University of Bonn Hospital, Bldg. 334, 2nd floor 
Sigmund Freud Str 25 
Bonn, Germany 53127 
Anil Rustgi, M.D. 
University of Pennsylvania 
Perelman School of Medicine 
3400 Civic Center Blvd, 4 S Pavilion 
Philadelphia PA, 19104 USA 
Samir Gupta, M.D. 
University of California San Diego 
Dept. of Gastroenterology, Moores Cancer Center 
3855 Health Sciences Dr. 
La Jolla CA, 92093 USA 
Fiona Laloo, M.D. 
Manchester Centre For Genomic Medicine 
Central Manchester University  
Saint Mary’s Hospital- Oxford Road 
Manchester M13 9WL, UK 
Giovanna da Silva, M.D. 
Cleveland Clinic Florida 
2950 Cleveland Clinic Blvd. 
Weston FL, 33331 USA 
Professor Eric Van Cutsem, M.D., Ph.D. 
Leuven Cancer Institute 
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Location Change Reason for 
Change 
University Hospitals Leuven 
3000 Leuven, Belgium 
Dr. Jennifer Weiss, M.D. 
University of Wisconsin-Madison 
Division of Gastroenterology and Hepatology 
UWM Centennial Building 
1686 Highland Avenue 
Madison, WI 53792 USA 
William Grady, M.D. 
Fred Hutchinson Cancer Research Center/University of Washington/ 
1100 Fairview Avenue N. 
D4-100 
Seattle, WA 98109 USA 
Douglas Riegert-Johnson, M.D. 
Mayo Clinic-Florida 
4500 San Pablo Road 
Jacksonville, FL 32224 USA 
Section 4.4 Clarification:…includes progression to more advanced duodenal 
polyposis (Stage 2, 3 or 4),  
 
Section 4.8 Changed: “….oligonucleotide primers designed to amplify a 172-bp 
fragment containing the polymorphic base at +316 (Applied Biosystems).  
Allele-specific TaqMan probes will be synthesized with different 5′ labels 
(6-carboxyflourescein or VIC) and the same 3′ quencher dye (6-
carboxytetramethylrhodamine).  Each PCR reaction (5 μL total) will 
contain 10 ng of participant DNA, 30 pmol of each primer, 12.5 pmol of 
each TaqMan probe, and 1× TaqMan Universal PCR Master Mix 
(Applied Biosystems).” To: … a PCR amplification of the targeted region 
and bi-directional cycle sequencing of purified target amplicon using 
PCR/Sanger sequencing primers.  The sequencing reaction will be 
analysed on an Applied Biosystems 3730 Genetic Analyzer. The PCR 
amplicon will be sequenced in both forward and reverse directions to 
confirm the SNP. 
Administrative  
Section 6.1 #17 Added after aspirin, “in excess of 700 mg weekly, 
#18 Added: “oral” before corticosteriods 
 
Section 6.2 #6:Added at the end of the sentence “and or randomization.” 
#10, Change: Colon/rectum/pouch with high grade dysplasia or cancer 
on biopsy or a large polyp (>1 
cm) not amenable to complete removal. 
To: Intact colon/rectum or retained rectum or ileal pouch:  
a) cancer on biopsy 
b) high grade dysplasia found on polyp biopsy where the polyp is not 
completely removed 
c) a large polyp (>1 cm) not completely removed. 
Administrative  
Section 8.1 #5, Change: Complete Physical Exam (includes body system 
assessment/review of systems -…To: Physical Exam/Review of body 
systems (includes body system assessment - … 
#10 Added: … that have an intact colon or rectum/pouch. …  
#11 Added: … For patients with permanent ileostomy, endoscopy not 
required; normal mucosal biopsies are performed on the visible 
ileostomy stoma.  
Administrative  
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Location Change Reason for 
Change 
#12 Added: … that have a duodenum. 
Section 8.1 #22 New number: Subject needs to be in the supine position for 10 
minutes prior to the EKG.   
#22 changed # to 23: 2-EKGs will done on the day PK samples are 
collected: after pre-dose sample but prior to dose, and after the 4 hr PK 
sample has been obtained. 
To: 2-EKGs will done on the day PK samples are collected: 1) before 
pre-dose sample and prior to dose, and 2) before the 4 hr PK sample is 
obtained.  
Updated: #23 to 24 and 24 to 25 
Administrative  
Section 8.2.2 Lower GI,  Changed: All randomized patients will have baseline … 
To: All randomized patients with an intact colon or rectum/pouch will 
have baseline … 
Upper GI Change: All randomized patients will have baseline and on-
study UGI endoscopy as part of this trial.  A complete physical exam 
including review of body systems, …Baseline blood tests within … 
To: All randomized patients with a duodenum will have baseline and on-
study UGI endoscopy as part of this trial. Subjects stratified to the 
duodenal group must have a duodenal biopsies of all polyps 1 cm or 
larger to determine HGD and histology required for determining Stage 3 
or 4 Spigelman status.  A physical exam/review of body systems, … 
Baseline blood and urine tests within … 
Administrative  
Section 8.2.5 Change: At the 3-month visit, patients will have a physical exam … 
To: At the 3-month visit, patients will have a physical exam/review of 
body systems … 
Added: At the 6-month …. Review or “body” systems 
Changed: At the 12 month visit patients will have a physical exam 
(including review of body systems, 
weight and vital signs) …To: At the 12 month visit patients will have a 
physical exam/review of body systems (including, weight and vital signs). 
Changed: At the 18 month visit patients will have a physical exam 
(including review of body systems, weight and vital signs)  To: At the 18 
month visit patients will have a physical exam/review of body systems 
(including, weight and vital signs).. 
Changed: At the 3-month visit … (PK), and EKGs (after the pre-dose 
sample, but prior to drug administration and after the 4-hour PK sample 
collection). To: … (PK), and EKGs (before the pre-dose sample, prior to 
drug administration and before the 4-hour PK sample collection.  Subject 
needs to be in the prone or lying down position for 10 minutes prior to 
colleting the EKG). 
Added to Month 6, 12, and 18: (Subject needs to be in the supine 
position for 10 minutes prior to the EKG). 
Administrative  
Section 8.2.6 Added: (Subject needs to be in the supine position for 10 minutes prior to 
the EKG) 
Changed: … physical exam (including review of body systems, weight 
To: … physical exam/review of body systems (including, weight … 
Administrative  
Section 8.2.9 Added to 3. a)….(Stage 2, 3 or 4) Administrative  
Section 9.2 Added: after.. Spigelman stage progression “ (Stage 2, 3, 4)” Administrative  
Section 9.4 Changed: Thereafter, a pre-dose blood sample (5 mL, lithium heparin 
vacutainer tube) will be collected and after this, a pre-dose EKG will be 
Administrative  
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Location Change Reason for 
Change 
obtained.  To: Prior to the pre-dose blood sample collection, a resting 
EKG will be obtained (patient needs to be in the supine position for 10 
minutes prior to colleting the EKG).  After the EKG was obtained, a pre-
dose blood sample (5 mL, lithium heparin vacutainer tube) will be 
collected.   
Table 5: added EKG – Prior to pre-dose sample collection and drug 
administration and EKG – Prior to 4 hour sample collection 
Table footer changed from: *EKGs need to be done after the pre-dose 
sample but before drug administration and after the 4 hour samples have 
been collected. 
To: *EKGs need to be done 1) before the pre-dose sample and before 
drug administration and 2) before the 4 hour samples are collected. 
Added: At the 4 hour time point and prior to the 4 hour blood sample 
collection, a resting EKG will be obtained (subject needs to be in the 
supine position for 10 minutes prior to the EKG).  After the EKG is 
obtained, the 4 hour time point blood sample (5 mL, lithium heparin 
vacutainer tube) will be collected. 
Section 11.7 Added: physical examination”/review of body systems”. Administrative c 
Section 11.9 Added before corticosteroids “oral” 
Added after aspirin “in excess of 700 mg weekly,” 
Changed: … Pradaxa®, and Plavix®) or other direct thrombin 
inhibitors), fluconazole…To: … Pradaxa®, Eliquis®, and other direct 
thrombin inhibitors, and Plavix®) fluconazole… 
Administrative  
Appendix A Added comment: 
All adenomas in the duodenum demonstrate at least low grade 
dysplasia; if intermediate grade use low grade for points. 
Administrative 
End   
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A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X / Sulindac 
Compared with CPP-1X, Sulindac as Single Agents in Patients with Familial Adenomatous Polyposis 
(FAP)  
 
List of Changes for Protocol Amendment 
From Version 3.1, 20March2015 to Version 3.1a, 23July2015 
 
Location Change Reason for 
Change 
Global Change Change Version 3.1, 20March2015 
To: Version 3.1a, 23July2015 
Update protocol 
version and date 
Section 1.6 Changed: SCHEMa to SCHEMA Administrative 
Reference number 
citations and  
measurements 
Formatted updated as superscript numbers. Administrative 
Section 8.1, Table 3 Formatted footnotes as superscript in table and listing of footnotes Administrative 
Appendices, 
Appendix E 
Formatted tables to fit on 1 page Administrative 
Protocol synopsis Version change for consistency with protocol version and date.  No 
changes were made to the synopsis document. 
Administrative 
End   
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Study ID: CPP FAP-310 A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of 
CPP-1X / Sulindac Compared with CPP-1X, Sulindac as Single Agents in Patients with Familial 
Adenomatous Polyposis (FAP)  
 
List of Changes for Protocol Amendment 
From Version 3.1a, 23July2015 to Version 4.0, 14March2016 
Location Change Reason for Change 
Global 
Change 
Changed: Version 3.1a, 23July2015 
To: Version 4.0, 14March2016 
Update protocol 
version and date 
Global 
Changes 
Corrected typographical and grammatical errors 
Updated cross reference Sections throughout the document 
Administrative 
changes 
Section 1.2 Added additional information on Legal Representative  
Cancer Prevent Pharma, Ltd 
Tower 42, Level 30 
International Finance Center 25 
London, EC2N 1HQ, United Kingdom 
Changed: Ockham Drug Safety contact to Chiltern Drug Safety Contact,  
Added: Email: dsafety@chiltern.com 
Administrative 
change 
Section 1.5 Added: contact information for Dr. Willingham and Dr. Cone and deleted 
information for Dr. Rigert Johnson. 
Update to 
participating sites 
Section 1.6 Changed: For enrolled subjects treatment will continue for 24 months, or 
until occurrence of an FAP-related event as defined in the protocol. Drugs 
taken once daily.  To: Randomized subjects will receive 24 months of 
treatment and complete their final assessment or come off-study for an FAP-
related event or for other reasons (for example, safety issues, non-compliance, 
withdrew consent, lost to follow-up). Subjects completing 24 months of 
treatment without an FAP event can continue treatment for up to 12 additional 
months until one of the following occurs: 1) subject has an FAP event or 
comes off study for other reasons, 2) all randomized subjects have reached a 
minimum of 24 months of treatment or have come off study prior to reaching 
24 months of treatment. 
Adds information on 
treatment extension 
for up to a 
maximum of 12 
additional months of 
treatment.  
 Move: “Drugs taken once daily” after “a total of 150 patients” Administrative 
change 
Section 2.2.3 Remove: “Dr. Patrick Lynch, the study Principal Investigator, reported 
results from this trial in abstract form at the 2012 Digestive Diseases Week 
(DDW) meeting in San Diego and the 2012 Collaborative Group of the 
Americas for Inherited Colorectal Cancer in Boston.” 
Updated with 
published ref.  
instead of meeting 
abstract. 
Section 2.3 Added: …patients treated for three (3) years with eflornithine… Clarification on 
duration of study 
treatment in 
referenced study. 
Section 2.2.4 Deleted:“2012”, Added publication reference. Administrative 
change 
Section 2.7.3 Added: “and the recent FDA Drug Safety Communication”, and reference Adds reference to 







Added a new section 3.2 on Rationale for Treatment Duration Extension.  See 
attached section at the end of this document. 
Provides the 
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Changed: This randomized, double-blind, phase III trial will compare the 
efficacy, safety and pharmacokinetics of the CPP-1X/sulindac combination 
versus CPP-1X and sulindac as single agents over a 24 month treatment 
period in patients with Familial Adenomatous Polyposis (FAP). 





Section 4.2 Bullet point #3 changed 24 months to 36 months. 
Added last 2 bullet points on initial 24 months of treatment and treatment 
extension: 
 Randomized subjects will receive 24 months of treatment and complete 
their final assessment or come off-study for an FAP-related event or for 
other reasons (for example, safety issues, non-compliance, withdrew 
consent, lost to follow-up).  
 Subjects completing 24 months of treatment without an FAP event can 
continue treatment for up to 12 additional months until one of the 
following occurs: 1) subject has an FAP event or comes off study for 
other reasons, 2) all randomized subjects have reached a minimum of 24 
months of treatment or have come off study prior to reaching 24 months 





initial treatment and 
treatment extension. 
Section 4.7 Changed on first paragraph: At the scheduled colonoscopy/proctoscopy at 
baseline, 6 months and 24 months… To: “At each colonoscopy/proctoscopy 
while on study treatment, a sample of normal rectal mucosa and a random 
urine sample will be obtained to assess …..” 
Clarifies time point 
sample collection 
and adds time points 
for treatment 
extension. 
Section 5.1 Changed “patients” To “subjects” Administrative 
change 
Section 5.2 Changed “patients” To “subjects” Administrative 
change 
Section 8.1 Added to the title: Table 3 … (Initial 24 months of treatment). 
And added to month 24 “X26“ for Informed consent 
Added to footnotes: 26 Subjects completing the initial 24 month treatment 
without an FAP-related event and participating in the extension study must be 
consented at this visit.  Go to table 4 for month 24 additional extension 
procedures. For those subjects not participating in the extension study, this 
will be the end of treatment visit. 
The table has been 
divided into the 
initial 24 months of 
treatment (Table 3) 
and Table 4 for 
treatment extension 
up to 36 months. 
Section 8.1 Added: New table # 4 and table 4 footnotes. See complete table and footnotes 




Section 8.2.4 Changed: Table 4 to table 5.   
Changed: On RX intervals “daily for 24 months” 
To: Daily for up to 36 months” 
Changed: Based on published data utilized to project event rates, patients 
will receive treatment for 24 months. To: Based on published data utilized to 





Section 8.2.5 Changed Section Heading: Follow-up During Treatment Intervention. 
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Location Change Reason for Change 
Changed: Refer to Section 8.1, Table 3 for patient assessments and the 
treatment schedule for screening, on-study, end of treatment and follow-up 
visits.  
To: Refer to Section 8.1, Table 3 and Table 4 for patient assessments and the 
treatment schedule for screening, on-study, end of treatment and follow-up 
visits.  
Added: During the initial 24 month drug intervention, patients will be 
followed monthly by phone interview or in person visits for 
assessment … 
information on 
initial treatment and 
treatment extension. 
Section 8.2.5 Added paragraph: At months 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 
22, 23 a follow-up visit via phone contact will be performed to assess for side 
effects, other medications, to remind subjects to complete their diary and to 





Changed: At the 6-month, visit…. A second normal rectal/pouch mucosal 
biopsy for polyamine determination. 
To: (CBC, chemistry panel, urinalysis), a random urine sample will be 
obtained for polyamine determination, … and their first on study treatment 
upper and lower endoscopy procedures with image and video 
documentation will be obtained… 
Added: At the month 12 and at the month 18 visit… a random urine sample 
will be obtained for polyamine determination… 
And: …endoscopy procedures with image and video documentation will be 
obtained. A normal mucosal biopsy sample for polyamine determination 
will be obtained during the colonoscopy/proctoscopy procedure...  
Clarifies time points 
for collection and 
adds time points for 







Changed section and contents: Final Intervention Visit/End of Treatment 
(Month 24 +/- 2 weeks or at end of treatment +/- 2 weeks). 
To new section and contents: Month 24 (+ 2 weeks) and modification of the 
whole section. See updated section at the end of this document.  




Section 8.2.7 Changed section heading to: Follow-Up (30-days post end of treatment visit 
+/- 1 week) Off Study.  
To: Initial 24 Month Treatment Intervention Early Termination (+ 2 weeks). 
Removed: (with normal mucosa biopsy and random urinalysis for polyamine 
analysis) 
Added to first paragraph: (CBC, chemistry panel, and urinalysis), a 
random urine sample will be obtained for polyamine determination… 
Added to second paragraph: “A normal mucosal biopsy sample for 
polyamine determination will be obtained during the 
colonoscopy/proctoscopy procedure.” 
Added to third paragraph: A random urine sample should be obtained for 
polyamine determination, if possible. 
Clarifies time points 
sample collection 
and adds time points 
for treatment 
extension. 





Changed section numbers: from 8.2.7 to 8.2.8 and 8.2.8 to 8.2.9 
Added to both titles: “Initial 24 Month Treatment Intervention” 
Updates information 
for initial 24 month 
treatment.  
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Sections 
8.2.10-8.2.14 
Added new sections and contents: Sections 8.2.10-8.2.13 






Added (~25% increase in disease burden) to the following sentence as 
follows: 
^Disease progression is based on endoscopic evaluations compared to 
baseline demonstrating a clinically significant increase in number 
and/or size of polyps (~25% increase in disease burden), presence of a 
large sessile or ulcerated adenoma not amenable to removal, high grade 
dysplasia in any adenoma, or in-situ or invasive cancer. 
Administrative 
Change 
Section 8.3.1 Changed on last paragraph: …Drug Safety Group at Ockham should… 
To: ...Drug Safety Group at Chiltern should… 
Clarifying change in 
safety group name. 
Section 8.3.2 
 
Moved from # 7: “The first day of study treatment initiation is the 
randomization date regardless of study visit and/or procedure delays.” and 
Move to the end of #6.  
Added to #6: (from randomization) 
Changed from #7: 24 months To: treatment 





Changed: …and at the 6 month and 24 month proctoscopy… 
To: …and at each endoscopy/proctoscopy… 
Clarifies time points 
for sample 
collection and adds 
time points for 
treatment extension. 
Section 10.1 Changed: HRQoL measures will be obtained at baseline and at 3, 6, 12, 18, 
and 24 months post-enrollment/end of treatment. 
To: HRQoL measures will be obtained at baseline, month 3, at every interim 
endoscopy visit, and at end of treatment 
Changed: In addition to the HRQoL... Data will be collected at baseline and 
at 3, 6, 12, 18, and 24 months post-enrollment/end of treatment and 
preference… 
To: In addition to the HRQoL…  Data will be collected at baseline, month 
3, at every interim endoscopy visit, and at end of treatment and 
preference… 
Changed: The modified version of the Cancer Worry Scale will also be 
administered at baseline and at 3, 6, 12, 18, and 24 months 
To: The modified version of the Cancer Worry Scale will also be 
administered at baseline, month 3, at every interim endoscopy visit, and at 
end of treatment and… 
Updates time points 
to include treatment 
extension.  
Section 10.2 Changed: … Dietary assessments via the FFQ will be obtained at baseline, 
12 months and 24 months/end of treatment… 
To: … Dietary assessments via the FFQ will be obtained at baseline, months 
12, 24 and 36/end of treatment… 
Update time points 
to include treatment 
extension. 
Section 11.1 Changed: …and months 3, 6, 12, 18 and 24 (end of treatment). 
To: …and months 3, 6, 12, 18, 24, 30 and 36/end of treatment. 
Update time points 




Changed: At the 3, 6, 12, 18 and 24 month visits… 
To: At months 3, 6, 12, 18, 24, 30 and 36/end of treatment… 
Update time points 
to include treatment 
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Changed: At the 3, 6, 12, 18 and 24 month visits… 
To: At months 3, 6, 12, 18, 24, 30 and 36/end of treatment… 
Update time points 
to include treatment 
extension. 
Section 11.5  Spelled out IB – Investigator’s Brochure 
Removed: page 73 
Administrative 
change 
Section 11.8 Added: …have become pregnant (for male subjects if their partner 
has become pregnant) at the time… 




Changed: Eligible patients who have given informed consent will enter the 
study the intent to participate for the full treatment period of 24 months.  
Accrual is expected to take 6-12 months.   
To: Eligible patients who have given informed consent will enter the study 
with the intent to participate for the full treatment period of 24 months.  
Accrual is expected to take 12-24 months.  Eligible patients who have given 
informed consent will enter the treatment extension phase with the intent to 
participate for the full study extension treatment period of up to 12 months. 
Explains the change 
in accrual time 





Changed: The analytic method for the primary analysis will be a time-to-
event analysis using the log-rank test.   
To: … analysis using the stratified log-rank test. 
Changed: If an FAP related event occurs, that patient will be said to have an 
observed or uncensored event and will be considered a treatment failure. 
To: If the endpoint determination cannot be made at the end of study clinic 
visit per the pre-specified study requirements, a blinded adjudication 
committee will review the reasons for such deviations.  If upon blinded 
adjudication it can be determined that a subject’s withdrawal is for reasons 
deemed unrelated to his or her endpoint status, that subject will be treated as a 
censored observation as of the last patient visit.  If upon blinded adjudication 
it cannot be determined that a subject’s withdrawal is unrelated to endpoint 
status, an imputed primary endpoint will be used in the primary analysis for 
such withdrawals.  The time to this imputed event will be from randomization 
to the last recorded patient visit.  All other subjects who complete their 
follow-up without a FAP-related event by the end of the study will be treated 
as a censored observation as of the actual follow-up time for the close-out 
visit. 
Prior to the primary analysis, balance will be assessed between the three arms 
in terms of key potential confounders measured at the baseline visit.  A brief 
list of such potential confounders will be presented to the DMC for approval 
prior to analysis.  If any of these variables is found significantly out of 
balance across the three groups using a 2 degree of freedom test of 
homogeneity at the 0.01 level of significance, it will be incorporated into the 
primary analysis using a stratified Cox model including that term in addition 
to the treatment arm.  The covariate-adjusted score test (adjusted stratified 
log-rank test) will serve as the primary result for the trial. 















Deleted: …who completed all 24 months of treatment and has primary 
endpoint determinations performed per protocol specifications. 
Added: … that fulfill all protocol eligibility, intervention, and outcome 
assessments. 
Updated to include 
treatment extension. 
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12.5.4 Changed :“Within the entire patient population there will be subsets who did 
not receive 24 months of daily medication. The patient diary…...” To: 
“Within the entire patient population there will be subsets who did not receive 
the full course of per protocol treatment.  The patient diary and pill count will 
define the extent of compliance.  This subgroup of patients will be 
categorized into various cohorts.  For consistency, an adjudication committee 
will be established, to review all study events (i.e., FAP-related events and 
dropouts) and categorize them either as censored observations or imputed 
endpoints.  For exploratory and sensitivity analysis the following dropout 





Added: Demographic features … and country among … 
Added to end of paragraph: Significance will be defined at the 0.05 level, 
unless otherwise noted.  Thus p-values less than or equal to 0.05 will be 
declared significant. 





Changed: and will include per treatment group enumeration of all patients 
randomized, number ineligible, early termination due to AE/SAE, the number 
of subjects with an SAE, deaths, dropout for other reasons, and the number of 
subjects…”  
To: and will include per treatment group enumeration of all patients 
randomized, the number deemed ineligible, the number of FAP-related 
events, and the number of study drop outs.  These will be further described in 
subgroups such as drop outs due to adverse events, serious adverse events, 
administrative withdrawals for non-compliance for more than 90 days, 
withdrawals of consent for continued follow-up, withdrawals for other 
reasons, and the number… 
Changed: Additional summaries will include reasons for patients 
discontinuing treatment and/or modifying treatment dosages, and a summary 
of patients’ treatment status.   
To: Additional summaries will include reasons for patients discontinuing 
treatment and/or modifying treatment dosages.   
Updates disposition 
to provide additional 





Added “freedom” to …one degree of freedom test..” 





Changed: Subgroups will be analyzed in the spirit of exploratory analyses 
included but not limited to various study populations and within each level of 
randomization strata. To: Subgroups will be analyzed in the spirit of 
exploratory analyses including but not limited to the various study 
populations and separately within each disease-prognosis stratum. 
Updated to match 
the Statistical 




Changed: … at baseline and months 3, 6, 12, 18, and 24 months post end of 
treatment. 
To: … at baseline and months 3, 6, 12, 18, 24, 30 and 36/end of treatment. 
Updated to include 




Changed: … at baseline, 12 months and 24 months/end of treatment… 
To: … at baseline, months 12, 24 and 36/end of treatment… 
Deleted: “The results of the FFQ will be used to corroborate results from 
another recent trial that indicate consumption of a diet high in polyamines is 
associated with reduced treatment efficacy.” 
Updated to include 
data on treatment 
extension. 
Section 12.7 Added: … The time to this imputed event will be from randomization to the 
last recorded patient visit.  A study event adjudication committee will be 
formed to further define the methods for defining imputed and censored 
Updated to match 
the Statistical 
Analysis Plan for 
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events.   
Changed: “September 1998” to “February 1998” 
Added: erroneous or appear as outliers will 
analyzing events.  
Section 12.8 Changed:  CPP will inform the DMC that there will be two study evaluations 
for the DMC to consider during the trial, one interim look for sample size 
reassessment and one look for futility (based on a blinded A/B comparison). 
The method for reassessment of sample size is based upon the FDA 
Guidance, “Adaptive Design Clinical Trials for Drugs and Biologics 
(February 2010)”.  There will be no hypothesis testing.  The DMC will 
perform an assessment of the observed trial event rate based on pooled data 
only.  They will make a recommendation to the sponsor on whether the 
pooled event rate is sufficient to preserve the integrity of the trial, and if not, 
to recommend a revised sample size.  For this assessment the study 
statistician will estimate the overall observed event rate and 90% confidence 
interval.  This assessment will be performed using data from a single time 
point, when enrollment is approximately 95% complete.  With this approach 
study enrollment can continue uninterrupted at the study sites, if it is decided 
to increase study sample size. 
The futility assessment will occur when approximately 50% of maximum trial 
information has been amassed.  Assuming a constant enrollment rate over 1 
year and full enrollment achieved at one year, that would occur at 
approximately 1.5 years from enrollment start.  At that time patients would 
have an average of approximately 1.0 year on study treatment. 
To: CPP will inform the DMC that there will be two study evaluations for the 
DMC to consider during the trial, one interim look for sample size 
reassessment and one look for futility. 
The method for reassessment of sample size is based upon the FDA 
Guidance, “Adaptive Design Clinical Trials for Drugs and Biologics 
(February 2010)”.  There will be no hypothesis testing.  The DMC will assess 
the observed trial event rate based on pooled data only.  They will make a 
recommendation to the sponsor on whether the pooled event rate is sufficient 
to preserve the integrity of the trial, and if not, to recommend a revised 
sample size.  For this assessment the study statistician will, if possible, 
estimate the overall observed event rate and 90% confidence interval.  This 
assessment will be performed using data from a single time point, when 
enrollment is approximately 95% complete.  If this type of assessment is not 
possible, then as assessment will be performed taking into consideration the 
total number of subjects randomized, total number of events, total number of 
dropouts, and cumulative study safety data. 
The futility assessment will be performed after a total of 45 adjudicated 
primary endpoints have occurred, which represents 50% of expected 
maximum trial information, or as soon thereafter as possible.   
The futility analysis will be performed for each of the two treatment 
comparisons contained in the primary objective:  
1. CPP-1X active + sulindac active vs. CPP-1X placebo + sulindac 
active,  
and 
2. CPP-1X active + sulindac active vs. CPP-1X active + sulindac 
Updates the 
explanation of the 
futility analysis to 
match the Statistical 
Analysis Plan.  
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Location Change Reason for Change 
placebo  
For the futility interim analysis, the futility stopping criterion of Z=0.50 is 
one-sided, and corresponds to a conditional power criterion of approximately 
0.12 (to two decimals).  That is, assuming between 52 and 55 expected total 
number of events have occurred by trial end in either of the two-arm 
comparisons, if the log-rank critical ratio Z-score were equal to 0.5 (or less) 
when one-half the expected total number of events had been observed, then 
under the design alternative hazard ratio of 0.4243, there would be only a 
12% probability (or less) of declaring a significant benefit of the combination 
therapy compared to the single agent therapy if the trial were to continue to 
the planned end. In that case, it would be reasonable for the DMC to consider 
stopping the trial for futility.  The futility analysis results will be presented in 
a simple manner whereby the DMC will be informed that the conditions 
indicating futility have been met (i.e. the futility boundary has been crossed, 
yes or no).  Unless the DMC requires it on ethical grounds, no early stopping 
for positive efficacy is proposed. 
Section 
Appendix B 
Added: Patients who cannot be allotted a particular stage (e.g., patients with 
mix polyposis) contact Cancer Prevention Pharmaceuticals for assistance with 
staging assignment. 
Deleted: InSiGHT meeting 2011, San Antonio, TX 
Updated publication 
of staging system. 
 Added footnote: * Stage I may also include larger, stable, asymptomatic 
desmoids 
Clarification of 
stage I based on 
reference 
publication. 




All section numbers, table numbers, reference numbers, where changed as 
needed to match the sited number throughout the document. 
Tables were re-numbered to accommodate to added tables. 
Administrative 
change 
End   
  
 
Company Confidential  Page 9 of 14 
 
Section 3.2 Rationale for Treatment Duration Extension 
At the time of this amendment, the accrual of study subjects was 95% complete.  The initial statistical analysis 
plan used detailed event rate projections based on an extensive review of the published literature (Refer to 
Appendix E) that determined 150 randomized subjects would be required for the primary endpoint analysis.  In 
February, 2016, a blinded data review was done to project a more realistic estimate of FAP-related event rates 
at the completion of the trial with a maximum of 24 months of treatment.  Based on this analysis, it is unlikely 
we will reach the required 90 events before the end of the study.  In order to reduce the risk of a false-negative 
trial (because of inadequate events after two years of study treatment in 150 randomized subjects), several 
mitigation options were explored. 
The most effective approach to ensure that the required total number of primary endpoint events is reached is 
an amendment extending the treatment duration from 24 months up to a maximum of 36 months for subjects 
that have not had an FAP related event. The study will conclude when the last randomized subject reaches 24 
months of treatment.  The treatment extension will not increase the overall total trial duration compared to 
recruiting additional subjects beyond 150 and following them for 24 months.  
In order to minimize bias introduced by offering up to an additional 12 months of treatment to patients who 
have reached 24 months without an FAP-related event, data will be obtained to prospectively define patients 
who accept or decline the additional months of study treatment.  Most importantly, it will be possible to 
identify the reasons why subjects decline the treatment extension, including real or perceived side effects of the 
study medications. 
To support the treatment extension, a blinded safety review was undertaken.  As of February 1, 2016, the CPP 
FAP-310 study had randomized 140 subjects to one of three treatment arms: (1) eflornithine 750 mg/day, (2) 
sulindac 150 mg/day, and (3) the combination at the same dosage, with a maximum treatment duration of 24 
months.  For the ongoing S0820 (PACES, NCT01349881), a study for prevention of recurrence of high risk 
adenoma and second primary colorectal cancers (managed by SWOG), 67 subjects had been randomized as of 
November 2015, with a maximum treatment duration of 36 months.  In this four arm trial, treatment groups 
include: (1) eflornithine 500 mg/day, (2) sulindac 150 mg/day, (3) the combination at the same dosage, and (4) 
placebo/placebo. 
Ongoing blinded evaluations of the active Phase III studies has not demonstrated any risks outside of those 
identified in the Reference Safety Information located in the Investigator’s Brochure.  There have been no 
deaths on either study.  Safety risks are formally evaluated by a data monitoring committee (DMC) for each 
study.  There have been three safety data monitoring committee meetings for CPP FAP-310 study.  To date, 
the DMC has not identified any safety issues and there have been no protocol modifications due to safety.  
Additionally, for CPP FAP-310, the Medical Monitor performs a monthly blinded review of all adverse events 
to evaluate for events not commonly associated with drug exposure or to look for an increase in events above 
what is typical for the population under study. 
There have been eight (8) serious adverse events (SAEs) that have been reported from the CPP FAP-310 study 
and five (5) that have been reported from the S0820 study, for a total of 13 serious adverse events.  No events 
were classified as SUSARs and no subject treatment arm assignments were unblinded.   
Overall (CPP FAP-310 and S0820 combined), ten (10) of the thirteen (13) SAEs were classified as not related 
to study treatment by the Investigators.  Gastrointestinal events included two (2) small bowel/intestinal 
obstructions.  This type of event is not uncommon in either patient population.  There were two (2) 
gastrointestinal events of ileus, one with diarrhea.  The CPP FAP-310 trial patient with ileus had additional 
episodes prior to taking the study drugs.  Ileus is an expected event in the FAP and post colon surgery patient 
populations.  There was one (1) procedural complication that involved a post-polypectomy bleed.  This is a 
common complication from an endoscopic excision.  There was one (1) event of pancreatitis in a subject with a 
prior history of pancreatitis.  Pancreatitis is a rare, but identified risk of sulindac.  The patient was hospitalized 
for six weeks and the event was a life-threatening, grade 4 serious adverse event.  The Investigator’s Brochure, 
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Sulindac package Insert and published reports indicate that pancreatitis is associated with the use of sulindac.66  
One (1) subject experienced sinusitis with fever and lymphopenia that required hospitalization with IV fluids.  
There was one (1) event in the nervous system disorders category that was seasonal migraine.  The subject had 
a history of this type of event.  For neoplasms, there was one (1) diagnosis of lung adenocarcinoma with a 
brain lesion, unrelated to treatment.  For vascular disorders, there was one (1) thromboembolic event (S0820 
study) in this category.  While the Investigator listed this event as not related, the Medical Monitor at Cancer 
Prevention Pharmaceuticals listed this event as possibly related.  This is a known risk of sulindac and is listed 
in the Investigator’s Brochure, Reference Safety Information. 
The remaining three (3) events were classified as being related to treatment.  One (1) event of worsening of 
depression was listed as possibly related to treatment.  Depression is covered in the Reference Safety 
Information as a known side effect of sulindac and with the side effect of emotional lability for eflornithine.  
For vascular disorders, there was one (1) thromboembolic event (DVT without pulmonary embolism) listed as 
possibly related to treatment.  This is a known risk of sulindac and is listed in the Reference Safety Information 
in the Investigator’s Brochure.  There was one (1) incidence of gastrointestinal bleeding that was evaluated as 
probably related to treatment.  Gastrointestinal bleeding is an uncommon, but known risk of sulindac.   
The constituents for this combination therapy, eflornithine and sulindac, are considered as having well-
established medicinal use within the meaning of Annex I to Directive 2001/83.  Both active substances have 
been authorized in medicinal products for various therapeutic indications for doses, duration and frequency 
exceeding that which is used in the CPP FAP-310 and S0820 Phase III clinical studies. 
Randomized clinical trials of eflornithine and sulindac alone or in combination indicate that these agents have 
minimal toxicities when used for treatment periods of 3 or more years in patients with risk of cancer.  The 
treatment duration for the S0820 (PACES) study is comparable with 3 years of treatment at a dose level of 500 
mg/day eflornithine and 150 mg/day sulindac.  The minimal toxicities observed to date in CPP FAP-310 for 
treatment of FAP patients with eflornithine and sulindac for up to 2 years supports the extension of the 
treatment time in CPP FAP-310 from 2 to up to 3 years at a dose level of 750 mg/day eflornithine and 150 
mg/day sulindac. 
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36 mo.  




 (± 1 wk) (± 2 wks) (± 1 wk) (± 2 wks17) ± 1 wk 
Informed Consent X          
Medical History19     X    X X13 
GI Symptoms     X    X X13 
Surgical History          X13 
Concomitant 
Medications 




 X12 X12 X12 X X12 X12 X12 X 
 
Adverse Events  X12 X12 X12 X X12 X12 X12 X X13 
Chemistry Panel1     X    X  
CBC2     X    X  
Urinalysis20     X    X  
Vital Signs3     X    X  
Physical Exam4     X    X  
Audiometry5         X  
EKG18     X    X  
Serum Preg. Test6   X6  X  X6  X  
Dispense 
Medications7 
X  X7 
 































HRQoL surveys 16     X    X  
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FAP Study Schedule Treatment Extension Footnotes 
Note: Shaded columns in patient schedule (Table 4) are protocol required in person visits. 
1. Chemistry panel includes – electrolytes (Na, K, CL, CO2), liver function tests (AST, ALT, Alkaline phosphatase, bilirubin), BUN, creatinine. 
2. CBC panel includes – hemoglobin, hematocrit, WBC, platelet count, automated differential. 
3. Vital signs – temperature, blood pressure, pulse, respirations. 
4. Physical Exam/Review of body systems (includes body system assessment - HEENT, hepatic, renal, genitourinary, reproductive, 
hematologic/immunologic, endocrine/metabolic, musculoskeletal, neurologic [i.e., grossly normal, walk into office, speech normal, no tremors, alert 
and oriented], dermatologic, cardiovascular, respiratory, gastrointestinal) – including height (baseline only), weight, vital signs. 
5. Audiometry will need to be done using air conduction methodology (250, 500, 1000, 2000, 4000 and 8000 Hz). 
6. Women of child-bearing bearing potential with no prior hysterectomy and pre-menopausal must use an effective contraception method and will have 
a serum pregnancy (HCG) done every 3 months while on study treatment (see Section 6.1, #11). 
7. Medications and patient diaries will be dispensed to the subject every 3 months (month 24, 27, 30, and 33) in person or by special arrangements. 
8. Patients are to record in their 3-month diaries: medication use, presence of symptoms, and a self-assessment of presence of gross blood or melena. 
9. Lower GI (LGI) endoscopy (proctoscopy or colonoscopy) will be done on all randomized patients that have an intact colon or rectum/pouch. 
10. During the LGI procedure, normal mucosal biopsy for polyamine analysis will be obtained at months 30 and 36/EOT visits. For patients with 
permanent ileostomy, endoscopy not required; normal mucosal biopsies are performed on the visible ileostomy stoma.  
11. On-study Upper GI (UGI) endoscopy will be done on all randomized patients that have a duodenum. 
12. Monthly (± 7 days) phone/email contact by the study coordinator to follow-up on medication/drug compliance review, concomitant medications, and 
adverse events. 
13. The follow-up will be done as phone call to the patient to review medical history, surgical history for any FAP-related surgical events, concomitant 
medications and adverse events. 
14. A food frequency recall questionnaire will be administered at month 36/EOT visit. US and Canada sites only. 
15. A random urine sample (15 mL minimum) will be collected at months 24, 30 and 36/EOT visits for polyamine analysis. 
16. HRQoL surveys will include EORTC QLQ-C30 and QLQ-CR29, EQ-5D health utility index assessment, and modified Cancer Worry Scale. They 
will be collected at months 30 and 36/EOT visits. 
17. EOT visit will occur within 2 weeks off study treatment for any cause including completion of treatment at 36 months. 
18. Subject needs to be in the supine position for 10 minutes prior to the EKG, including EKGs collected during PK sampling.  
19. Medical history includes – standard review of major systems, with particular attention to cardiovascular, cerebrovascular, peripheral vascular, 
gastrointestinal and hearing issues. Interaction with outside physicians should be documented. 
20. Urinalysis panel includes – color, clarity/appearance, specific gravity, pH, protein, glucose, ketones and blood. 
21. These procedures are in addition to those listed for Month 24 on the initial treatment schedule (Table 3).  
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8.2.6 Month 24 (+/- 2 weeks) 
Subjects completing the initial 24 months of study treatment, without an FAP related event, and have 
completed the 24 month visit procedures as outlined below may be eligible to participate in the 12 month 
treatment extension (See Section 8.2.10).  For those subjects that do not go on to the treatment extension, this 
will be the end of treatment visit.  It must be documented in the subject’s medical record why the subject 
declined participation in the treatment extension if they met the requirements for participation, see Section 
8.2.10. 
All patients will have a follow-up history and physical exam/review of body systems (including, weight and 
vital signs), along with toxicity assessment.  Repeat blood laboratory tests (CBC, chemistry panel, and 
urinalysis), a random urine sample will be obtained for polyamine determination, EKG (Subject needs to be in 
the supine position for 10 minutes prior to the EKG) and audiometry will be performed. Women of child 
bearing potential will also have a serum pregnancy test performed. Concomitant medications, adverse events 
and medication compliance will also be reviewed. Quality of life questionnaires (EORTC QLQ-C30, EORTC 
QLQ-CR29, EQ-5D and the modified Cancer Worry Scale) will be provided to the subject to complete.  A 
food frequency questionnaire will be provided to the subject to complete at North American (United States and 
Canada) sites only.  
Repeat upper and lower endoscopies with image and video documentation will be obtained.  A normal mucosal 
biopsy sample for polyamine determination will be obtained during the colonoscopy/proctoscopy procedure. 
8.2.10 Treatment Extension Intervention (Months 25 - 36) 
Subjects completing the initial 24 months of study treatment, without an FAP related event, and have 
completed all the 24 month visit procedures as outlined in Section 8.2.7, and Table 3 and Table 4 may be 
eligible to participate in the 12 month treatment extension.  
In order to participate, a subject must meet the following requirements: 
1. Subject has completed 24 months of treatment without an FAP related event. 
2. Subject has completed all the month 24 visit procedures. 
3. Subject is no more than 14 days beyond the 24 month visit. 
4. Subject was randomized on or before December 31, 2015. 
5. Subject has signed the informed consent for treatment extension. 
Once the above requirements are met, the subject will have drug and diary dispensed. 
At months 25, 26, 28, 29, 31, 32, 34 and 35 a follow-up visit via phone contact to assess for side effects, other 
medications, to remind subjects to complete their diary and to continue to take their study medications. 
At the 27 month visit patients will have drug and diary dispensing. Women of child bearing potential will also 
have a serum pregnancy test performed.  Concomitant medications, adverse events and medication compliance 
will also be reviewed. 
At the 30 month visit, patients will have a physical exam/review of body systems (including weight and vital 
signs), blood samples obtained for laboratory tests (CBC, chemistry panel, urinalysis), a random urine sample 
will be obtained for polyamine determination, EKG (Subject needs to be in the supine position for 10 minutes 
prior to the EKG) and their first on study treatment upper and lower endoscopy procedures.  A normal 
rectal/pouch mucosal biopsy urine sample for polyamine determination will be obtained during the 
colonoscopy/proctoscopy procedure.  Women of child bearing potential will also have a serum pregnancy test 
performed. Concomitant medications, adverse events and medication compliance will also be reviewed. 
Quality of life questionnaires (EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and the modified Cancer 
Worry Scale) will be provided to the subject to complete. 
At the 33 month visit patients will have drug and diary dispensing. Women of child bearing potential will also 
have a serum pregnancy test performed.  Concomitant medications, adverse events and medication compliance 
will also be reviewed. 
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At the 36 month visit patients will have a physical exam/review of body systems (including, weight and vital 
signs), blood samples obtained for laboratory tests (CBC, chemistry panel, urinalysis), a random urine sample 
will be obtained for polyamine determination, audiometry testing, EKG (Subject needs to be in the supine 
position for 10 minutes prior to the EKG) and their second set of on study treatment endoscopy procedures. A 
normal mucosal biopsy sample for polyamine determination will be obtained during the 
colonoscopy/proctoscopy procedure.  Women of child bearing potential will also have a serum pregnancy test 
performed. Concomitant medications, adverse events and medication compliance will also be reviewed. 
Quality of life questionnaires (EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and the modified Cancer 
Worry Scale) will be provided to the subject to complete.  A food frequency questionnaire will be provided to 
the subject to complete at North American (United States and Canada) sites only. 
8.2.11 Treatment Extension - End of Treatment/Early Termination (+/- 2 weeks) 
Within 2 weeks of final study pill treatment for any cause, all patients will have a follow-up history and 
physical exam/review of body systems (including, weight and vital signs), along with toxicity assessment.  
Repeat blood laboratory tests (CBC, chemistry panel, and urinalysis), EKG (Subject needs to be in the supine 
position for 10 minutes prior to the EKG) and audiometry will be performed. Women of child bearing potential 
will also have a serum pregnancy test performed. Concomitant medications, adverse events and medication 
compliance will also be reviewed. Quality of life questionnaires (EORTC QLQ-C30, EORTC QLQ-CR29, 
EQ-5D and the modified Cancer Worry Scale) will be provided to the subject to complete.  A food frequency 
questionnaire will be provided to the subject to complete at North American (United States and Canada) sites 
only.  
Repeat upper and lower endoscopies with image and video documentation will be obtained at the Month 36 
visit or if the patient has completed at least 3 months of treatment from the previous on-study upper and lower 
endoscopy procedures (including baseline). A normal mucosal biopsy will be obtained during the 
colonoscopy/proctoscopy procedure and a urine sample will be collected for polyamine determination. 
If the patient has an unscheduled upper/lower endoscopy for any reason, these procedures should be captured 
with image and video documentation including the collection of a normal mucosal biopsy, if possible.  A 
normal mucosal biopsy will be obtained during the colonoscopy/proctoscopy procedure and a urine sample 
will be collected for polyamine determination. 
If there is a cumulative delay/suspension of study medication for greater than 90 days from randomization for 
any reason, the patient will need to be formally taken off-study treatment and complete the End of Treatment 
(EOT) assessments. 
8.2.12 Treatment Extension Follow-Up (30-days post end of treatment visit +/- 1 week) Off Study 
Thirty-days (30) after completion of the treatment extension evaluations, patients will be contacted by phone 
for a clinical update in regard to symptoms and interval medical history.  Concomitant medications and 
adverse events will also be reviewed. The patient will provide a clinical update and procedure date for any 
FAP-related surgical event or major endoscopic excisional event that has occurred since the last contact. These 
include partial colectomy, colectomy with IRA, total procto-colectomy, proctectomy, pouch resection, sub-
mucosal resection, trans-duodenal excision, ampullectomy, duodenectomy, or Whipple procedure. 
An FAP-related event at any disease site (colon/rectum/pouch, duodenum) will lead to discontinuation of the 
study treatment but follow-up of the subject will continue until the end of the 30 day follow-up period. 
8.2.13 Termination of Treatment Extension Procedures 
Once all randomized subjects have reached a minimum of 24 months of treatment or have come off study prior 
to reaching 24 months of treatment, the treatment extension will be closed.  Any subject that is active in the 
treatment extension will be scheduled for an end of treatment visit. This visit should be scheduled within 30 
days upon notification of the closure of the treatment extension.  Subjects may continue to take study 
medication until the end of treatment visit.  
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List of Changes for Protocol Amendment 
From Version 4.0, 14March2016 to Version 4.1, 27December2016 
Location Change Reason for Change 
Global Change Changed: Version 4.0, 14March2016 
To: Version 4.1, 27December2016 
Update protocol version 
and date 
Section 2.7.3 Added: (Actavis, formerly Watson laboratories, Inc.) Administrative change 
Section 8.2.5 At the month 6, 12 and 18, deleted repeated words “…and urine sample” Administrative change 
Section 8.2.10 at the month 30 and 36, deleted repeated words “…and urine sample” Administrative change 
Section 9.4 Changed 1st paragraph, from …+ 2 weeks to + 1 week Administrative change 
Section 11.2 Changed 1st paragraph, from …12 and 24 (end of treatment) to 12, 24 and 36 (end 
of treatment) 
Administrative change 
Section 11.9 Fixed formatting Administrative change 
Section 12.1 Deleted 3rd paragraph: “The decision to seek regulatory approval based upon the 
results of the primary objective will be taken sequentially.  If the result of 
comparison 1 is significant at level 0.05, FDA approval will be sought.  If 
comparison 1 is significant, then if the result of comparison 2 is also significant at 
level 0.05, EMA approval will be sought as well.  But if the result of comparison 
1 is not significant at level 0.05, neither FDA nor EMA approval will be sought.  
This procedure is formally equivalent to a closed sequential test procedure for 
controlling the probability of making a false claim that regulatory criteria are 
satisfied at level 0.05. 
Administrative change 
Section 12.1 Revised text from: 
If the endpoint determination cannot be made at the end of study clinic visit per 
the pre-specified study requirements, a blinded adjudication committee will 
review the reasons for such deviations.  If upon blinded adjudication it can be 
determined that a subject’s withdrawal is for reasons deemed unrelated to his or 
her endpoint status, that subject will be treated as a censored observation as of the 
last patient visit.  If upon blinded adjudication it cannot be determined that a 
subject’s withdrawal is unrelated to endpoint status, an imputed primary endpoint 
will be used in the primary analysis for such withdrawals.  The time to this 
imputed event will be from randomization to the last recorded patient visit.  All 
other subjects who complete their follow-up without a FAP-related event by the 
end of the study will be treated as a censored observation as of the actual follow-
up time for the close-out visit. 
To: If upon blinded adjudication it can be determined that a subject’s withdrawal 
is for reasons deemed unrelated to his or her endpoint status, that subject will be 
treated as a censored observation as of the last recorded clinic visit.   
If upon blinded adjudication the CEC considers the early withdrawal to be 
consistent with disease progression (not specifically an FAP-related event as 
defined in the FAP-310 protocol), the patient will be determined to have an 
imputed FAP-related event.  The time to this imputed event will be from 
randomization to the last recorded clinic visit. 
Administrative change 
Section 12.4 3rd paragraph, revised: 
To achieve this number of events, 171 subjects have been randomized and some 
will receive up to 3 years of treatment. we plan to have a 3 year study (with up to 
12 months enrollment assuming no sample size reassessment plus 2 years of 
treatment and follow-up for the last-enrolled patients). 
Administrative change 
Section 12.4.5 Revised: 
Within the entire patient population there will be subsets who did not receive the 
full course of per protocol treatment.  The patient diary and pill count will define 
the extent of compliance.  This subgroup of patients will be categorized into 
various cohorts.  For consistency, an adjudication committee will be established, 




Location Change Reason for Change 
them either as censored observations or imputed endpoints.  For exploratory and 
sensitivity analysis the following dropout subsets will be included in secondary 
analyses: 
To: Within the entire study patient population there will be subsets who did not 
receive the full course of per protocol treatment.  The major indicators for 
premature withdrawal are delineated below.  The patient diary and pill count will 
define the extent of treatment compliance during the study. 
Since the goal of this trial is to delay the time to FAP-related disease progression, 
there may be some patients with polyposis progression and/or disease related 
symptoms who will discontinue treatment.  An independent blinded Clinical 
Events Committee (CEC), also referred to as an adjudication committee will be 
established (vide infra), to review and confirm all Investigator determined FAP-
related events and to assess all other off-study subjects for symptoms or signs of 
possible disease related progression that may or may not be delineated in the 
protocol. 
For exploratory and sensitivity analyses the following dropout subsets will be 
included in secondary analyses: 
Section 12.7 Revised Sentence: For the primary time to event analysis, the only possible 
patient outcome is an observed FAP-related event, an imputed FAP-related event 
or a censored observation. 
Deleted:  
A patient will be considered a treatment failure if for any reason, the endpoint 
determination cannot be made per the pre-specified protocol.  The time to this 
imputed event will be from randomization to the last recorded patient visit.  A 
study event adjudication committee will be formed to further define the methods 
for defining imputed and censored events.  Any secondary or sensitivity analysis 
that includes this assumption will be clearly noted.  Similarly, any sensitivity 
analysis that incorporates the last observation carried forward (LOCF) method, to 
compensate for early patient dropouts or missing data, will be clearly noted. 
Added:  
Secondary analysis data include the presence of a specific genetic mutation, and 
urinary metabolite concentrations (see Section 3.2.2).  The main analysis of the 
secondary objectives will include collected data only, without imputing or 
weighting data to compensate for missing data.  For sensitivity analyses involving 
secondary endpoints with missing data, we will use the last observation carried 
forward (LOCF) method to complete the missing data.  Any sensitivity analysis 
that incorporates LOCF will be clearly noted.  Sensitivity analyses of these data 
will be performed to explore study results more fully, in a manner consistent with 
ICH Guidance “E9 Statistical Principles for Clinical Trials (February, 1998)”. 
Administrative change 
Section 12.8 2nd paragraph, 1st sentence deleted: …“at a later time”…. Administrative change 
 5th paragraph  
1st sentence added: “A pre-specified interim futility analysis will be conducted in 
a blinded manner.”  
2nd sentence deleted “adjudicated”  
Administrative change 
Section 15 Added: CEC, Clinical Events Committee (also referred to as an adjudication 
committee) 
Administrative change 
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List of Changes for Protocol CPP FAP-310 Amendment 
From Version 4.1, 27December2016 to Version 5.0, 21July2017 
Location Change Reason for Change 
Global Change Version 4.1, 27December2016 to Version 5.0, 21July2017 Protocol version, date, rev.
Global Change Fixed: Formatting 
Corrected: Typographical errors  
Updated: Table of Contents, listing of tables, reference numbers, table numbers, 
and section numbers. 
Administrative change. 
Sec 1.5  Added: Jewell Samadder M.D. as one of the study Co-Principal Investigators 
Changed: PI for Huntsman Cancer Institute from Jewell Samadder, MD to 
Priyanka Kanth, MD 
Updated address for Samir Gupta, M.D. 
Administrative change. 
Sec 1.6 Deleted: Subjects completing 24 months of treatment without an FAP event can 
continue treatment for up to 12 additional months until one of the following 
occurs: 1) subject has an FAP event or comes off study for other reasons, 2) all 
randomized subjects have reached a minimum of 24 months of treatment or have 
come off study prior to reaching 24 months of treatment or 
Revised to: Subjects completing 24 months of treatment without an FAP-related 
event may continue on treatment for up to 48 months based on their 
randomization date as follows: 
1. If randomized between November 2015 and April 2016 eligible for up to 
36 months of treatment 
2. If randomized between May 2015 and October 2015 eligible for up to 42 
months of treatment 
3. If randomized between July 2014 and April 2015 eligible for up to 48 
months of treatment 
or until one of the following occurs: 
1. Subject has an FAP-related event or comes off study for other reasons 
2. Trial end-date of April 30, 2019 has been reached 
3. 90 FAP-related events have occurred 
4. Less than 90 FAP-related events have accrued prior to April 30, 2019 
and an earlier trial end-date has been set by the Sponsor and reviewed by 
the DMC. 
5. An earlier trial end date prior to April 30, 2019 has been recommended 
by the DMC for safety reason and approved by the Sponsor
Changes maximum 
treatment duration and 
adds information on initial 
treatment and treatment 
extension. 
Sec 3.2 Revised Section 3.2 Rationale for Treatment Duration Extension up to 48 
Months. 
Section was rewritten to provide rationale for treatment extension up to 48 
months. 
Provides the rationale and 
data for treatment 
extension duration. 
Sec 3.3 Changed “36” to “48”-month maximum treatment Changes maximum 
treatment duration.
Sec 4.2 5th bullet point Revised to  
 Subjects completing 24 months of treatment without an FAP-related 
event can continue on treatment for up to 48 months based on their 
randomization date as follows: 
1. If randomized between November 2015 and April 2016 eligible 
for up to 36 months of treatment 
2. If randomized between May 2015 and October 2015 eligible for 
up to 42 months of treatment 
3. If randomized between July 2014 and April 2015 eligible for up 
to 48 months of treatment 
or until one of the following occurs:
Changes maximum 
treatment duration and 
adds information on initial 
treatment, treatment 
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1. Subject has an FAP-related event or comes off study for other 
reasons 
2. Trial end-date of April 30, 2019 has been reached 
3. 90 FAP-related events have occurred 
4. Less than 90 FAP-related events have accrued prior to April 30, 
2019 and an earlier trial end-date has been set by the Sponsor 
and reviewed by the DMC 
5. An earlier trial end date prior to April 30, 2019 has been 
recommended by the DMC for safety reason and approved by 
the Sponsor. 
Sec 4.4 Revised 1st sentence: 
“The primary objective of this trial is to determine whether the combination of 
CPP-1X plus sulindac is superior to either treatment individually, in delaying the 
time from the date of randomization to the date of the first occurrence of any 
FAP-related event in the subject as a whole.”
Clarifies time to an FAP-
related event. 
Sec 5.1 1st sentence deleted: “Hydrochloride” and “monohydrochloride monohydrate.” 
2nd sentence deleted “The clinical dosage form is a yellow, film-coated convex 
table containing 250 mg of eflornithine HCl, monohydrate. Revised with “The 
clinical dosage form of CPP-1X (eflornithine HCl) is a yellow, film-coated 
convex tablet containing 231 mg per tablet of anhydrous eflornithine HCl as 
eflornithine HCl monohydrate (250 mg per tablet).”
Clarifies drug description. 
Sec 5.2, 5.2.1, 
5.2.2 
Added: “(Actavis, formerly…) Administrative change. 
Sec 7 Revised sentence “Since an individual may have more than one disease site 
involved, the trial will assess the time from the date of randomization to the 
date of the first occurrence of any FAP-related event in the subject as a 
whole.”   




Updated: Table 4 and footnotes with assessments out to 48 months. Supports treatment 
extension duration.
Sec 8.2.4,  
Table 5 
Changed: “36” to “48” months. Supports treatment 
extension duration.
Sec 8.2.5 Paragraph 3 and 4 Added: “(+ 1 week)” 
Revised the rest of the section for consistency with Table 3 “Initial 24-month 
Treatment Intervention Assessments” 
Administrative change. 
Sec 8.2.6 Revised as follows: 
Subjects will be formally taken off-study treatment and complete the End of 
Treatment (EOT) assessments if there is a cumulative delay/suspension of study 
medication for any reason of: 
 > 90 days from randomization to month 36 
 > 105 days from randomization to month 42 
 > 120 days from randomization to month 48 
A temporary suspension from taking study medication as stated above (for 
example, due to a non-FAP disease related surgery or procedure), will be 




Sec 8.2.9 Revised Treatment Extension Intervention (Months 25-48) to be consistent with 
Table 4, FAP Study Schedule (Treatment Extension to a maximum of 48 months) 
Supports treatment 
extension duration.
Sec 8.2.10  Revised for Treatment extension – End of Treatment/Early Termination 
Repeat upper and lower endoscopies with image and video documentation will be 
obtained at the end of treatment visit if the subject has completed at least 3 months 
of treatment from the previous on-study upper and lower endoscopy procedures 
(including month-24). A normal mucosal biopsy will be obtained during the 
colonoscopy/proctoscopy procedure and a urine sample will be collected for 
polyamine determination. 
Clarifies treatment 
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Location Change Reason for Change 
If the subject has an unscheduled upper/lower endoscopy for any reason, these 
procedures should be captured with image and video documentation including the 
collection of a normal mucosal biopsy, if possible.  A random urine sample should 
be obtained for polyamine determination, if possible.
Sec 8.2.12 Changed: Once all randomized subjects have reached a minimum of 24 months 
of treatment or have come off study prior to reaching 24 months of treatment, the 
treatment extension will be closed.  Any subject that is active in the treatment 
extension will be scheduled for an end of treatment visit. This visit should be 
scheduled within 30 days upon notification of the closure of the treatment 
extension.  Subjects may continue to take study medication until the end of 
treatment visit. 
To: Subjects on the treatment extension can continue on treatment for up to 48 
months based on their date of randomization as follows: 
1. If randomized between November 2015 and April 2016 eligible for up to 
36 months 
2. If randomized between May 2015 and October 2015 eligible for up to 42 
months 
3. If randomized between July 2014 and April 2015 eligible for up to 48 
months 
or until one of the following occurs: 
1. Subject has an FAP-related event or comes off study for other reasons 
2. Trial end-date of April 30, 2019 has been reached 
3. 90 FAP-related events have occurred 
4. Less than 90 FAP-related events have accrued prior to April 30, 2019 
and an earlier trial end-date has been set by the Sponsor and reviewed by 
the DMC 
5. An earlier trial end date prior to April 30, 2019 has been recommended 




Sec 8.2.13  Added new section: Treatment Compliance  
Subjects will be formally taken off-study treatment and complete the End of 
Treatment (EOT) assessments if there is a cumulative delay/suspension of study 
medication for any reason of: 
 > 90 days from randomization to month 36 
 > 105 days from randomization to month 42 or 
 > 120 days from randomization to month 48
Supports treatment 
compliance. 
Sec 8.2.14 Revised 1st sentence to: “The time from the date of randomization to the date 
of the first occurrence of any FAP-related event at any disease site 
(colon/rectum/pouch, duodenum) will lead to discontinuation of the study 
treatment.  Follow-up of the subject for FAP-related events will continue, per 
protocol, until the end of the 30 day post-treatment.”
Clarifies time to an FAP-
related event. 
Sec 8.3.2 #6 Added: ……for any reason as follows: 
 > 90 days from randomization to month 36 
 > 105 days from randomization to month 42  
 > 120 days from randomization to month 48
Supports subject treatment 
compliance. 
Sec 10.2 Changed: months 12, 24, and 36 To months 12, 24, 36 and 48 Supports treatment 
extension duration.




Sec11.2 Changed: months 12, 24 and 36 To months 12, 24, 36 and 48  




Sec 11.5 Revised “For the EU, Reference Safety Information is located in the IB Ver CPP-
201-IB05 and subsequent versions” To “The Reference Safety Information (RSI) 
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Sec 11.7 Added: All adverse events are to be documented from the day the subject receives 
his/her first study treatment through 30 days after the subject’s off study treatment 
date (date of last dose). 
Clarifies safety reporting 
procedures. 
Sec 11.8  Revised Section:  
 A female subject is pregnant or may have become pregnant at the time of 
investigational drug exposure, the investigational drug will be immediately 
discontinued until further assessment. If it is determined that study drug should 
be permanently discontinued, all study required procedures for study 
discontinuation and follow-up must be completed unless contraindicated by the 
pregnancy.   
 For male subjects, if their partner is pregnant or may have become pregnant, the 
male subject must agree to the use of a barrier birth control method as stated in 
section 6.1 #11 [Male subjects (including men who have had vasectomies) 
whose partners are pregnant should use condoms while the partner is pregnant. 
If the partner is still pregnant when the subject goes off study, the subject should 
continue condom uses for at least 2 weeks afterwards].  If he does not agree to 
the above, he will be terminated from the study and all study required 
procedures for study discontinuation and follow-up must be completed. 
The Investigator must notify the Medical Monitor within 24 hours of learning of 
the pregnancy and record the pregnancy on the Pregnancy Reporting Form and 
submit it to Cancer Prevention Pharmaceuticals via fax or email. 
Clarifies pregnancy 
reporting and procedures. 
Sec 11.9 Added: off study treatment date, “and concomitant medications for AES recorded 
within the 30-day post-EOT.” 
Clarifies safety reporting 
procedures.
Sec 12 Revised sentence first paragraph: 
“… than each agent alone in delaying the time from the date of randomization 
to the date of the first occurrence of any FAP-related event in Familial 
Adenomatous Polyposis (FAP) patients.” 
Changed: 12 to 24 months  
Revised 4th paragraph, ITT definition as follows: 
For the primary efficacy analyses, we will use the intent-to-treat (ITT) population, 
defined as all subjects that have been randomized to one of the three study 
arms. 






Clarifies (ITT) population. 
Sec 12.1 Revised as follows 
“….is superior to either single-agent treatment individually in delaying the time 
from the date of randomization to the date of the first occurrence of any FAP-
related event.  Section 8.2.14 provides complete detail on FAP-related events. 
Thus the primary objective contains two treatment comparisons:  
1. CPP-1X placebo + sulindac active vs. CPP-1X active + sulindac 
active,  
and 
2. CPP-1X active + sulindac placebo vs. CPP-1X active + sulindac active 
 
The combination of CPP-1X active + sulindac active is specified as the reference 
treatment because it is common to both comparisons. 
The analytic method for the primary analysis will be a time-to-event analysis 
using the stratified log-rank test, as previously described. The discrete time 
version of the log-rank statistic using visit month number 0, 6, 12, 18, 24, 30, 36, 
42, 48 will be used.  Stratified discrete-time Cox proportional hazards regression 
models will be used for secondary assessments.85  Graphical analyses (log-minus-
log plots) will be used to check the assumption of constant hazard ratios.   
The analytic method for the primary analysis will be a time-to-event analysis 
using the stratified log-rank test.  Cox proportional hazards regression models will 
be used for secondary assessments85.  Graphical analyses (log-minus-log plots) 
will be used to check the assumption of constant hazard ratios.
Supports primary efficacy 
objective and analysis. 
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If an FAP-related event occurs, that patient will be said to have an observed or 
uncensored event and will be considered a treatment failure.  If a subject’s 
withdrawal is for reasons deem unrelated to his or her endpoint status, that subject 
will be treated as a censored observation as of the last recorded clinic visit 
(endoscopic disease assessment). If an FAP related event occurs, that patient will 
be said to have an observed or uncensored event and will be considered a 
treatment failure.  If upon blinded adjudication it can be determined that a 
subject’s withdrawal is for reasons deemed unrelated to his or her endpoint status, 
that subject will be treated as a censored observation as of the last recorded clinic 
visit. If upon blinded adjudication the CEC considers the early withdrawal to be 
consistent with disease progression (not specifically an FAP-related event as 
defined in the CPP FAP-310 protocol), the patient will be determined to have an 
imputed FAP-related event.  The time to this imputed event will be from 
randomization to the last recorded clinic visit. 
Sec 12.4 Revised the following: 
1) The level of statistical significance is set at 0.05, using a 2-sided log-rank test 
for time-to-first FAP-related event in discrete time (visit month number), for each 
of the two between-group comparisons (i.e. single agent sulindac vs. CPP-1X plus 
sulindac and single agent CPP-1X vs. CPP-1X plus sulindac) 
 
3) Power of at least 85% to detect the above-mentioned treatment effect 
comparing either of the two single treatment arms to the combination arm; 
Added: The following calculations are based on our review of limited single-
agent data for eflornithine and sulindac, in which the 2-year event free rates imply 
a single overall event free rate of 60% for combination treatment group and 30% 
in each single agent treatment group.   
Deleted last paragraph: This is based on our review of limited single-agent data 
for eflornithine and sulindac, in which the 2-year event free rates imply a single 
overall event free rate of 60% for combination treatment group and 30% in each 
single agent treatment group. 
Supports sample size 
determination. 
Sec 12.5.1 Revised ITT definition: “The intent-to-treat population includes all patients that 
have been randomized to one of the three study arms (CPP-1X plus sulindac,…..)” 
Clarifies (ITT) population. 
Sec 12.5.4 Added: These results will be for quality assurance purposes and will not be used 
for the primary endpoint analysis to assess clinical benefit. 
 CEC reviewed and adjudicated subject outcomes 
Deleted: the following dropout subsets
Clarifies (ITT) population. 
Sec 12.6.2 Deleted: …non-compliance for more than 90 days, withdrawals … Administrative change.
Sec 12.6.5 Added:  42 and 48 assessment points 
5th para deleted: “This trial has three strata and three treatment options with 150 




Sec 12.6.6 Added: 36, 42 and 48 assessment points. Supports treatment 
extension duration.
Sec 12.7 3rd paragraph deleted: “(See Section 3.2.2) Administrative change.
Sec 12.8 5th paragraph changed from: 
For the futility interim analysis, the futility stopping criterion of Z=0.50 is one-
sided, and corresponds to a conditional power criterion of approximately 0.12 (to 
two decimals).  That is, assuming between 52 and 55 expected total number of 
events have occurred by trial end in either of the two-arm comparisons, if the log-
rank critical ratio Z-score were equal to 0.5 (or less) when one-half the expected 
total number of events had been observed, then under the design alternative 
hazard ratio of 0.4243, there would be only a 12% probability (or less) of 
declaring a significant benefit of the combination therapy compared to the single 
agent therapy if the trial were to continue to the planned end. In that case, it would 
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be reasonable for the DMC to consider stopping the trial for futility.  The futility 
analysis results will be presented in a simple manner whereby the DMC will be 
informed that the conditions indicating futility have been met (i.e. the futility 
boundary has been crossed, yes or no).  Unless the DMC requires it on ethical 
grounds, no early stopping for positive efficacy is proposed. 
 
To: The futility analysis will be performed for each of the two treatment 
comparisons contained in the primary objective:  
1. CPP-1X placebo + sulindac active vs. CPP-1Xactive + sulindac 
active,  
and 
2. CPP-1X active + sulindac placebo vs. CPP-1X active + sulindac 
active  
The futility analysis efficacy component will use a modified Haybittle-Peto 
stopping rule based on the stratified log-rank Z-score.  If that Z-score equals or 
exceeds 3.2905 in absolute value, for either two-arm comparison, the difference 
between treatment arms would be declared statistically significant at the two-
tailed 0.001 level of significance.  In that case it may be reasonable for the DMC 
to initiate a conversation about stopping the trial on ethical grounds.  Assuming 
this is not the case and the trial continues to its planned end, the Z-score criterion 
for declaring significance at the 5% level at the end of the trial will be increased in 
magnitude to plus or minus 1.962 in order to preserve the overall type I error rate 
for the trial at 0.05. 
 
For the futility analysis, the DMC will be provided with the numerical value of the 
stratified log-rank Z-score.  The futility analysis uses a one-sided futility stopping 
criterion of Z = −0.50. That is, if the Z-score is less than or equal to −0.50, an 
investigation will be initiated to consider stopping the trial for futility or 
discontinuing one of the single-agent treatment arms.  The futility stopping 
criterion of Z = −0.50 is consistent with a conditional power of less than 20%.  
That is, assuming between 44 and 60 FAP-related events have occurred by trial 
end in either of the two-arm comparisons (where between 52 and 55 are 
expected), if the log-rank critical ratio Z-score were equal to −0.5 (or less) when 
one-half the expected total number of events had been observed (namely, 45 
across all three arms), then under the design alternative hazard ratio of 2.3569, 
there would be no more than a 20% chance of declaring a significant benefit of the 
combination therapy compared to the single agent therapy if the trial were to 
continue to the planned end. In that case, it would be reasonable for the DMC to 
consider stopping or altering the trial on grounds of futility.  The DMC will also 
be provided with the conditional power of the observed Z-score for each two-arm 
comparison. 
Any numerical values generated from the futility analysis (such as Z-score, 
conditional power, etc.) must be treated as confidential by the DMC and 
Independent Statistician at the CRO.  If the DMC recommendation is to continue 
the study as planned, such numerical values will not be forwarded or conveyed in 
any manner to the Steering Committee, sponsor, or any other parties. 




Study ID: CPP FAP-310 A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of 
CPP-1X / Sulindac Compared with CPP-1X, Sulindac as Single Agents in Patients with Familial 
Adenomatous Polyposis (FAP)  
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Global  Version 5.0, 21July2017 to Version 5.1 09April2018 Admin. change.
Sec. 4.3 Changed “A total of 150 eligible patients…” To “At least 150 eligible patients… Admin. Change for 
consistency with Sec. 
12.0
Sec. 12.0 3rd para 
Revised “A total of 150 eligible patients will be enrolled in this study, 50 per treatment 
group.” To “At least 150 eligible patients will be enrolled in this study, with at least 50 per 
treatment group.” 
To be consistent with 
language in SAP Ver. 
5.0, April 02, 2018. 
Sec. 12.1 5th para 
Deleted “The discrete time version of the log rank statistic using visit month number 0, 6, 
12, 18, 24, 30, 36, 42, 48 will be used.” 
Changed “Stratified discrete time…” To The stratified Cox proportional hazards…..” 
 
7th para, 2nd sentence 




Revised “Prior to the primary analysis, balance will be assessed between the three arms in 
terms of key potential confounders measured at the baseline visit.  If any of these variables 
is found significantly out of balance across the three groups using a 2 degree of freedom 
test of homogeneity at the 0.01 level of significance, it will be incorporated into the 
primary analysis using a stratified Cox model including that term in addition to the 
treatment arm.  The covariate-adjusted score test (adjusted stratified log-rank test) will 
serve as the primary result for the trial.”  
To “Prior to the primary analysis, balance will be assessed between the three arms in terms 
of key potential confounders measured at the baseline visit.  If any of these variables is 
found significantly out of balance across the three groups using a 2 degree of freedom test 
of homogeneity at the 0.01 level of significance, it will be incorporated into -a sensitivity 
analysis using a stratified Cox model including that term in addition to the treatment arm.  
The primary result for the trial will be the unadjusted stratified log-rank test.  The 
covariate-adjusted score test (adjusted stratified log-rank test) will serve only as a 
secondary analysis to aide in the interpretation of the primary result. 
To be consistent with 
language in SAP Ver. 
5.0, April 02, 2018. 
Sec. 12.4 Deleted and Revised text that follows. 
Deleted “For the purposes of power calculations, we assume the following:  
1) The level of statistical significance is set at 0.05, using a 2-sided log-rank test for 
time-to-first FAP-related event in discrete time (visit month number), for each of the 
two between-group comparisons (i.e. single agent sulindac vs. CPP-1X plus sulindac 
and single agent CPP-1X vs. CPP-1X plus sulindac) 
2) A doubling of the time to occurrence of the primary event from either of the single 
agent treatment arms to the combination treatment group; 
3) Power of at least 85% to detect the above-mentioned treatment effect comparing 
either of the two single treatment arms to the combination arm; 
4) The two single-agent treatment groups have the same event rate. 
The following calculations are based on our review of limited single-agent data for 
eflornithine and sulindac, in which the 2-year event free rates imply a single overall event 
To be consistent with 
language in SAP Ver. 
5.0, April 02, 2018. 
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free rate of 60% for combination treatment group and 30% in each single agent treatment 
group.   
For this situation, 49 events would be needed for the two-group situation at the 2-sided 
0.05 level with 85% power and the doubling of the time to primary event.88,89 Assuming 
two-year event proportions of 70% in either of the two single-agent groups and 40% in the 
combination arm with 50 patients per arm, the expected number of patients with an FAP-
related event in either of the two single-agent groups would be 35 and 20 in the 
combination arm.  Thus we expect to have 55 patients with a FAP-related event in each 
comparison, achieving almost 89% power.  The standard deviation around this expectation 
is 4.74, so we would be highly likely to observe at least the required 49 events.  Even if the 
total number of events in either comparison were only 43, there will still be 80% power to 
detect the design effect size, namely, a hazard rate ratio of (log 0.30)/(log 0.60) 
corresponding to the doubling of event-free follow-up over two years (approximately equal 
to 2.3569).  For completeness, the design effect size is equivalent to a hazard rate ratio of 
(log 0.60)/(log 0.30) for the combination treatment relative to a single-agent treatment 
(approximately equal to 0.42428). 
In total we expect to observe 35+35+20=90 primary endpoints among the three groups 
(plus or minus 5.7).” 
Revised to “The primary endpoint of this trial, time to meaningful clinical events in an 
orphan disease population, is novel and to date there are no published trials to draw upon 
that have incorporated the exact FAP-related endpoint of this trial.  Available data from 
primary literature sources include clinical studies where polyps were counted over a fixed 
time period, in different FAP populations (see Appendix E for tabulated listing).   
From these data a reasonable range of event frequencies was estimated to produce the 
sample size and power calculations incorporated into this trial.  These time-to-event 
estimates were reviewed by key FAP opinion leaders prior to finalization of the study 
design.  The following reflects the possible range of FAP events it was thought plausible to 
observe. 
For the purposes of power calculations, we assume the following:  
1) The level of statistical significance is set at 0.05, using a 2-sided stratified log-rank test 
for time-to-first FAP-related event in continuous time, for each of the two between-
group comparisons (i.e. single agent sulindac vs. CPP-1X plus sulindac and single agent 
CPP-1X vs. CPP-1X plus sulindac).  The only covariates in the log-rank test will be the 
treatment groups; 
2) A doubling of the two-year event-free proportion from either of the single agent 
treatment arms to the combination treatment group;  
3) Power of at least 85% to detect the above-mentioned treatment effect comparing either 
of the two single treatment arms to the combination arm; 
4) The two single-agent treatment groups have approximately the same event rate. 
The following calculations are based on our review of limited single-agent data for 
eflornithine and sulindac, where FAP clinical trial primary endpoints involved polyp 
counting.  Extrapolating these data to two-year event-free proportions implies a single 
overall two-year event-free proportion of at least 60% to 70% for the combination 
treatment group and 30% in each single agent treatment group.   
Because the power of time-to-event analyses depends on the total number of observed 
primary endpoints (“events”) and the hazard ratio in a given two-arm comparison of a 
single-agent versus combination therapy, we translate the above doubling of two-year 
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event-free proportions into hazard ratios under a simplifying assumption of exponentially 
distributed time-to-event.   
Furthermore, the stratified log-rank test is an optimal test (locally most powerful) under the 
assumption that the ratio of the two groups’ hazard functions remains constant over time 
(the proportional hazards assumption).  Note that the much stronger assumption, that the 
individual hazard functions themselves remain constant over time, would be dubious in this 
trial.  Therefore, irrespective of how the two-year event-free proportions are translated into 
hazard ratios, it is the latter which forms the design alternative parameter for the trial. 
Under the exponential assumption, the hazard ratio (HR) comparing one treatment arm to 
another is given by the natural logarithm of the two-year event-free proportion for the first 
arm divided by the natural logarithm of the two-year event-free proportion for the other 
arm.  Thus if the combination arm is assumed to have a two-year event-free proportion of 
60%, which is double that of the 30% two-year event-free proportions assumed for the 
single-agent arms, the HR is {log(0.60) / log(0.30)} = 0.4243.  This is the design 
alternative hazard ratio for this trial as it represents the minimum clinically meaningful 
treatment effect desired for the combination therapy compared to either single-agent 
therapy.  Insofar as the combination therapy may have a two-year event-free proportion of 
at least 60%, and may prove to be perhaps 70% or greater, the design alternative HR of 
0.4243 is conservative; the true (albeit unknown) HR is thought possibly to range from 
0.4243 down to 0.30 = {log(0.70) / log(0.30)}. 
Given that the primary hypotheses are stated in terms of comparing either single-agent arm 
to the combination arm, we note that the equivalent design alternative hazard ratio becomes  
{log(0.30) / log(0.60)} = 1/0.4243 = 2.357. 
For the anticipated range of hazard ratios, 25 to 49 events would be needed for each two-
group comparison at the 2-sided 0.05 level to achieve 85% power. 88,89  Assuming two-year 
event proportions of 70% in either of the two single-agent groups and 30% to 40% in the 
combination arm with 50 patients per arm, the expected number of patients with an FAP-
related event in either of the two single-agent groups would be 35 and 15 - 20 in the 
combination arm.  The study design expectation is to have 50 - 55 patients with a FAP-
related event in each two arm comparison, achieving at least 85% power under the design 
alternative.  The standard deviation around the expectation of 55 events is 4.74, so 
observing the required number of 49 events or more would be highly likely (the probability 
is about 91%).  If the total number of events in either comparison were only 43, there will 
still be 80% power to declare a significant treatment difference under the design alternative 
of 0.4243.   
As the two-year event proportion in the combination arm decreases from 40% with a 
corresponding decrease in the hazard ratio, the likelihood of observing the required number 
of events to maintain 85% power actually increases.  For example, at the lower expectation 
of 50 events arising from an assumed two-year event proportion of 30% in the combination 
arm, the standard deviation of the total number of events in a two-arm comparison 
decreases to 4.58 and the probability that the observed number of events will exceed the 25 
required to achieve 85% at a HR of 0.30 is virtually certain.” 
Sec. 12.5.4 Deleted “Since the goal of this trial is to delay the time to FAP-related disease progression, 
there may be some patients with polyposis progression and/or disease related symptoms 
who will discontinue treatment.  An independent blinded Clinical Events Committee 
(CEC), also referred to as an adjudication committee will be established (vide infra), to 
review and confirm all Investigator determined FAP-related events and to assess all other 
off-study subjects for symptoms or signs of possible disease related progression that may 
or may not be delineated in the protocol.  These results will be for quality assurance 
purposes and will not be used for the primary endpoint analysis to assess clinical benefit.” 
 “CEC reviewed and adjudicated subject outcomes”
To be consistent with 
language in SAP Ver. 
5.0, April 02, 2018. 
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From Version 5.0, 21July2017 To Version 5.1, 09April2018 
Location Change Reason for Change 
Sec. 12.6.6 Added “(only if end of treatment)” after 42 months  
Sec. 12.7 Deleted “Secondary analysis data include the presence of a specific genetic mutation, and 
urinary metabolite concentrations (see Section Error! Reference source not found.).  The 
primary analysis of the secondary objectives will include collected data only, without 
imputing or weighting data to compensate for missing data.  Sensitivity analyses of these 
data will be performed to explore study results more fully, in a manner consistent with ICH 
Guidance “E9 Statistical Principles for Clinical Trials (February, 1998)”. 
Administrative, 
repeat of the 3rd 
paragraph. 




Study ID: CPP FAP-310 A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of 
CPP-1X / Sulindac Compared with CPP-1X, Sulindac as Single Agents in Patients with Familial 
Adenomatous Polyposis (FAP)  
List of Changes for Protocol CPP FAP-310 Amendment 
From Version 5.1, 09April2018 to Version 5.2, 17January2019 
Location Change 
Global Version 5.1 09April2018 to Version 5.2, 17January2019 
 
All administrative revisions in this amendment were made to be consistent with the language in the 
SAP Ver. 5.1 and Ver. 5.2. 
Global Updated: Table of Contents, listing of tables, reference numbers, and section numbers. 
Updated: Minor typographical errors 
Sec. 4.5 Deleted: 
Secondary efficacy outcomes in this study will include the following: 
To evaluate the potentially effect modifying properties of: 
a. Presence or absence of an ODC polymorphism 
b. The excretion of 4 urinary polyamines (diacetylspermine, n1-acetylspermidine, n8-
acetylspermidine and decarboxylated SAM). 
Revised to: 
Secondary Efficacy Analyses: 
Any improvement observed by the investigator during upper gastrointestinal (UGI) and lower 
gastrointestinal (LGI) visualization (i.e. endoscopy and colonoscopy) at the 6 and 12-month study 
visits will be described using the variables UGI Observed Improvement (UGIOI), and LGI 
Observed Improvement (LGIOI).  Each patient will have one pair of UGIOI and LGIOI outcomes 
(refer to Protocol Section 12.0 and the Statistical Analysis Plan for more detail). 
 
Deleted:  
1. Median time to event for each treatment group will be determined. This will be explored 
for each of the study populations (i.e. ITT, per protocol, and others). 
2. Safety outcomes will be assessed by summary analysis of adverse events and clinical 
laboratory abnormalities. 
3. Pharmacokinetic outcomes will be assessed by evaluating the population pharmacokinetics 
for CPP-1X (eflornithine) and sulindac. 
4. Evaluate tissue and dietary polyamine levels. 
5. Subject reported quality of life will be evaluated using HRQoL and subject utilities. 
6. A pilot evaluation of an FAP-specific assessment, the time to the first FAP-related 
beneficent event, will be studied.  This will involve analyzing the endoscopic polyposis 
data for regression of pre-colectomy colorectal polyposis, rectal/pouch polyposis, and 
regression of duodenal polyposis. 
7. An analysis of the components and subgroups included in the primary analysis, and their 
contribution to the primary outcome. 
Revised with: 
Other Secondary Outcomes in this Study Include the Following:  
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List of Changes for Protocol CPP FAP-310 Amendment 
From Version 5.1, 09April2018 to Version 5.2, 17January2019 
Location Change 
To explore how study treatment group relates to other efficacy outcomes, genotype, phenotype, 
disease locations and endoscopic findings, additional analyses are planned (refer to the Statistical 
Analysis Plan for more details).   
The UGIOI and LGIOI outcomes will be tabulated and summarized using the month 6 visit scores, 
alone.  Similarly, the UGIOI and LGIOI outcomes will tabulated and summarized across all study 
visits. 
As both part of the primary analysis, and further explored in these additional analyses, median time 
to event for each treatment group will be determined.  This will be explored for each of the study 
populations (i.e. ITT, per protocol, and others), study disease stratum groups, and in the disease site 
subgroups. 
Pharmacokinetic data (plasma concentrations measured at patient visits) will be used to estimate 
population pharmacokinetic parameters for the CPP-1X (eflornithine), sulindac, and CPP-1X 
(eflornithine) + sulindac treatment groups (i.e., for each analyte for those patients on combination 
treatment). 
The subcategories of FAP events will be explored by disease stratum groups, and by disease site 
subgroups.  
The presence or absence of ODC polymorphisms, including the single nucleotide polymorphisms 
(SNPS) rs2302615 and rs2302616 and their relation to treatment group and outcome will be tested 
with the likelihood ratio test. 
The excretion of 5 urinary polyamines (diacetylspermine, n1-acetylspermidine, n8-
acetylspermidine, decarboxylated SAM, and putrescine) will be assessed in relation to treatment 
group and outcome, using the single point concentration data gathered from the urine samples 
harvested at each study visit. 
Patient reported health related quality of life measures will be evaluated using HRQoL.  
Tissue and dietary polyamine levels, as collected at patient study visits will be analyzed together 
with the results of the dietary questionnaires and related to treatment group and study outcomes. 
Safety outcome data and analyses are described in detail in the Statistical Analysis Plan. 
Sec. 12.1 Added after 2nd paragraph: 
These two treatment comparisons will be performed sequentially as described below. 
The combination of CPP-1X active + sulindac active is specified as the reference treatment group 
because it is common to both comparisons.  In addition, because the purpose of the combination 
treatment is to delay the time from randomization to FAP-related disease progression compared to 
single-agent treatments, formulating the hypothesis tests in this manner will allow a positive rather 
than a negative Z-score for the test statistic to be interpreted as supportive of this purpose. 
Each comparison will be performed at the 2-sided 0.05 level of statistical significance. 
As explained in the Statistical Analysis Plan, the decision to seek regulatory approval based upon 
the results of the primary objective will be taken sequentially. 
CPP will sequentially perform the two primary comparisons as part of the primary analysis, each at 
the 2-sided p = 0.05 level.  All information concerning these comparisons will be clearly provided 
to both Agencies.  The single treatment comparison requested by FDA will be available, as will the 
two comparisons requested by EMA, both at the requested level of alpha.  This approach fulfills 
the differing requirements for the primary comparison as asked for by each Agency.  
We note that this approach is both a fixed-sequence and gatekeeping approach.  It is fixed-
sequence in that the comparison of combination with single-agent Sulindac takes place before the 
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From Version 5.1, 09April2018 to Version 5.2, 17January2019 
Location Change 
comparison of combination with single-agent Eflornithine and the first serves as a gatekeeper for 
the second (i.e., no declaration of significance in the second comparison will be made if the first 
comparison is not significant at the 0.05 level).  Therefore, the type I error in the sequential testing 
is well controlled.  In addition, because both tests must be significant for EMA approval, the type I 
error of the second test in the sequence is less than 0.05. 
Deleted:  
The combination of CPP-1X active + sulindac active is specified as the reference treatment because 
it is common to both comparisons. 
Each comparison will be performed at the 2-sided p = 0.05 level. 
deleted from 9th paragraph: “as previously described.” 
Added new 11th paragraph: 
“If a subject has not progressed or is not known to have died at the date of analysis cut-off, time to 
first FAP-related event will be censored at the date of the last adequate endoscopy procedures 
before the cut-off date.  Similarly, if a subject discontinues study participation due to toxicity and 
begins receiving other therapy, the time to FAP event will be censored at the date of the last 
adequate endoscopy procedure.” 
Sec. 12.2 Deleted: 
Secondary efficacy outcomes in this study will include the following: 
To evaluate the potentially effect modifying properties of: 
a. Presence or absence of an ODC polymorphism 
b. The excretion of 4 urinary polyamines (diacetylspermine, n1-acetylspermidine, n8-
acetylspermidine and decarboxylated SAM) 
These secondary variables will be assessed regardless of study outcome, but their use as potential 
label claims will only apply if a statistically significant treatment effect is found in the primary 
analysis.  For the secondary efficacy analysis, for each secondary variable, a corresponding term 
will be added to the primary analysis as well as an interaction term (product of the treatment 
indicator and secondary variable).  The coefficient of the interaction term (only) will be tested to 
determine if the secondary variable alters the magnitude of the treatment effect. Corresponding to 
each of the two primary analyses, the Hochberg step-up method will be employed to control the 
overall family-wise error rate with overall alpha set at the two-sided 0.05 level. 
Added: 
Any improvement observed by the investigator during upper gastrointestinal (UGI) and lower 
gastrointestinal (LGI) visualization (i.e. endoscopy and colonoscopy) at the 6 and 12-month study 
visits will be described using the variables UGI Observed Improvement (UGIOI), and LGI 
Observed Improvement (LGIOI).  Each patient will have one pair of UGIOI and LGIOI outcomes 
(refer to the Statistical Analysis Plan for more detail). 
UGIOI and LGIOI are binary outcomes derived from numerical determinations (henceforth, 
“investigator change scores” or more briefly, “scores”) assigned by the investigator during each 
procedure, using a scale (–2, –1, 0, +1, +2) which corresponds, respectively, to the investigator’s 
overall qualitative assessment of: much worse, worse, no change, improved, much improved.  At 
the month 6 procedures the investigator scores UGI and LGI findings as changes from baseline.  At 
the month 12 procedures, the UGI and LGI findings are scored relative to the month 6 procedures. 
The UGIOI (and respectively, the LGIOI) secondary endpoint independently summarizes the 
corresponding 6- and 12-month investigator change scores according to whether or not there was 
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Location Change 
any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to 
baseline or month 6), under the condition that there be no worsening at either timepoint (compared 
to the preceding timepoint).  Refer to the Statistical Analysis Plan for further details on the planned 
analysis.  
12.3 Deleted:  
1. Median time to event for each treatment group will be determined. This will be explored 
for each of the study populations (i.e. ITT, per protocol, and others). 
2. Safety outcomes will be assessed by summary analysis of adverse events and clinical 
laboratory abnormalities. 
3. Pharmacokinetic outcomes will be assessed by evaluating the population pharmacokinetics 
for CPP-1X (eflornithine) and sulindac. 
4. Evaluate tissue and dietary polyamine levels. 
5. Patient reported quality of life will be evaluated using HRQoL and patient utilities. 
6. A pilot evaluation of an FAP-specific assessment, the time to the first FAP-related 
beneficent event, will be studied.  This will involve analyzing the endoscopic polyposis 
data for regression of pre-colectomy colorectal polyposis, rectal/pouch polyposis, and 
regression of duodenal polyposis. 
7. An analysis of the components and subgroups included in the primary analysis, and their 
contribution to the primary outcome. 
Added: 
To explore how study treatment group relates to other efficacy outcomes, genotype, phenotype, 
disease locations and endoscopic findings, additional analyses are planned.  These analyses will be 
performed in the ITT group, the Per Protocol Group, and other defined subgroups (see protocol 
Section 12.5, Populations for Analysis and the Statistical Analysis Plan) wherever possible and will 
all be clearly noted as such. 
The UGIOI and LGIOI outcomes will be tabulated and summarized using the month 6 visit scores, 
alone.  Similarly, the UGIOI and LGIOI outcomes will tabulated and summarized across all study 
visits. 
As both part of the primary analysis, and further explored in these additional analyses, median time 
to event for each treatment group will be determined. This will be explored for each of the study 
populations (i.e. ITT, per protocol, and others), study disease stratum groups, and in the Disease 
Site subgroups (refer to the Statistical Analysis Plan for more details). 
Pharmacokinetic data (plasma concentrations measured at patient visits) will be used to estimate 
population pharmacokinetic parameters for the CPP-1X (eflornithine), sulindac, and CPP-1X 
(eflornithine) + sulindac treatment groups (i.e., for each analyte for those patients on combination 
treatment). 
The subcategories of FAP events will be explored by disease stratum groups, and by Disease Site 
subgroups (refer to the Statistical Analysis Plan). 
The presence or absence of ODC polymorphisms, including the single nucleotide polymorphisms 
(SNPS) rs2302615 and rs2302616 and their relation to treatment group and outcome will be tested 
with the likelihood ratio test. 
The excretion of 5 urinary polyamines (diacetylspermine, n1-acetylspermidine, n8-
acetylspermidine, decarboxylated SAM, and putrescine) will be assessed in relation to treatment 
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Location Change 
group and outcome, using the single point concentration data gathered from the urine samples 
harvested at each study visit. 
Patient reported health related quality of life measures will be evaluated using HRQoL (refer to 
Statistical Analysis Plan for more details). 
Tissue and dietary polyamine levels, as collected at patient study visits will be analyzed together 
with the results of the dietary questionnaires and related to treatment group and study outcomes. 
Safety outcome data and analyses are described in detail in the Statistical Analysis Plan. 
Sec. 12.4 Deleted statement after 2nd paragraph: “For the purpose of power calculations, we assume the 
following:” and Inserted section title: 12.4.1 Power Calculation Assumptions: 
After 2nd paragraph from section 12.4.1, inserted section title: 12.4.2 Hazard Rates 
Sec. 12.8 Added above paragraph 5 header: “Prespecified Interim Efficacy and Futility Analysis”  
Revised first sentence under this header to: “A pre-specified interim efficacy and futility 
analysis…” Deleted from 2nd sentence: “futility”; added last sentence: Refer to the Statistical 
Analysis Plan for more details. 
Changed, 2nd paragraph: “The futility analysis To “The analysis……” 
Changed:  3rd paragraph: The futility analysis efficacy component… To: the efficacy analysis… 
Sec. 15 Deleted from the listing of Abbreviations 
CEC, Clinical Events Committee (also referred to as an adjudication committee) 
Added: LGIOI: LGI Observed Improvement; UGIOI: UGI Observed Improvement 
END of Changes 
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1. LIST OF ABBREVIATIONS 
Abbreviation Term 
AE Adverse Event
ANCOVA Analysis of covariance
CPP Cancer Prevention Pharmaceuticals, Inc.
CPP-1X Eflornithine, DFMO, Difluoromethylornithine
CTCAE Common Terminology Criteria for Adverse Events
DMC/DSMB Data Monitoring Committee/Data Safety Monitoring Board 
EFS Event-Free Survival
EMA European Medicines Agency 
EORTC European Organisation for Research and Treatment of Cancer 
FAP Familial Adenomatous Polyposis
FDA Food and Drug Administration
FFQ Food Frequency Questionnaire
HRQoL Health Related Quality of Life
ICH International Conference on Harmonization 
ITT Intent-To-Treat
LOCF Last Observation Carried Forward
NASR 
Nutrition Assessment Shared Resource (Fred Hutchinson Cancer 
Research Center)
NCI National Cancer Institute
ODC Ornithine Decarboxylase
QLQ Quality of Life Questionnaire
SAM S-Adenosyl Methionine
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SAS Statistical Analysis System
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2. INTRODUCTION 
This Statistical Analysis Plan (SAP) describes the proposed statistical analysis of the Cancer 
Prevention Pharmaceuticals, Inc. (CPP) study CPP FAP-310 entitled: “A DOUBLE-BLIND, 
RANDOMIZED, PHASE III TRIAL OF THE SAFETY AND EFFICACY OF CPP-1X/SULINDAC 
COMPARED WITH CPP-1X, SULINDAC AS SINGLE AGENTS IN PATIENTS WITH FAMILIAL 
ADENOMATOUS POLYPOSIS (FAP)”. 
The purpose of this document is to apply sound analytic principles through description and pre-
specification of the statistical approaches and data handling conventions for key analyses and the 
randomization processes. 
This plan will focus on analysis of the primary and secondary endpoints, intended to assess the 
extent to which the combination treatment (CPP-1X 750 mg daily + sulindac 150 mg daily) is 
more effective than each of the two single agent treatments alone (CPP-1X 750 mg daily + 
placebo, and sulindac 150 mg daily + placebo) in delaying the time to the first FAP-related event 
in FAP patients. Sample size and total FAP related events will be discussed, along with study 
population definitions.  In addition, we will summarize our approach regarding the analysis of 
safety data, pharmacokinetic data, and patient reported quality of life data.  The composition, 
charter, and initial tasks of the Data Monitoring Committee (DMC) will be described, along with 
planned interim analyses. 
 
3. STUDY OBJECTIVES AND ENDPOINTS 
3.1 Overview of Study 
This is a randomized, double-blind, phase III trial in patients with FAP to evaluate the safety and 
efficacy of the combination product 750 mg CPP-1X + 150 mg sulindac versus each of the two 
single-agent products: 1) 750 mg CPP-1X; and 2) 150 mg sulindac.  The primary study 
comparisons will be made between the combination product and each single agent product, 
separately. 
Eligible patients who have given informed consent will enter the study with the intent to 
participate for the full treatment period of 24 months.  Accrual is expected to take 6 – 12 months.  
A stratified randomization procedure will be used based on FAP-related time-to-first-event 
prognosis.  The event prognosis groups are represented by 1) best (i.e., longest projected time to 
first FAP-related event) - rectal/pouch polyposis, 2) intermediate - duodenal polyposis, and 3) 
worst - pre-colectomy.  If a subject has two or more of these disease sites, the most severe 
prognosis stratum will be assigned for randomization (e.g. worst > intermediate > best).  Since 
an individual may have more than one disease site involved, the trial will assess time to any 
defined FAP-related event in the patient as a whole.  In order to minimize potential treatment 
arm imbalance a centralized randomization process will be used to balance treatment groups 
within disease prognostic strata. 
The stratification is predicated on the following projected event rates for the disease site specific 
eligibility criteria (rectal/pouch polyposis, duodenal polyposis, pre-colectomy) which are 
provided in the clinical study protocol (Appendix D) and summarized in Table 3.1. 
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Table 3.1 Projected Event Free Rate by Disease Site  
Disease Site Projected 2-year Event Free Rate Without Treatment
Rectum/Pouch Polyposis Excisional intervention and/or high risk adenoma – 40 - 60% 
Duodenal Polyposis Excisional intervention, Spigelman stage progression, cancer – 50%
Pre-colectomy Colectomy, proctocolectomy – 10%
 
The stratified randomization will be reflected in stratified analyses for the primary and secondary 
endpoints.  For design purposes only, however, the following simplified assumptions were made: 
an overall event free proportion of 30% in the single agent treatment group and 60% in the 
combination treatment group after 24 months of study treatment.  This is described further in 
Table 3.2 below.  See Section 5.1 for sample size and power calculations. 
Table 3.2 Overall Event Free Proportions After Two Years of Follow-up* 
Treatment S(t) t (months) Median Time to Event (months)
Combination 0.6 24 32.566
Single Agent 0.3 24 13.817
*These proportions are assumed for design purposes only.  The median times to event are based on the 
assumption of an exponential time-to-event function S(t) in each group. 
 
A total of 150 eligible patients will be enrolled in this study, 50 per treatment group.  Patients 
will be randomized to one of three treatment groups within the prognostic strata defined above in 
equal proportions (i.e., 1:1:1 randomization): 1) CPP-1X plus sulindac, 2) CPP-1X placebo plus 
sulindac, 3) CPP-1X plus sulindac placebo.  The study is double blinded, so neither patients nor 
Investigator nor Sponsor will be aware of treatment assignment. 
The grading of adverse events will be based on the current version of the NCI Common 
Terminology Criteria for Adverse Events (CTCAE Version 4). 
Refer to the CPP FAP-310 protocol for the details of the treatment and study schedule, and 
description of study procedures and tests. 
3.2 Study Objectives and Primary Hypothesis Testing 
The primary study analysis will be performed using the intent-to-treat (ITT) population (see 
Section 4.1) 
The primary objective of this trial is to determine whether the combination of CPP-1X + sulindac 
is superior to either single-agent treatment individually in delaying time to the first occurrence of 
any FAP-related event. 
Thus the primary objective contains two treatment comparisons:  
1. CPP-1X active + sulindac active vs. CPP-1X placebo + sulindac active,  
and 
2. CPP-1X active + sulindac active vs. CPP-1X active + sulindac placebo  
Each comparison will be performed at the 2-sided p = 0.05 level.  
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As explained in Section 3.2.1 below, the decision to seek regulatory approval based upon the 
results of the primary objective will be taken sequentially. 
If the result of comparison 1 is significant at level 0.05, FDA approval will be sought.  If 
comparison 1 is significant, then if the result of comparison 2 is also significant at level 0.05, 
EMA approval will be sought as well.  But if the result of comparison 1 is not significant at level 
0.05, neither FDA nor EMA approval will be sought.  This procedure is formally equivalent to a 
closed sequential test procedure for controlling the probability of making a false claim that 
regulatory criteria are satisfied at level 0.05. 
3.2.1 Regulatory Review of Primary Outcome Compliance 
CPP has received advice from both the FDA and the EMA concerning the test method and 
criteria (Sections 3.2 and 5) to be used when analyzing the primary study outcome, including the 
value of alpha. 
The US Food and Drug Administration (FDA) noted that the comparison of CPP-1X + sulindac 
vs. CPP-1X + placebo will not provide information about the treatment effect of CPP-1X (i.e. 
eflornithine), and therefore this result will not be included in the product label.  Therefore the 
primary analysis of import to FDA is the comparison of CPP-1X + sulindac vs. sulindac + 
placebo. 
The European Medicines Agency (EMA) noted that for the three arm trial design the superiority 
of the combination treatment must be tested against both mono-components.  The combination 
treatment must be shown to be superior to both mono-components, or else the results will be 
considered inconclusive.  As a consequence, consistent with EMA/SWAP commentary, alpha 
does not need to be adjusted for multiplicity and two separate 5% two-sided test will suffice. 
To harmonize the advice provided by these two Agencies, CPP will perform two comparisons as 
part of the primary analysis, each at the 2-sided p = 0.05 level.  All information concerning these 
comparisons will be clearly provided to both Agencies.  The single treatment comparison 
requested by FDA will be available, as will the two comparisons requested by EMA, both at the 
requested level of alpha.  This approach fulfills the differing requirements for the primary 
comparison as asked for by each Agency.  
3.2.2 Secondary Efficacy Analyses 
1. To evaluate the potentially effect-modifying properties of: 
a. Presence or absence of an ODC polymorphism. 
b. To evaluate the excretion of 4 urinary polyamines (diacetylspermine, n1-
acetylspermidine, n8-acetylspermidine, and decarboxylated SAM). 
These five secondary variables will be assessed regardless of study outcome, but their use as 
potential label claims will only apply if a statistically significant treatment effect is found in the 
primary analysis. For the secondary efficacy analysis, for each secondary variable, a 
corresponding term will be added to the primary analysis as well as an interaction term (product 
of the treatment indicator and secondary variable).  The coefficient of the interaction term (only) 
will be tested to determine if the secondary variable alters the magnitude of the treatment effect. 
Corresponding to each of the two primary analyses, the Hochberg step-up method[1] will be 
employed to control the overall family-wise error rate with overall alpha set at the two-sided 0.05 
level. 
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3.2.3 Other Secondary Outcomes 
1. Safety outcomes will be assessed by summary analysis of adverse events and clinical 
laboratory abnormalities. 
2. Pharmacokinetic outcomes will be assessed by evaluating the population pharmacokinetics 
for CPP-1X (eflornithine) and sulindac. 
3. Evaluate tissue and dietary polyamine levels. 
4. Patient reported quality of life will be evaluated using HRQoL and patient utilities. 
5. A pilot evaluation of an FAP-specific assessment, the time to the first FAP-related 
beneficent event, will be studied.  This will involve analyzing the endoscopic polyposis data 
for regression of pre-colectomy colorectal polyposis, rectal/pouch polyposis, and regression 
of duodenal polyposis. 
6. An analysis of the components and subgroups included in the primary analysis, and their 
contribution to the primary outcome. 
4. POPULATIONS FOR ANALYSIS 
4.1 Intent-to-Treat (ITT) Population 
The intent-to-treat population includes all patients who have signed a voluntary and fully 
informed consent form, have been deemed eligible to participate by the Investigator based on the 
screening assessments, and have been randomized to one of the three study arms.  Patients will 
be analyzed in the group to which they were randomized, whether or not they received their 
assigned treatment, any treatment whatsoever, or completed their treatment course and follow-
up. 
4.2 Safety Population 
The safety population is defined as all ITT patients who received at least one dose of study 
medication.  Patients who do not receive any study treatment (CPP-1X or sulindac or their 
combination) are excluded from this population.  Patients will be analyzed in the treatment group 
according to which actual treatment was initially received. 
4.3 Per Protocol Population 
The per-protocol population is defined as the subset of the ITT population who completed all 24 
months of treatment and have primary endpoint determinations performed per protocol 
specifications. 
4.4 Other Populations 
Within the entire study patient population there will be subsets who did not receive 24 months of 
daily medication.  The patient diary and pill count will define the extent of compliance.  This 
subgroup of patients will be categorized into various cohorts only for purposes of exploratory 
and sensitivity analysis, including: 
 Patients withdrawn for personal reasons 
 Treatment discontinued because of disease symptoms 
 Treatment discontinued because of patient symptoms 
 Compliance <80% treatments taken 
 Treatment discontinued because of intercurrent medical or surgical illness. 
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5. DETERMINATION OF SAMPLE SIZE AND STATISTICAL METHODS 
5.1 Determination of Sample Size 
For the purposes of power calculations, we assume the following:  
1) The level of statistical significance is set at 0.05, using a 2-sided log-rank test for time-to-first 
FAP-related event, for each of the two between-group comparisons (i.e. CPP-1X plus sulindac 
vs. CPP-1X and CPP-1X plus sulindac vs. sulindac); 
2) A doubling of the time to occurrence of the primary event from either of the single agent 
treatment arms to the combination treatment group; 
3) Power of at least 85% to detect the above-mentioned treatment effect comparing the 
combination arm vs. either of the two single treatment arms; 
4) The two single-agent treatment groups have the same event rate. 
For this situation, 49 events would be needed for each two-group comparison at the 2-sided 0.05 
level with 85% power and the doubling of the time to primary event[2].  Assuming two-year 
event proportions of 70% in either of the two single-agent groups and 40% in the combination 
arm with 50 patients per arm, the expected number of patients with an FAP related event in 
either of the two single-agent groups would be 35 and 20 in the combination arm. Thus we 
expect to have 55 patients with a FAP related event in each comparison, achieving almost 89% 
power.  The standard deviation around this expectation is 4.74, so we would be highly likely to 
observe at least the required 49 events.  Even if the total number of events in either comparison 
were only 43, there will still be 80% power to detect the design effect size, namely, a hazard rate 
ratio of 0.4243 = (ln 0.60)/(ln 0.30) corresponding to the doubling of event-free follow-up over 
two years. 
In total we expect to observe 35+35+20=90 primary endpoints among the three groups (plus or 
minus 5.7).  To achieve this number of events, we plan to have a 3 year study (with up to 12 
months enrollment assuming no sample size reassessment plus 2 years of treatment and follow-
up for the last-enrolled patients). 
This is based on our review of limited single-agent data for eflornithine and sulindac, in which 
the 2-year event free rates imply a single overall event free rate of 60% for combination 
treatment group and 30% in each single agent treatment group.  This is described further in Table 
5.1 below. 
 
Table 5.1 Estimated Overall Event Free Proportions after Two Years of Follow-up 
Treatment S(t) t (months) Median Time to Event (months)* 
Combination 0.6 24 32.5660
Single Agent 0.3 24 13.8172
*Based on an assumed exponential time-to-event distribution. 
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5.2 Data Monitoring Committee (DMC) 
A Data Monitoring Committee (DMC) will oversee the performance and safety conduct of this 
study.  The DMC will consist of at least three members (two MDs and one statistician as voting 
members) who will receive confidential reports on a periodic basis.  The DMC will be 
responsible for decisions regarding possible termination of the study for either futility or safety 
reasons. 
A detailed DMC Charter will be produced separately at a later time by the DMC membership.  It 
is anticipated that any reviews of study data will be performed in a blinded manner, looking at 
pooled data (all treatment groups combined into one group) to assess mission-critical parameters 
such as overall recruitment and event rates.  Any pre-specified interim analyses will be 
conducted in a blinded (A versus B) manner.  Of course, patient safety issues take precedence 
over bias-protection and control of type I error, and so the DMC will have the privilege of 
breaking the blind on a need-to-know basis if safety issues of concern arise in order to consider 
risk-benefit issues.  Details concerning DMC responsibilities and duties may be submitted as a 
stand-alone document to the FDA, including items such as specification of early termination 
rules and other matters as the DMC deems to be important and relevant to the ethical conduct of 
this study. 
CPP will inform the DMC that there will be two study evaluations for the DMC to consider 
during the trial, one interim look for sample size reassessment and one look for futility (based on 
a blinded A/B comparison). 
The method for reassessment of sample size is based upon the FDA Guidance, “Adaptive Design 
Clinical Trials for Drugs and Biologics (February 2010)”.  There will be no hypothesis testing.  
The DMC will perform an assessment of the observed trial event rate based on pooled data only.  
They will make a recommendation to the sponsor on whether the pooled event rate is sufficient 
to preserve the integrity of the trial, and if not, to recommend a revised sample size.  For this 
assessment the study statistician will estimate the overall observed event rate and 90% 
confidence interval.  This assessment will be performed using data from a single time point, 
when enrollment is approximately 95% complete.  With this approach study enrollment can 
continue uninterrupted at the study sites, if it is decided to increase study sample size. 
The futility assessment will occur when approximately 50% of maximum trial information has 
been amassed.  Assuming a constant enrollment rate over 1 year and full enrollment achieved at 
one year, that would occur at approximately 1.5 years from enrollment start.  At that time 
patients would have an average of approximately 1.0 year on study treatment.  The details of the 
futility analysis are provided in Table 5.2 below.  Unless the DMC requires it on ethical grounds, 
no early stopping for positive efficacy is proposed. 




1.5 years Efficacy criterion Z=1.96 at terminal analysis. 
Futility criterion of Z=0.50 at interim analysis. 
Total Type I error for end of study comparison =  0.0471. 
NB: Assuming D = 52 events, power = 0.8566.  Assuming D = 55 events, 
power = 0.8750. 
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5.3 Statistical Methods 
5.3.1 Demographic and Baseline Characteristics 
Patients in the three populations (see Section 4) will be summarized for demographic and 
baseline characteristics in a descriptive fashion.  Namely, categorical and continuous-valued data 
will be displayed using standard summary statistics (e.g., frequency tables, n, means, medians, 
standard deviations, and ranges).  Data will be presented per group and overall. 
Demographic features summarized will include age, gender, race and the institution at which 
each patient registered, among other features.  Baseline characteristics will include laboratory 
values and disease-related characteristics, as well as any other relevant values (Tables 9.1-9.3 
Section 9, Appendices).  Categorical data will be compared among groups using chi-squared 
methods, while continuous-valued data will be compared using standard nonparametric methods 
(e.g., the Kruskal-Wallis test)[3]. 
5.3.2 Patient Disposition and Treatment Summaries 
Subjects will be assigned for analysis to the treatment group to which they were randomized, 
regardless of whether the patients received any treatment. 
Patient disposition and treatment will be summarized for the ITT and safety populations defined 
previously.  Patient disposition will be consistent with the CONSORT criteria[4], and will 
include per treatment group enumeration of all patients randomized, number ineligible, early 
termination due to AE/SAE, the number of subjects with an SAE, deaths, dropout for other 
reasons, and the number of subjects lost to follow-up.  Additional summaries will include 
reasons for patients discontinuing treatment and/or modifying treatment dosages, and a summary 
of patients’ treatment status. A listing of screened and ineligible patients along with the reason 
for each also will be summarized (Tables 9.4 - 9.7 in Section 9, Appendices). 
5.3.3 Analytic Methods for Time-to Event Data 
The analytic method for the primary analysis will be a time-to-event analysis using the log-rank 
test, as previously described.  Cox proportional hazards regression models will be used for 
secondary assessments[5].  Graphical analyses (log-minus-log plots) will be used to check the 
assumption of constant hazard ratios. 
For the primary analysis, two log-rank tests will be performed with treatment coded as a binary 
value (i.e., 0 or 1). Time to event curves will be displayed using the method of Kaplan and 
Meier[6].  Additional analyses involving the overall 3-treatment group comparison, and use of 
additional study populations (see Section 4) for the two pairwise treatment comparisons, will be 
performed as supplemental analyses. 
If an FAP related event occurs, that patient will be said to have an observed or uncensored event 
and will be considered a treatment failure. Generally, a patient will be considered a treatment 
failure if for any reason, the endpoint determination cannot be made per the pre-specified study 
requirements.  The time to this imputed event will be from randomization to the last recorded 
patient visit.  See Section 5.3.6 below for further details of handling missing data.  A patient who 
is lost to follow-up for reasons deemed unrelated to his or her endpoint status will be treated as a 
censored observation as of the last patient visit.  If a patient does not have a FAP related event at 
the 24 month close-out visit, the patient will be treated as a censored observation as of the actual 
follow-up time for the close-out visit. 
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5.3.4 Analytic Methods for Categorical or Continuous-Valued Secondary Outcome and 
Safety Data 
For categorical data, comparisons will be made between treatment groups using standard chi-
squared techniques as the primary approach.  In particular, the Cochran-Mantel-Haenszel one 
degree of freedom test will be used to reflect the stratified randomization.  Exact p-values and 
95% confidence intervals by the point-probability method will be reported[7]. 
For continuous endpoints, standard analysis of covariance (ANCOVA) methods will be used as 
the primary approach to compare treatment groups at end of treatment with the following 
covariates: baseline value, binary indicator variables for the two highest-risk stratification levels 
used in the randomization (using the lowest-risk, i.e., rectum/pouch polyposis, group as the 
reference stratum), and a binary treatment indicator (1=combination treatment, 0=single 
treatment). 
For ordered categorical data, a Kruskal-Wallis nonparametric test for ordered categorical 
response will be used to compare treatment groups[3]. 
5.3.5 Assessment of Toxicities 
Treatment-emergent adverse events will be enumerated and analyzed according to the incidence, 
intensity, type of adverse events, and clinically significant changes in the patient’s physical 
examination findings, vital signs and clinical laboratory results. Safety variables will be tabulated 
and presented for all patients in the safety and per-protocol populations as defined previously.  
Adverse events will be graded and coded using the NCI Common Terminology Criteria for 
Adverse Events (CTCAE, Version 4).  Treatment-emergent events will be tabulated, where 
treatment-emergent is defined as any adverse event that occurs after administration of the first 
dose of study drug and through 30 days after the last dose of study drug, or any event that is 
present at baseline and continues after the first dose of study treatment but worsens in intensity.  
Events that are considered related to treatment (possibly, probably or definitely drug-related) will 
also be tabulated separately.  Tables that enumerate adverse events by severity will be provided.  
Deaths, serious adverse events and events resulting in study discontinuation will be tabulated in 
data listings including additional relevant information on each patient.  Tables will be presented 
both overall (all arms combined), by each treatment group separately, and by cell. Where 
appropriate, statistical comparisons between treatment arms will be provided (Tables 9.8 - 9.17 
in Section 9, Appendices) using the above-mentioned methods for analysis of categorical data. 
5.3.6 General Procedures for Handling Missing Data 
Every reasonable effort will be made to continue follow-up of all study participants, including 
those who discontinue randomized therapy, to prevent data loss. It is recognized that missing 
values represent a potential source of bias in a clinical trial and so every effort will be undertaken 
to fulfill all the requirements of the protocol concerning the collection and management of data. 
For the primary time to event analysis, the only possible patient outcome is an observed FAP-
related event or a censored observation.  Participants who are lost to follow-up for reasons 
deemed unrelated to their health status will be censored at the time their status is last known, 
based upon data collected at the last recorded clinic visit.  For patients who may have missed a 
study visit, every effort will be made to obtain endoscopic results at their close-out visit and 
those endoscopy results will be used for the primary analysis.  A patient will be considered a 
treatment failure if for any reason, the endpoint determination cannot be made per the pre-
specified protocol.  The time to this imputed event will be from randomization to the last 
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recorded patient visit.  Any secondary or sensitivity analysis that includes this assumption will be 
clearly noted.  Similarly, any sensitivity analysis that incorporates the last observation carried 
forward (LOCF) method, to compensate for early patient dropouts or missing data, will be 
clearly noted. 
Secondary analysis data include the presence of a specific genetic mutation, and urinary 
metabolite concentrations (see Section 3.2.2).  The primary analysis of the secondary objectives 
will include collected data only, without imputing or weighting data to compensate for missing 
data.  Sensitivity analyses of these data will be performed to explore study results more fully, in 
a manner consistent with ICH Guidance “E9 Statistical Principles for Clinical Trials 
(September, 1998)”. 
All available efficacy and safety data will be included in data listings and tabulations. Data that 
are potentially spurious or erroneous or appear as outliers will be examined using standard data 
management operating procedures, prior to database lock and statistical analysis.  These 
procedures will be fully described in the study report. 
5.3.7 Subgroup Analyses 
Subgroups will be analyzed in the spirit of exploratory analyses including but not limited to the 
various study populations (see Section 4) and separately within each disease-prognosis stratum. 
5.4 Health Related Quality of Life (HRQoL) Statistical Methods 
For this study four (4) instruments to measure HRQoL and patient preferences or utilities will be 
administered to subjects at baseline and at 3, 6, 12, 18, and 24 months post-enrollment/end of 
treatment.  These instruments include the EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and 
a modified Cancer Worry Scale. 
 The EORTC QLQ-C30 is a self-administered quality of life questionnaire[8] with multi-
dimensional scales. It consists of both multi-item scales and single item measures, 
including five functioning domains, a global quality of life domain, three symptom 
domains and six single items. 
 The EORTC QLQ-CR29 gastrointestinal/colorectal sub-module[9] is composed of 4 
functional and 18 symptom related sub-scales.  The 4 functional scales include body 
image, weight, anxiety and sexual function.  The symptom related scales include single 
item and multi-item questions concerning stool frequency, bleeding and mucous 
discharge, stool leakage, abdominal bloating, flatulence, embarrassment and site-specific 
pain among others. 
 The EuroQoL EQ-5D is a standardized instrument for use as a measure of health outcome 
and is applicable to a wide range of health conditions and treatments[10, 11].  It provides 
a simple descriptive profile and a single index value for health status. 
 The Cancer Worry Scale[12] is a brief psychometric instrument that was designed to 
assess both the frequency of worrying about “getting cancer some day” and measuring 
the impact of worry on mood and performing daily activities.  This scale was originally 
developed by Caryn Lerman and her colleagues to study breast cancer and has been 
modified for use in this FAP trial. 
The validity and reliability of both the QLQ-C30 and the QLQ-CR29 questionnaires have been 
studied by the EORTC Study Group on Quality of Life and both instruments will be scored 
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according to the EORTC Scoring Manual and analyzed accordingly.  For each single item or 
multi-item sub-scale, a linear transformation will be applied to standardize raw scores to range 
between 0 and 100.  HRQoL secondary endpoints will include all single item or multi-item sub-
scales from both the EORTC QLQ-C30 and QLQ-CR29 and patients will be considered as 
deteriorated (or improved) for a given single item or multi-item sub-scale if their change score 
from baseline was 10 points or more on the standardized scale.  
Patient preferences (or utilities) will also be assessed using the EuroQoL EQ-5D.  Preference 
weights among the treatment arms will be determined using the EuroQol EQ-5D assessment of 
individual health states[10, 11].  Quality-adjusted survival among the three treatment arms will 
be generated by multiplying the utility value by the amount of time spent in a specified health 
state.  
The modified version of the Cancer Worry Scale will also be administered and it will be scored 
according to the guidance provided by Lerman et al[12]. 
This trial has three strata and three treatment options with 150 patients to be entered. HRQoL 
data will be obtained while patients are receiving treatment. At the time of an FAP-related event 
(primary outcome), additional long-term clinical follow-up and QoL data will not be obtained as 
part of this trial. Hence, HRQoL trends comparing the nine subsets will be obtained, but 
comparative longitudinal analyses defining the impact of an FAP-related event on QoL will not 
be feasible until subsequent long-term studies are performed. 
5.5 Dietary Assessment 
The Food Frequency Questionnaire (FFQ) is the most common dietary assessment tool used in 
large epidemiologic studies of diet and health.  The self-administered FFQ booklet asks 
participants to report the frequency of consumption and portion size of approximately 125 line 
items over a defined period of time (e.g. the last month; the last three months).  Each line item is 
defined by a series of foods or beverages.  Additional questions on food purchasing and 
preparation methods enable the analysis software to further refine nutrient calculations.  The 
FFQ was developed by the Nutrition Assessment Shared Resource (NASR) of the Fred 
Hutchinson Cancer Research Center. NASR periodically updates its standard FFQ to reflect U.S. 
food consumption patterns and major changes in the market place[13, 14].  Data from the FFQ 
will be analyzed using a polyamine database[15] and will calculate the average daily levels of 
putrescine, spermidine, and spermine in the diet.  Dietary assessments via the FFQ will be 
obtained at baseline, 12 months and 24 months/end of treatment for subjects at North American 
(U.S. and Canada) sites only.  Clinical study sites outside of North America will not be included 
because the foods on the North American food frequency questionnaire not the same as those 
widely consumed in Europe and elsewhere.  The results of the FFQ will be used to corroborate 
results from another recent trial[16] that indicate consumption of a diet high in polyamines is 
associated with reduced treatment efficacy.  The results of this trial, along with the earlier 
findings of Zell et. al.[17] could lead to dietary restrictions in combination with the combined 
eflornithine-sulindac therapy. 
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6. RANDOMIZATION ALGORITHM AND STRATIFICATION FACTORS  
A total of 150 eligible patients will be enrolled in this study.  Patients will be randomized to one 
of three treatment groups in equal proportions (i.e., 1:1:1 randomization): 1) CPP-1X plus 
sulindac, 2) CPP-1X-placebo plus sulindac, 3) CPP-1X plus sulindac placebo. 
A stratified randomization procedure will be used with stratification based on FAP-related time-
to-first-event prognosis.  The event prognosis groups are represented by 1) best (i.e., longest 
projected time to first FAP-related event) - rectal/pouch polyposis, 2) intermediate - duodenal 
polyposis, and 3) worst - pre-colectomy.  If a subject has two or more of these disease sites, the 
most severe prognosis stratum will be assigned for randomization (e.g. worst > intermediate > 
best).  Since an individual may have more than one disease site involved, the trial will assess 
time to any defined FAP-related event in the patient as a whole.  In order to minimize potential 
treatment arm imbalance a centralized randomization process will be used to balance among 
treatment groups within prognostic strata. 
 
7. OTHER ISSUES AND FURTHER DETAILS 
7.1 Statistical Software Used in Data Analysis 
All analyses will be performed using SAS statistical analysis software version 9.1 or later.  If 
other software is used (i.e. WinNonPop for population pharmacokinetics, SAS macros for futility 
analysis, etc.), it will be clearly described in the clinical and statistical study reports. 
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9. APPENDICES 
 
9.1 Appendix: Sample Study Clinical Report Tables  
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Table 9.1 - Registration by Institution 








Institution 1  ## Institution 3  ##
Institution 2  ## Total  ##
 
Table 9.2 - Patient Demographics 
Registrations ending XX/XX/20XX 
  Total Total 
  (n=##) (n=##) 
AGE       HISPANIC  
 Median  ##.#    Unknown ## ##%  
 Minimum  ##.#     
 Maximum ##.#    RACE  
      White ## ##%  
SEX       Black ## ##%  
 Males  ##   ##%   
Native 
American  ##  ##%  
 Females  ##   ##%  
 
Table 9.3 - Patient Characteristics, Overall and by Marginal Arm 
Characteristic Overall (n/N 
(%)) 
Arm 1 (n/N (%)) Arm 2 (n/N (%)) Arm 3 (n/N (%)) Overall 
P-value 
Factor 1 n/N (%) n/N (%) n/N (%) n/N (%) #.### 
Factor 2 n/N (%) n/N (%) n/N (%) n/N (%) #.### 
Factor 3 n/N (%) n/N (%) n/N (%) n/N (%) #.### 
 
Table 9.4 - Summary of Treatment Status 





Death     
On Treatment     
Progression     
Pt pref, not toxicity     
Med req, toxicity     
Treat completed per protocol     
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Table 9.5 - Summary of Treatment Status and Eligibility 
 Eligibility  
Treatment Status 
(Reason off Tx) 
Ineligible, 
Exception No Yes Total 
Death     
On Treatment     
Progression     
Pt pref, not toxicity     
Med req, toxicity     
Treat completed per protocol     
Total     
 
Table 9.6 - Listing of Patients Off Treatment Due to Toxicity 
Patient Drug (Placebo / CPP-1X / Sulindac) Explanation/Comments 
   
   
 
Table 9.7 – Drugs/Dose Interrupted or Discontinued While on Study 
Drug (CPP-1X, Sulindac) 
Action Count Percent 
None   
Dose Interrupted   
Discontinued Drug   
 





Date Adverse Event Severity Action Taken 
Attributable 
to Study Drug
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Table 9.9 - Treatment-Related Treatment-Emergent Adverse Events Grade 3 or Higher by 
Organ System 
System Adverse Event Count 
% of Treated Patients by 
treatment group  
Allergy/immunology    
Blood/Bone Marrow    
 
Table 9.10 - All Treatment-Emergent Adverse Events Grade 3 or Higher by Organ System 
System Adverse Event Count 
% of Treated Patients by 
Treatment Group 
Allergy/immunology    
Blood/Bone Marrow    
 
Table 9.11 – Treatment-Related Treatment-Emergent Adverse Events by Organ System 
System Adverse Event Count 
% of Treated Patients by 
Treatment Group 
Allergy/immunology    
Blood/Bone Marrow    
 
Table 9.12 - All Treatment-Emergent Adverse Events by Organ System 
System Adverse Event Count 
% of Treated Patients by 
Treatment Group 
Allergy/immunology    
Blood/Bone Marrow    
 
Table 9.13 - Treatment-Related Treatment-Emergent Adverse Events by Frequency of 
Occurrence 
Adverse Event Count % of Treated Patients 
Adverse Event 1   
Adverse Event 2   
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Table 9.14 - All Treatment-Emergent Adverse Events by Frequency of Occurrence 
Adverse Event Count % of Treated Patients 
Adverse Event 1   
Adverse Event 2   
 
Table 9.15 - Treatment-Emergent Adverse Events Attributable to Treatment 
 Toxicity Degree 
 Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Adverse Event N (%) N (%) N (%) N (%) N (%) N (%) 
Adverse Event 1 ## (##%) ## (##%) ## (##%) ## (##%) ## (##%) ## (##%) 
             
 
Table 9.16 - Treatment-Emergent All Adverse Events 
 Toxicity Degree 
 Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Adverse Event N (%) N (%) N (%) N (%) N (%) N (%) 
Adverse Event 1 ## (##%) ## (##%) ## (##%) ## (##%) ## (##%) ## (##%) 
 





Date of Last 
Treatment Date of Death 
Days from Last 
Treatment to Death 
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1. LIST OF ABBREVIATIONS 
Abbreviation Term 
AE Adverse Event 
ANCOVA Analysis of covariance 
CPP Cancer Prevention Pharmaceuticals, Inc. 
CPP-1X Eflornithine, DFMO, Difluoromethylornithine 
CRO Contract Research Organization 
CTCAE Common Terminology Criteria for Adverse Events 
DMC/DSMB Data Monitoring Committee/Data Safety Monitoring Board 
EDC Electronic Data Capture System 
EFS Event-Free Survival 
EMA European Medicines Agency 
EORTC European Organisation for Research and Treatment of Cancer 
FAP Familial Adenomatous Polyposis 
FDA Food and Drug Administration 
FFQ Food Frequency Questionnaire 
HRQoL Health Related Quality of Life 
ICH International Conference on Harmonization 
ITT Intent-To-Treat 
LGI Lower Gastrointestinal 
LGIOI LGI Observed Improvement 
LOCF Last Observation Carried Forward 
NASR 
Nutrition Assessment Shared Resource (Fred Hutchinson Cancer 
Research Center) 
NCI National Cancer Institute 
ODC Ornithine Decarboxylase 
QLQ Quality of Life Questionnaire 
SAM S-Adenosyl Methionine 
SAE Serious Adverse Event 
SAP Statistical Analysis Plan 
SAS Statistical Analysis System 
UGI Upper Gastrointestinal 
UGIOI UGI Observed Improvement 
Z-score 
The value of the critical ratio (score statistic divided by its 
standard error) based on the stratified log-rank statistic. 
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2. INTRODUCTION 
This Statistical Analysis Plan (SAP) describes the proposed statistical analysis of the Cancer 
Prevention Pharmaceuticals, Inc. (CPP) study CPP FAP-310 entitled: “A DOUBLE-BLIND, 
RANDOMIZED, PHASE III TRIAL OF THE SAFETY AND EFFICACY OF CPP-1X/SULINDAC 
COMPARED WITH CPP-1X, SULINDAC AS SINGLE AGENTS IN PATIENTS WITH FAMILIAL 
ADENOMATOUS POLYPOSIS (FAP)”. 
The purpose of this document is to apply sound analytic principles through description and pre-
specification of the statistical approaches and data handling conventions for key analyses and the 
randomization processes. 
This plan will focus on analysis of the primary and secondary endpoints, intended to assess the 
extent to which the combination treatment (CPP-1X 750 mg daily + sulindac 150 mg daily) is 
more effective than each of the two single agent treatments alone (CPP-1X 750 mg daily + 
placebo, and sulindac 150 mg daily + placebo) in delaying the time from the date of 
randomization to the date of the first occurrence of any FAP-related event in FAP patients.  
Sample size and total FAP-related events will be discussed, along with study population 
definitions.  In addition, we will summarize our approach regarding the analysis of safety data, 
pharmacokinetic data, and patient reported quality of life data.  The composition, charter, and 
initial tasks of the Data Monitoring Committee (DMC) will be described, along with planned 
interim analyses. 
3. STUDY OBJECTIVES AND ENDPOINTS 
3.1 Overview of Study 
This is a randomized, double-blind, phase III trial in patients with FAP to evaluate the safety and 
efficacy of the combination product 750 mg CPP-1X + 150 mg sulindac versus each of the two 
single-agent products: 1) 750 mg CPP-1X; and 2) 150 mg sulindac.  The primary study 
comparisons will be made between the combination product and each single agent product, 
separately. 
Eligible patients who have given informed consent will enter the study with the intent to 
participate for the full treatment period of 24 months.  Based on a subject’s date of 
randomization, patients will be offered continued preparticipation in blinded treatment for up to a 
total of 36, 42 or 48 months of treatment if they have completed the initial 24 months of 
treatment without an FAP event until one of the following occurs: 1) subject has an FAP event or 
comes off study for other reasons, 2) all randomized subjects have reached a minimum of 24, 36, 
42 or 48 months of treatment.  
A stratified randomization procedure will be used based on FAP-related time-to-first-event 
prognosis.  The event prognosis groups are represented by 1) best (i.e., longest projected time to 
first FAP-related event) - rectal/pouch polyposis, 2) intermediate - duodenal polyposis, and 3) 
worst - pre-colectomy.  If a subject has two or more of these disease sites, the most severe 
prognosis stratum will be assigned for randomization (e.g. worst > intermediate > best).  Since 
an individual may have more than one disease site involved, the trial will assess time to any 
defined FAP-related event in the patient as a whole.  In order to minimize potential treatment 
arm imbalance a centralized randomization process will be used to balance treatment groups 
within disease prognostic strata. 
IND 103,678  Cancer Prevention Pharmaceuticals, Inc. 
Company Confidential  FAP – CPP-1X (Eflornithine HCl)/Sulindac 
SAP Final Ver. 5.2, January 25, 2019   Page 7 of 25 
The stratification is predicated on the following projected event rates for the disease site specific 
eligibility criteria (rectal/pouch polyposis, duodenal polyposis, pre-colectomy) which are 
provided in the clinical study protocol (Appendix E) and summarized in Table 3.1. 
Table 3.1 Projected Event Free Rate by Disease Site  
Disease Site Projected 2-year Event Free Rate Without Treatment 
Rectum/Pouch Polyposis Excisional intervention and/or high risk adenoma – 40 - 60% 
Duodenal Polyposis Excisional intervention, Spigelman stage progression, cancer – 50% 
Pre-colectomy Colectomy, proctocolectomy – 10% 
 
The stratified randomization will be reflected in stratified analyses for the primary and secondary 
endpoints.  For design purposes only, however, the following simplified assumptions were made: 
an overall event free proportion of 30% in the single agent treatment group and 60% in the 
combination treatment group after 24 months of study treatment.  This is described further in 
Table 3.2 below.  See Section 5.1 for sample size and power calculations. 
Table 3.2 Overall Event Free Proportions After Two Years of Follow-up* 
Treatment S(t) t (months) Median Time to Event (months) 
Combination 0.6 24 32.566 
Single Agent 0.3 24 13.817 
*These proportions are assumed for design purposes only.  The median times to event are based on the 
assumption of an exponential time-to-event function S(t) in each group. 
 
At least 150 eligible patients will be enrolled in this study, with at least 50 per treatment group.  
Patients will be randomized to one of three treatment groups within the prognostic strata defined 
above in equal proportions (i.e., 1:1:1 randomization): 1) CPP-1X plus sulindac, 2) CPP-1X 
placebo plus sulindac, 3) CPP-1X plus sulindac placebo.  The study is double blinded, so neither 
patients nor Investigator nor Sponsor will be aware of treatment assignment. 
The grading of adverse events will be based on the current version of the NCI Common 
Terminology Criteria for Adverse Events (CTCAE Version 4.03). 
Refer to the CPP FAP-310 protocol for the details of the treatment and study schedule, and 
description of study procedures and tests. 
3.2 Study Objectives 
The primary study analysis will be performed using the intent-to-treat (ITT) population which is 
defined in Section 4.1.  Statistical methods for the primary analysis are described in Sections 5.1 
and 5.5.3. 
The primary objective of this trial is to determine whether the combination of CPP-1X + sulindac 
is superior to either single-agent treatment individually in delaying time from the date of 
randomization to the date to the first occurrence of any FAP-related event. 
Thus the primary objective contains two treatment comparisons:  
1. CPP-1X placebo + sulindac active vs. CPP-1X active + sulindac active,  
and 
2. CPP-1X active + sulindac placebo vs. CPP-1X active + sulindac active  
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These two treatment comparisons will be performed sequentially, as described below. 
The combination of CPP-1X active + sulindac active is specified as the reference treatment 
group because it is common to both comparisons.  In addition, because the purpose of the 
combination treatment is to delay the time from randomization to FAP-related disease 
progression compared to single-agent treatments, formulating the hypothesis tests in this manner 
will allow a positive rather than a negative Z-score for the test statistic to be interpreted as 
supportive of this purpose. 
Each comparison will be performed at the 2-sided 0.05 level of statistical significance. 
As explained in Section 3.2.1 below, the decision to seek regulatory approval based upon the 
results of the primary objective will be taken sequentially. 
3.2.1 Primary Analysis 
The primary analysis will be a time-to-event analysis using the stratified log-rank test. Graphical 
analyses (log-minus-log plots) will be used to check the assumption of constant hazard ratios 
with the COX model.  See Section 7.3 below for further details of the calculation of the stratified 
log-rank statistic. The strata are the patient’s sites of disease involvement at baseline, which is 
determined prior to randomization, and are:  Rectal/pouch polyposis, Duodenal polyposis, and 
Pre-colectomy.   
For the primary analysis, two stratified log-rank tests will be performed with treatment coded as 
a binary value (i.e., 0 or 1). Time to event curves will be displayed using the method of Kaplan 
and Meier[8].  Additional analyses involving the overall 3-treatment group comparison and use 
of additional study populations (see Section 4.) for the two pairwise treatment comparisons, will 
be performed as supplemental analyses. Refer to section 5.5.3 for further details. 
3.2.2 Regulatory Review of Primary Outcome Compliance 
CPP has received advice from both the FDA and the EMA concerning the test method and 
criteria (Sections 3.2 and 5.) to be used when analyzing the primary study outcome, including the 
value of alpha. 
The US Food and Drug Administration (FDA) noted that the comparison of single agent CPP-1X 
vs. combination treatment will not provide information about the treatment effect of CPP-1X (i.e. 
eflornithine), and therefore this result will not be included in the product label.  Therefore, the 
primary analysis of import to FDA is the comparison of single agent sulindac vs. combination 
treatment. 
The European Medicines Agency (EMA) noted that for the three arm trial design the superiority 
of the combination treatment must be tested against both mono-components.  The combination 
treatment must be shown to be superior to both mono-components, or else the results will be 
considered inconclusive.  As a consequence, consistent with EMA/SAWP commentary, alpha 
does not need to be adjusted for multiplicity and two separate 5% two-sided tests will suffice. 
To harmonize the advice provided by these two Agencies, CPP will sequentially perform the two 
primary comparisons as part of the primary analysis, each at the 2-sided p = 0.05 level.  All 
information concerning these comparisons will be clearly provided to both Agencies.  The single 
treatment comparison requested by FDA will be available, as will the two comparisons requested 
by EMA, both at the requested level of alpha.  This approach fulfills the differing requirements 
for the primary comparison as asked for by each Agency.  
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We note that this approach is both a fixed-sequence and gatekeeping approach.  It is fixed-
sequence in that the comparison of combination with single-agent Sulindac takes place before 
the comparison of combination with single-agent Eflornithine and the first serves as a gatekeeper 
for the second (i.e., no declaration of significance in the second comparison will be made if the 
first comparison is not significant at the 0.05 level).  Therefore, the type I error in the sequential 
testing is well controlled.  In addition, because both tests must be significant for EMA approval, 
the type I error of the second test in the sequence is less than 0.05. 
3.2.3 Secondary Efficacy Analyses 
Any improvement observed by the investigator during upper gastrointestinal (UGI) and lower 
gastrointestinal (LGI) visualization (i.e. endoscopy and colonoscopy) at the 6 and 12-month 
study visits will be described using the variables UGI Observed Improvement (UGIOI), and LGI 
Observed Improvement (LGIOI).  Each patient will have one pair of UGIOI and LGIOI 
outcomes. 
UGIOI and LGIOI are binary outcomes derived from numerical determinations (henceforth, 
“investigator change scores” or more briefly, “scores”) assigned by the investigator during each 
procedure, using a scale (–2, –1, 0, +1, +2) which corresponds, respectively, to the investigator’s 
overall qualitative assessment of: much worse, worse, no change, improved, much improved.  At 
the month 6 procedures the investigator scores UGI and LGI findings as changes from baseline.  
At the month 12 procedures, the UGI and LGI findings are scored relative to the month 6 
procedures. 
The UGIOI (and respectively, the LGIOI) secondary endpoint independently summarizes the 
corresponding 6- and 12-month investigator change scores according to whether or not there was 
any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to 
baseline or month 6), under the condition that there be no worsening at either timepoint 
(compared to the preceding timepoint).  Here are the specific possibilities (where “Improvement” 
stands for either the UGIOI or LGIOI secondary endpoint): 
• If the 6-month score is –2 or –1, Improvement=NO irrespective of the 12-month score. 
 
• If the 6-month score is 0, then Improvement=YES if and only if the 12-month score is +1 
or +2.  Otherwise Improvement=NO. 
 
• If the 6-month score is +1 or +2, then Improvement=YES if and only if the 12-month 
score is greater than or equal to 0.  Otherwise Improvement=NO. 
Any patient who drops out of the study before the month 12 assessment will be considered 
Improvement=NO. 
These binary UGIOI and LGIOI secondary efficacy endpoints will be compared in a manner 
analogous to the primary analysis, using the same two primary treatment comparisons (1: CPP-
1X placebo + sulindac active vs. CPP-1X active + sulindac active; and 2: CPP-1X active + 
sulindac placebo vs. CPP-1X active + sulindac active), and conditioning on the three disease site 
strata (Rectum/Pouch Polyposis, Duodenal Polyposis, Pre-colectomy).  The null hypothesis of no 
association between treatment group and Improvement endpoints will be tested using the exact 
Mantel-Haenszel procedure for combining the evidence contained in the fourfold tables 
(Treatment=Single agent vs. Combination cross-classified by Improvement=YES vs. NO) across 
the three strata.  For each of the two treatment comparisons, exact Mantel-Haenszel p-values will 
be calculated for both the UGI and LGI assessments (using the point-probability method based 
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on the convolution of three independent central hypergeometric distributions; see [1]).   
The overall type I error for the secondary efficacy analysis will be controlled using the Hochberg 
step-up method for multiple comparisons[2].  This analysis will be performed in the ITT 
population.  The primary analysis will serve as a gatekeeper to control the overall type I error 
rate at 0.05 for both primary and secondary analyses.  That is, significance for the secondary 
efficacy analysis will be declared only if the primary p-value is 0.05 or less, when the p-values 
are tested sequentially per the Hochberg method[2].  
Further analyses of the secondary endpoints may be conducted to evaluate and provide additional 
evidence to support its validity and confirm its clinical relevance. 
3.2.4 Other Secondary Outcomes 
To explore how study treatment group relates to other efficacy outcomes, genotype, phenotype, 
disease locations and endoscopic findings, additional analyses are planned.  These analyses will 
be performed in the ITT group, the Per Protocol Group, and other defined subgroups (see Section 
4 Populations for Analysis) wherever possible and will all be clearly noted as such. 
The UGIOI and LGIOI outcomes will be tabulated and summarized using the month 6 visit 
scores, alone.  Similarly, the UGIOI and LGIOI outcomes will tabulated and summarized across 
all study visits. 
As both part of the primary analysis, and further explored in these additional analyses, median 
time to event for each treatment group will be determined. This will be explored for each of the 
study populations (i.e. ITT, per protocol, and others), study disease stratum groups, and in the 
Disease Site subgroups (see below). 
Pharmacokinetic data (plasma concentrations measured at patient visits) will be used to estimate 
population pharmacokinetic parameters for the CPP-1X (eflornithine), sulindac, and CPP-1X 
(eflornithine) + sulindac treatment groups (i.e. for each analyte for those patients on combination 
treatment). 
The subcategories of FAP events will be explored by disease stratum groups, and by Disease Site 
subgroups (see below).  The subcategories of FAP events include: 
Table 3.3  Disease Site Subgroups 
No Group Description 
1 Disease Progression Indicating Need 
for Colectomy with IRA or Total 
Procto-Colectomy 
Applies only to subjects with FAP surgical 
status of precolectomy (field name: 
DIAGSXST, code 1) 
2 Excisional intervention by surgical 
snare or trans-anal excision to remove 
any polyp >=10mm in size (per 
pathology report) and/or pathologic 
evidence of high grade dysplasia 
Excisional intervention does not apply to 
subjects with FAP surgical status of colectomy 
with ileostomy (field name: DIAGSXST, code 
4) or subjects with FAP surgical status of 
precolectomy (field name: DIAGSXST, code 
1). For all remaining subjects, all >5 mm polyps 
must have been removed at baseline 
also 
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No Group Description 
High grade dysplasia does not apply to subjects 
with FAP surgical status of colectomy with 
ileostomy (field name: DIAGSXST, code 4) 
3 Disease Progression Indicating Need 
for Proctectomy 
Does not apply to subjects with FAP surgical 
status of proctocolectomy with ileal pouch 
anastomosis (IPAA) (field name: DIAGSXST, 
code 3) or FAP surgical status of colectomy 
with ileostomy (field name: DIAGSXST, code 
4) 
4 Disease Progression Indicating Need 
for Pouch resection 
Does not apply to subjects with FAP surgical 
status of precolectomy (field name: 
DIAGSXST, code 1). or FAP surgical status of 
colectomy with ileostomy (field name: 
DIAGSXST, code 4) or FAP surgical status of 
colectomy with ileorectal anastomosis (IRA) 
(field name: DIAGSXST, code 2) 
5 Development of cancer in rectum or 
pouch 
Does not apply to subjects with FAP surgical 
status of colectomy with ileostomy (field name: 
DIAGSXST, code 4) 
6 Progression in Spigelman Stage to 
more advanced stage (Stage 2, 3, 4) 
Does not apply to subjects without duodenum 
(determined by abdominal surgical procedure of 
duodenectomy, duodenohemipancreatomy, or 
Whipple procedure (field name SXPROC) and 
screening/baseline upper GI endoscopy not 
done (field name UGIND, Boolean data type) 
7 Disease Progression indicating need 
for excisional intervention (sub-
mucosal resection, trans-duodenal 
excision, duodenectomy, 
ampullectomy, Whipple procedure) 
Does not apply to subjects without duodenum 
(determined by abdominal surgical procedure of 
duodenectomy, duodenohemipancreatomy, or 
Whipple procedure (field name SXPROC) and 
screening/baseline upper GI endoscopy not 
done (field name UGIND, Boolean data type) 
8 Development of cancer in duodenum Does not apply to subjects without duodenum 
(determined by abdominal surgical procedure of 
duodenectomy, duodenohemipancreatomy, or 
Whipple procedure (field name SXPROC) and 
screening/baseline upper GI endoscopy not 
done (field name UGIND, Boolean data type) 
9 Spigelman stage (no progression) 
 
Does not apply to subjects without duodenum 
(determined by abdominal surgical procedure of 
duodenectomy, duodenohemipancreatomy, or 
Whipple procedure (field name SXPROC) and 
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No Group Description 
screening/baseline upper GI endoscopy not 
done (field name UGIND, Boolean data type) 
10 >= 10 mm polyp in rectum pouch 
 
Does not apply to subjects with FAP surgical 
status of colectomy with ileostomy (field name: 
DIAGSXST, code 4) or subjects with FAP 
surgical status of precolectomy (field name: 
DIAGSXST, code 1). For all remaining 
subjects, all >5 mm polyps must have been 
removed at baseline. 
11 High grade dysplasia (rectum-pouch) 
 
Does not apply to subjects with FAP surgical 
status of colectomy with ileostomy (field name: 
DIAGSXST, code 4) 
 
These subcategories will be analyzed within the assigned disease strata (i.e. assigned at time of 
randomization).  Separately, they will be analyzed by Disease Site, according to the concept of 
“the patient as a whole” meaning that all known disease sites will be considered because patients 
more often than not have more than one diseased organ system.  For example, a patient 
randomized to treatment in the Duodenal Polyposis stratum who is also known to have colonic 
polyps will appear in the analyses for both Disease Site subgroups (Duodenal and Colonic).  The 
total number of patients in the Duodenal Disease Site subgroup will include, for example, all 
patients randomized in the Duodenal Polyposis stratum + all other patients with known duodenal 
disease (irrespective of whether they have rectal/pouch disease).  A similar approach will be 
taken for the Rectum/Pouch Polyposis group and Pre-colectomy strata. 
The presence or absence of ODC polymorphisms, including the single nucleotide polymorphisms 
(SNPS) rs2302615 and rs2302616 and their relation to treatment group and outcome will be 
tested with the likelihood ratio test. 
The excretion of 5 urinary polyamines (diacetylspermine, n1-acetylspermidine, n8-
acetylspermidine, decarboxylated SAM, and putrescine) will be assessed in relation to treatment 
group and outcome, using the single point concentration data gathered from the urine samples 
harvested at each study visit. 
Patient reported health related quality of life measures will be evaluated using HRQoL (see 
Section 5.6 Health Related Quality of Life (HRQoL) Statistical Methods for more details). 
Tissue and dietary polyamine levels, as collected at patient study visits will be analyzed together 
with the results of the dietary questionnaires (see Section 5.7 Dietary Assessment) and related to 
treatment group and study outcomes. 
Safety outcome data and analyses are described in Section 5.5.5 Assessment of Toxicities. 
4. POPULATIONS FOR ANALYSIS 
4.1 Intent-to-Treat (ITT) Population 
The intent-to-treat population includes all patients that have been randomized to one of the three 
study arms.  Patients will be analyzed in the group to which they were randomized, whether or 
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not they received their assigned treatment, any treatment whatsoever, or completed their 
treatment course and follow-up. 
4.2 Safety Population 
The safety population is defined as all ITT patients who received at least one dose of study 
medication.  Patients who do not receive any study treatment (CPP-1X or sulindac or their 
combination) are excluded from this population.  Patients will be analyzed in the treatment group 
according to which actual treatment was initially received. 
4.3 Per Protocol Population 
The per-protocol population is defined as the subset of the ITT population that fulfill all protocol 
eligibility, intervention, and outcome assessments. 
4.4 Other Populations 
Within the entire study patient population there will be subsets who did not receive the full 
course of per protocol treatment.  The major indicators for premature withdrawal are delineated 
below.  The patient diary and pill count will define the extent of treatment compliance during the 
study. 
For exploratory and sensitivity analyses the following subsets will be included in secondary 
analyses: 
• Patients withdrawn for personal reasons 
• Treatment discontinued because of disease symptoms 
• Treatment discontinued because of patient symptoms 
• Compliance <80% treatments taken 
• Treatment discontinued because of intercurrent medical or surgical illness. 
5. DETERMINATION OF SAMPLE SIZE AND STATISTICAL METHODS 
5.1 Determination of Sample Size 
The primary endpoint of this trial, time to meaningful clinical events in an orphan disease 
population, is novel and to date there are no published trials to draw upon that have incorporated 
the exact FAP-related endpoint of this trial.  Available data from primary literature sources 
include clinical studies where polyps were counted over a fixed time period, in different FAP 
populations (see protocol for tabulated listing).   
From these data a reasonable range of event frequencies was estimated to produce the sample 
size and power calculations incorporated into this trial.  These time-to-event estimates were 
reviewed by key FAP opinion leaders prior to finalization of the study design.  The following 
reflects the possible range of FAP events it was thought plausible to observe. 
5.2 Power Calculation Assumptions  
1) The level of statistical significance is set at 0.05, using a 2-sided stratified log-rank test for 
time-to-first FAP-related event in continuous time, for each of the two between-group 
comparisons (i.e. single agent sulindac vs. CPP-1X plus sulindac and single agent CPP-1X vs. 
CPP-1X plus sulindac).  The only covariates in the log-rank test will be the treatment groups 
(see section 7.3 for details); 
2) A doubling of the two-year event-free proportion from either of the single agent treatment 
arms to the combination treatment group;  
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3) Power of at least 85% to detect the above-mentioned treatment effect comparing either of the 
two single treatment arms to the combination arm; 
4) The two single-agent treatment groups have approximately the same event rate. 
The following calculations are based on our review of limited single-agent data for eflornithine 
and sulindac, where FAP clinical trial primary endpoints involved polyp counting.  Extrapolating 
these data to two-year event-free proportions implies a single overall two-year event-free 
proportion of at least 60% to 70% for the combination treatment group and 30% in each single 
agent treatment group.  This is described further in Table 3.2. 
5.3 Hazard Rates 
Because the power of time-to-event analyses depends on the total number of observed primary 
endpoints (“events”) and the hazard ratio in a given two-arm comparison of a single-agent versus 
combination therapy, we translate the above doubling of two-year event-free proportions into 
hazard ratios under a simplifying assumption of exponentially distributed time-to-event.  Note 
that the primary analysis described below, in Section 7.3, does not rely on such an assumption 
and provides a statistically valid test of the null hypothesis even if hazard rates are not constant.  
Furthermore, the stratified log-rank test is an optimal test (locally most powerful) under the 
assumption that the ratio of the two groups’ hazard functions remains constant over time (the 
proportional hazards assumption).  Note that the much stronger assumption, that the individual 
hazard functions themselves remain constant over time, would be dubious in this trial.  
Therefore, irrespective of how the two-year event-free proportions are translated into hazard 
ratios, it is the latter which forms the design alternative parameter for the trial. 
Under the exponential assumption, the hazard ratio (HR) comparing one treatment arm to 
another is given by the natural logarithm of the two-year event-free proportion for the first arm 
divided by the natural logarithm of the two-year event-free proportion for the other arm.  Thus if 
the combination arm is assumed to have a two-year event-free proportion of 60%, which is 
double that of the 30% two-year event-free proportions assumed for the single-agent arms, the 
HR is {log(0.60) / log(0.30)} = 0.4243.  This is the design alternative hazard ratio for this trial 
as it represents the minimum clinically meaningful treatment effect desired for the combination 
therapy compared to either single-agent therapy.  Insofar as the combination therapy may have a 
two-year event-free proportion of at least 60%, and may prove to be perhaps 70% or greater, the 
design alternative HR of 0.4243 is conservative; the true (albeit unknown) HR is thought 
possibly to range from 0.4243 down to 0.30 = {log(0.70) / log(0.30)} (see discussion below). 
Given that the primary hypotheses are stated in terms of comparing either single-agent arm to the 
combination arm, we note that the equivalent design alternative hazard ratio becomes  
{log(0.30) / log(0.60)} = 1/0.4243 = 2.357. 
For the anticipated range of hazard ratios, 25 to 49 events would be needed for each two-group 
comparison at the 2-sided 0.05 level to achieve 85% power [3, 4].  Assuming two-year event 
proportions of 70% in either of the two single-agent groups and 30% to 40% in the combination 
arm with 50 patients per arm, the expected number of patients with an FAP-related event in 
either of the two single-agent groups would be 35 and 15 - 20 in the combination arm.  The study 
design expectation is to have 50 - 55 patients with a FAP-related event in each two arm 
comparison, achieving at least 85% power under the design alternative.  The standard deviation 
around the expectation of 55 events is 4.74, so observing the required number of 49 events or 
more would be highly likely (the probability is about 91%).  If the total number of events in 
either comparison were only 43, there will still be 80% power to declare a significant treatment 
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difference under the design alternative of 0.4243.   
As the two-year event proportion in the combination arm decreases from 40% with a 
corresponding decrease in the hazard ratio, the likelihood of observing the required number of 
events to maintain 85% power actually increases.  For example, at the lower expectation of 50 
events arising from an assumed two-year event proportion of 30% in the combination arm, the 
standard deviation of the total number of events in a two-arm comparison decreases to 4.58 and 
the probability that the observed number of events will exceed the 25 required to achieve 85% at 
a HR of 0.30 is virtually certain. 
5.4 Data Monitoring Committee (DMC)DMC General Information  
A Data Monitoring Committee (DMC) will oversee the performance and safety conduct of this 
study.  The DMC will consist of at least three members (two MDs and one statistician as voting 
members) who will receive confidential reports on a periodic basis.  The DMC will be 
responsible for decisions regarding possible termination of the study for either futility or safety 
reasons. 
A detailed DMC Charter will be produced separately by the DMC membership.  It is anticipated 
that any reviews of study data will be performed in a blinded manner, looking at pooled data (all 
treatment groups combined into one group) to assess mission-critical parameters such as overall 
recruitment and event rates.  Of course, patient safety issues take precedence over bias-protection 
and control of type I error, and so the DMC will have the privilege of breaking the blind on a 
need-to-know basis if safety issues of concern arise in order to consider risk-benefit issues.  
Details concerning DMC responsibilities and duties may be submitted as a stand-alone document 
to the FDA and EMA, including items such as specification of early termination rules and other 
matters as the DMC deems to be important and relevant to the ethical conduct of this study. 
CPP will inform the DMC that there will be two study evaluations for the DMC to consider 
during the trial, one interim look for sample size reassessment and one look for efficacy and 
futility. 
The method for reassessment of sample size is based upon the FDA Guidance, Adaptive Design 
Clinical Trials for Drugs and Biologics (February 2010).  There will be no hypothesis testing.  
The DMC will assess the observed trial event rate based on pooled data only.  They will make a 
recommendation to the sponsor on whether the pooled event rate is sufficient to preserve the 
integrity of the trial, and if not, to recommend a revised sample size.  For this assessment the 
study statistician will, if possible, estimate the overall observed event rate and 90% confidence 
interval.  This assessment will be performed using data from a single time point, when 
enrollment is approximately 95% complete.  If this type of assessment is not possible, then an 
assessment will be performed taking into consideration the total number of subjects randomized, 
total number of events, total number of dropouts, and cumulative study safety data. 
5.4.2 Prespecified Interim Efficacy and Futility Analysis 
A pre-specified interim efficacy and futility analysis will be conducted as described below.  The 
assessment will be performed after a total of 45 primary endpoints have occurred, which 
represents 50% of expected maximum trial information, or as soon thereafter as possible.  After 
reviewing the analysis results in a closed session, the DMC will provide recommendations 
regarding possible termination of the study for either futility, efficacy, or safety reasons, to the 
Sponsor Steering Committee. 
The analysis will be performed for each of the two treatment comparisons contained in the 
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primary objective:  
1. CPP-1X placebo + sulindac active vs. CPP-1X active + sulindac active, 
and 
2. CPP-1X active + sulindac placebo vs. CPP-1X active + sulindac active. 
As stated above in Section 3.2, the combination of CPP-1X active + sulindac active is specified 
as the reference treatment group because it is common to both comparisons and formulating the 
hypothesis tests in this manner will allow a positive rather than a negative Z-score for the test 
statistic to be interpreted as supportive of this purpose. 
The efficacy analysis will use a modified Haybittle-Peto stopping rule based on the stratified log-
rank Z-score.  If that Z-score equals or exceeds 3.2905 in absolute value, for either two-arm 
comparison, the difference between treatment arms would be declared statistically significant at 
the two-tailed 0.001 level of significance.  In that case it may be reasonable for the DMC to 
initiate a conversation about stopping the trial on ethical grounds.  Assuming this is not the case 
and the trial continues to its planned end, the Z-score criterion for declaring significance at the 
5% level at the end of the trial will be increased in magnitude to plus or minus 1.962 in order to 
preserve the overall type I error rate for the trial at 0.05. 
For the futility analysis, the DMC will be provided with the numerical value of the stratified log-
rank Z-score.  The futility analysis uses a one-sided futility stopping criterion of Z = −0.50. That 
is, if the Z-score is less than or equal to −0.50, an investigation will be initiated to consider 
stopping the trial for futility or discontinuing one of the single-agent treatment arms.  The futility 
stopping criterion of Z = −0.50 is consistent with a conditional power of less than 20%.  That is, 
assuming between 44 and 60 FAP-related events have occurred by trial end in either of the two-
arm comparisons (where between 52 and 55 are expected), if the log-rank critical ratio Z-score 
were equal to −0.5 (or less) when one-half the expected total number of events had been 
observed (namely, 45 across all three arms), then under the design alternative hazard ratio of 
2.3569, there would be no more than a 20% chance of declaring a significant benefit of the 
combination therapy compared to the single agent therapy if the trial were to continue to the 
planned end. In that case, it would be reasonable for the DMC to consider stopping or altering 
the trial on grounds of futility.  The DMC will also be provided with the conditional power of the 
observed Z-score for each two-arm comparison. 
The details of the efficacy and futility analysis are provided in Table 5.1 below which presents a 
schematic diagram of the procedure.  Also Table 5.2 provides more precise conditional power 
values corresponding to the futility criterion Z = −0.50 as a function of the total number of events 
in either two-arm comparison.  See Section 7.4 below for further details of the conditional power 
calculation. 
Any numerical values generated from the futility analysis (such as Z-score, conditional power, 
etc.) must be treated as confidential by the DMC and Independent Statistician at the CRO.  If the 
DMC recommendation is to continue the study as planned, such numerical values will not be 
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Table 5.1 Interim Futility Analysis Details 
Estimated Look Time Point Description 
 
When 45 primary endpoints have 
occurred, corresponding to when 
50% of maximum trial information 
has been amassed 
Efficacy criterion Z = 1.962 at terminal analysis. 
Futility criterion of Z = −0.50 or less at interim analysis. 
Type I error for exiting the upper efficacy boundary at or 
before terminal analysis = 0.024952.* 
Type I error for exiting the lower efficacy boundary at or 
before terminal analysis = 0.001928.* 
Total Type I error for end of study comparison  =  0.026936.* 
Assuming 52 events at trial end in either two-arm 
comparison, power = 0.8705. 
Assuming 55 events at trial end in either two-arm 
comparison, power = 0.8881. 
 
*Assume one interim analysis at ½ information time with upper efficacy boundary at Be 
= 3.2905, lower efficacy boundary at −Be, and one-sided futility boundary  
Bf  = −0.50.  Assume upper efficacy terminal criterion C = 1.9602 and lower efficacy 
terminal criterion −C.  Then the probability of exiting the upper efficacy boundary at 
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and the probability of exiting the lower efficacy boundary at either interim or terminal 






e dzzCzB )()2()(  , 
where )(z  is the standard normal probability density function and )(z  is the standard normal 
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Information Fraction (1 = Total Expected Number of FAP events / 4)
Stop for futility----->
Z = −0.5
Continue until trial end----->
Reject Ho in favor 
of combination Tx
Reject Ho in favor 







Reject Ho in favor 
of combination Tx
Reject Ho in favor 
of single agent Tx
 
 
Table 5.2 Conditional Power at the Futility Boundary as a Function of Number of FAP 
Events at the Time of Futility Analysis, Using Futility Criterion Z = −0.5 
Total FAP events  
in either two-arm comparison 
at time of futility analysis 
Assumed number of FAP-related events  
in either two-arm comparison 




30 60 0.177 
29 58 0.167 
28 56 0.157 
27 54 0.148 
26 52 0.138 
25 50 0.129 
24 48 0.120 
23 46 0.111 
22 44 0.103 
 
5.5 Statistical Methods 
5.5.1 Demographic and Baseline Characteristics 
Patients in the three populations (see Section 4.) will be summarized for demographic and 
baseline characteristics in a descriptive fashion.  Namely, categorical and continuous-valued data 
will be displayed using standard summary statistics (e.g., frequency tables, n, means, medians, 
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standard deviations, and ranges).  Data will be presented per group and overall. 
Demographic features summarized will include age, gender, race, institution at which each 
patient registered, and country, among other features.  Baseline characteristics will include 
laboratory values and disease-related characteristics, as well as any other relevant values.  
Categorical data will be compared among groups using chi-squared methods, while continuous-
valued data will be compared using standard nonparametric methods (e.g., the Kruskal-Wallis 
test)[5].  Significance will be defined at the 0.05 level, unless otherwise noted.  Thus p-values 
less than or equal to 0.05 will be declared significant. 
5.5.2 Patient Disposition and Treatment Summaries 
Subjects will be assigned for analysis to the treatment group to which they were randomized, 
regardless of whether the patients received any treatment. 
Patient disposition and treatment will be summarized for the ITT and safety populations defined 
previously (see Section 4.2).  Patient disposition will be consistent with the CONSORT 
criteria[6], and will include per treatment group enumeration of all patients randomized, the 
number deemed ineligible, the number of FAP-related events, and the number of study drop outs.  
These will be further described in subgroups such as drop outs due to adverse events, serious 
adverse events, administrative withdrawals for non-compliance for more than 90 days from 
randomization to month 36 or more than 105 days from randomization to month 42 or more than 
120 days from randomization to month 48, withdrawals of consent for continued follow-up, 
withdrawals for other reasons, and the number lost to follow-up.  Additional summaries will 
include reasons for patients discontinuing treatment and/or modifying treatment dosages.  A 
listing of screened and ineligible patients along with the reason for each also will be summarized. 
5.5.3 Analytic Methods for Time-to-Event Data 
The analytic method for the primary analysis will be a time-to-event analysis using the stratified 
log-rank test, as previously described.  The stratified Cox proportional hazards regression models 
will be used for secondary assessments[7].  Graphical analyses (log-minus-log plots) will be used 
to check the assumption of constant hazard ratios.  See Section 7.3 below for further details of 
the calculation of the stratified log-rank statistic. 
For the primary analysis, two stratified log-rank tests will be performed with treatment coded as 
a binary value (i.e., 0 or 1). Time to event curves will be displayed using the method of Kaplan 
and Meier[8].  Additional analyses involving the overall 3-treatment group comparison, and use 
of additional study populations (see Section 4.) for the two pairwise treatment comparisons, will 
be performed as supplemental analyses. 
If an FAP-related event occurs, that patient will be said to have an observed or uncensored event 
and will be considered a treatment failure.  If a subject withdraws, that subject will be treated as 
a censored observation as of the last recorded clinic visit (endoscopic disease assessment). 
If a subject has not progressed or is not known to have died at the date of analysis cut-off, time to 
first FAP-related event will be censored at the date of the last adequate endoscopy procedures 
before the cut-off date.  Similarly, if a subject discontinues study participation due to toxicity and 
begins receiving other therapy, the time to FAP event will be censored at the date of the last 
adequate endoscopy procedure.   
If a subject has two or more missing assessments, time to first FAP-related event for the subject 
will be censored at the time of last adequate evaluation prior to the missing assessment. 
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If a subject has no baseline assessment, time to first FAP-related event for the subject will be 
censored at the date of randomization. 
See Section 5.5.6 below for further details of handling missing data.  Every effort will be made 
to minimize the occurrence of censoring and missing data. 
Prior to the primary analysis, balance will be assessed between the three arms in terms of key 
potential confounders measured at the baseline visit.  If any of these variables is found 
significantly out of balance across the three groups using a 2 degree of freedom test of 
homogeneity at the 0.01 level of significance, it will be incorporated into a sensitivity analysis 
using a stratified Cox model including that term in addition to the treatment arm.  The primary 
result for the trial will be the unadjusted stratified log-rank test.  The covariate-adjusted score test 
(adjusted stratified log-rank test) will serve only as a secondary analysis to aid in the 
interpretation of the primary result. 
5.5.4 Analytic Methods for Categorical or Continuous-Valued Secondary Outcome and 
Safety Data 
For categorical data, comparisons will be made between treatment groups using standard chi-
squared techniques as the primary approach.  In particular, the Cochran-Mantel-Haenszel one 
degree of freedom test will be used to reflect the stratified randomization.  Exact p-values and 
95% confidence intervals by the point-probability method will be reported[1]. 
For continuous endpoints, standard analysis of covariance (ANCOVA) methods will be used as 
the primary approach to compare treatment groups at end of treatment with the following 
covariates: baseline value, binary indicator variables for the two highest-risk stratification levels 
used in the randomization (using the lowest-risk, i.e., rectum/pouch polyposis, group as the 
reference stratum), and a binary treatment indicator (1=combination treatment, 0=single 
treatment). 
For ordered categorical data, a Kruskal-Wallis nonparametric test for ordered categorical 
response will be used to compare treatment groups[5]. 
5.5.5 Assessment of Toxicities 
Treatment-emergent adverse events will be enumerated and analyzed according to the incidence, 
intensity, type of adverse events, and clinically significant changes in the patient’s physical 
examination findings, vital signs and clinical laboratory results. Safety variables will be tabulated 
and presented for all patients in the safety and per-protocol populations as defined previously.  
Adverse events will be graded and coded using the NCI Common Terminology Criteria for 
Adverse Events (CTCAE, Version 4.03).  Treatment-emergent events will be tabulated, where 
treatment-emergent is defined as any adverse event that occurs after administration of the first 
dose of study drug and through 30 days after the last dose of study drug, or any event that is 
present at baseline and continues after the first dose of study treatment but worsens in intensity.  
Events that are considered related to treatment (possibly, probably or definitely drug-related) will 
also be tabulated separately.  Tables that enumerate adverse events by severity will be provided.  
Deaths, serious adverse events and events resulting in study discontinuation will be tabulated in 
data listings including additional relevant information on each patient.  Tables will be presented 
both overall (all arms combined), by each treatment group separately, and by cell. Where 
appropriate, statistical comparisons between treatment arms will be provided using the above-
mentioned methods for analysis of categorical data. 
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5.5.6 General Procedures for Handling Missing Data 
Every reasonable effort will be made to continue follow-up of all study participants, including 
those who discontinue randomized therapy, to prevent data loss. It is recognized that missing 
values represent a potential source of bias in a clinical trial and so every effort will be undertaken 
to fulfill all the requirements of the protocol concerning the collection and management of data. 
For the primary time to event analysis, the only possible patient outcome is an observed FAP-
related event or a censored observation.  Participants who are lost to follow-up will be censored 
at the time their status is last known, based upon data collected at the last recorded clinic visit.  
For patients who may have missed a study visit, every effort will be made to obtain endoscopic 
results at their close-out visit and those endoscopy results will be used for the primary analysis 
Secondary analysis data include the presence of a specific genetic mutation, and urinary metabolite 
concentrations (see Section 3.2.3).  The main analysis of the secondary objectives will include 
collected data only, without imputing or weighting data to compensate for missing data.  For 
sensitivity analyses involving secondary endpoints with missing data, we will use the last 
observation carried forward (LOCF) method to complete the missing data.  Any sensitivity 
analysis that incorporates LOCF will be clearly noted.  Sensitivity analyses of these data will be 
performed to explore study results more fully, in a manner consistent with ICH Guidance “E9 
Statistical Principles for Clinical Trials (February, 1998)”. 
All available efficacy and safety data will be included in data listings and tabulations. Data that 
are potentially spurious or erroneous or appear as outliers will be examined using standard data 
management operating procedures, prior to database lock and statistical analysis.  These 
procedures will be fully described in the study report. 
5.5.7 Subgroup Analyses 
Subgroups will be analyzed in the spirit of exploratory analyses including but not limited to the 
various study populations (see Section 4) and separately within each disease-prognosis stratum. 
5.6 Health Related Quality of Life (HRQoL) Statistical Methods 
For this study four (4) instruments to measure HRQoL and patient preferences or utilities will be 
administered to subjects at baseline and at 3, 6, 12, 18, 24, 30, 36, 42 and 48 months post-
enrollment/end of treatment.  These instruments include the EORTC QLQ-C30, EORTC QLQ-
CR29, EQ-5D, and a modified Cancer Worry Scale. 
• The EORTC QLQ-C30 is a self-administered quality of life questionnaire[9] with multi-
dimensional scales. It consists of both multi-item scales and single item measures, 
including five functioning domains, a global quality of life domain, three symptom 
domains and six single items. 
• The EORTC QLQ-CR29 gastrointestinal/colorectal sub-module[10] is composed of 4 
functional and 18 symptom related sub-scales.  The 4 functional scales include body 
image, weight, anxiety and sexual function.  The symptom related scales include single 
item and multi-item questions concerning stool frequency, bleeding and mucous 
discharge, stool leakage, abdominal bloating, flatulence, embarrassment and site-specific 
pain among others. 
• The EuroQoL EQ-5D is a standardized instrument for use as a measure of health outcome 
and is applicable to a wide range of health conditions and treatments[11, 12].  It provides 
a simple descriptive profile and a single index value for health status. 
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• The Cancer Worry Scale[13] is a brief psychometric instrument that was designed to 
assess both the frequency of worrying about “getting cancer some day” and measuring 
the impact of worry on mood and performing daily activities.  This scale was originally 
developed by Caryn Lerman and her colleagues to study breast cancer and has been 
modified for use in this FAP trial. 
The validity and reliability of both the QLQ-C30 and the QLQ-CR29 questionnaires have been 
studied by the EORTC Study Group on Quality of Life and both instruments will be scored 
according to the EORTC Scoring Manual and analyzed accordingly.  For each single item or 
multi-item sub-scale, a linear transformation will be applied to standardize raw scores to range 
between 0 and 100.  HRQoL secondary endpoints will include all single item or multi-item sub-
scales from both the EORTC QLQ-C30 and QLQ-CR29 and patients will be considered as 
deteriorated (or improved) for a given single item or multi-item sub-scale if their change score 
from baseline was 10 points or more on the standardized scale.  
Patient preferences (or utilities) will also be assessed using the EuroQoL EQ-5D.  Preference 
weights among the treatment arms will be determined using the EuroQol EQ-5D assessment of 
individual health states[11, 12].  Quality-adjusted survival among the three treatment arms will 
be generated by multiplying the utility value by the amount of time spent in a specified health 
state. 
The modified version of the Cancer Worry Scale will also be administered and it will be scored 
according to the guidance provided by Lerman et al[13]. 
HRQoL data will be obtained while patients are receiving treatment. At the time of an FAP-
related event (primary outcome), additional long-term clinical follow-up and QoL data will not 
be obtained as part of this trial. Hence, HRQoL trends comparing the nine subsets will be 
obtained, but comparative longitudinal analyses defining the impact of an FAP-related event on 
QoL will not be feasible until subsequent long-term studies are performed. 
5.7 Dietary Assessment 
The Food Frequency Questionnaire (FFQ) is the most common dietary assessment tool used in 
large epidemiologic studies of diet and health.  The self-administered FFQ booklet asks 
participants to report the frequency of consumption and portion size of approximately 125 line 
items over a defined period of time (e.g. the last month; the last three months).  Each line item is 
defined by a series of foods or beverages.  Additional questions on food purchasing and 
preparation methods enable the analysis software to further refine nutrient calculations.  The 
FFQ was developed by the Nutrition Assessment Shared Resource (NASR) of the Fred 
Hutchinson Cancer Research Center.  NASR periodically updates its standard FFQ to reflect 
U.S. food consumption patterns and major changes in the market place[14, 15].  Data from the 
FFQ will be analyzed using a polyamine database[16-18] and will calculate the average daily 
levels of putrescine, spermidine, and spermine in the diet.  Dietary assessments via the FFQ will 
be obtained at baseline, months 12, 24, 36, 42 (only if end of treatment), and 48/end of treatment 
for subjects at North American (U.S. and Canada) sites only.  Clinical study sites outside of 
North America will not be included because the foods on the North American food frequency 
questionnaire are not the same as those widely consumed in Europe and elsewhere.  
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6. RANDOMIZATION ALGORITHM AND STRATIFICATION FACTORS 
At least 150 eligible patients will be randomized in this study.  Patients will be randomized to 
one of three treatment groups in equal proportions (i.e., 1:1:1 randomization): 1) CPP-1X plus 
sulindac, 2) CPP-1X-placebo plus sulindac, 3) CPP-1X plus sulindac placebo. 
A stratified randomization procedure will be used with stratification based on FAP-related time-
to-first-event prognosis.  The event prognosis groups are represented by 1) best (i.e., longest 
projected time to first FAP-related event) - rectal/pouch polyposis, 2) intermediate - duodenal 
polyposis, and 3) worst - pre-colectomy.  If a subject has two or more of these disease sites, the 
most severe prognosis stratum will be assigned for randomization (e.g. worst > intermediate > 
best).  Since an individual may have more than one disease site involved, the trial will assess 
time to any defined FAP-related event in the patient as a whole.  In order to minimize potential 
treatment arm imbalance a centralized randomization process will be used to balance among 
treatment groups within prognostic strata. 
7.  OTHER ISSUES AND FURTHER DETAILS 
7.1 Statistical Software Used in Data Analysis 
All analyses will be performed using SAS statistical analysis software version 9.1 or later.  If other 
software is used (i.e. WinNonPop for population pharmacokinetics, SAS macros for futility 
analysis, etc.), it will be clearly described in the clinical and statistical study reports. 
7.2 Draft Tables, Listings and Figures 
The TLF (Tables, Listings, Figures) templates and shells are noted as Ver. 2.0, October 6, 2014 
(SAP Ver. 3.0 September 30, 2014) based on revision provided from Data 
Management/Statistical Group at Ockham now Chiltern.  These draft templates have been 
removed as an Appendix to the amended SAP and are available upon request. 
7.3 Details of Calculating the Stratified Log-rank Z-Score 
Patient follow-up will be analyzed in continuous time, although it is recognized that FAP event 
detection will cluster around scheduled study visits, at months 6, 12, 18, 24, 30, 36, 42 and 48 
and event times may be tied as follow-up time is measured only to the nearest day. Censorings 
are possible at the baseline visit (month 0) for patients who dropped out of the trial before their 
first follow-up visit.  The primary test statistic will be the stratified log-rank statistic.  Each two-
arm comparison will be performed separately.  This will be implemented in SAS by specifying 
the TIES=DISCRETE option in PROC PHREG.  The single agent treatments, respectively, will 
be coded as 1 and the combination treatment will be coded as 0.  The square root of the score test 
chi-squared statistic will be calculated and the sign of the estimated log hazard ratio (+ if the 
HR>1 and − if the HR<1) will be attached.  This results in the stratified log-rank Z-score.  In 
symbols, 2)ˆ( XsignZk =  , where ̂  denotes the estimated log hazard ratio coefficient for 
treatment A in the Cox model and where X2 denotes the SCORE TEST chi-squared statistic 
reported within the “Testing Global Null Hypothesis: BETA=0” table at the top of the PHREG 
results section.   
The following sample PHREG procedure could be used in SAS to derive the stratified log-rank 
Z-score: 
proc phreg data=TwoArmData; 
model time*censor(1) =  Treatment / rl ties=discrete; 
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strata Stratification_Factor; 
title "Stratified Cox Regression Analysis for Single Agent vs Combination"; 
run; 
quit; 
NB:  The model includes the variables time, censor, and treatment, only. 
 
7.4  Details of Calculating Conditional Power 



















Zk is the value of the stratified log-rank test statistic from the observed data at interim analysis; 
z1−/2 is the critical value for a two-tailed test at =0.05, namely +1.962 adjusted for the interim 
efficacy analysis; 
IK = the information number expected at trial end = ¼ times the total expected number of events;  
Ik = the information number at futility analysis = ¼ times the observed number of events at 
interim analysis; 
θ is the log hazard ratio at the design alternative, log 2.3569 = −log 0.42428 = +0.85736; and 
)(  is the standard normal cumulative distribution function. 
 
Example.  Suppose at the time of interim analysis, the number of FAP-related events are as follows:  
For single-agent treatment A, 20; for single-agent treatment B, 16; and for combination treatment 
C, 9.  Then in the two-arm comparison of A versus C, there would be a total of 29 events, so the 
information number is Ik=29/4=7.25.  We assume that there will be double this number for the 
corresponding comparison at the end of the trial; thus IK = 14.5.  Suppose the Z-score at the futility 
analysis happens to just equal the futility criterion, i.e., suppose Zk = −0.50.  Then applying the 

















This is the conditional power at the futility boundary.  Suppose, however, that the observed Z-
score at the futility analysis were actually +0.50 instead of −0.5.  Then the −0.5 in the first term of 
the above expression would be replaced by Zk=+0.50, and the resulting observed conditional power 
would be 0.5135, a non-futile result. 
Note that the probability of a significant negative result at the terminal analysis, given that there is 
no stopping for futility at the interim analysis, is not included in the above expression.  That is 
because practical interest for futility analysis resides only in the conditional probability of a 
significant benefit of the combination treatment.  In any case, the term which has been omitted is 
numerically negligible. 
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Summary of SAP Changes Ver. 2.0 11April2013 to Ver. 3.0 30September2014 
 
Section Change or Revision 
Global Changes Changed version to Ver. 3.0 September 30, 2014, corrected typographical errors, updated 
TOC 
3.2 Study Objectives and 
Primary Hypothesis Testing 
Clarified report sections where the study analysis and ITT population are defined, as 
follows:  
“The primary study analysis will be performed using the intent-to-treat (ITT) population 
which is defined in Section 4.1.  Statistical methods for the primary analysis are described 
in Section 5.1” 
5.1 Determination of Sample 
Size, #1 
Reiterated (i.e. was stated elsewhere in the document) that, “The level of statistical 
significance is set at 0.05, using a 2-sided stratified log-rank test for time-to-first FAP-
related event, for each of the two between-group comparisons (i.e. CPP-1X plus sulindac 
vs. CPP-1X and CPP-1X plus sulindac vs. sulindac);”  
5.2 Data Monitoring 
Committee 
Clarified the futility analysis: “The futility assessment will be performed in a blinded A 
versus B manner” and add the following section:  
For the futility interim analysis, the futility stopping criterion of Z=0.50 is one-sided, and 
corresponds to a conditional power criterion of approximately 0.12 (to two decimals). That 
is, assuming between 52 and 55 expected total number of events by trial end, if the log-
rank critical ratio Z-score were equal to 0.5 (or less) when one-half the expected total 
number of events had been observed, then under the design alternative hazard ratio of 
0.4243, there would be only a 12% probability (or less) of declaring a significant benefit of 
the combination therapy compared to the single agent therapy if the trial were to continue 
to the planned end. In that case, it would be reasonable for the DMC to consider stopping 
the trial for futility. Futility analysis results will be presented in a simple manner where the 
DMC will be informed that the conditions indicating futility have been met. 
5.3.3 Analytic Methods for 
Time-to Event Data 
Clarified that both the log rank test and the Cox proportional hazards regression models 
will be stratified. 
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Study ID: CPP FAP-310, A Double-Blind, Randomized, Phase III Trial of the Safety and 
Efficacy of CPP-1X / Sulindac Compared with CPP-1X, Sulindac as Single Agents in Patients 
with Familial Adenomatous Polyposis (FAP)  
 
Summary of SAP Changes Ver. 3.0, 30September2014 to Ver. 4.0, 15February2016 
Section Change or Revision 
Global Changes Changed version to Ver. 4.0 February 15, 2016; updated TOC, updated references 
Section 1. List of 
Abbreviations 
Added AC – Adjudication Committee; CRO – Contract Research Organization; EDC – 
Electronic Data Capture 
Section 3.1, Overview of 
Study 
Added to 2nd paragraph: 
Subjects completing 24 months of treatment without an FAP event may continue treatment 
for up to 12 additional months until one of the following occurs: 1) subject has an FAP 
event or comes off study for other reasons, 2) all randomized subjects have reached a 
minimum of 24 months of treatment or have come off study prior to reaching 24 months of 
treatment. 
Deleted Accrual is expected to take 6 – 12 months. 
Paragraph 4, Changed Appendix D to Appendix E 
Updated CTCAE version from Version 4 to Version 4.03 
Section 3.2 Study Objectives 
and Primary Hypothesis 
Testing 
1st paragraph, Inserted “Section” in front of 5.1 
Section 3.2.1 Regulatory 
Review of Primary Outcome 
Compliance 
Changed SWAP to SAWP 
Section 4.3 Per Protocol 
Population 
Changed “The per protocol population is defined as the subset of the ITT population who 
completed all 24 months of treatment and have primary endpoint determination performed 
per protocol specifications.” 
To “The per-protocol population is defined as the subset of the ITT population that fulfill 
all protocol eligibility, intervention, and outcome assessments.” 
Section 4.4 Other Populations Revised the first paragraph to read: 
Within the entire study patient population there will be subsets who did not receive the full 
course of per protocol treatment.  The patient diary and pill count will define the extent of 
compliance.  This subgroup of patients will be categorized into various cohorts.  For 
consistency, an adjudication committee will be established, to review all study events (i.e. 
FAP related events and dropouts), and categorize them either as censored observations or 
imputed endpoints (see Section 5.2.2).  For exploratory and sensitivity analysis the 
following dropout subsets will be included in secondary analyses: 
Section 5.2 Changed section title to Data Monitoring Committee (DMC) and Adjudication Committee 
(AC) 
Section 5.2.1 Data Monitoring 
Committee (DMC) 
2nd paragraph, Changed “….document to FDA” to “document to FDA and EMA” 
3rd paragraph, Deleted “(based on a blinded A/B comparison). 
4th paragraph  
3rd sentence changed “perform an assessment of” to “assess” 
5th sentence added….study statistician will, “if possible”, estimate the overall….. 
7th sentence deleted “With this approach study enrollment can continue uninterrupted at 
the study sites, if it is decided to increase study sample size.” Replaced text with the 
following “If this type of assessment is not possible, then an assessment will be 
performed taking into consideration the total number of subjects randomized, total 
number of events, total number of dropouts, and cumulative study safety data.” 
5th paragraph: revised as follows: 
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The futility assessment will be performed after a total of 45 adjudicated primary endpoints 
have occurred, which represents 50% of expected maximum trial information, or as soon 
thereafter as possible. 
The futility analysis will be performed for each of the two treatment comparisons contained 
in the primary objective:  
1. CPP-1X active + sulindac active vs. CPP-1X placebo + sulindac active,  
and 
2. CPP-1X active + sulindac active vs. CPP-1X active + sulindac placebo  
7th paragraph:  
2nd sentence revised as “That is, assuming between 52 and 55 expected total number of 
events have occurred by trial end in either of the two-arm comparisons, if the log-rank 
critical……” 
4th and 5th sentence revised as “The futility analysis results will be presented in a simple 
manner whereby the DMC will be informed that the conditions indicating futility have 
been met (i.e. the futility boundary has been crossed, yes or no).” 
Table 5.2 Interim Futility 
Analysis Details 
First column – Estimated Look Time Point 
Deleted 1.5 years.  Added “When 45 adjudicated primary endpoints have occurred, 
corresponding to when 50% of maximum trial information has been amassed.” 
 
Second column – Description: Updated to read as follows: 
Efficacy criterion Z=1.96 at terminal analysis. 
Futility criterion of Z=0.50 or less at interim analysis. 
Total Type I error for end of study comparison  =  0.0471. 
NB: Assuming D = 52 events at trial end in either two-arm comparison, power = 0.8566.  
Assuming D = 55 events at trial end in either two-arm comparison, power = 0.8750. 
Added New Section 5.2.2 
Adjudication Committee 
(AC) 
Added  A blinded adjudication committee (AC) will be formed for the purpose of 
reviewing all possible primary outcomes, for all randomized patients.  The committee will 
be composed of one or more clinical specialists with experience and expertise in treatment 
of FAP.  The process will follow other reported AC review procedures used in clinical 
trials with interim analyses[3]. 
To organize the review process, a subject profile document will be developed in advance of 
the first review cycle, which will contain all information deemed necessary for the AC 
review. Elements of the profile will include subject eligibility, baseline characteristics, 
investigator assessment of primary endpoint status, other information related to study 
primary endpoint status, and related investigator comments, as collected by the EDC 
system.  On a periodic basis, upon request from the Sponsor, the CRO will prepare one 
profile document for each subject that has completed the treatment phase of the study.  If 
auxiliary information is requested by the AC, documents will be made available to the AC 
where ever possible. 
The AC will review the profile information in a secure manner and submit a reviewer 
worksheet, indicating their assessment of whether or not the data indicate that the subject 
reached an FAP-related event.  For each withdrawal from follow-up for reasons other than 
an FAP-related event (including those subjects that decline the extended treatment after 
completing 24 months of treatment), the AC will determine whether or not the reasons 
recorded for the withdrawal can be deemed unrelated to endpoint status.  If the AC deems 
the reasons for withdrawal unrelated to endpoint status, the withdrawal will be entered as a 
censored observation as of the time of the last recorded clinic visit.  If the AC cannot deem 
the withdrawal as unrelated to endpoint status, the withdrawal will be considered an 
imputed primary endpoint on grounds of treatment failure.  The follow-up time will be as 
of the last recorded clinic visit. 
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The committee will be blinded to treatment assignment without exception.  All AC review 
results will be forwarded on to the CRO for data entry and future reporting of AC findings. 
The AC will be instructed to apply the following criterion to determine whether or not the 
withdrawal is “unrelated to endpoint status.”  The key is to determine whether or not the 
censoring is plausibly non-informative about the additional time it would take to observe 
an FAP-related event if the subject continued in the trial.  More precisely, the AC will first 
be asked to contemplate the statistical distribution of the additional time to wait for an 
actual FAP-related event for the given subject, assuming counterfactually that the subject 
had not withdrawn and instead continued in the trial, while taking account of the reasons 
the subject has in fact given for his or her withdrawal.  This distribution need not be known 
explicitly, merely conceptually, as in a thought experiment.  According to the reasons 
given, the AC may assume the subject would remain on or come off study medication in 
the hypothetical continuation, whichever the clinically relevant assumption might be.  Then 
the AC will be asked to again contemplate the same statistical distribution (i.e., the 
additional waiting time to an actual FAP-related event assuming counterfactually that the 
subject had not withdrawn and instead continued in the trial), but this time completely 
ignoring the reasons given for the subject’s withdrawal (assuming the same hypothetical 
continuation or discontinuation of study medication as in the first instance).  If these two 
distributions are plausibly the same, then the withdrawal is non-informative about the 
additional waiting time to an FAP-related event and the censoring time is statistically 
independent of the time to an FAP-related event.  In other words, the withdrawal is 
“unrelated to endpoint status” and will be handled as a censored observation.  If the two 
distributions are plausibly different, then the withdrawal is informative and the censoring 
time is not statistically independent of the time to an FAP-related event.  In other words, 
the withdrawal is not “unrelated to endpoint status” and will be handled as an imputed 
primary endpoint on grounds of treatment failure. Examples of reasons related or unrelated 
to endpoint status will be given to the AC. 
These adjudication decisions are required because for a time-to-event analysis with 
censoring, the censoring times must be statistically independent of the times to primary 
endpoint. Distinguishing between independent censored observations and imputed primary 
endpoints on grounds of treatment failure will also enhance the clinical meaningfulness of 
the comparisons in the trial.  
Section 5.3.1, Demographic 
and Baseline Characteristics 
2nd paragraph: Added ‘and country” 
Deleted “(Tables 9.1-9.3, Section 9 Appendices) 
Added last sentence “Significance will be defined at the 0.05 level, unless otherwise noted.  
Thus p-values less than or equal to 0.05 will be declared significant.” 
Section 5.3.2 Patient 
Disposition and Treatment 
Summaries  
2nd paragraph 
Deleted “and will include pretreatment group enumeration of all patients randomized, 
number ineligible, early termination due to AE/SAE, the number of subjects with an SAE, 
deaths, dropout for other reasons, and the number of subjects,”  
Changed To “and will include per treatment group enumeration of all patients randomized, 
the number deemed ineligible, the number of FAP related events, and the number of study 
drop outs.  These will be further described in subgroups such as drop outs due to adverse 
events, serious adverse events, administrative withdrawals for non-compliance for more 
than 90 days, withdrawals of consent for continued follow-up, withdrawals for other 
reasons, and the number lost to follow-up.” 
Changed “Additional summaries will include reasons for patients discontinuing treatment 
and/or modifying treatment dosages and a summary of patients’ treatment status.  To 
“Additional summaries will include reasons for patients discontinuing treatment and/or 
modifying treatment dosages.” 
Deleted in the last paragraph, last sentence “(Tables 9.4-9.7 in Section 9, Appendices).” 
Section 5.3.3 3rd paragraph 
Revised “If an FAP related event occurs, that patient will be said to have an observed or 
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uncensored event and will be considered a treatment failure.  As explained above in 
Section 5.2.2, if the endpoint determination cannot be made at the end of study clinic visit 
per the pre-specified study requirements, a blinded adjudication committee will review the 
reasons for such deviations.  If upon blinded adjudication it can be determined that a 
subject’s withdrawal is for reasons deemed unrelated to his or her endpoint status, that 
subject will be treated as a censored observation as of the last patient visit.  If upon blinded 
adjudication it cannot be determined that a subject’s withdrawal is unrelated to endpoint 
status, an imputed primary endpoint will be used in the primary analysis for such 
withdrawals.  The time to this imputed event will be from randomization to the last 
recorded patient visit.   All other subjects who complete their follow-up without a FAP 
related event by the end of the study will be treated as a censored observation as of the 
actual follow-up time for the close-out visit.  See Section 5.3.6 below for further details of 
handling missing data.” 
Added paragraph 4 as follows 
“Prior to the primary analysis, balance will be assessed between the three arms in terms of 
key potential confounders measured at the baseline visit.  A brief list of such potential 
confounders will be presented to the DMC for approval prior to analysis.  If any of these 
variables is found significantly out of balance across the three groups using a 2 degree of 
freedom test of homogeneity at the 0.01 level of significance, it will be incorporated into 
the primary analysis using a stratified Cox model including that term in addition to the 
treatment arm.  The covariate-adjusted score test (adjusted stratified log-rank test) will 
serve as the primary result for the trial.” 
Section 5.3.5 Assessment of 
Toxicities 
Deleted “(Tables 9.8 – 9.17, in Section 9 Appendices)” 
Section 5.3.6 General 
Procedures for Handling 
Missing Data 
2nd paragraph, Added 6th sentence “A study event adjudication committee (AC) will be 
formed to further define the methods for defining imputed and censored events (see 
Sections 4.4 and 5.2.2).” 
3rd paragraph: Changed ICH reference from “September, 1998” to “February, 1998” 
Section 5.4 Health Related 
Quality of Life Statistical 
Methods 
1st sentence Added “…24 , 30 and 36 months…” 
Section 5.5 Dietary 
Assessment 
Deleted last sentence “The results of the FFQ will be used to corroborate results from 
another recent trial that indicate consumption of a diet high in polyamines is associated 
with reduced treatment efficacy.  The results of this trial, along with the earlier findings of 
Zell et. Al could lead to dietary restrictions in combination with the combined eflornithine 
sulindac therapy.” 
Section 7.2, Draft Tables 
Listings and Figures 
Added Section as these have been deleted as an appendix to the SAP. 
“The TLF (Tables, Listings, Figures) templates and shells are noted as Ver. 2.0, October 6, 
2014 (SAP Ver. 3.0 September 30, 2014) based on revision provided from Data 
Management/Statistical Group at Ockham now Chiltern.  These draft templates have been 
removed as an Appendix to the amended SAP and are available upon request.” 
References Added Schoenfeld D Biometrica (1981) 68, 316-319, also cited on page 10 Section 5.1. 
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Summary of SAP Changes Ver. 4.0, 15February2016 to Ver. 4.1, 27December2016 
Section Change or Revision 
Global Changes Changed version to Ver. 4.1 27 December, 2016; updated TOC 
Section 1. List of 
Abbreviations 
Deleted AC – Adjudication Committee;  
Added CEC Clinical Events Committee (also referred to an Adjudication Committee) 
Section 3.2 Study Objectives 
and Primary Hypothesis 
Testing 
1st paragraph, Inserted: “Sections” in front of 5.1 added: “and 5.3.3” at the end of the 
paragraph. 
Deleted: last paragraph 
Section 4.4 Other Populations Revised the first 3 paragraphs from: “Within the entire study patient population there 
will be subsets who did not receive the full course of per protocol treatment.  The patient 
diary and pill count will define the extent of compliance.  This subgroup of patients will be 
categorized into various cohorts.  For consistency, an adjudication committee will be 
established, to review all study events (i.e. FAP related events and dropouts), and 
categorize them either as censored observations or imputed endpoints (see Section 5.2.2).   
For exploratory and sensitivity analysis the following dropout subsets will be included in 
secondary analyses:” 
Revised to: “Within the entire study patient population there will be subsets who did not 
receive the full course of per protocol treatment.  The major indicators for premature 
withdrawal are delineated below.  The patient diary and pill count will define the extent of 
treatment compliance during the study. 
Since the goal of this trial is to delay the time to FAP-related disease progression, there 
may be some patients with polyposis progression and/or disease related symptoms who will 
discontinue treatment.   An independent blinded Clinical Events Committee (CEC), also 
referred to as an adjudication committee will be established (vide infra), to review and 
confirm all Investigator determined FAP-related events and to assess all other off-study 
subjects for symptoms or signs of possible disease related progression that may or may not 
be delineated in the protocol. Section 5.2.2 provides detailed information as to decision 
making between the censoring vs. imputed FAP-related event.   
For exploratory and sensitivity analyses the following dropout subsets will be included in 
secondary analyses:” 
Section 5.1 Determination of 
Sample Size 
3rd paragraph revised from: “In total we expect to observe 35+35+20=90 primary 
endpoints among the three groups (plus or minus 5.7).  To achieve this number of events, 
we plan to have a 3 year study (with up to 12 months enrollment assuming no sample size 
reassessment plus 2 years of treatment and follow-up for the last-enrolled patients).” 
Revised to: “In total we expect to observe 35+35+20=90 primary endpoints among the 
three groups (plus or minus 5.7).  To achieve this number of events, 171 subjects have been 
randomized and some will receive up to 3 years of treatment. “ 
End of 4th paragraph revised from: “Table 5.1 below.” 
Revised to: “table 3.2” 
Deleted: “Table 5.1 Estimated Overall Event Free Proportions after Two Years of Follow-
up 
Treatment S(t) t (months) Median Time to Event (months)* 
Combination 0.6 24 32.5660 
Single Agent 0.3 24 13.8172 
*Based on an assumed exponential time-to-event distribution.” 
Section 5.2 Changed section title to: Data Monitoring Committee (DMC) and Clinical Events 
Committee (CEC) 
 
Section 5.2.1 Data Monitoring 
Committee (DMC) and Clinical 
Events Committee (CEC) 
2nd paragraph, Deleted: …separately at a later time… 
2nd paragraph, Deleted: …event rates. “Pre-specified interim analyses will be conducted 
in a blinded (A versus B) manner.” 
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5th paragraph added first sentence: “A pre-specified interim futility analysis will be 
conducted in a blinded manner.”  
5th paragraph, Deleted: …total of 45 “adjudicated”… 
Table 5.2 Interim Futility 
Analysis Details 
First column – Estimated Look Time Point 
Deleted: adjudicated 
Added New Section 5.2.2 
Adjudication Committee 
(AC) 
Changed section title to: Clinical Events Committee (CEC) 
First 4 paragraphs revised from: “A blinded adjudication committee (AC) will be 
formed for the purpose of reviewing all possible primary outcomes, for all randomized 
patients.  The committee will be composed of one or more clinical specialists with 
experience and expertise in treatment of FAP.  The process will follow other reported AC 
review procedures used in clinical trials with interim analyses[4]. 
To organize the review process, a subject profile document will be developed in advance of 
the first review cycle, which will contain all information deemed necessary for the AC 
review. Elements of the profile will include subject eligibility, baseline characteristics, 
investigator assessment of primary endpoint status, other information related to study 
primary endpoint status, and related investigator comments, as collected by the EDC system.  
On a periodic basis, upon request from the Sponsor, the CRO will prepare one profile 
document for each subject that has completed the treatment phase of the study.  If auxiliary 
information is requested by the AC, documents will be made available to the AC where ever 
possible. 
The AC will review the profile information in a secure manner and submit a reviewer 
worksheet, indicating their assessment of whether or not the data indicate that the subject 
reached an FAP-related event.  For each withdrawal from follow-up for reasons other than 
an FAP-related event (including those subjects that decline the extended treatment after 
completing 24 months of treatment), the AC will determine whether or not the reasons 
recorded for the withdrawal can be deemed unrelated to endpoint status.  If the AC deems 
the reasons for withdrawal unrelated to endpoint status, the withdrawal will be entered as a 
censored observation as of the time of the last recorded clinic visit.  If the AC cannot deem 
the withdrawal as unrelated to endpoint status, the withdrawal will be considered an imputed 
primary endpoint on grounds of treatment failure.  The follow-up time will be as of the last 
recorded clinic visit. 
The committee will be blinded to treatment assignment without exception.  All AC review 
results will be forwarded on to the CRO for data entry and future reporting of AC findings.”
Revised to: “An independent, blinded  CEC will be formed for the purpose of reviewing, 
confirming or adjudicating primary FAP-disease related endpoint status for all randomized 
patients.  The committee will be composed of clinical specialists with experience and 
expertise in treatment of FAP.  The process will follow other reported CEC review 
procedures. [4]. 
To organize the review process, a subject profile document will be developed which will 
contain all information deemed necessary for the CEC review.  Elements of the profile will 
include subject eligibility, baseline characteristics, investigator assessment of primary 
endpoint status, other information related to study primary endpoint status, and related 
investigator comments, as collected by the EDC system.  On a periodic basis, the CRO will 
prepare one profile document for each subject that has a reported FAP-related event, 
completed the treatment phase, or has come off study for other reasons (e.g., withdrew 
consent, lost to follow-up, adverse event). If auxiliary information is requested by the CEC, 
documents will be made available to the CEC where ever possible. 
The CEC will review the profile information in a secure manner and submit a reviewer 
worksheet, with their assessment of whether the data indicate that the subject reached an 
FAP-related event.  For each withdrawal from follow-up for reasons other than an FAP-
related event (including those subjects that decline the extended treatment after completing 
24 months of treatment), the CEC will determine whether the reasons recorded for the 
withdrawal can be deemed related to FAP disease progression not otherwise defined in the 
protocol or unrelated to endpoint status.  If the CEC deems the reasons for withdrawal 
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unrelated to endpoint status, the withdrawal will be entered as a censored observation as of 
the time of the last recorded clinic visit.  
If the CEC assesses and adjudicates the patient status at the completion of treatment or at the 
time off-study for clinical symptoms or signs likely related to FAP disease progression an 
imputed primary endpoint as of the last recorded clinic visit will be entered. 
The committee will be blinded to treatment assignment without exception.” 
Deleted: Last 2 paragraphs
Section 5.3.3, Analytic 
Methods for Time-to Event 
Data 
 
3nd paragraph Deleted: “As explained above in Section 5.2.2, if the endpoint 
determination cannot be made at the end of study clinic visit per the pre-specified study 
requirements, a blinded adjudication committee will review the reasons for such 
deviations.” 
4th paragraph changed: from: “last patient visit to: last recorded clinic visit” 
5th paragraph deleted and changed to: “If upon blinded adjudication the CEC considers 
the early withdrawal to be consistent with disease progression (not specifically an FAP-
related event as defined in the FAP-310 protocol), the patient will be determined to have an 
imputed FAP-related event.  The time to this imputed event will be from randomization to 
the last recorded clinic visit.” 
Section 5.3.6 General 
Procedures for Handling 
Missing Data 
2nd paragraph, Added fist sentence 1st paragraph: “an imputed FAP-related event”;  
2nd paragraph Deleted: “A patient will be considered a treatment failure if for any reason, 
the endpoint determination cannot be made per the pre-specified protocol.  The time to this 
imputed event will be from randomization to the last recorded patient visit.  A study event 
adjudication committee (AC) will be formed to further define the methods for defining 
imputed and censored events (see Sections 4.4 and 5.2.2).  Any secondary or sensitivity 
analysis that includes this assumption will be clearly noted.  Similarly, any sensitivity 
analysis that incorporates the last observation carried forward (LOCF) method, to 
compensate for early patient dropouts or missing data, will be clearly noted.” 
3rd paragraph Revised from: “Secondary analysis data include the presence of a specific 
genetic mutation, and urinary metabolite concentrations (see Section 3.2.2).  The primary 
analysis of the secondary objectives will include collected data only, without imputing or 
weighting data to compensate for missing data.  Sensitivity analyses of these data will be 
performed to explore study results more fully, in a manner consistent with ICH Guidance 
“E9 Statistical Principles for Clinical Trials (February, 1998)”.” 
Changed to: “Secondary analysis data include the presence of a specific genetic mutation, 
and urinary metabolite concentrations (see Section 3.2.2).  The main analysis of the 
secondary objectives will include collected data only, without imputing or weighting data to 
compensate for missing data.  For sensitivity analyses involving secondary endpoints with 
missing data, we will use the last observation carried forward (LOCF) method to complete 
the missing data.  Any sensitivity analysis that incorporates LOCF will be clearly noted.  
Sensitivity analyses of these data will be performed to explore study results more fully, in a 
manner consistent with ICH Guidance “E9 Statistical Principles for Clinical Trials 
(February, 1998)”.” 
Section 5.5 Dietary 
Assessment 
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Global 
Changes 
Changed version to Ver. 4.2, May 15, 2017 
TOC Updated: Table of Contents, and list of tables and figures 
Sec. 1 List of 
Abbreviations 
Added: Z-score, The value of the critical ratio (score statistic divided by its standard error) based 
on the stratified log-rank statistic. 






Revised from:  
1. CPP-1X active + sulindac active vs. CPP-1X placebo + sulindac active,  
and 
2. CPP-1X active + sulindac active vs. CPP-1X active + sulindac placebo  
 
Each comparison will be performed at the 2-sided p = 0.05 level. 
Revised to:  
3. CPP-1X placebo + sulindac active vs. CPP-1X active + sulindac active,  
and 
4. CPP-1X active + sulindac placebo vs. CPP-1X active + sulindac active  
 
The combination of CPP-1X active + sulindac active is specified as the reference treatment group 
because it is common to both comparisons.  In addition, because the purpose of the combination 
treatment is to delay the time to FAP-related disease progression compared to single-agent 
treatments, formulating the hypothesis tests in this manner will allow a positive rather than a 
negative Z-score for the test statistic to be interpreted as supportive of this purpose. 
 







Revised from:  
The US Food and Drug Administration (FDA) noted that the comparison of CPP-1X + sulindac vs. 
CPP-1X + placebo will not provide information about the treatment effect of CPP-1X (i.e. 
eflornithine), and therefore this result will not be included in the product label.  Therefore, the primary 
analysis of import to FDA is the comparison of CPP-1X + sulindac vs. sulindac + placebo. 
 
Revised to:  
The US Food and Drug Administration (FDA) noted that the comparison of single agent CPP-1X vs. 
combination treatment will not provide information about the treatment effect of CPP-1X (i.e. 
eflornithine), and therefore this result will not be included in the product label.  Therefore, the primary 
analysis of import to FDA is the comparison of single agent sulindac vs. combination treatment. 
Sect.5.1 
Determination 
of Sample Size 
Revised from:  
1) The level of statistical significance is set at 0.05, using a 2-sided stratified log-rank test for 
time-to-first FAP-related event, for each of the two between-group comparisons (i.e. CPP-
1X plus sulindac vs. CPP-1X and CPP-1X plus sulindac vs. sulindac); 
 
Revised to:  
1) The level of statistical significance is set at 0.05, using a 2-sided stratified log-rank test for 
time-to-first FAP-related event in discrete time (visit month number), for each of the two 
between-group comparisons (i.e. single agent sulindac vs. CPP-1X plus sulindac and single 
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Revised from:  
3) Power of at least 85% to detect the above-mentioned treatment effect comparing the 
combination arm vs. either of the two single treatment arms; 
Revised to:  
3) Power of at least 85% to detect the above-mentioned treatment effect comparing either of 
the two single treatment arms to the combination arm; 
 
Added paragraph after 4):   
The following calculations are based on our review of limited single-agent data for eflornithine and 
sulindac, in which the 2-year event free rates imply a single overall event free rate of 60% for 
combination treatment group and 30% in each single agent treatment group. This is described 
further in Table 3.2. 
 
Revised from: 
Even if the total number of events in either comparison were only 43, there will still be 80% power 
to detect the design effect size, namely, a hazard rate ratio of 0.4243 = (ln 0.60)/(ln 0.30) 
corresponding to the doubling of event-free follow-up over two years. 
 
In total we expect to observe 35+35+20=90 primary endpoints among the three groups (plus or 
minus 5.7).  To achieve this number of events, 171 subjects have been randomized and some will 
receive up to 3 years of treatment.  
 
This is based on our review of limited single-agent data for eflornithine and sulindac, in which the 
2-year event free rates imply a single overall event free rate of 60% for combination treatment 
group and 30% in each single agent treatment group.  This is described further in Table 3.2. 
 
Revised to: 
Even if the total number of events in either comparison were only 43, there will still be 80% power 
to detect the design effect size, namely, a hazard rate ratio of (log 0.30)/(log 0.60) corresponding to 
the doubling of event-free follow-up over two years (approximately equal to 2.3569).  For 
completeness, the design effect size is equivalent to a hazard rate ratio of (log 0.60)/(log 0.30) for 
the combination treatment relative to a single-agent treatment (approximately equal to 0.42428). 
 
In total we expect to observe 35+35+20=90 primary endpoints among the three groups (plus or 
minus 5.7). 





Paragraph 3,  
Revised from: 
CPP will inform the DMC that there will be two study evaluations for the DMC to consider during 
the trial, one interim look for sample size reassessment and one look for futility. 
Revised to: 
CPP will inform the DMC that there will be two study evaluations for the DMC to consider during 
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Paragraph 5 
Revised from: A pre-specified interim futility analysis will be conducted in a blinded manner.  The 
futility assessment will be performed after a total of 45 primary endpoints have occurred, which 
represents 50% of expected maximum trial information, or as soon thereafter as possible. 
Revised to: A pre-specified interim efficacy and futility analysis will be conducted as described 
below.  The assessment will be performed after a total of 45 primary endpoints have occurred, 
which represents 50% of expected maximum trial information, or as soon thereafter as possible.  
After reviewing the analysis results in a closed session, the DMC will provide recommendations 
regarding possible termination of the study for either futility, efficacy, or safety reasons, to the 




The futility analysis will be performed for each of the two treatment comparisons contained in the 
primary objective:  
1. CPP-1X active + sulindac active vs. CPP-1X placebo + sulindac active, 
and 
2. CPP-1X active + sulindac active vs. CPP-1X active + sulindac placebo 
For the futility interim analysis, the futility stopping criterion of Z=0.50 is one-sided, and 
corresponds to a conditional power criterion of approximately 0.12 (to two decimals).  That is, 
assuming between 52 and 55 expected total number of events have occurred by trial end in either of 
the two-arm comparisons, if the log-rank critical ratio Z-score were equal to 0.5 (or less) when one-
half the expected total number of events had been observed, then under the design alternative 
hazard ratio of 0.4243, there would be only a 12% probability (or less) of declaring a significant 
benefit of the combination therapy compared to the single agent therapy if the trial were to continue 
to the planned end. In that case, it would be reasonable for the DMC to consider stopping the trial 
for futility.  The futility analysis results will be presented in a simple manner whereby the DMC 
will be informed that the conditions indicating futility have been met (i.e. the futility boundary has 
been crossed, yes or no).  The details of the futility analysis are provided in Error! Reference 
source not found. below.  Unless the DMC requires it on ethical grounds, no early stopping for 
positive efficacy is proposed. 
Revised to: 
The analysis will be performed for each of the two treatment comparisons contained in the primary 
objective:  
1. CPP-1X placebo + sulindac active vs. CPP-1X active + sulindac active, 
and 
2. CPP-1X active + sulindac placebo vs. CPP-1X active + sulindac active. 
As stated above in Section 3.2, the combination of CPP-1X active + sulindac active is specified as 
the reference treatment group because it is common to both comparisons and formulating the 
hypothesis tests in this manner will allow a positive rather than a negative Z-score for the test 
statistic to be interpreted as supportive of this purpose. 
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The efficacy analysis will use a modified Haybittle-Peto stopping rule based on the stratified log-
rank Z-score.  If that Z-score equals or exceeds 3.2905 in absolute value, for either two-arm 
comparison, the difference between treatment arms would be declared statistically significant at the 
two-tailed 0.001 level of significance.  In that case it may be reasonable for the DMC to initiate a 
conversation about stopping the trial on ethical grounds.  Assuming this is not the case and the trial 
continues to its planned end, the Z-score criterion for declaring significance at the 5% level at the 
end of the trial will be increased in magnitude to plus or minus 1.962 in order to preserve the 
overall type I error rate for the trial at 0.05. 
For the futility analysis, the DMC will be provided with the numerical value of the stratified log-
rank Z-score.  The futility analysis uses a one-sided futility stopping criterion of Z = −0.50. That is, 
if the Z-score is less than or equal to −0.50, an investigation will be initiated to consider stopping 
the trial for futility or discontinuing one of the single-agent treatment arms.  The futility stopping 
criterion of Z = −0.50 is consistent with a conditional power of less than 20%.  That is, assuming 
between 44 and 60 FAP-related events have occurred by trial end in either of the two-arm 
comparisons (where between 52 and 55 are expected), if the log-rank critical ratio Z-score were 
equal to −0.5 (or less) when one-half the expected total number of events had been observed 
(namely, 45 across all three arms), then under the design alternative hazard ratio of 2.3569, there 
would be no more than a 20% chance of declaring a significant benefit of the combination therapy 
compared to the single agent therapy if the trial were to continue to the planned end. In that case, it 
would be reasonable for the DMC to consider stopping or altering the trial on grounds of futility.  
The DMC will also be provided with the conditional power of the observed Z-score for each two-
arm comparison. 
The details of the efficacy and futility analysis are provided in Error! Reference source not 
found. below.  Figure 5.1 presents a schematic diagram of the procedure, and Table 5.2 provides 
more precise conditional power values corresponding to the futility criterion Z = −0.50 as a function 
of the total number of events in either two-arm comparison.  See Section 7.4 below for further 










Efficacy criterion Z=1.96 at terminal analysis. 
Futility criterion of Z=0.50 or less at interim analysis. 
Total Type I error for end of study comparison  =  0.0471. 
NB: Assuming D = 52 events at trial end in either two-arm comparison, power = 0.8566.  Assuming 
D = 55 events at trial end in either two-arm comparison, power = 0.8750. 
Revised To: 
Efficacy criterion Z = 1.962 at terminal analysis. 
Futility criterion of Z = −0.50 or less at interim analysis. 
Type I error for exiting the upper efficacy boundary at or before terminal analysis = 0.024952.* 
Type I error for exiting the lower efficacy boundary at or before terminal analysis = 0.001984.* 
Total Type I error for end of study comparison  =  0.026936.* 
Assuming 52 events at trial end in either two-arm comparison, power = 0.8705.   
Assuming 55 events at trial end in either two-arm comparison, power = 0.8881. 
 
*Assume one interim analysis at ½ information time with upper efficacy boundary at Be = 
3.2905, lower efficacy boundary at −Be, and one-sided futility boundary  
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Bf  = −0.50.  Assume upper efficacy terminal criterion C = 1.9602 and lower efficacy 
terminal criterion −C.  Then the probability of exiting the upper efficacy boundary at either 






e dzzCzB )()2()(   
and the probability of exiting the lower efficacy boundary at either interim or terminal 






e dzzCzB )()2()(  , 
where )(z  is the standard normal probability density function and )(z  is the 
standard normal cumulative distribution function. 
Sect. 5.2.1  
 







































Sect. 5.2.1  
 
Added:  Table 5.2 Conditional Power at the Futility Boundary as a Function of Number of 
FAP Events at the Time of Futility Analysis, Using Futility Criterion Z = -0.5 
Total FAP events  
in either two-arm 
comparison 
at time of futility analysis 
Assumed number of FAP-
related events  
in either two-arm 
comparison 




30 60 0.177 
29 58 0.167 
28 56 0.157 
27 54 0.148 
26 52 0.138 
25 50 0.129 
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24 48 0.120 
23 46 0.111 




3rd paragraph 4th sentence, deleted the following text:  





Time to Event 
Data 
1st paragraph  
Revised from: 
The analytic method for the primary analysis will be a time-to-event analysis using the stratified 
log-rank test, as previously described. Stratified Cox proportional hazards regression models will be 
used for secondary assessments[7].  Graphical analyses (log-minus-log plots) will be used to check 
the assumption of constant hazard ratios. 
 
Revised to:  
The analytic method for the primary analysis will be a time-to-event analysis using the stratified 
log-rank test, as previously described. The discrete time version of the log-rank statistic using visit 
month number 0, 6, 12, 18, 24, 30, 36 will be used.  Stratified discrete-time Cox proportional 
hazards regression models will be used for secondary assessments[7].  Graphical analyses (log-
minus-log plots) will be used to check the assumption of constant hazard ratios.  See Section 7.3 
below for further details of the calculation of the discrete time stratified log-rank statistic. 
New Sect. 7.3 Added Section:  
7.3 Details of Calculating the Discrete-time Stratified Log-rank Z-Score 
Patient follow-up will be analyzed in discrete time, with events occurring at the 6, 12, 18, 24, 30, 36 
month visits and censorings also possible at the baseline visit at month 0 for patients who dropped 
out of the trial before their first follow-up visit.  Therefore, the primary test statistic will be the 
discrete-time stratified log-rank statistic, which is equivalent to the score-test statistic from Cox’s 
original discrete-time partial likelihood function. Each two-arm comparison will be performed 
separately This will be implemented in SAS by specifying the TIES=DISCRETE option in PROC 
PHREG.  The single agent treatments will be coded as 1 and the combination treatment will be 
coded as 0.  The square root of the score test chi-squared statistic will be calculated and the sign of 
the estimated log hazard ratio (+ if the HR>1 and − if the HR<1) will be attached.  This results in 
discrete-time stratified log-rank Z-score.  In symbols, 2)ˆ( XsignZk   , where ̂  denotes the 
estimated log hazard ratio coefficient for treatment A in the Cox model and where X2 denotes the 
SCORE TEST chi-squared statistic reported within the “Testing Global Null Hypothesis: BETA=0” 
table at the top of the PHREG results section.  The following sample PHREG procedure could be 
used in SAS to derive the stratified log-rank Z-score: 
proc phreg data=TwoArmData; 
model time*censor(1) =  Treatment / rl ties=discrete; 
strata Stratification_Factor; 








Study ID: CPP FAP-310, A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of 
CPP-1X / Sulindac Compared with CPP-1X, Sulindac as Single Agents in Patients with Familial 
Adenomatous Polyposis (FAP)  
 
Summary of SAP Changes Ver. 4.1, December 27, 2016 to Ver. 4.2 May 15, 2017 
Company Confidential  Page 7 of 7 
Section Change or Revision 
New Sect. 7.4 Added Section:  
7.4 Details of Calculating Conditional Power 



















Zk is the value of the stratified log-rank test statistic from the observed data at interim analysis; 
z1−/2 is the critical value for a two-tailed test at =0.05, namely +1.962 adjusted for the interim 
efficacy analysis; 
IK = the information number expected at trial end = ¼ times the total expected number of events;  
Ik = the information number at futility analysis = ¼ times the observed number of events at interim 
analysis; 
θ is the log hazard ratio at the design alternative, log 2.3569 = −log 0.42428 = +0.85736; and )(  
is the standard normal cumulative distribution function. 
 
Example.  Suppose at the time of interim analysis, the number of FAP-related events are as follows:  
For single-agent treatment A, 20; for single-agent treatment B, 16; and for combination treatment C, 
9.  Then in the two-arm comparison of A versus C, there would be a total of 29 events, so the 
information number is Ik=29/4=7.25.  We assume that there will be double this number for the 
corresponding comparison at the end of the trial; thus IK = 14.5.  Suppose the Z-score at the futility 
analysis happens to just equal the futility criterion, i.e., suppose Zk = −0.50.  Then applying the above 














This is the conditional power at the futility boundary.  Suppose, however, that the observed Z-score 
at the futility analysis were actually +0.50 instead of −0.5.  Then the −0.5 in the first term of the 
above expression would be replaced by Zk=+0.50, and the resulting observed conditional power 
would be 0.5135, a non-futile result. 
Note that the probability of a significant negative result at the terminal analysis, given that there is 
no stopping for futility at the interim analysis, is not included in the above expression.  That is 
because practical interest for futility analysis resides only in the conditional probability of a 




Added Ref 20 
Jennison, C. and B. W. Turnbull (2000). Group sequential methods with applications to clinical trials. 
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Global  Changed version to Ver. 4.3, July21, 2017
Sec 2. 2nd paragraph revised sentence as follows: 
“…delaying the time from the date of randomization to the date of the first occurrence of any 
FAP-related event….” 
Sec. 3.1 2nd paragraph revised with treatment extension assessment points. 
Eligible patients who have given informed consent will enter the study with the intent to 
participate for the full treatment period of 24 months.  Based on a subject’s date of randomization, 
patients will be offered continued preparticipation in blinded treatment for up to a total of 36, 42 
or 48 months of treatment if they have completed the initial 24 months of treatment without an 
FAP event may continue treatment for up to 12 additional months until one of the following 
occurs: 1) subject has an FAP event or comes off study for other reasons, 2) all randomized 
subjects have reached a minimum of 24, 36, 42 or 48 months of treatment,  
Sec. 3.2 2nd paragraph added:  “from the date of randomization to the date” 
4th paragraph added:…is to delay the time “from randomization” to FAP-related disease 
progression…. 
Sec. 4.1 Revised definition of ITT population to:  “The intent-to-treat population includes all patients that 
have been randomized to one of the three study arms.”
Sec. 4.4 4th paragraph revised CEC review and process: 
Section 5.2.2 provides detailed information on the CEC process and how the results will be used 
for sensitivity analyses and quality assurance purposes.   
For exploratory and sensitivity analyses the following subsets will be included in secondary 
analyses: 
 CEC reviewed and adjudicated subject outcomes
Sec. 5.2.2 1st paragraph deleted: “primary FAP-disease related” 
4th paragraph revised: 
If upon blinded adjudication the CEC considers the early withdrawal to be consistent with disease 
progression (not specifically an FAP-related event as defined in the FAP-310 protocol), the patient 
will be determined to have an imputed FAP-related event.  The time to this imputed event will be 
from randomization to the last recorded clinic visit. 
If upon blinded adjudication it can be determined that a subject’s withdrawal is for reasons 
deemed unrelated to his or her endpoint status, that subject will be treated as a censored 
observation as of the last recorded clinic visit. If the CEC deems the reasons for withdrawal 
unrelated to endpoint status, the withdrawal will be entered as a censored observation as of the 
time of the last recorded clinic visit.  
If the CEC assesses and adjudicates the patient status at the completion of treatment or at the time 
off-study for clinical symptoms or signs likely related to FAP disease progression an imputed 
primary endpoint as of the last recorded clinic visit will be entered. 
The committee will be blinded to treatment assignment without exception. 
Added last sentence: CEC determined imputed FAP-related events will be used for sensitivity 
analyses and will not be used for the primary endpoint assessment of clinical benefit. 
Sec. 5.3.2 2nd paragraph , 3rd sentence revised:
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These will be further described in subgroups such as drop outs due to adverse events, serious 
adverse events, administrative withdrawals for non-compliance for more than90 days90 days from 
randomization to month 36 or more than 105 days from randomization to month 42 or more than 
120 days from randomization to month 48, withdrawals of consent for continued follow-up, 
withdrawals for other reasons, and the number lost to follow-up.
5.3.3 1st paragraph added: “, 42 and 48” 
Paragraphs 3 – 6 revised as follows: 
If an FAP-related event occurs, that patient will be said to have an observed or uncensored event 
and will be considered a treatment failure.  If a subject withdraws, that subject will be treated as a 
censored observation as of the last recorded clinic visit (endoscopic disease assessment). 
If a subject has not progressed or is not known to have died at the date of analysis cut-off, time to 
first FAP-related event will be censored at the date of the last adequate endoscopy procedures 
before the cut-off date. 
If a subject has two or more missing assessments, time to first FAP-related event for the subject 
will be censored at the time of last adequate evaluation prior to the missing assessment. 
If a subject has no baseline assessment, time to first FAP-related event for the subject will be 
censored at the date of randomization. 
If upon blinded adjudication it can be determined that a subject’s withdrawal is for reasons 
deemed unrelated to his or her endpoint status, that subject will be treated as a censored 
observation as of the last recorded clinic visit. 
If upon blinded adjudication the CEC considers the early withdrawal to be consistent with disease 
progression (not specifically an FAP-related event as defined in the FAP-310 protocol), the patient 
will be determined to have an imputed FAP-related event.  The time to this imputed event will be 
from randomization to the last recorded clinic visit. 
8th paragraph deleted: A brief list of such potential confounders will be presented to the DMC for 
approval prior to analysis. 
5.3.6 2nd paragraph deleted: “an imputed FAP related event”, and next sentence deleted “for reasons 
deemed unrelated to their health status”….
5.4 Added: “36, 42 and 48” months 
Last paragraph deleted: “This trial has three strata and three treatment options with 150 patients to 
be entered.” 
5.5 Added:  Dietary assessments via the FFQ will be obtained at baseline, “months 12, 24, 36, 42 (only 
if end of treatment), and 48…”
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Global  Changed version to Ver. 5.0, April 02, 2018
Sec. 3.1 6th paragraph, Changed, “A total of 150 eligible subjects will be enrolled, 50 per treatment 
group.” To “At least 150 eligible subjects will be enrolled, with at least 50 per treatment group.”
Sec. 4.4 Deleted the following text  
Since the goal of this trial is to delay the time to FAP related disease progression, there may be 
some patients with polyposis progression and/or disease related symptoms with will discontinue 
treatment.  An independent blinded Clinical Events Committee (CEC), also referred to as an 
adjudication committee will be established (vide infra), to review and confirm all Investigator 
determined FAP-related events and to assess all other off-study subjects for symptoms or signs of 
possible disease related progression that may or may not be delineated in the protocol. 
 
Section 5.2.2 provides detailed information on the CEC process and the results will be used for 
sensitivity analyses and quality assurance purposes. 
 
 CEC reviewed and adjudicated subject outcomes 
Sec. 5.1 Deleted and Revised (see below): 
For the purposes of power calculations, we assume the following:  
1) The level of statistical significance is set at 0.05, using a 2-sided stratified log-rank test for 
time-to-first FAP-related event in discrete time (visit month number), for each of the two 
between-group comparisons (i.e. single agent sulindac vs. CPP-1X plus sulindac and single 
agent CPP-1X vs. CPP-1X plus sulindac); 
2) A doubling of the time to occurrence of the primary event from either of the single agent 
treatment arms to the combination treatment group; 
3) Power of at least 85% to detect the above-mentioned treatment effect comparing either of the 
two single treatment arms to the combination arm; 
4) The two single-agent treatment groups have the same event rate. 
The following calculations are based on our review of limited single-agent data for eflornithine 
and sulindac, in which the 2-year event free rates imply a single overall event free rate of 60% for 
combination treatment group and 30% in each single agent treatment group.  This is described 
further in Error! Reference source not found.. 
For this situation, 49 events would be needed for each two-group comparison at the 2-sided 0.05 
level with 85% power and the doubling of the time to primary event[2, 3].  Assuming two-year 
event proportions of 70% in either of the two single-agent groups and 40% in the combination arm 
with 50 patients per arm, the expected number of patients with an FAP-related event in either of 
the two single-agent groups would be 35 and 20 in the combination arm.  Thus we expect to have 
55 patients with a FAP-related event in each comparison, achieving almost 89% power.  The 
standard deviation around this expectation is 4.74, so we would be highly likely to observe at least 
the required 49 events.  Even if the total number of events in either comparison were only 43, 
there will still be 80% power to detect the design effect size, namely, a hazard rate ratio of (log 
0.30)/(log 0.60) corresponding to the doubling of event-free follow-up over two years 
(approximately equal to 2.3569).  For completeness, the design effect size is equivalent to a 
hazard rate ratio of (log 0.60)/(log 0.30) for the combination treatment relative to a single-agent 
treatment (approximately equal to 0.42428). 
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Revised with:  
The primary endpoint of this trial, time to meaningful clinical events in an orphan disease 
population, is novel and to date there are no published trials to draw upon that have incorporated 
the exact FAP-related endpoint of this trial.  Available data from primary literature sources 
include clinical studies where polyps were counted over a fixed time period, in different FAP 
populations (see protocol for tabulated listing).   
From these data a reasonable range of event frequencies was estimated to produce the sample size 
and power calculations incorporated into this trial.  These time-to-event estimates were reviewed 
by key FAP opinion leaders prior to finalization of the study design.  The following reflects the 
possible range of FAP events it was thought plausible to observe. 
 
For the purposes of power calculations, we assume the following:  
 
1) The level of statistical significance is set at 0.05, using a 2-sided stratified log-rank test for 
time-to-first FAP-related event in continuous time, for each of the two between-group 
comparisons (i.e. single agent sulindac vs. CPP-1X plus sulindac and single agent CPP-1X vs. 
CPP-1X plus sulindac).  The only covariates in the log-rank test will be the treatment groups 
(see section 7.3 for details); 
2) A doubling of the two-year event-free proportion from either of the single agent treatment arms 
to the combination treatment group;  
3) Power of at least 85% to detect the above-mentioned treatment effect comparing either of the 
two single treatment arms to the combination arm; 
4) The two single-agent treatment groups have approximately the same event rate. 
 
The following calculations are based on our review of limited single-agent data for eflornithine 
and sulindac, where FAP clinical trial primary endpoints involved polyp counting.  Extrapolating 
these data to two-year event-free proportions implies a single overall two-year event-free 
proportion of at least 60% to 70% for the combination treatment group and 30% in each single 
agent treatment group.  This is described further in Table 3.2. 
 
Because the power of time-to-event analyses depends on the total number of observed primary 
endpoints (“events”) and the hazard ratio in a given two-arm comparison of a single-agent versus 
combination therapy, we translate the above doubling of two-year event-free proportions into 
hazard ratios under a simplifying assumption of exponentially distributed time-to-event.  Note that 
the primary analysis described below, in Section 7.3, does not rely on such an assumption and 
provides a statistically valid test of the null hypothesis even if hazard rates are not constant.  
Furthermore, the stratified log-rank test is an optimal test (locally most powerful) under the 
assumption that the ratio of the two groups’ hazard functions remains constant over time (the 
proportional hazards assumption).  Note that the much stronger assumption, that the individual 
hazard functions themselves remain constant over time, would be dubious in this trial.  Therefore, 
irrespective of how the two-year event-free proportions are translated into hazard ratios, it is the 
latter which forms the design alternative parameter for the trial. 
Under the exponential assumption, the hazard ratio (HR) comparing one treatment arm to another 
is given by the natural logarithm of the two-year event-free proportion for the first arm divided by 
the natural logarithm of the two-year event-free proportion for the other arm.  Thus if the 
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combination arm is assumed to have a two-year event-free proportion of 60%, which is double 
that of the 30% two-year event-free proportions assumed for the single-agent arms, the HR is 
{log(0.60) / log(0.30)} = 0.4243.  This is the design alternative hazard ratio for this trial as it 
represents the minimum clinically meaningful treatment effect desired for the combination therapy 
compared to either single-agent therapy.  Insofar as the combination therapy may have a two-year 
event-free proportion of at least 60%, and may prove to be perhaps 70% or greater, the design 
alternative HR of 0.4243 is conservative; the true (albeit unknown) HR is thought possibly to 
range from 0.4243 down to 0.30 = {log(0.70) / log(0.30)} (see discussion below). 
Given that the primary hypotheses are stated in terms of comparing either single-agent arm to the 
combination arm, we note that the equivalent design alternative hazard ratio becomes  
{log(0.30) / log(0.60)} = 1/0.4243 = 2.357. 
 
For the anticipated range of hazard ratios, 25 to 49 events would be needed for each two-group 
comparison at the 2-sided 0.05 level to achieve 85% power[2,3] Assuming two-year event 
proportions of 70% in either of the two single-agent groups and 30% to 40% in the combination 
arm with 50 patients per arm, the expected number of patients with an FAP-related event in either 
of the two single-agent groups would be 35 and 15 - 20 in the combination arm.  The study design 
expectation is to have 50 - 55 patients with a FAP-related event in each two arm comparison, 
achieving at least 85% power under the design alternative.  The standard deviation around the 
expectation of 55 events is 4.74, so observing the required number of 49 events or more would be 
highly likely (the probability is about 91%).  If the total number of events in either comparison 
were only 43, there will still be 80% power to declare a significant treatment difference under the 
design alternative of 0.4243.   
 
As the two-year event proportion in the combination arm decreases from 40% with a 
corresponding decrease in the hazard ratio, the likelihood of observing the required number of 
events to maintain 85% power actually increases.  For example, at the lower expectation of 50 
events arising from an assumed two-year event proportion of 30% in the combination arm, the 
standard deviation of the total number of events in a two-arm comparison decreases to 4.58 and 
the probability that the observed number of events will exceed the 25 required to achieve 85% at a 
HR of 0.30 is virtually certain.
Sec. 5.2.2 Deleted section on CEC 
Sec. 5.3.3 Deleted: The discrete time version of the log-rank statistic using visit month number 0, 6, 12, 18, 
24, 30, 36, 42, and 48 will be used.   
 
Revised sentence as follows: 
The Sstratified discrete time Cox proportional hazards regression models….. 
 
Revised sentence as follows:  
See Section 7.3 below for further details of the calculation of the discrete time stratified long-rank 
statistic. 
 
See Section 5.3.6 below for further details of handling missing data.  Added sentence: Every effort 
will be made to minimize the occurrence of censoring and missing data.  
 
Deleted at the end of the section “Every effort will be made to minimize the use of censoring.”
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Last paragraph:  
Revised: Prior to the primary analysis, balance will be assessed between the three arms in terms of 
key potential confounders measured at the baseline visit.  If any of these variables is found 
significantly out of balance across the three groups using a 2 degree of freedom test of homogeneity 
at the 0.01 level of significance, it will be incorporated into the primary analysis using a stratified 
Cox model including that term in addition to the treatment arm.  The covariate-adjusted score test 
(adjusted stratified log-rank test) will serve as the primary result for the trial. 
 
To: Prior to the primary analysis, balance will be assessed between the three arms in terms of key 
potential confounders measured at the baseline visit.  If any of these variables is found significantly 
out of balance across the three groups using a 2 degree of freedom test of homogeneity at the 0.01 
level of significance, it will be incorporated into a sensitivity analysis using a stratified Cox model 
including that term in addition to the treatment arm.  The primary result for the trial will be the 
unadjusted stratified log-rank test.  The covariate-adjusted score test (adjusted stratified log-rank 
test) will serve only as a secondary analysis to aid in the interpretation of the primary result.
Sec. 6 Changed: “A total of 150 eligible patients will be randomized in this study To “At least 150 
eligible patients will be randomized in this study.” 
Sec. 7.3 Revised: 
Patient follow-up will be analyzed in discrete time, with events occurring at the 6, 12, 18, 24, 30, 
36, 42 and 48 month visits and censorings also possible at the baseline visit at month 0 for patients 
who dropped out of the trial before their first follow-up visit.  Therefore, the primary test statistic 
will be the discrete-time stratified log-rank statistic, which is equivalent to the score-test statistic 
from Cox’s original discrete-time partial likelihood function.   
 
To:  
Patient follow-up will be analyzed in continuous time, although it is recognized that FAP event 
detection will cluster around scheduled study visits, at months 6, 12, 18, 24, 30, 36, 42 and 48 and 
event times may be tied as follow-up time is measured only to the nearest day. Censorings are 
possible at the baseline visit (month 0) for patients who dropped out of the trial before their first 
follow-up visit.  The primary test statistic will be the stratified log-rank statistic. 
 
Revised:  
This results in the discrete time stratified log-rank Z-score.   
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Global  • Changed version 5.0 April 2, 2018 to Ver. 5.1, July 30, 2018 
• Standardized the term P-value for uniformity 
• Fixed: Formatting and corrected typographical errors  
• Updated: Table of Contents, reference numbers, table numbers, and section numbers. 
Sec. 1 Deleted: CEC abbreviation and term, from list of abbreviations. 
Added:  
LGI, Lower Gastrointestinal 
LGIOI, LGI Observed Improvement 
UGI, Upper Gastrointestinal 
UGIOI, UGI Observed Improvement 
Sec. 3.2 Added after 3rd paragraph: “These two treatment comparisons will be performed sequentially, 
as described below.” 
Sec. 3.2.1 Added to 4th paragraph, first sentence: “sequentially” perform “the” two “primary” 
comparisons…... 
Added last paragraph:  
“We note that this approach is both a fixed-sequence and gatekeeping approach.  It is fixed-
sequence in that the comparison of combination with single-agent Sulindac takes place before the 
comparison of combination with single-agent Eflornithine and the first serves as a gatekeeper for 
the second (i.e., no declaration of significance in the second comparison will be made if the first 
comparison is not significant at the 0.05 level).  Therefore, the type I error in the sequential testing 
is well controlled.  In addition, because both tests must be significant for EMA approval, the type 
I error of the second test in the sequence is less than 0.05.” 
Sec. 3.2.2 Deleted: 
To evaluate the potentially effect-modifying properties of: 
a. Presence or absence of an ODC polymorphism. 
b. To evaluate the excretion of 4 urinary polyamines (diacetylspermine, n1-
acetylspermidine, n8-acetylspermidine, and decarboxylated SAM). 
These five secondary variables will be assessed regardless of study outcome, but their use as 
potential label claims will only apply if a statistically significant treatment effect is found in the 
primary analysis. For the secondary efficacy analysis, for each secondary variable, a 
corresponding term will be added to the primary analysis as well as an interaction term (product of 
the treatment indicator and secondary variable).  The coefficient of the interaction term (only) will 
be tested to determine if the secondary variable alters the magnitude of the treatment effect. 
Corresponding to each of the two primary analyses, the Hochberg step-up method[1] will be 
employed to control the overall family-wise error rate with overall alpha set at the two-sided 0.05 
level. 
Replaced section with the following text:  
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Any improvement observed by the investigator during upper gastrointestinal (UGI) and lower 
gastrointestinal (LGI) visualization (i.e. endoscopy and colonoscopy) at the 6 and 12-month study 
visits will be described using the variables UGI Observed Improvement (UGIOI), and LGI 
Observed Improvement (LGIOI).  Each patient will have one pair of UGIOI and LGIOI outcomes. 
UGIOI and LGIOI are binary outcomes derived from numerical determinations (henceforth, 
“investigator change scores” or more briefly, “scores”) assigned by the investigator during each 
procedure, using a scale (–2, –1, 0, +1, +2) which corresponds, respectively, to the investigator’s 
overall qualitative assessment of: much worse, worse, no change, improved, much improved.  At 
the month 6 procedures the investigator scores UGI and LGI findings as changes from baseline.  
At the month 12 procedures, the UGI and LGI findings are scored relative to the month 6 
procedures. 
The UGIOI (and respectively, the LGIOI) secondary endpoint independently summarizes the 
corresponding 6- and 12-month investigator change scores according to whether or not there was 
any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to 
baseline or month 6), under the condition that there be no worsening at either timepoint 
(compared to the preceding timepoint).  Here are the specific possibilities (where “Improvement” 
stands for either the UGIOI or LGIOI secondary endpoint): 
• If the 6-month score is –2 or –1, Improvement=NO irrespective of the 12-month score. 
• If the 6-month score is 0, then Improvement=YES if and only if the 12-month score is +1 
or +2.  Otherwise Improvement=NO. 
• If the 6-month score is +1 or +2, then Improvement=YES if and only if the 12-month 
score is greater than or equal to 0.  Otherwise Improvement=NO. 
Any patient who drops out of the study before the month 12 assessment will be considered 
Improvement=NO. 
These binary UGIOI and LGIOI secondary efficacy endpoints will be compared in a manner 
analogous to the primary analysis, using the same two primary treatment comparisons (1: CPP-1X 
placebo + sulindac active vs. CPP-1X active + sulindac active; and 2: CPP-1X active + sulindac 
placebo vs. CPP-1X active + sulindac active), and conditioning on the three disease site strata 
(Rectum/Pouch Polyposis, Duodenal Polyposis, Pre-colectomy).  The null hypothesis of no 
association between treatment group and Improvement endpoints will be tested using the exact 
Mantel-Haenszel procedure for combining the evidence contained in the fourfold tables 
(Treatment=Single agent vs. Combination cross-classified by Improvement=YES vs. NO) across 
the three strata.  For each of the two treatment comparisons, exact Mantel-Haenszel P-values will 
be calculated for both the UGI and LGI assessments (using the point-probability method based on 
the convolution of three independent central hypergeometric distributions; see [1]).   
The overall type I error for the secondary efficacy analysis will be controlled using the Hochberg 
step-up method for multiple comparisons[2].  This analysis will be performed in the ITT 
population.  The primary analysis will serve as a gatekeeper to control the overall type I error rate 
at 0.05 for both primary and secondary analyses. That is, significance for the secondary efficacy 
analysis will be declared only if the primary P-value is 0.05 or less, when the p-values are tested 
sequentially per the Hochberg method[2]. 
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1. Median time to event for each treatment group will be determined. This will be explored for 
each of the study populations (i.e. ITT, per protocol, and others).   
2. Safety outcomes will be assessed by summary analysis of adverse events and clinical 
laboratory abnormalities. 
3. Pharmacokinetic outcomes will be assessed by evaluating the population pharmacokinetics 
for CPP-1X (eflornithine) and sulindac. 
4. Evaluate tissue and dietary polyamine levels. 
5. Patient reported quality of life will be evaluated using HRQoL and patient utilities. 
6. A pilot evaluation of an FAP-specific assessment, the time to the first FAP-related beneficent 
event, will be studied.  This will involve analyzing the endoscopic polyposis data for 
regression of pre-colectomy colorectal polyposis, rectal/pouch polyposis, and regression of 
duodenal polyposis. 
7. An analysis of the components and subgroups included in the primary analysis, and their 
contribution to the primary outcome.   
Replaced with the following: 
To explore how study treatment group relates to other efficacy outcomes, genotype, phenotype, 
disease locations and endoscopic findings, additional analyses are planned.  These analyses will be 
performed in the ITT group, the Per Protocol Group, and other defined subgroups [see Section 4 
Populations for Analysis] wherever possible and will all be clearly noted as such. 
The UGIOI and LGIOI outcomes will be tabulated and summarized using the month 6 visit 
scores, alone.  Similarly, the UGIOI and LGIOI outcomes will tabulated and summarized across 
all study visits. 
As both part of the primary analysis, and further explored in these additional analyses, median 
time to event for each treatment group will be determined. This will be explored for each of the 
study populations (i.e. ITT, per protocol, and others), study disease stratum groups, and in the 
Disease Site subgroups (see below). 
Pharmacokinetic data (plasma concentrations measured at patient visits) will be used to estimate 
population pharmacokinetic parameters for the CPP-1X (eflornithine), sulindac, and CPP-1X 
(eflornithine) + sulindac treatment groups (i.e., for each analyte for those patients on combination 
treatment). 
The subcategories of FAP events will be explored by disease stratum groups, and by Disease Site 
subgroups (see below).  The subcategories of FAP events include: 
Table 3.1  Disease Site Subgroups 
No Group Description 
1 Disease Progression Indicating Need 
for Colectomy with IRA or Total 
Procto-Colectomy 
Applies only to subjects with FAP surgical 
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2 Excisional intervention by surgical 
snare or trans-anal excision to remove 
any polyp >=10mm in size (per 
pathology report) and/or pathologic 
evidence of high grade dysplasia 
Excisional intervention does not apply to 
subjects with FAP surgical status of colectomy 
with ileostomy (field name: DIAGSXST, code 
4) or subjects with FAP surgical status of 
precolectomy (field name: DIAGSXST, code 1). 
For all remaining subjects, all >5 mm polyps 
must have been removed at baseline 
also 
High grade dysplasia does not apply to subjects 
with FAP surgical status of colectomy with 
ileostomy (field name: DIAGSXST, code 4) 
3 Disease Progression Indicating Need 
for Proctectomy 
Does not apply to subjects with FAP surgical 
status of proctocolectomy with ileal pouch 
anastomosis (IPAA) (field name: DIAGSXST, 
code 3) or FAP surgical status of colectomy with 
ileostomy (field name: DIAGSXST, code 4) 
4 Disease Progression Indicating Need 
for Pouch resection 
Does not apply to subjects with FAP surgical 
status of precolectomy (field name: DIAGSXST, 
code 1). or FAP surgical status of colectomy 
with ileostomy (field name: DIAGSXST, code 
4) or FAP surgical status of colectomy with 
ileorectal anastomosis (IRA) (field name: 
DIAGSXST, code 2) 
5 Development of cancer in rectum or 
pouch 
Does not apply to subjects with FAP surgical 
status of colectomy with ileostomy (field name: 
DIAGSXST, code 4) 
6 Progression in Spigelman Stage to 
more advanced stage (Stage 2, 3, 4) 
Does not apply to subjects without duodenum 
(determined by abdominal surgical procedure of 
duodenectomy, duodenohemipancreatomy, or 
Whipple procedure (field name SXPROC) and 
screening/baseline upper GI endoscopy not done 
(field name UGIND, Boolean data type) 
7 Disease Progression indicating need 
for excisional intervention (sub-
mucosal resection, trans-duodenal 
excision, duodenectomy, 
ampullectomy, Whipple procedure) 
Does not apply to subjects without duodenum 
(determined by abdominal surgical procedure of 
duodenectomy, duodenohemipancreatomy, or 
Whipple procedure (field name SXPROC) and 
screening/baseline upper GI endoscopy not done 
(field name UGIND, Boolean data type) 
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8 Development of cancer in duodenum Does not apply to subjects without duodenum 
(determined by abdominal surgical procedure of 
duodenectomy, duodenohemipancreatomy, or 
Whipple procedure (field name SXPROC) and 
screening/baseline upper GI endoscopy not done 
(field name UGIND, Boolean data type) 
9 Spigelman stage (no progression) 
 
Does not apply to subjects without duodenum 
(determined by abdominal surgical procedure of 
duodenectomy, duodenohemipancreatomy, or 
Whipple procedure (field name SXPROC) and 
screening/baseline upper GI endoscopy not done 
(field name UGIND, Boolean data type) 
10 >= 10 mm polyp in rectum pouch 
 
Does not apply to subjects with FAP surgical 
status of colectomy with ileostomy (field name: 
DIAGSXST, code 4) or subjects with FAP 
surgical status of precolectomy (field name: 
DIAGSXST, code 1). For all remaining subjects, 
all >5 mm polyps must have been removed at 
baseline. 
11 High grade dysplasia (rectum-pouch) 
 
Does not apply to subjects with FAP surgical 
status of colectomy with ileostomy ((field name: 
DIAGSXST, code 4) 
 
These subcategories will be analyzed within the assigned disease strata (i.e. assigned at time of 
randomization).  Separately, they will be analyzed by Disease Site, according to the concept of 
“the patient as a whole” meaning that all known disease sites will be considered because patients 
more often than not have more than one diseased organ system.  For example, a patient 
randomized to treatment in the Duodenal Polyposis stratum who is also known to have colonic 
polyps will appear in the analyses for both Disease Site subgroups (Duodenal and Colonic).  The 
total number of patients in the Duodenal Disease Site subgroup will include, for example, all 
patients randomized in the Duodenal Polyposis stratum + all other patients with known duodenal 
disease (irrespective of whether they have rectal/pouch disease).  A similar approach will be taken 
for the Rectum/Pouch Polyposis group and Pre-colectomy strata. 
The presence or absence of ODC polymorphisms, including the single nucleotide polymorphisms 
(SNPS) rs2302615 and rs2302616 and their relation to treatment group and outcome will be tested 
with the likelihood ratio test. 
The excretion of 5 urinary polyamines (diacetylspermine, n1-acetylspermidine, n8-
acetylspermidine, decarboxylated SAM, and putrescine) will be assessed in relation to treatment 
group and outcome, using the single point concentration data gathered from the urine samples 
harvested at each study visit. 
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Section Change or Revision 
Patient reported health related quality of life measures will be evaluated using HRQoL (see 
Section 5.6 Health Related Quality of Life (HRQoL) Statistical Methods for more details). 
Tissue and dietary polyamine levels, as collected at patient study visits will be analyzed together 
with the results of the dietary questionnaires (see Section 5.7 Dietary Assessment) and related to 
treatment group and study outcomes. 
Safety outcome data and analyses are described in Section 5.5.5 Assessment of Toxicities. 
Sec. 5.1 After 2nd paragraph, changed from: “For the purposes of power calculations, we assume the 
following:” 
To: Section header 5.2 Power Calculation Assumptions.  
After 2nd paragraph on section 5.2, added Section header: 5.3 Hazard Rates 




Deleted: ”and Clinical Events Committee (CEC)” 
Renamed section header 5.4.1 from: DMC To: DMC General Information 
After 4th paragraph from 5.4.1, Added section header: 5.4.2 Prespecified Interim Efficacy and 
Futility Analysis 
Sec. 5.4.2 6th paragraph, revised first sentence, from: “The details of the efficacy and futility analysis are 
provided in Table 5.1 below presents a schematic diagram of the procedure.  Also Table 5.2…”  
To: “The details of the efficacy and futility analysis are provided in Table 5.1 below which 
presents a schematic diagram of the procedure.  Also Table 5.2…” 
5.5.3 Added sentence to 4th paragraph: “Similarly, if a subject discontinues study participation due to 
toxicity and begins receiving other therapy, the time to FAP event will be censored at the date of 
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Section Change or Revision 
Global  Changed version Ver. 5.1, July 30, 2018 to January 25, 2019 
Updated: Table of Contents, reference numbers, table numbers, and section numbers as required. 
Sec. 3.2 Changed section title: 
From: 3.2 Study Objectives and Primary Hypothesis Testing 
To: 3.2 Study Objectives 
Sec. 3.2.1 Added sub-section:  
3.2.1  Primary Analysis 
The primary analysis will be a time-to-event analysis using the stratified log-rank test. 
Graphical analyses (log-minus-log plots) will be used to check the assumption of constant 
hazard ratios with the COX model.  See Section 7.3 below for further details of the 
calculation of the stratified log-rank statistic. The strata are the patient’s sites of disease 
involvement at baseline, which is determined prior to randomization, and are: 
Rectal/pouch polyposis, Duodenal polyposis, and Precolectomy.  
For the primary analysis, two stratified log-rank tests will be performed with treatment 
coded as a binary value (i.e., 0 or 1). Time to event curves will be displayed using the 
method of Kaplan and Meier[8].  Additional analyses involving the overall 3-treatment 
group comparison and use of additional study populations (see Section 4.) for the two 
pairwise treatment comparisons, will be performed as supplemental analyses. Refer to 
section 5.5.3 for further details. 
Section 
3.2.3 
Added the following sentence at the end of the section:
 
Further analyses of the secondary endpoints may be conducted to evaluate and provide 
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Section Change or Revision 
Global  Changed version Ver. 5.1, July 30, 2018 to January 25, 2019 
Updated: Table of Contents, reference numbers, table numbers, and section numbers as required. 
Sec. 3.2 Changed section title: 
From: 3.2 Study Objectives and Primary Hypothesis Testing 
To: 3.2 Study Objectives 
Sec. 3.2.1 Added sub-section:  
3.2.1  Primary Analysis 
The primary analysis will be a time-to-event analysis using the stratified log-rank test. 
Graphical analyses (log-minus-log plots) will be used to check the assumption of constant 
hazard ratios with the COX model.  See Section 7.3 below for further details of the 
calculation of the stratified log-rank statistic. The strata are the patient’s sites of disease 
involvement at baseline, which is determined prior to randomization, and are: 
Rectal/pouch polyposis, Duodenal polyposis, and Precolectomy.  
For the primary analysis, two stratified log-rank tests will be performed with treatment 
coded as a binary value (i.e., 0 or 1). Time to event curves will be displayed using the 
method of Kaplan and Meier[8].  Additional analyses involving the overall 3-treatment 
group comparison and use of additional study populations (see Section 4.) for the two 
pairwise treatment comparisons, will be performed as supplemental analyses. Refer to 
section 5.5.3 for further details. 
Section 
3.2.3 
Added the following sentence at the end of the section:
 
Further analyses of the secondary endpoints may be conducted to evaluate and provide 
additional evidence to support its validity and confirm its clinical relevance. 
End  
 
